<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  
  <meta name="renderer" content="webkit">
  <meta http-equiv="X-UA-Compatible" content="IE=edge" >
  <link rel="dns-prefetch" href="http://example.com">
  <title>Hongtu Liu</title>
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
  <meta property="og:type" content="website">
<meta property="og:title" content="Hongtu Liu">
<meta property="og:url" content="http://example.com/page/7/index.html">
<meta property="og:site_name" content="Hongtu Liu">
<meta property="og:locale" content="en_US">
<meta property="article:author" content="Hongtu Liu">
<meta name="twitter:card" content="summary">
  
    <link rel="alternative" href="/atom.xml" title="Hongtu Liu" type="application/atom+xml">
  
  
    <link rel="icon" href="/favicon.png">
  
  <link rel="stylesheet" type="text/css" href="/./main.0cf68a.css">
  <style type="text/css">
  
    #container.show {
      background: linear-gradient(200deg,#a0cfe4,#e8c37e);
    }
  </style>
  

  

<meta name="generator" content="Hexo 5.3.0"></head>

<body>
  <div id="container" q-class="show:isCtnShow">
    <canvas id="anm-canvas" class="anm-canvas"></canvas>
    <div class="left-col" q-class="show:isShow">
      
<div class="overlay" style="background: #4d4d4d"></div>
<div class="intrude-less">
	<header id="header" class="inner">
		<a href="/" class="profilepic">
			<img src="" class="js-avatar">
		</a>
		<hgroup>
		  <h1 class="header-author"><a href="/"></a></h1>
		</hgroup>
		

		<nav class="header-menu">
			<ul>
			
				<li><a href="/">Home</a></li>
	        
				<li><a href="/categories">Categories</a></li>
	        
				<li><a href="/tags/%E9%9A%8F%E7%AC%94/">随笔</a></li>
	        
			</ul>
		</nav>
		<nav class="header-smart-menu">
    		
    			
    			<a q-on="click: openSlider(e, 'innerArchive')" href="javascript:void(0)">All Items</a>
    			
            
    			
    			<a q-on="click: openSlider(e, 'friends')" href="javascript:void(0)">Links</a>
    			
            
    			
    			<a q-on="click: openSlider(e, 'aboutme')" href="javascript:void(0)">About Me</a>
    			
            
		</nav>
		<nav class="header-nav">
			<div class="social">
				
					<a class="github" target="_blank" href="#" title="github"><i class="icon-github"></i></a>
		        
					<a class="weibo" target="_blank" href="#" title="weibo"><i class="icon-weibo"></i></a>
		        
					<a class="rss" target="_blank" href="#" title="rss"><i class="icon-rss"></i></a>
		        
					<a class="zhihu" target="_blank" href="#" title="zhihu"><i class="icon-zhihu"></i></a>
		        
			</div>
		</nav>
	</header>		
</div>

    </div>
    <div class="mid-col" q-class="show:isShow,hide:isShow|isFalse">
      
<nav id="mobile-nav">
  	<div class="overlay js-overlay" style="background: #4d4d4d"></div>
	<div class="btnctn js-mobile-btnctn">
  		<div class="slider-trigger list" q-on="click: openSlider(e)"><i class="icon icon-sort"></i></div>
	</div>
	<div class="intrude-less">
		<header id="header" class="inner">
			<div class="profilepic">
				<img src="" class="js-avatar">
			</div>
			<hgroup>
			  <h1 class="header-author js-header-author"></h1>
			</hgroup>
			
			
			
				
			
				
			
				
			
			
			
			<nav class="header-nav">
				<div class="social">
					
						<a class="github" target="_blank" href="#" title="github"><i class="icon-github"></i></a>
			        
						<a class="weibo" target="_blank" href="#" title="weibo"><i class="icon-weibo"></i></a>
			        
						<a class="rss" target="_blank" href="#" title="rss"><i class="icon-rss"></i></a>
			        
						<a class="zhihu" target="_blank" href="#" title="zhihu"><i class="icon-zhihu"></i></a>
			        
				</div>
			</nav>

			<nav class="header-menu js-header-menu">
				<ul style="width: 70%">
				
				
					<li style="width: 33.333333333333336%"><a href="/">Home</a></li>
		        
					<li style="width: 33.333333333333336%"><a href="/categories">Categories</a></li>
		        
					<li style="width: 33.333333333333336%"><a href="/tags/%E9%9A%8F%E7%AC%94/">随笔</a></li>
		        
				</ul>
			</nav>
		</header>				
	</div>
	<div class="mobile-mask" style="display:none" q-show="isShow"></div>
</nav>

      <div id="wrapper" class="body-wrap">
        <div class="menu-l">
          <div class="canvas-wrap">
            <canvas data-colors="#eaeaea" data-sectionHeight="100" data-contentId="js-content" id="myCanvas1" class="anm-canvas"></canvas>
          </div>
          <div id="js-content" class="content-ll">
            
  
    <article id="post-20210605" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/06/05/20210605/">20210605</a>
    </h1>
  

        
        <a href="/2021/06/05/20210605/" class="archive-article-date">
  	<time datetime="2021-06-04T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210605</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#%E4%B8%83%E5%8D%83%E4%BA%BA%E5%A4%A7%E4%BC%9A"><span class="toc-number">2.</span> <span class="toc-text">七千人大会</span></a></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><h1 id="七千人大会"><a href="#七千人大会" class="headerlink" title="七千人大会"></a>七千人大会</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.google.com/search?q=%E5%88%98%E5%B0%91%E5%A5%87%E5%9C%A8%E4%B8%83%E5%8D%83%E4%BA%BA%E5%A4%A7%E4%BC%9A%E4%B8%8A%E7%9A%84%E8%AE%B2%E8%AF%9D&newwindow=1&client=ubuntu&sxsrf=ALeKk03TYyTxhX3_pU3J7jrFzLA1tuMvbQ:1622896551213&ei=p2-7YN-vDPTogwe3-JOgCg&oq=%E5%88%98%E5%B0%91%E5%A5%87%E5%9C%A8%E4%B8%83%E5%8D%83%E4%BA%BA%E5%A4%A7%E4%BC%9A%E4%B8%8A%E7%9A%84%E8%AE%B2%E8%AF%9D&gs_lcp=Cgdnd3Mtd2l6EANQks46WJLOOmCO1DpoAXAAeACAAYECiAGBApIBAzItMZgBAKABAqABAaoBB2d3cy13aXrAAQE&sclient=gws-wiz&ved=0ahUKEwifn8TjwIDxAhV09OAKHTf8BKQQ4dUDCA4&uact=5">刘少奇在七千人大会上的讲话 - Google Search</a></li>
<li><a target="_blank" rel="noopener" href="http://202.107.204.217/kcms/detail/detail.aspx?filename=FLDS202005012&dbcode=CJFQ&dbname=CJFD2020">最是大节见真知——刘少奇在七千人大会上的讲话 - 中国学术期刊网络出版总库</a></li>
<li><a target="_blank" rel="noopener" href="http://www.cqvip.com/qk/82224a/202005/7102054428.html">最是大节见真知——刘少奇在七千人大会上的讲话-【维普官方网站】-www.cqvip.com-维普网</a></li>
<li><a target="_blank" rel="noopener" href="http://m.wyzxwk.com/content.php?classid=21&id=398564">【文献】毛泽东：七千人大会上的讲话全文－乌有之乡</a></li>
<li><a target="_blank" rel="noopener" href="https://www.dwnews.com/%E4%B8%AD%E5%9B%BD/59712828/%E5%88%98%E5%B0%91%E5%A5%87%E5%8F%91%E8%A8%80%E4%B8%83%E5%8D%83%E4%BA%BA%E5%A4%A7%E4%BC%9A%E4%B8%8A%E7%9A%84%E8%87%B4%E5%91%BD%E6%8E%8C%E5%A3%B0">刘少奇发言：七千人大会上的致命掌声｜多维新闻｜中国</a></li>
<li><a target="_blank" rel="noopener" href="http://www.youzikankan.com/">游子看看</a></li>
<li><a target="_blank" rel="noopener" href="http://www.hybsl.cn/beijingcankao/beijingfenxi/2016-01-11/56397.html">中庸：刘少奇在七千人大会上讲话的效果和影响-胡耀邦史料信息网</a></li>
<li><a target="_blank" rel="noopener" href="http://www.hybsl.cn/beijingcankao/beijingfenxi/2020-03-05/71005.html">张虹生：我和父亲张闻天-胡耀邦史料信息网</a></li>
<li><a target="_blank" rel="noopener" href="https://www.marxists.org/chinese/reference-books/qibenyu/index.htm">戚本禹回忆录（2016）</a></li>
<li><a target="_blank" rel="noopener" href="https://www.marxists.org/chinese/reference-books/index-class-struggling.htm">中文马克思主义文库·参考图书·阶级斗争文献</a></li>
</ul>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
	<div class="article-tag tagcloud">
		<i class="icon-price-tags icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color1">七千人大会</a>
        		</li>
      		
		</ul>
	</div>

      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/06/05/20210605/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210601" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/06/01/20210601/">20210601</a>
    </h1>
  

        
        <a href="/2021/06/01/20210601/" class="archive-article-date">
  	<time datetime="2021-05-31T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210601</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#%E6%89%8B%E6%9C%BA%E7%AE%97%E5%91%BD%E8%BD%AF%E4%BB%B6%E6%8E%92%E8%A1%8C%E6%A6%9C"><span class="toc-number">1.</span> <span class="toc-text">手机算命软件排行榜</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#1"><span class="toc-number">1.1.</span> <span class="toc-text">1</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%B7%B1%E5%BA%A6%E6%98%9F%E5%BA%A7%E9%A2%84%E6%B5%8B%E5%B9%B3%E5%8F%B0iOS"><span class="toc-number">1.1.1.</span> <span class="toc-text">深度星座预测平台iOS</span></a></li></ol></li><li class="toc-item toc-level-2"><a class="toc-link" href="#2"><span class="toc-number">1.2.</span> <span class="toc-text">2</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#%E7%81%B5%E5%8D%A0%E5%A4%A9%E4%B8%8B%EF%BC%88predictor%EF%BC%89%EF%BC%8C%E4%B8%93%E4%B8%9A%E7%9A%84%E5%8D%A0%E5%8D%9C%E8%BD%AF%E4%BB%B6iOS"><span class="toc-number">1.2.1.</span> <span class="toc-text">灵占天下（predictor），专业的占卜软件iOS</span></a></li></ol></li><li class="toc-item toc-level-2"><a class="toc-link" href="#3"><span class="toc-number">1.3.</span> <span class="toc-text">3</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#%E7%B4%AB%E5%BE%AE%E5%A4%A7%E5%B8%88%EF%BC%8C%E8%BF%90%E5%8A%BF%E6%8F%AD%E7%A7%98%EF%BC%8C%E6%8E%92%E7%9B%98%E3%80%81%E8%A7%A3%E7%9B%98iOS%E5%B0%8F%E7%A8%8B%E5%BA%8F"><span class="toc-number">1.3.1.</span> <span class="toc-text">紫微大师，运势揭秘，排盘、解盘iOS小程序</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%96%87%E5%A2%A8%E5%A4%A9%E6%9C%BA%E7%B4%AB%E5%BE%AE%E6%96%97%E6%95%B0appiOS"><span class="toc-number">1.3.2.</span> <span class="toc-text">文墨天机紫微斗数appiOS</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E9%A2%86%E5%85%88%E7%9A%84%E5%91%A8%E6%98%93%E5%91%BD%E7%90%86%E5%92%A8%E8%AF%A2%E6%9C%8D%E5%8A%A1%E5%B9%B3%E5%8F%B0iOS"><span class="toc-number">1.3.3.</span> <span class="toc-text">领先的周易命理咨询服务平台iOS</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E7%81%B5%E6%9C%BA%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BDapp"><span class="toc-number">1.3.4.</span> <span class="toc-text">灵机八字算命app</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%8D%A0%E5%8D%9C%E5%A4%A7%E5%B8%88appiOS"><span class="toc-number">1.3.5.</span> <span class="toc-text">占卜大师appiOS</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%87%86%E7%A1%AE%E9%A2%84%E6%B5%8B%E4%BD%A0%E7%9A%84%E7%8E%B0%E5%9C%A8%E5%92%8C%E5%B0%86%E6%9D%A5%EF%BC%8C%E6%8C%87%E5%AF%BC%E4%BD%A0%E5%A6%82%E4%BD%95%E6%8C%A1%E7%81%BE%E8%BD%AC%E8%BF%90iOS"><span class="toc-number">1.3.6.</span> <span class="toc-text">准确预测你的现在和将来，指导你如何挡灾转运iOS</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%B4%AA%E9%93%9F%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%EF%BC%8C%E6%8F%90%E4%BE%9B%E4%BD%A0%E4%B8%80%E7%94%9F%E7%9A%84%E8%BF%90%E6%B0%94%E8%B6%8B%E5%8A%BF%E5%88%86%E6%9E%90iOS"><span class="toc-number">1.3.7.</span> <span class="toc-text">洪铟八字算命，提供你一生的运气趋势分析iOS</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%AE%89%E5%8D%93%E6%89%8B%E6%9C%BAiOS"><span class="toc-number">1.3.8.</span> <span class="toc-text">安卓手机iOS</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E7%81%B5%E6%9C%BA%E5%A6%99%E7%AE%97%E6%98%AF%E4%B8%80%E4%B8%AA%E6%B6%B5%E7%9B%96%E6%98%9F%E5%BA%A7%E3%80%81%E7%AD%BE%E5%8D%A6%E3%80%81%E5%85%AB%E5%AD%97%E3%80%81%E5%A1%94%E7%BD%97%E3%80%81%E7%94%9F%E8%82%96%E3%80%81%E8%BF%90%E5%8A%BF%E7%AD%89%E5%90%84%E7%A7%8D%E5%91%BD%E7%90%86%E5%92%8C%E5%A8%B1%E4%B9%90%E6%B5%8B%E7%AE%97%E7%9A%84%E7%9A%84%E7%BB%BC%E5%90%88%E5%9E%8B%E5%BA%94%E7%94%A8"><span class="toc-number">1.3.9.</span> <span class="toc-text">灵机妙算是一个涵盖星座、签卦、八字、塔罗、生肖、运势等各种命理和娱乐测算的的综合型应用</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%98%93%E5%A5%87%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%E5%A4%A7%E5%B8%88%EF%BC%8C%E7%AE%97%E7%AE%97%E4%BD%A0%E7%9A%84%E8%BF%90%E5%8A%BF"><span class="toc-number">1.3.10.</span> <span class="toc-text">易奇八字算命大师，算算你的运势</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%E5%85%8D%E8%B4%B9%E6%B5%8B%E5%85%AB%E5%AD%97%E6%B5%8B%E5%90%8D%E5%AD%97%EF%BC%8C%E7%94%9F%E8%BE%B0%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%E5%A9%9A%E5%A7%BB%E9%85%8D%E5%AF%B9%EF%BC%8C%E6%89%B9%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%E6%9C%80%E5%87%86%E7%9A%84%E7%94%9F%E8%BE%B0%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%E7%AD%89%E8%BF%99%E9%87%8C%E9%83%BD%E8%83%BD%E6%89%BE%E5%88%B0"><span class="toc-number">1.3.11.</span> <span class="toc-text">八字算命免费测八字测名字，生辰八字算命婚姻配对，批八字算命最准的生辰八字算命等这里都能找到</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%A5%87%E9%97%A8%E9%81%81%E7%94%B2%E6%8E%92%E7%9B%98%E8%BD%AF%E4%BB%B6%EF%BC%8C%E8%83%BD%E5%A4%9F%E5%B8%AE%E5%8A%A9%E5%AD%A6%E4%B9%A0%E5%A5%87%E9%97%A8%E9%81%81%E7%94%B2%E7%9A%84%E4%BA%BA%E5%AE%8C%E6%88%90%E6%8E%92%E7%9B%98%EF%BC%8C%E8%8A%82%E7%9C%81%E7%94%A8%E6%88%B7%E6%89%8B%E5%8A%A8%E6%8E%92%E7%9B%98%E7%9A%84%E6%97%B6%E9%97%B4iOS%E5%B0%8F%E7%A8%8B%E5%BA%8F"><span class="toc-number">1.3.12.</span> <span class="toc-text">奇门遁甲排盘软件，能够帮助学习奇门遁甲的人完成排盘，节省用户手动排盘的时间iOS小程序</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%85%AB%E5%AD%97%E7%AE%97%E5%91%BD%EF%BC%8C%E7%B4%AB%E5%BE%AE%E6%96%97%E6%95%B0%E7%94%9F%E8%BE%B0%E5%8D%A0%E5%8D%9C"><span class="toc-number">1.3.13.</span> <span class="toc-text">八字算命，紫微斗数生辰占卜</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%98%93%E7%A5%88%E5%91%A8%E6%98%93%E7%AE%97%E5%91%BD"><span class="toc-number">1.3.14.</span> <span class="toc-text">易祈周易算命</span></a></li></ol></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#%E4%BB%80%E4%B9%88%E7%AE%97%E5%91%BD%E8%BD%AF%E4%BB%B6%E5%87%86%EF%BC%9F8%E6%AC%BE%E6%89%8B%E6%9C%BA%E7%AE%97%E5%91%BD%E8%BD%AF%E4%BB%B6%E4%B8%8B%E8%BD%BD%E6%8E%A8%E8%8D%90"><span class="toc-number">2.</span> <span class="toc-text">什么算命软件准？8款手机算命软件下载推荐</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#%E4%B8%80%E3%80%81%E5%91%A8%E6%98%93%E7%AE%97%E5%91%BD%E5%AE%9D"><span class="toc-number">2.1.</span> <span class="toc-text">一、周易算命宝</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E4%BA%8C%E3%80%81%E7%B4%AB%E5%BE%AE%E6%96%97%E6%95%B0"><span class="toc-number">2.2.</span> <span class="toc-text">二、紫微斗数</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E4%B8%89%E3%80%81%E7%B4%AB%E5%BE%AE%E5%A4%A7%E5%B8%88%E6%98%9F%E5%BA%A7%E7%AE%97%E5%91%BD"><span class="toc-number">2.3.</span> <span class="toc-text">三、紫微大师星座算命</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E5%9B%9B%E3%80%81%E7%81%B5%E6%9C%BA%E5%A6%99%E7%AE%97"><span class="toc-number">2.4.</span> <span class="toc-text">四、灵机妙算</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E4%BA%94%E3%80%81%E7%81%B5%E6%9C%BA%E7%AE%97%E5%91%BD%E5%8D%A0%E5%8D%9C%E5%A4%A7%E5%B8%88"><span class="toc-number">2.5.</span> <span class="toc-text">五、灵机算命占卜大师</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E5%85%AD%E3%80%81%E7%AE%97%E5%91%BD%E5%85%AB%E5%AD%97%E9%A3%8E%E6%B0%B4%E7%BD%97%E7%9B%98"><span class="toc-number">2.6.</span> <span class="toc-text">六、算命八字风水罗盘</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E4%B8%83%E3%80%81%E7%AE%97%E5%91%BD%E5%85%AB%E5%AD%97%E8%BF%90%E7%A8%8B%E5%A4%A7%E5%B8%88"><span class="toc-number">2.7.</span> <span class="toc-text">七、算命八字运程大师</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E5%85%AB%E3%80%81%E7%A5%9E%E7%AE%97%E5%AE%9D%E5%85%B8"><span class="toc-number">2.8.</span> <span class="toc-text">八、神算宝典</span></a></li></ol></li></ol>
</div>

        <h1 id="手机算命软件排行榜"><a href="#手机算命软件排行榜" class="headerlink" title="手机算命软件排行榜"></a>手机算命软件排行榜</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/tag/suanming/">2021好用的手机算命软件排行榜前十名_手机算命app哪个好</a></li>
</ul>
<p>算命软件是集八字算命软件、姓名算命软件、周易算命软件、星座算命软件、风水算命软件等于一体的综合算命软件。手机安卓算命软件哪个好,算命软件哪个最准最全？历趣网悉心整理了手机安卓算命软件排行榜、免费算命软件手机版。历趣小编为大家推荐最流行的算命软件。</p>
<p><strong>相关合集推荐</strong><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/tag/suangua/">算卦</a><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/tag/zhanbu/">占卜</a><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/tag/jiemeng/">解梦</a></p>
<h2 id="1"><a href="#1" class="headerlink" title="1"></a><strong>1</strong></h2><p><img src="https://images.liqucn.com/mini/120x120/img/h19/h86/img_localize_826303edccd347f74f91db92238df272_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/992913.shtml">准了app</a><em>2021-04-08__生活 / 55.3MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/992913.shtml">下载</a></p>
<h3 id="深度星座预测平台iOS"><a href="#深度星座预测平台iOS" class="headerlink" title="深度星座预测平台iOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/992913.shtml">深度星座预测平台</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/992913.shtml">iOS</a></h3><h2 id="2"><a href="#2" class="headerlink" title="2"></a><strong>2</strong></h2><p><img src="https://images.liqucn.com/mini/120x120/img/h00/h67/img_localize_4fc7a16d0056b002dd6a10e296f54c8b_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/33164.shtml">灵占天下八字算命2021</a><em>2021-06-01__娱乐 / 100MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/33164.shtml">下载</a></p>
<h3 id="灵占天下（predictor），专业的占卜软件iOS"><a href="#灵占天下（predictor），专业的占卜软件iOS" class="headerlink" title="灵占天下（predictor），专业的占卜软件iOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/33164.shtml">灵占天下（predictor），专业的占卜软件</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/33164.shtml">iOS</a></h3><h2 id="3"><a href="#3" class="headerlink" title="3"></a><strong>3</strong></h2><p><img src="https://images.liqucn.com/mini/120x120/img/h08/h38/img_localize_22d0de76f8786e0cb3df2674171757cf_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/418953.shtml">紫微大师app</a><em>2021-05-15__生活 / 153MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/418953.shtml">下载</a></p>
<h3 id="紫微大师，运势揭秘，排盘、解盘iOS小程序"><a href="#紫微大师，运势揭秘，排盘、解盘iOS小程序" class="headerlink" title="紫微大师，运势揭秘，排盘、解盘iOS小程序"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/418953.shtml">紫微大师，运势揭秘，排盘、解盘</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/418953.shtml">iOS</a><a target="_blank" rel="noopener" href="https://os-mini.liqucn.com/rj/418953.shtml">小程序</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h13/h63/img_localize_afc0ffe9d506bff5fdfd1129f1b7dac5_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/681231.shtml">文墨天机紫微斗数app</a><em>2021-04-30__生活 / 21.4MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/681231.shtml">下载</a></li>
</ul>
<h3 id="文墨天机紫微斗数appiOS"><a href="#文墨天机紫微斗数appiOS" class="headerlink" title="文墨天机紫微斗数appiOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/681231.shtml">文墨天机紫微斗数app</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/681231.shtml">iOS</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h18/h60/img_localize_409751a109211a11bfb5b3eb509c7818_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/929802.shtml">帮帮测app官方</a><em>2021-01-23__生活 / 40.4MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/929802.shtml">下载</a></li>
</ul>
<h3 id="领先的周易命理咨询服务平台iOS"><a href="#领先的周易命理咨询服务平台iOS" class="headerlink" title="领先的周易命理咨询服务平台iOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/929802.shtml">领先的周易命理咨询服务平台</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/929802.shtml">iOS</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h09/h79/img_localize_736d49a12c962f1c4674f484b7a44b68_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/489433.shtml">灵机八字算命app</a><em>2021-03-22__生活 / 18.6MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/489433.shtml">下载</a></li>
</ul>
<h3 id="灵机八字算命app"><a href="#灵机八字算命app" class="headerlink" title="灵机八字算命app"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/489433.shtml">灵机八字算命app</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/h004/h79/img201112291739250_120x120.jpg"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/42380.shtml">1518占卜大师app</a><em>2019-05-17__娱乐 / 1.72MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/42380.shtml">下载</a></li>
</ul>
<p>一个手机占卜应用，解梦、测试，随时随地占卜测算,属于您的私人掌上神算子。</p>
<h3 id="占卜大师appiOS"><a href="#占卜大师appiOS" class="headerlink" title="占卜大师appiOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/42380.shtml">占卜大师app</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/42380.shtml">iOS</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h06/h57/img_localize_6b211ee3110d51bdc88be6e567eb7d46_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/328490.shtml">知命占卜</a><em>2021-02-22__生活 / 30.8MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/328490.shtml">下载</a></li>
</ul>
<h3 id="准确预测你的现在和将来，指导你如何挡灾转运iOS"><a href="#准确预测你的现在和将来，指导你如何挡灾转运iOS" class="headerlink" title="准确预测你的现在和将来，指导你如何挡灾转运iOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/328490.shtml">准确预测你的现在和将来，指导你如何挡灾转运</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/328490.shtml">iOS</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h10/h50/img_localize_a532939e66029cb7f28a2987e13a5eb0_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/524860.shtml">洪铟八字算命最新版</a><em>2021-05-08__娱乐 / 20.1MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/524860.shtml">下载</a></li>
</ul>
<h3 id="洪铟八字算命，提供你一生的运气趋势分析iOS"><a href="#洪铟八字算命，提供你一生的运气趋势分析iOS" class="headerlink" title="洪铟八字算命，提供你一生的运气趋势分析iOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/524860.shtml">洪铟八字算命，提供你一生的运气趋势分析</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/524860.shtml">iOS</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h14/h06/img_localize_8e3bd70fa56a8daf25177cd54019fbb3_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/702784.shtml">佛滔命理大师app</a><em>2020-04-22__生活 / 76.6MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/702784.shtml">下载</a></li>
</ul>
<h3 id="安卓手机iOS"><a href="#安卓手机iOS" class="headerlink" title="安卓手机iOS"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/702784.shtml">安卓手机</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/702784.shtml">iOS</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h00/h34/img_localize_dfe1ad7847bf8c4965637492d5d9efc9_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/16792.shtml">灵机妙算手机版免费</a><em>2021-05-12__娱乐 / 39.6MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/16792.shtml">下载</a></li>
</ul>
<h3 id="灵机妙算是一个涵盖星座、签卦、八字、塔罗、生肖、运势等各种命理和娱乐测算的的综合型应用"><a href="#灵机妙算是一个涵盖星座、签卦、八字、塔罗、生肖、运势等各种命理和娱乐测算的的综合型应用" class="headerlink" title="灵机妙算是一个涵盖星座、签卦、八字、塔罗、生肖、运势等各种命理和娱乐测算的的综合型应用"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/16792.shtml">灵机妙算是一个涵盖星座、签卦、八字、塔罗、生肖、运势等各种命理和娱乐测算的的综合型应用</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h10/h45/img_localize_d79df257cdebd644aed26c3d8629cf6c_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/522246.shtml">易奇八字算命大师</a><em>2021-05-17__娱乐 / 92.1MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/522246.shtml">下载</a></li>
</ul>
<h3 id="易奇八字算命大师，算算你的运势"><a href="#易奇八字算命大师，算算你的运势" class="headerlink" title="易奇八字算命大师，算算你的运势"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/522246.shtml">易奇八字算命大师，算算你的运势</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h19/h84/img_localize_191ee353def794e0e3af8e78b133de96_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/991874.shtml">八字算命大师app</a><em>2020-06-26__生活 / 9.96MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/991874.shtml">下载</a></li>
</ul>
<h3 id="八字算命免费测八字测名字，生辰八字算命婚姻配对，批八字算命最准的生辰八字算命等这里都能找到"><a href="#八字算命免费测八字测名字，生辰八字算命婚姻配对，批八字算命最准的生辰八字算命等这里都能找到" class="headerlink" title="八字算命免费测八字测名字，生辰八字算命婚姻配对，批八字算命最准的生辰八字算命等这里都能找到"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/991874.shtml">八字算命免费测八字测名字，生辰八字算命婚姻配对，批八字算命最准的生辰八字算命等这里都能找到</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h14/h24/img_localize_08e7243693b9ffb3d215764225cc5a02_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/711978.shtml">奇门遁甲排盘软件手机版</a><em>2020-11-04__生活 / 27.5MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/711978.shtml">下载</a></li>
</ul>
<h3 id="奇门遁甲排盘软件，能够帮助学习奇门遁甲的人完成排盘，节省用户手动排盘的时间iOS小程序"><a href="#奇门遁甲排盘软件，能够帮助学习奇门遁甲的人完成排盘，节省用户手动排盘的时间iOS小程序" class="headerlink" title="奇门遁甲排盘软件，能够帮助学习奇门遁甲的人完成排盘，节省用户手动排盘的时间iOS小程序"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/711978.shtml">奇门遁甲排盘软件，能够帮助学习奇门遁甲的人完成排盘，节省用户手动排盘的时间</a><a target="_blank" rel="noopener" href="https://os-ios.liqucn.com/rj/711978.shtml">iOS</a><a target="_blank" rel="noopener" href="https://os-mini.liqucn.com/rj/711978.shtml">小程序</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h10/h80/img_localize_156a64078275c2632bc516ebfd029303_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/539588.shtml">灵动紫微斗数</a><em>2021-06-01__娱乐 / 21.0MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/539588.shtml">下载</a></li>
</ul>
<h3 id="八字算命，紫微斗数生辰占卜"><a href="#八字算命，紫微斗数生辰占卜" class="headerlink" title="八字算命，紫微斗数生辰占卜"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/539588.shtml">八字算命，紫微斗数生辰占卜</a></h3><ul>
<li><img src="https://images.liqucn.com/mini/120x120/img/h20/h44/img_localize_d48ff134bff6bc2be66c1874a9b44556_512x512_120x120.png"><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/1021584.shtml">易祈周易算命</a><em>2020-01-15__生活 / 64.5MB</em><a target="_blank" rel="noopener" href="https://www.liqucn.com/rj/1021584.shtml">下载</a></li>
</ul>
<h3 id="易祈周易算命"><a href="#易祈周易算命" class="headerlink" title="易祈周易算命"></a><a target="_blank" rel="noopener" href="https://os-android.liqucn.com/rj/1021584.shtml">易祈周易算命</a></h3><h1 id="什么算命软件准？8款手机算命软件下载推荐"><a href="#什么算命软件准？8款手机算命软件下载推荐" class="headerlink" title="什么算命软件准？8款手机算命软件下载推荐"></a>什么算命软件准？8款手机算命软件下载推荐</h1><p>2018-03-16 15:20:26苏叶<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/" title="下载之家">下载之家</a></p>
<ul>
<li><a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/news/20180316/135924_all.html">什么算命软件准？8款手机算命软件下载推荐_软件评测_下载之家</a></li>
</ul>
<p>手机查看</p>
<p>新的一年到来，对喜欢算命的朋友来说，有的就想知道自己再2018年运势如何？当然，时代的进步，网上也是出现了各种各样的算命软件。那么，有朋友就在问小编：什么算命软件准？针对这个问题，小编今天就给大家带来几个手机算命软件，以供大家参考。</p>
<h2 id="一、周易算命宝"><a href="#一、周易算命宝" class="headerlink" title="一、周易算命宝"></a><strong>一、周易算命宝</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316034129963.png" alt="周易算命宝" title="周易算命宝"></p>
<p>周易算命宝</p>
<p>周易算命宝是一个为用户提供生辰八字算命，八字合婚测试以及周公解梦大全查询的APP。八字算命-提供八字命盘、五行分析、八字论命、爱情事业、财运健康查询。八字合婚-提供夫妻命宫、夫妻缘分以及双方的默契、相旺与子女同步查询。周公解梦-将原版周公解梦大全结合现代文字表述，附以案例分析让用户更加清晰了解梦境内外所关联的原因。</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/121354.html">周易算命宝安卓版</a></strong></p>
<h2 id="二、紫微斗数"><a href="#二、紫微斗数" class="headerlink" title="二、紫微斗数"></a><strong>二、紫微斗数</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316034105572.png" alt="紫微斗数" title="紫微斗数"></p>
<p>紫微斗数</p>
<p>紫微斗数app这是一款关于命理学紫薇都数的应用，紫微斗数app通过黄道12宫来对应每个人的每一种生命特质，紫微斗数app基于此来推算一个人命理，当然紫微斗数app这是一款免费的软件，信则灵，不信则不灵。</p>
<p><strong>软件介绍</strong></p>
<p>紫微斗数app港澳台著名影星江美仪鼎力推荐、着名玄爱本应用作为「灵机」品牌下的紫微斗数命理学代表，由大陆、香港和台湾多位专业紫微大师携手合作，致力打造最先进最准确的紫微排盘命理应用，是苹果市场上最专业最准确的测算类应用。</p>
<p>紫微斗数app是香港风水天后麦玲玲、香港风水命理人气王李丞责、香港着名玄学家陈定邦、香港大学进修学院玄学家何汉明、中国岭南地区着名风水命理大师何树荣、台湾面相改运第一人罗镇等众多命理界一级大师均表明对灵机的认可和支持！</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/94239.html">紫微斗数安卓版</a></strong></p>
<h2 id="三、紫微大师星座算命"><a href="#三、紫微大师星座算命" class="headerlink" title="三、紫微大师星座算命"></a><strong>三、紫微大师星座算命</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316034055762.png" alt="紫微大师星座算命" title="紫微大师星座算命"></p>
<p>紫微大师星座算命</p>
<p>不是所有人都有幸遇到紫微大师指点，每一秒一个用户加持中。你是下一个幸运儿？性格分析，心理测试，塔罗，生辰八字，星座算命，命理占卜，生肖配对，姓名日历，周易风水，求签六爻卦，相面手相，八卦易经综合预测第一平台。</p>
<p><strong>软件特色</strong></p>
<p>全球紫微斗数APP论命排名第一；</p>
<p>学习紫微斗数第一必备工具；</p>
<p>鼻祖传人30年首次公开单传秘笈算法；</p>
<p>大数据时代500万科学统计验证准确率100%；</p>
<p>宝典级婚恋、职场、商场、创富攻心神术；</p>
<p>100多个问题解盘人生百态事强大自我助梦成功；</p>
<p>铁断结婚、离婚、小三、创业、升迁、暴富、怀孕年份；</p>
<p>帮您30岁前知天命带着棋谱下棋绝杀 九大版块；</p>
<p>命盘：运用销量第一的紫微排盘王app帮你专业排出命盘；</p>
<p>解盘：40多个问题宫位对应一一帮你全局分析一生；</p>
<p>紫微占卜：80多个问题帮你占卜流年、流月、流日遇事的各种问题；</p>
<p>运势解码：根据独家创世能量体系每年、每月、每日能量运势一目了然吉凶可见；</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/95735.html">紫微大师星座算命安卓版</a></strong></p>
<h2 id="四、灵机妙算"><a href="#四、灵机妙算" class="headerlink" title="四、灵机妙算"></a><strong>四、灵机妙算</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316034038154.png" alt="灵机妙算" title="灵机妙算"></p>
<p>灵机妙算</p>
<p>灵机妙算为你解读流年运程，流月运程，生肖运程，八字命理，提供最专业精准的性格分析、事业分析、健康分析、婚恋分析助你新的一年万事如意。还有著名易学导师撰写的转运方法，命运的走势有其自身的规律，只要掌握规律，命运就会转变。最专业精准的周易、八字、紫微斗数指导人生规则，星座运程提供每天十二星座运程信息。</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/62371.html">灵机妙算安卓版</a></strong></p>
<h2 id="五、灵机算命占卜大师"><a href="#五、灵机算命占卜大师" class="headerlink" title="五、灵机算命占卜大师"></a><strong>五、灵机算命占卜大师</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316033913824.png" alt="灵机算命占卜大师" title="灵机算命占卜大师"></p>
<p>灵机算命占卜大师</p>
<p>灵机算命占卜大师预测，事业、财运、学业、健康、拜访、占一卦知进退，万事如愿以偿。别感叹命运不公，知命，改运有秘诀！今日运势如何？未来的婚姻如何？财运如何？适合买吗？股票会不会涨？何时买房子？事业进展？彷徨，迷茫，犹豫，人生十字路口，如何抉择？尽在灵机算命占卜大师！</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/124167.html">灵机算命占卜大师安卓版</a></strong></p>
<h2 id="六、算命八字风水罗盘"><a href="#六、算命八字风水罗盘" class="headerlink" title="六、算命八字风水罗盘"></a><strong>六、算命八字风水罗盘</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316033904268.png" alt="算命八字风水罗盘" title="算命八字风水罗盘"></p>
<p>算命八字风水罗盘</p>
<p>八字排盘是中国人民传统文化的结晶，经历几千年的岁月而沉淀下来，具有丰富的科学理论，是经过科学鉴证的解说命理工具。八字排盘提供算命，为您通晓未来，让你为接下来的未来做好充分的准备。</p>
<p><strong>功能介绍</strong></p>
<p>1、八字算命：命理老师亲自指导，看排盘，周易占卜测算，为您专业提供命理信息；<br>2、运程分析：大运年表、流年运程为您分析一生运程起伏，流年趋吉避凶。十神、命宫详解让您知晓先天运势、命运的主轴、行运的源头。<br>3、婚恋配对：看桃花，定姻缘，帮你找到身边的那个TA；<br>4、命主分析：性格、事业、星座分析全面独到，预测您人生的贫贱富贵，让您更了解自己。<br>5、健康养生：提供养生要点，为您调整饮食和生活起居，助您保持健康。 在搜索查找播放器，聊天，漫画，导航，新闻，阅读，FM，天气，无秘，宝宝助手，微代驾，双色球，妈妈帮，辣妈帮，周公解梦的应用，还不如解开自己八字秘密。</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/105258.html">算命八字风水罗盘安卓版</a></strong></p>
<h2 id="七、算命八字运程大师"><a href="#七、算命八字运程大师" class="headerlink" title="七、算命八字运程大师"></a><strong>七、算命八字运程大师</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316033830475.png" alt="算命八字运程大师" title="算命八字运程大师"></p>
<p>算命八字运程大师</p>
<p>算命八字运程大师是一款专业的八字算命占卜应用，从八字剖析运势发展！</p>
<p><strong>应用特色：</strong></p>
<p>1 八字算命：全面测算一个人的八字命盘，姻缘桃花，手相算命，事业财富。<br>2 八字婚姻：按生辰八字来算命，按脸相手相算命，姻缘测算。<br>3 星座运势：十二星座运程每周更新，星座每日运势，每周运势，每月运势。<br>4 风水占卜：通过周易风水占卜，提供占卜参考。</p>
<p><strong>下载地址：<a target="_blank" rel="noopener" href="https://www.xiazaizhijia.com/shouji/124542.html">算命八字运程大师安卓版</a></strong></p>
<h2 id="八、神算宝典"><a href="#八、神算宝典" class="headerlink" title="八、神算宝典"></a><strong>八、神算宝典</strong></h2><p><img src="https://img.xiazaizhijia.com/uploads/2018/0316/20180316033735625.png" alt="神算宝典" title="神算宝典"></p>
<p>神算宝典</p>
<p>神算宝典app是一款极具中国风特色的真人在线预测应用，神算宝典app从浩如烟海的易学典籍中去伪存真，依托几千年来无数前贤继承发展的易经文化及其他预测方法，实现在易学专家的指导下，使人能够做到预知祸福，趋利避害。</p>
<p><strong>功能介绍</strong></p>
<p>1.神算解卦：多位大师为您解卦，并指引明路，从此富贵贫贱不再神秘，吉凶祸福不必烦恼。<br>2.运势锦囊：运势缥缈无踪迹，一道谜题破玄机。打开锦囊将获得一道谜题，参透谜题可了解近期个人运势，趋吉避凶。<br>3.合姻生肖：查看三个隐藏在卡牌中的生肖，配对您的最佳伴侣，开启一世美好姻缘！<br>4.周公解梦：用周易卜卦的方法，推算此阶段的旺衰状态，推定梦象的吉凶，旺者吉，衰者凶，你属于哪种呢？<br>5.天机测算：掐指一算天机现，所求何事，让诸葛丞相为您卜一卦，祝您事事顺风顺水！<br>6.婚恋吉日：做事挑个好日子，百事吉利，万事如意。</p>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
	<div class="article-tag tagcloud">
		<i class="icon-price-tags icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color3">算命</a>
        		</li>
      		
		</ul>
	</div>

      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/06/01/20210601/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210531" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/31/20210531/">20210531</a>
    </h1>
  

        
        <a href="/2021/05/31/20210531/" class="archive-article-date">
  	<time datetime="2021-05-30T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210531</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br></pre></td><td class="code"><pre><span class="line"># BigData work frame</span><br><span class="line">i&#x3D;&#39;&#x2F;media&#x2F;ht&#x2F;ht_5T&#x2F;Work&#x2F;Funding&#x2F;2017_重大专项&#x2F;Management&#x2F;BigData_Frame.xlsx&#39;; setsid et $&#123;i&#125;</span><br><span class="line">#</span><br><span class="line">cd &#x2F;media&#x2F;ht&#x2F;ht_5T&#x2F;Work&#x2F;Funding&#x2F;2017_重大专项&#x2F;Management</span><br><span class="line">rm BigData_Frame.xlsx</span><br><span class="line">ln -s BigData_Frame_20210425_1305.xlsx BigData_Frame.xlsx</span><br></pre></td></tr></table></figure>
      

      
    </div>
    <div class="article-info article-info-index">
      
      
      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/31/20210531/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210530" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/30/20210530/">20210530</a>
    </h1>
  

        
        <a href="/2021/05/30/20210530/" class="archive-article-date">
  	<time datetime="2021-05-29T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210530</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#%E5%8D%81%E5%9B%9B%E4%BA%94%E6%8C%87%E5%8D%97"><span class="toc-number">2.</span> <span class="toc-text">十四五指南</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#%E6%96%87%E4%BB%B6%E5%8F%91%E5%B8%83%E6%B5%81%E7%A8%8B"><span class="toc-number">2.1.</span> <span class="toc-text">文件发布流程</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Downloaded-guidances"><span class="toc-number">2.2.</span> <span class="toc-text">Downloaded guidances</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%BE%81%E6%B1%82%E6%84%8F%E8%A7%81%E7%A8%BF"><span class="toc-number">2.2.1.</span> <span class="toc-text">征求意见稿</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%AD%A3%E5%BC%8F%E6%8C%87%E5%8D%97"><span class="toc-number">2.2.2.</span> <span class="toc-text">正式指南</span></a></li></ol></li></ol></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><h1 id="十四五指南"><a href="#十四五指南" class="headerlink" title="十四五指南"></a>十四五指南</h1><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">cd &#x2F;media&#x2F;ht&#x2F;ht_5T&#x2F;Work&#x2F;Funding&#x2F;2021_十四五&#x2F;Guidances&#x2F;MOST # 李颖下载</span><br></pre></td></tr></table></figure>

<h2 id="文件发布流程"><a href="#文件发布流程" class="headerlink" title="文件发布流程"></a>文件发布流程</h2><ul>
<li><a target="_blank" rel="noopener" href="https://www.scimall.org.cn/article/detail?id=5518489">国家重点研发计划“生物安全关键技术研究”重点专项2021年度项目申报指南 学术资讯 - 科技工作者之家</a></li>
<li><a target="_blank" rel="noopener" href="https://service.most.gov.cn/kjjh_tztg_all/20210517/4308.html">国家科技管理信息系统公共服务平台</a></li>
</ul>
<ol>
<li>以【科技部关于发布国家重点研发计划“农业生物重要性状形成与环境适应性基础研究”等“十四五”重点专项2021年度项目申报指南的通知】为例。发布文件编号为：国科发资〔2021〕140号</li>
<li>以上文件包含以下指南的发布<ul>
<li>“农业生物重要性状形成与环境适应性基础研究”重点专项咨询电话：010-68598087</li>
<li>“农业生物种质资源挖掘与创新利用”重点专项咨询电话：010-68598087</li>
<li>“北方干旱半干旱与南方红黄壤等中低产田能力提升科技创新”重点专项咨询电话：010-59199375</li>
<li>“黑土地保护与利用科技创新”重点专项咨询电话：010-68598074</li>
<li>“农业面源、重金属污染防控和绿色投入品研发”重点专项咨询电话：010-59199368</li>
<li>“重大病虫害防控综合技术研发与示范”重点专项咨询电话：010-59199380</li>
<li>“畜禽新品种培育与现代牧场科技创新”重点专项咨询电话：010-68598497</li>
<li>“动物疫病综合防控关键技术研发与应用”重点专项咨询电话：010-59199381</li>
<li>“林业种质资源培育与质量提升”重点专项咨询电话：010-68598076</li>
<li>“工厂化农业关键技术与智能农机装备”重点专项咨询电话：010-68511832</li>
<li>“食品制造与农产品物流科技支撑”重点专项咨询电话：010-68510207</li>
<li>“乡村产业共性关键技术研发与集成应用”重点专项咨询电话：010-68598200</li>
</ul>
</li>
</ol>
<h2 id="Downloaded-guidances"><a href="#Downloaded-guidances" class="headerlink" title="Downloaded guidances"></a>Downloaded guidances</h2><h3 id="征求意见稿"><a href="#征求意见稿" class="headerlink" title="征求意见稿"></a>征求意见稿</h3><ul>
<li>05-生物安全关键技术研究.pdf</li>
<li>06-病原学与防疫技术体系研究.pdf</li>
<li>07-常见多发病防治研究.pdf</li>
<li>08-诊疗装备与生物医用材料.pdf</li>
<li>09-生育健康及妇女儿童健康保障.pdf</li>
<li>10-生物与信息融合_BT与IT融合_ht.pdf</li>
<li>十四五指南_Sum.pdf</li>
</ul>
<h3 id="正式指南"><a href="#正式指南" class="headerlink" title="正式指南"></a>正式指南</h3><ul>
<li>1_病原学与防疫技术体系研究.pdf</li>
<li>2_常见多发病防治研究.pdf</li>
<li>3_干细胞研究与器官修复.pdf</li>
<li>4_生物安全关键技术研究.pdf</li>
<li>5_生物大分子与微生物组.pdf</li>
<li>6_生育健康及妇女儿童健康保障.pdf</li>
</ul>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/30/20210530/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210527" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/27/20210527/">20210527</a>
    </h1>
  

        
        <a href="/2021/05/27/20210527/" class="archive-article-date">
  	<time datetime="2021-05-26T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210527</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#%E5%B1%B1%E8%A5%BF%E7%96%BE%E6%8E%A7"><span class="toc-number">2.</span> <span class="toc-text">山西疾控</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#%E5%AE%A1%E8%AE%A1"><span class="toc-number">3.</span> <span class="toc-text">审计</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Antibody-Purification"><span class="toc-number">4.</span> <span class="toc-text">Antibody Purification</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#HHOV"><span class="toc-number">5.</span> <span class="toc-text">HHOV</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Water-Quality-101-What-Is-ORP-in-Water-Testing"><span class="toc-number">6.</span> <span class="toc-text">Water Quality 101: What Is ORP in Water Testing?</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#What-Is-Oxidation-Reduction-Potential-ORP"><span class="toc-number">6.1.</span> <span class="toc-text">What Is Oxidation Reduction Potential (ORP)?</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Oxidation-and-Reduction-Basics"><span class="toc-number">6.2.</span> <span class="toc-text">Oxidation and Reduction Basics</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Why-ORP-Readings-Are-Important-to-Water-Testing"><span class="toc-number">6.3.</span> <span class="toc-text">Why ORP Readings Are Important to Water Testing</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Common-Uses-for-ORP-Meters"><span class="toc-number">6.4.</span> <span class="toc-text">Common Uses for ORP Meters</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Adjusting-ORP-Levels"><span class="toc-number">6.5.</span> <span class="toc-text">Adjusting ORP Levels</span></a></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Antibody-purification"><span class="toc-number">7.</span> <span class="toc-text">Antibody purification</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Ab-purification"><span class="toc-number">7.1.</span> <span class="toc-text">Ab purification</span></a></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Shortcut-key-to-open-terminal-in-macos"><span class="toc-number">8.</span> <span class="toc-text">Shortcut key to open terminal in macos</span></a></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><h1 id="山西疾控"><a href="#山西疾控" class="headerlink" title="山西疾控"></a>山西疾控</h1><ul>
<li>自评</li>
<li>预算执行<ul>
<li>财务科代表</li>
</ul>
</li>
</ul>
<h1 id="审计"><a href="#审计" class="headerlink" title="审计"></a>审计</h1><p>票据打印，个别需要封面</p>
<h1 id="Antibody-Purification"><a href="#Antibody-Purification" class="headerlink" title="Antibody Purification"></a>Antibody Purification</h1><p><a target="_blank" rel="noopener" href="https://m.ebiotrade.com/newsf/2020-9/2020918102849449.htm">https://m.ebiotrade.com/newsf/2020-9/2020918102849449.htm</a><br><a target="_blank" rel="noopener" href="http://www.detaibio.com/topics/antibody-purifications/chromatography-methods.html">http://www.detaibio.com/topics/antibody-purifications/chromatography-methods.html</a><br><a target="_blank" rel="noopener" href="http://blog.sciencenet.cn/blog-454912-713842.html">http://blog.sciencenet.cn/blog-454912-713842.html</a></p>
<figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">setsid chromium-browser \</span><br><span class="line">https:&#x2F;&#x2F;m.ebiotrade.com&#x2F;newsf&#x2F;2020-9&#x2F;2020918102849449.htm http:&#x2F;&#x2F;www.detaibio.com&#x2F;topics&#x2F;antibody-purifications&#x2F;chromatography-methods.html http:&#x2F;&#x2F;blog.sciencenet.cn&#x2F;blog-454912-713842.html</span><br></pre></td></tr></table></figure>
<hr>
<ul>
<li><p>抗体指南<br><a target="_blank" rel="noopener" href="https://zhuanlan.zhihu.com/p/211454883">https://zhuanlan.zhihu.com/p/211454883</a></p>
</li>
<li><p>抗体厂家<br><a target="_blank" rel="noopener" href="https://m.sohu.com/a/212097589_99982681/?pvid=000115_3w_a">https://m.sohu.com/a/212097589_99982681/?pvid=000115_3w_a</a></p>
</li>
</ul>
<h1 id="HHOV"><a href="#HHOV" class="headerlink" title="HHOV"></a>HHOV</h1><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">setsid chromium-browser \</span><br><span class="line">https:&#x2F;&#x2F;anrcatalog.ucanr.edu&#x2F;pdf&#x2F;8149.pdf https:&#x2F;&#x2F;blog.jencoi.com&#x2F;what-is-orp-in-water-testing https:&#x2F;&#x2F;www.who.int&#x2F;water_sanitation_health&#x2F;dwq&#x2F;gdwq0506.pdf</span><br></pre></td></tr></table></figure>
<ul>
<li><a target="_blank" rel="noopener" href="https://anrcatalog.ucanr.edu/pdf/8149.pdf">Oxidation-Reduction Potential (ORP) for Water Disinfection Monitoring, Control, and Documentation</a></li>
<li><a target="_blank" rel="noopener" href="https://blog.jencoi.com/what-is-orp-in-water-testing">Water Quality 101: What Is ORP in Water Testing?</a></li>
<li><a target="_blank" rel="noopener" href="https://www.who.int/water_sanitation_health/dwq/gdwq0506.pdf">GDWPR</a></li>
</ul>
<h1 id="Water-Quality-101-What-Is-ORP-in-Water-Testing"><a href="#Water-Quality-101-What-Is-ORP-in-Water-Testing" class="headerlink" title="Water Quality 101: What Is ORP in Water Testing?"></a>Water Quality 101: What Is ORP in Water Testing?</h1><p>October 4, 2018 | By<a target="_blank" rel="noopener" href="https://blog.jencoi.com/author/meryl-kremer">Meryl Kremer</a>|<a target="_blank" rel="noopener" href="https://blog.jencoi.com/topic/orp">ORP</a></p>
<p><img src="https://blog.jencoi.com/hs-fs/hubfs/standing_by_pool.jpg?width=600&name=standing_by_pool.jpg" alt="ORP | Jenco Instruments"></p>
<p>You may have heard of ORP, but what does it mean and what role does it play in water-quality testing? We’ve laid out the basics of ORP to help you get up to speed.</p>
<p>Also check out our deep dive into ORP’s role in water contamination in<a target="_blank" rel="noopener" href="https://blog.jencoi.com/orps-role-in-water-contamination">this post</a>, and<a target="_blank" rel="noopener" href="https://blog.jencoi.com/what-is-ph-in-water-testing">Water Quality 101: What is pH in Water Testing</a>.</p>
<h2 id="What-Is-Oxidation-Reduction-Potential-ORP"><a href="#What-Is-Oxidation-Reduction-Potential-ORP" class="headerlink" title="What Is Oxidation Reduction Potential (ORP)?"></a>What Is Oxidation Reduction Potential (ORP)?</h2><p>Oxidation reduction potential, or ORP, is a measure of a substance’s ability to either oxidize or reduce another substance. It is measured by the electrodes of an ORP meter. A positive reading on an ORP meter means that the substance is an oxidizing agent; a negative reading indicates that the substance is a reducing agent.  </p>
<h2 id="Oxidation-and-Reduction-Basics"><a href="#Oxidation-and-Reduction-Basics" class="headerlink" title="Oxidation and Reduction Basics"></a>Oxidation and Reduction Basics</h2><p>If a substance doesn’t have enough electrons, it will actively attempt to acquire them through the process of oxidation—a chemical reaction in which one agent is oxidized (i.e., loses electrons to another agent). Because substances with positive ORP readings are looking to acquire electrons, they are considered oxidizing agents.</p>
<p>On the other hand, electrons that have a surplus of ions can afford to lose ions to oxidizing agents without becoming destabilized themselves. For this reason, they are referred to as antioxidizing agents, or reducing agents. The higher or lower an ORP reading (positive or negative), the more oxidizing or antioxidizing a substance is, respectively.  </p>
<h2 id="Why-ORP-Readings-Are-Important-to-Water-Testing"><a href="#Why-ORP-Readings-Are-Important-to-Water-Testing" class="headerlink" title="Why ORP Readings Are Important to Water Testing"></a>Why ORP Readings Are Important to Water Testing</h2><p>ORP is integral to water testing because it indicates how sanitized or contaminated water is based on its oxidation and reduction properties. In order to be safe to consume, recycle, or come in contact with our skin, water is treated with a sanitizing agent to have a higher oxidation potential, producing a higher ORP reading. By routinely monitoring ORP levels, it’s possible to monitor the effectiveness of a sanitizing agent and adjust your water treatment plan accordingly.  </p>
<h2 id="Common-Uses-for-ORP-Meters"><a href="#Common-Uses-for-ORP-Meters" class="headerlink" title="Common Uses for ORP Meters"></a>Common Uses for ORP Meters</h2><p>There are many reasons why someone would be interested in knowing the ORP of a substance. Perhaps the most common application is water-quality testing of chlorinated swimming pools. Because a substance’s ORP is affected by all agents that are present in the substance, an ORP measurement is considered more informative than a  pH reading alone, which only recognizes acids (hydrogen ions) and bases (hydroxide ions). Larger pools will often have inline ORP sensors, whereas backyard pools that lack built-in monitors may require testing with a portable ORP monitor.</p>
<p>When you add chlorine to a pool, the chlorine gives up its own electron surplus to neutralize or oxidize potentially harmful bacteria. Active chlorine electrons increase the ORP level of the water, thus neutralizing contaminants. For chlorinated pools and spas, a safe ORP reading is usually between 650 millivolts (mV) and 750 mV. As time passes and chlorine breaks down and loses its oxidation potential, the overall ORP reading for the water gradually decreases. Although ORP levels typically correlate with the ratio of sanitizer in the water, ORP does not measure sanitizer levels; rather, it measures the net oxidation and reduction properties of all agents present.</p>
<p>In addition to being used to monitor water quality in chlorinated pools, ORP meters are widely used in the food processing and water treatment industries to ensure that water is free of contaminants and safe to recycle or consume. Bottled water or tap water that is contaminant-free will have a positive ORP value.  </p>
<h2 id="Adjusting-ORP-Levels"><a href="#Adjusting-ORP-Levels" class="headerlink" title="Adjusting ORP Levels"></a>Adjusting ORP Levels</h2><p>When it comes to swimming pools, ORP levels can usually be adjusted by adding more active chlorine to the water to boost its antioxidizing potential.  More sophisticated water purification systems may involve a more complex balancing of total dissolved solids (TDS) in water to achieve a more favorable oxidation reduction potential.</p>
<p>For more information about how to interpret ORP readings and use ORP meters, research your chosen ORP meters and its unique features.</p>
<p>Interested in purchasing a mobile or inline ORP meters? Click the button below to learn about different models and features and find a distributor.</p>
<h1 id="Antibody-purification"><a href="#Antibody-purification" class="headerlink" title="Antibody purification"></a>Antibody purification</h1><p>keyword, antibody purification  </p>
<p><a target="_blank" rel="noopener" href="https://patents.google.com/patent/KR101243425B1/en?q=antibody%20purification&oq=antibody%20purification&authuser=0">https://patents.google.com/patent/KR101243425B1/en?q=antibody+purification&amp;oq=antibody+purification</a><br>KR101243425B1</p>
<h2 id="Ab-purification"><a href="#Ab-purification" class="headerlink" title="Ab purification"></a>Ab purification</h2><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">setsid chromium-browser \</span><br><span class="line">https:&#x2F;&#x2F;m.ebiotrade.com&#x2F;newsf&#x2F;2020-9&#x2F;2020918102849449.htm http:&#x2F;&#x2F;www.detaibio.com&#x2F;topics&#x2F;antibody-purifications&#x2F;chromatography-methods.html http:&#x2F;&#x2F;blog.sciencenet.cn&#x2F;blog-454912-713842.html</span><br></pre></td></tr></table></figure>
<hr>
<ul>
<li><p>抗体指南<br><a target="_blank" rel="noopener" href="https://zhuanlan.zhihu.com/p/211454883">https://zhuanlan.zhihu.com/p/211454883</a></p>
</li>
<li><p>抗体厂家<br><a target="_blank" rel="noopener" href="https://m.sohu.com/a/212097589_99982681/?pvid=000115_3w_a">https://m.sohu.com/a/212097589_99982681/?pvid=000115_3w_a</a></p>
</li>
</ul>
<h1 id="Shortcut-key-to-open-terminal-in-macos"><a href="#Shortcut-key-to-open-terminal-in-macos" class="headerlink" title="Shortcut key to open terminal in macos"></a>Shortcut key to open terminal in macos</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.idownloadblog.com/2019/04/19/ways-open-terminal-mac/">7 simple ways to open Terminal on Mac</a></li>
<li><a target="_blank" rel="noopener" href="https://stackoverflow.com/questions/35954184/is-there-a-keyboard-shortcut-hotkey-to-open-terminal-in-macos">Is there a keyboard shortcut (hotkey) to open Terminal in macOS? - Stack Overflow</a></li>
<li><a target="_blank" rel="noopener" href="https://apple.stackexchange.com/questions/256259/how-to-open-terminal-in-mac-using-keyboard-shortcut">macos - How to open terminal in Mac using keyboard shortcut? - Ask Different</a></li>
<li><a target="_blank" rel="noopener" href="https://www.howtogeek.com/210147/how-to-open-terminal-in-the-current-os-x-finder-location/#:~:text=In%20our%20case%2C%20when%20we,open%20a%20new%20Terminal%20window.">How to Open Terminal in the Current OS X Finder Location</a></li>
</ul>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
	<div class="article-tag tagcloud">
		<i class="icon-price-tags icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color5">山西疾控</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color3">审计</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color2">Antibody Purification</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color1">Water</a>
        		</li>
      		
		</ul>
	</div>

      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/27/20210527/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210520" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/20/20210520/">20210520</a>
    </h1>
  

        
        <a href="/2021/05/20/20210520/" class="archive-article-date">
  	<time datetime="2021-05-19T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210520</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#VPN"><span class="toc-number">2.</span> <span class="toc-text">VPN</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Getting-Started-Qv2ray"><span class="toc-number">3.</span> <span class="toc-text">Getting Started | Qv2ray</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#ClinicalTrials-gov"><span class="toc-number">4.</span> <span class="toc-text">ClinicalTrials.gov</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Glossary-of-Common-Site-Terms"><span class="toc-number">4.1.</span> <span class="toc-text">Glossary of Common Site Terms</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Downloading-Content-for-Analysis-ClinicalTrials-gov"><span class="toc-number">4.2.</span> <span class="toc-text">Downloading Content for Analysis - ClinicalTrials.gov</span></a></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Web-Log"><span class="toc-number">5.</span> <span class="toc-text">Web Log</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Search-of-COVID-19-List-Results-ClinicalTrials-gov"><span class="toc-number">5.1.</span> <span class="toc-text">Search of: COVID-19 - List Results - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#URL-in-mermaid"><span class="toc-number">5.2.</span> <span class="toc-text">URL in mermaid</span></a></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Download"><span class="toc-number">6.</span> <span class="toc-text">Download</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#HIV-treatment"><span class="toc-number">7.</span> <span class="toc-text">HIV treatment</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Selected-clinical-trials"><span class="toc-number">7.1.</span> <span class="toc-text">Selected clinical trials</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#Early-and-Intermittent-Antiretroviral-Therapy-in-Naive-HIV-Infected-Adults-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.1.</span> <span class="toc-text">Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults - Full Text View - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Effectiveness-of-Antiretroviral-Therapy-During-Acute-HIV-Infection-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.2.</span> <span class="toc-text">Effectiveness of Antiretroviral Therapy During Acute HIV Infection - Full Text View - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Study-to-Evaluate-the-Activity-and-Tolerability-of-Lopinavir-Ritonavir-and-Lamivudine-Bitherapy-in-HIV-Patients-With-Viral-Suppression-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.3.</span> <span class="toc-text">Study to Evaluate the Activity and Tolerability of Lopinavir&#x2F;Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression - Full Text View - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Research-on-Effect-of-Traditional-Chinese-Medicine-TCM-on-Immune-Reconstitution-of-HIV-AIDS-Patients-After-Highly-Active-Antiretroviral-Therapy-HAART-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.4.</span> <span class="toc-text">Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV&#x2F;AIDS Patients After Highly Active Antiretroviral Therapy (HAART) - Full Text View - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#The-Effect-of-Combination-of-Traditional-Chinese-Medicine-TCM-and-Highly-Active-Antiretroviral-Therapy-HAART-on-Immune-Reconstitution-of-HIV-AIDS-Patients-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.5.</span> <span class="toc-text">The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV&#x2F;AIDS Patients - Full Text View - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Lactoferrin-Treatment-in-HIV-Patients-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.6.</span> <span class="toc-text">Lactoferrin Treatment in HIV Patients - Full Text View - ClinicalTrials.gov</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#New-Era-Study-Treatment-With-Multi-Drug-Class-MDC-HAART-in-HIV-Infected-Patients-Full-Text-View-ClinicalTrials-gov"><span class="toc-number">7.1.7.</span> <span class="toc-text">New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients - Full Text View - ClinicalTrials.gov</span></a></li></ol></li></ol></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br></pre></td><td class="code"><pre><span class="line">TZ&#x3D;GMT date -d &#39;2017-01-29 08:58:09 CST&#39; +&#39;%F %T %Z&#39;</span><br><span class="line">#</span><br><span class="line">i&#x3D;&#39;2021-05-20T17:53:06.658Z&#39;</span><br><span class="line">i&#x3D;&#39;2021-05-20 17:53:06.658&#39;</span><br><span class="line">TZ&#x3D;&#39;Asia&#x2F;Shanghai&#39; date -d &#39;2021-05-20 18:22:06.658 GMT&#39; +&#39;%F %T %Z&#39; # 0222</span><br><span class="line">TZ&#x3D;&#39;Asia&#x2F;Shanghai&#39; date -d &#39;2021-05-20 18:22:06.658 GMT&#39; +&#39;%F %H:%M:%S.%N %Z&#39; # 0222</span><br><span class="line">TZ&#x3D;&#39;Asia&#x2F;Shanghai&#39; date -d &#39;2021-05-20 18:22:06.658 GMT&#39; +&#39;%F %H:%M:%S.%3N %Z&#39; # 0222</span><br><span class="line">date -d &#39;2021-05-20 18:22:06.658 GMT&#39; +&#39;%F %H:%M:%S.%3N %Z&#39; TZ&#x3D;&#39;Asia&#x2F;Shanghai&#39; # 0222</span><br><span class="line">#</span><br><span class="line">TZ&#x3D;GMT date -d $&#123;i&#125; &#39;CST&#39; +&#39;%F %T %Z&#39;</span><br><span class="line">date +&quot;%Z %z&quot;</span><br><span class="line">#</span><br><span class="line">cut -d&quot;,&quot; -f2- </span><br><span class="line">cat 2.csv | cut -d&quot;Z&quot; -f2- &gt; Data.csv</span><br></pre></td></tr></table></figure>
<h1 id="VPN"><a href="#VPN" class="headerlink" title="VPN"></a>VPN</h1><ul>
<li><a target="_blank" rel="noopener" href="https://free-ss.site/">免费上网账号</a></li>
<li><a target="_blank" rel="noopener" href="https://m.ssrtool.us/free_ssr">SSCAP/SSTAP 小工具/SSR/SS/V2Ray/Vmess/Socks5免费账号</a></li>
</ul>
<h1 id="Getting-Started-Qv2ray"><a href="#Getting-Started-Qv2ray" class="headerlink" title="Getting Started | Qv2ray"></a><a target="_blank" rel="noopener" href="https://qv2ray.net/getting-started/">Getting Started | Qv2ray</a></h1><ul>
<li><a target="_blank" rel="noopener" href="https://github.com/Qv2ray/Qv2ray">GitHub - Qv2ray/Qv2ray: Linux / Windows / macOS 跨平台 V2Ray 客户端 | 支持 VMess / VLESS / SSR / Trojan / Trojan-Go / NaiveProxy / HTTP / HTTPS / SOCKS5 | 使用 C++ / Qt 开发 | 可拓展插件式设计</a></li>
<li><a target="_blank" rel="noopener" href="https://www.v2fly.org/guide/install.html#%E5%B9%B3%E5%8F%B0%E6%94%AF%E6%8C%81">下载安装 | V2Fly.org</a></li>
<li><a target="_blank" rel="noopener" href="https://github.com/v2fly/v2ray-core">GitHub - v2fly/v2ray-core: A platform for building proxies to bypass network restrictions.</a>, Core</li>
<li><a target="_blank" rel="noopener" href="https://github.com/v2fly/v2ray-core/releases">Releases · v2fly/v2ray-core · GitHub</a>, Core</li>
</ul>
<figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br></pre></td><td class="code"><pre><span class="line"># QV2Ray</span><br><span class="line">#</span><br><span class="line">sudo apt install gnupg ca-certificates curl</span><br><span class="line">sudo apt update; sudo apt install qv2ray</span><br><span class="line">#</span><br><span class="line">flatpak install flathub com.github.Qv2ray</span><br><span class="line">flatpak run com.github.Qv2ray # run</span><br><span class="line"></span><br></pre></td></tr></table></figure>

<ul>
<li><a target="_blank" rel="noopener" href="https://merlinblog.xyz/wiki/freess.html">免费节点 | SS / SSR / V2Ray 节点分享 - Sabrina的万事屋</a>, 免费订阅</li>
<li><a target="_blank" rel="noopener" href="https://www.facebook.com/groups/139561307215714/">免费翻墙,vpn,ssr,V2ray,免费ss节点订阅,翻墙技术研究中心</a></li>
<li><a target="_blank" rel="noopener" href="https://sites.google.com/site/ssrandv2rayandss/zui-xin-mian-fei-shou-feiv2ray-ding-yue-de-zhi">最新免费收费v2ray订阅地址</a></li>
<li><a target="_blank" rel="noopener" href="https://raw.githubusercontent.com/ssrsub/ssr/master/v2ray">https://raw.githubusercontent.com/ssrsub/ssr/master/v2ray</a></li>
<li><a target="_blank" rel="noopener" href="https://qv2ray.net/lang/zh/getting-started/step3.html#%E5%88%86%E4%BA%AB%E9%93%BE%E6%8E%A5">导入节点到 Qv2ray | Qv2ray</a></li>
<li><a target="_blank" rel="noopener" href="https://appimage.github.io/Qv2ray/">Qv2ray – AppImageHub</a></li>
<li><a target="_blank" rel="noopener" href="https://qv2ray.net/getting-started/step2.html#download-v2ray-core-files">Configuring V2Ray Core | Qv2ray</a></li>
<li><a target="_blank" rel="noopener" href="https://github.com/v2fly/v2ray-core/releases">Releases · v2fly/v2ray-core · GitHub</a></li>
<li><a target="_blank" rel="noopener" href="https://www.v2fly.org/guide/start.html#%E5%AE%A2%E6%88%B7%E7%AB%AF">新手上路 | V2Fly.org</a></li>
<li><a target="_blank" rel="noopener" href="https://github.com/v2fly/v2ray-core/releases">Releases · v2fly/v2ray-core · GitHub</a></li>
<li><a target="_blank" rel="noopener" href="https://tracker.debian.org/pkg/golang-v2ray-core">golang-v2ray-core - Debian Package Tracker</a></li>
<li><a target="_blank" rel="noopener" href="https://flathub.org/apps/details/com.github.Qv2ray">Qv2ray—Linux Apps on Flathub</a></li>
<li><a target="_blank" rel="noopener" href="https://github.com/Qv2ray/qv2ray.github.io">GitHub - Qv2ray/qv2ray.github.io: :star2: Qv2ray 项目官方文档 :star2: ，使用 Vuepress / Markdown， 欢迎帮助完善 &amp; 提交 PR！</a></li>
</ul>
<figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">setsid chromium-browser https:&#x2F;&#x2F;merlinblog.xyz&#x2F;wiki&#x2F;freess.html  https:&#x2F;&#x2F;www.facebook.com&#x2F;groups&#x2F;139561307215714&#x2F;  https:&#x2F;&#x2F;sites.google.com&#x2F;site&#x2F;ssrandv2rayandss&#x2F;zui-xin-mian-fei-shou-feiv2ray-ding-yue-de-zhi  https:&#x2F;&#x2F;raw.githubusercontent.com&#x2F;ssrsub&#x2F;ssr&#x2F;master&#x2F;v2ray  https:&#x2F;&#x2F;qv2ray.net&#x2F;lang&#x2F;zh&#x2F;getting-started&#x2F;step3.html#%E5%88%86%E4%BA%AB%E9%93%BE%E6%8E%A5  https:&#x2F;&#x2F;appimage.github.io&#x2F;Qv2ray&#x2F;  https:&#x2F;&#x2F;qv2ray.net&#x2F;getting-started&#x2F;step2.html#download-v2ray-core-files  https:&#x2F;&#x2F;github.com&#x2F;v2fly&#x2F;v2ray-core&#x2F;releases  https:&#x2F;&#x2F;www.v2fly.org&#x2F;guide&#x2F;start.html#%E5%AE%A2%E6%88%B7%E7%AB%AF  https:&#x2F;&#x2F;github.com&#x2F;v2fly&#x2F;v2ray-core&#x2F;releases  https:&#x2F;&#x2F;tracker.debian.org&#x2F;pkg&#x2F;golang-v2ray-core  https:&#x2F;&#x2F;flathub.org&#x2F;apps&#x2F;details&#x2F;com.github.Qv2ray  https:&#x2F;&#x2F;github.com&#x2F;Qv2ray&#x2F;qv2ray.github.io  chrome:&#x2F;&#x2F;downloads&#x2F;</span><br></pre></td></tr></table></figure>
<h1 id="ClinicalTrials-gov"><a href="#ClinicalTrials-gov" class="headerlink" title="ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/">ClinicalTrials.gov</a></h1><ul>
<li>ClinicalTrials.gov Identifier</li>
</ul>
<ul>
<li><p>Primary outcome measure</p>
<p>  In a clinical study’s protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.</p>
</li>
<li><p>Secondary outcome measure</p>
<p>  In a clinical study’s protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.    </p>
</li>
<li><p>First submitted that met QC criteria</p>
<p>  The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM’s QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.</p>
</li>
</ul>
<h2 id="Glossary-of-Common-Site-Terms"><a href="#Glossary-of-Common-Site-Terms" class="headerlink" title="Glossary of Common Site Terms"></a>Glossary of Common Site Terms</h2><p>This glossary will help you understand words and phrases frequently used on ClinicalTrials.gov. Many of these words are also used by clinical researchers and others in the same or a similar manner. But the definitions below are provided to explain content on ClinicalTrials.gov only. </p>
<p>For help with medical terms, see the <a target="_blank" rel="noopener" href="https://medlineplus.gov/encyclopedia.html">MedlinePlus® Medical Encyclopedia</a>. </p>
<p>Study record managers should refer to the <a target="_blank" rel="noopener" href="https://prsinfo.clinicaltrials.gov/definitions.html">Protocol Registration Data Element Definitions</a>, <a target="_blank" rel="noopener" href="https://prsinfo.clinicaltrials.gov/expanded_access_definitions.html">Expanded Access Data Element Definitions</a>, and <a target="_blank" rel="noopener" href="https://prsinfo.clinicaltrials.gov/results_definitions.html">Results Data Element Definitions</a> for help with the data items required to register a study and submit results using the ClinicalTrials.gov Protocol Registration and Results System.</p>
<hr>
<ul>
<li>Accepts healthy volunteers<br>A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study.</li>
<li>Active comparator arm<br>An arm type in which a group of participants receives an intervention/treatment considered to be effective (or active) by health care providers.</li>
<li>Adverse event<br>An unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain amount of time after the study has ended. This change may or may not be caused by the intervention/treatment being studied.</li>
<li>Age or age group<br>A type of eligibility criteria that indicates the age a person must be to participate in a clinical study. This may be indicated by a specific age or the following age groups:</li>
</ul>
<p>The age groups are: </p>
<pre><code>* Child (birth-17)
* Adult (18-64)
* Older Adult (65+)</code></pre>
<ul>
<li>All-cause mortality<br>A measure of all deaths, due to any cause, that occur during a clinical study.</li>
<li>Allocation<br>A method used to assign participants to an arm of a clinical study. The types of allocation are randomized allocation and nonrandomized.</li>
<li>Arm<br>A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment , or no intervention, according to the trial’s protocol .</li>
<li>Arm type<br>A general description of the clinical trial arm. It identifies the role of the intervention that participants receive. Types of arms include experimental arm , active comparator arm , placebo comparator arm , sham comparator arm , and no intervention arm .</li>
<li>Baseline characteristics<br>Data collected at the beginning of a clinical study for all participants and for each arm or comparison group. These data include demographics, such as age, sex/gender, race and ethnicity, and study-specific measures (for example, systolic blood pressure, prior antidepressant treatment).</li>
<li>Canceled submission<br>Indicates that the study sponsor or investigator recalled a submission of study results before quality control (QC) review took place. If the submission was canceled on or after May 8, 2018, the date is shown. After submission of study results, a study record cannot be modified until QC review is completed, unless the submission is canceled.</li>
<li>Certain agreements<br>Information required by the Food and Drug Administration Amendments Act of 2007 . In general, this is a description of any agreement between the sponsor of a clinical study and the principal investigator (PI) that does not allow the PI to discuss the results of the study or publish the study results in a scientific or academic journal after the study is completed.</li>
<li>Certification<br>A sponsor or investigator may submit a certification to delay submission of results information if they are applying for FDA approval of a new drug or device, or new use of an already approved drug or device. A sponsor or investigator who submits a certification can delay results submission up to 2 years after the certification/extension first submitted date, unless certain events occur sooner. See <a target="_blank" rel="noopener" href="https://prsinfo.clinicaltrials.gov/results_definitions.html#DelayResultsType">Delay Results Type</a> in the Results Data Element definitions for more information about this certification.</li>
<li>Certification/extension first posted<br>The date on which information about a certification to delay submission of results or an extension request was first available on ClinicalTrials.gov. ClinicalTrials.gov does not indicate whether the submission was a certification or extension request. There is typically a delay between the date the study sponsor or investigator submitted the certification or extension request and the first posted date .</li>
<li>Certification/extension first submitted<br>The date on which the study sponsor or investigator first submitted a certification or an extension request to delay submission of results. A sponsor or investigator who submits a certification can delay results submission up to 2 years after this date, unless certain events occur sooner. There is typically a delay between the date the certification or extension request was submitted and the date the information is first available on ClinicalTrials.gov ( certification/extension first posted ).</li>
<li>Certification/extension first submitted that met QC criteria<br>The date on which the study sponsor or investigator first submitted a certification or an extension request that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a certification or extension request one or more times before NLM’s QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria. Meeting QC criteria for an extension request does not mean that the National Institutes of Health (NIH) has determined that the request demonstrates good cause. The process for review and granting of extension requests by the NIH is being developed.</li>
<li>City and distance<br>In the search feature, the City field is used to find clinical studies with locations in a specific city. The Distance field is used to find studies with locations within the specified distance from a city in number of miles. For example, if you choose Illinois as the state , identifying “Chicago” as the city and “100 miles” as the distance will find all studies listing a location within 100 miles of Chicago.</li>
<li>Clinical study<br>A research study involving human volunteers (also called participants) that is intended to add to medical knowledge. There are two types of clinical studies: interventional studies (also called clinical trials) and observational studies .</li>
<li>Clinical trial<br>Another name for an interventional study .</li>
<li>ClinicalTrials.gov identifier (NCT number)<br>The unique identification code given to each clinical study upon registration at ClinicalTrials.gov. The format is “NCT” followed by an 8-digit number (for example, NCT00000419).</li>
<li>Collaborator<br>An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.</li>
<li>Condition/disease<br>The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.</li>
<li>Contact<br>The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.</li>
<li>Country<br>In the search feature, the Country field is used to find clinical studies with locations in a specific country. For example, if you choose the United States, you can then narrow your search by selecting a state and identifying a city and distance .</li>
<li>Cross-over assignment<br>A type of intervention model describing a clinical trial in which groups of participants receive two or more interventions in a specific order. For example, two-by-two cross-over assignment involves two groups of participants. One group receives drug A during the initial phase of the trial, followed by drug B during a later phase. The other group receives drug B during the initial phase, followed by drug A. So during the trial, participants “cross over” to the other drug. All participants receive drug A and drug B at some point during the trial but in a different order, depending on the group to which they are assigned.</li>
<li>Data Monitoring Committee (DMC)<br>A group of independent scientists who monitor the safety and scientific integrity of a clinical trial . The DMC can recommend to the sponsor that the trial be stopped if it is not effective, is harming participants, or is unlikely to serve its scientific purpose. Members are chosen based on the scientific skills and knowledge needed to monitor the particular trial. Also called a data safety and monitoring board, or DSMB.</li>
<li>Early Phase 1 (formerly listed as Phase 0)<br>A phase of research used to describe exploratory trials conducted before traditional phase 1 trials to investigate how or whether a drug affects the body. They involve very limited human exposure to the drug and have no therapeutic or diagnostic goals (for example, screening studies, microdose studies).</li>
<li>Eligibility criteria<br>The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers , has age or age group requirements, or is limited by sex .</li>
<li>Enrollment<br>The number of participants in a clinical study. The “estimated” enrollment is the target number of participants that the researchers need for the study.</li>
<li>Exclusion criteria<br>A type of eligibility criteria . These are reasons that a person is not allowed to participate in a clinical study.</li>
<li>Expanded access<br>A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA) . Also called compassionate use. There are different expanded access types . </li>
</ul>
<p>For more information, see FDA <a target="_blank" rel="noopener" href="https://www.fda.gov/news-events/public-health-focus/expanded-access">Expanded Access: Information for Patients</a>.</p>
<ul>
<li>Expanded access status<ul>
<li><strong>Available:</strong> Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.</li>
<li><strong>No longer available:</strong> Expanded access was available for this intervention previously but is not currently available and will not be available in the future.</li>
<li><strong>Temporarily not available:</strong> Expanded access is not currently available for this intervention but is expected to be available in the future.</li>
<li><strong>Approved for marketing:</strong> The intervention has been approved by the U.S. Food and Drug Administration for use by the public.</li>
</ul>
</li>
<li>Expanded access type<br>Describes the category of expanded access under U.S. Food and Drug Administration (FDA) regulations. There are three types of expanded access: <ul>
<li><strong>Individual Patients</strong>: Allows a single patient, with a serious disease or condition who cannot participate in a clinical trial, access to a drug or biological product that has not been approved by the FDA . This category also includes access in an emergency situation.</li>
<li><strong>Intermediate-size Population</strong>: Allows more than one patient (but generally fewer patients than through a Treatment IND/Protocol) access to a drug or biological product that has not been approved by the FDA . This type of expanded access is used when multiple patients with the same disease or condition seek access to a specific drug or biological product that has not been approved by the FDA .</li>
<li><strong>Treatment IND/Protocol</strong>: Allows a large, widespread population access to a drug or biological product that has not been approved by the FDA . This type of expanded access can only be provided if the product is already being developed for marketing for the same use as the expanded access use.</li>
</ul>
</li>
<li>Experimental arm<br>An arm type in which a group of participants receives the intervention/treatment that is the focus of the clinical trial.</li>
<li>Extension request<br>In certain circumstances, a sponsor or investigator may request an extension to delay the standard results submission deadline (generally one year after the primary completion date ). The request for an extension must demonstrate good cause (for example, the need to preserve the scientific integrity of an ongoing masked trial). All requests must be reviewed and granted by the National Institutes of Health. This process for review and granting of extension requests is being developed. See <a target="_blank" rel="noopener" href="https://prsinfo.clinicaltrials.gov/results_definitions.html#DelayResultsType">Delay Results Type</a> in the Results Data Element definitions for more information.</li>
<li>Factorial assignment<br>A type of intervention model describing a clinical trial in which groups of participants receive one of several combinations of interventions. For example, two-by-two factorial assignment involves four groups of participants. Each group receives one of the following pairs of interventions: (1) drug A and drug B, (2) drug A and a placebo, (3) a placebo and drug B, or (4) a placebo and a placebo. So during the trial, all possible combinations of the two drugs (A and B) and the placebos are given to different groups of participants.</li>
<li>FDAAA 801 Violations<br>A FDAAA 801 Violation is shown on a study record when the U.S. Food and Drug Administration (FDA) has issued a Notice of Noncompliance to the responsible party of an applicable clinical trial. A Notice of Noncompliance indicates that the FDA has determined the responsible party was not in compliance with the registration or results reporting requirements for the clinical trial under the Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801).</li>
</ul>
<p>The National Library of Medicine (NLM) is required by FDAAA 801 to add information to a study record about any FDAAA 801 Violation. This information is provided by the FDA. There are three categories of information that may be included:</p>
<pre><code>* Violation: Shown when the FDA issues a Notice of Noncompliance and posts the Notice of Noncompliance on its designated webpage. There are three types of violations:
  * Failure to submit required clinical trial information
  * Submission of false or misleading clinical trial information
  * Failure to submit primary and secondary outcomes
* Correction: Shown when the FDA confirms that the responsible party has updated the study record to correct the violation and posts the correction notice on its designated webpage. Because of the time for FDA review and processing, there may be a delay between the date when the study record was updated and the addition of correction information to the FDAAA 801 Violation information.
* Penalty: Shown when the FDA imposes a penalty for the violation and posts the penalty notice on its designated webpage.</code></pre>
<ul>
<li>First posted<br>The date on which the study record was first available on ClinicalTrials.gov. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.</li>
<li>First submitted<br>The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record’s availability on ClinicalTrials.gov (the first posted date).</li>
<li>First submitted that met QC criteria<br>The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM’s QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.</li>
<li>Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801)<br>U.S. Public Law 110-85, which was enacted on September 27, 2007. Section 801 of FDAAA amends Section 402 of the U.S. Public Health Service Act to expand ClinicalTrials.gov and create a clinical study results database . For more information on FDAAA 801, see the <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/history">History, Policies, and Laws</a> page on this site.</li>
<li>Funder type<br>Describes the organization that provides funding or support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting. Organizations listed as sponsors and collaborators for a study are considered the funders of the study. ClinicalTrials.gov refers to four types of funders: <ul>
<li>U.S. National Institutes of Health</li>
<li>Other U.S. Federal agencies (for example, Food and Drug Administration, Centers for Disease Control and Prevention, or U.S. Department of Veterans Affairs)</li>
<li>Industry (for example: pharmaceutical and device companies)</li>
<li>All others (including individuals, universities, and community-based organizations)</li>
</ul>
</li>
<li>Gender-based eligibility<br>A type of eligibility criteria that indicates whether eligibility to participate in a clinical study is based a person’s self-representation of gender identity or gender (yes, no). Gender is distinct from sex .</li>
<li>Group/cohort<br>A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.</li>
<li>Human subjects protection review board<br>A group of people who review, approve, and monitor the clinical study’s protocol . Their role is to protect the rights and welfare of people participating in a study (referred to as human research subjects), such as reviewing the informed consent form . The group typically includes people with varying backgrounds, including a community member, to make sure that research activities conducted by an organization are completely and adequately reviewed. Also called an institutional review board, or IRB, or an ethics committee.</li>
</ul>
<p>For more information, see <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn#Participating">Participating in Studies</a> on this site.</p>
<ul>
<li>Inclusion criteria<br>A type of eligibility criteria . These are the reasons that a person is allowed to participate in a clinical study.</li>
<li>Informed consent<br>A process used by researchers to communicate to potential and enrolled participants the risks and potential benefits of participating in a clinical study. </li>
</ul>
<p>For more information, see <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn#Participating">Participating in Studies</a> on this site.</p>
<ul>
<li>Informed consent form (ICF)<br>The document used in the informed consent or process.</li>
<li>Intervention model<br>The general design of the strategy for assigning interventions to participants in a clinical study. Types of intervention models include: single group assignment , parallel assignment , cross-over assignment , and factorial assignment .</li>
<li>Intervention/treatment<br>A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.</li>
<li>Interventional study (clinical trial)<br>A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study’s protocol . Participants may receive diagnostic, therapeutic, or other types of interventions.</li>
<li>Investigator<br>A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator .</li>
<li>Last update posted<br>The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study’s sponsor or investigator (the last update submitted date) and the last update posted date.</li>
<li>Last update submitted<br>The most recent date on which the study sponsor or investigator submitted changes to a study record to ClinicalTrials.gov. There is typically a delay of a few days between the last update submitted date and when the date changes are posted on ClinicalTrials.gov (the last update posted date).</li>
<li>Last update submitted that met QC criteria<br>The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.</li>
<li>Last verified<br>The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study’s recruitment status is shown as unknown .</li>
<li>Listed location countries<br>Countries in which research facilities for a study are located. A country is listed only once, even if there is more than one facility in the country. The list includes all countries as of the last update submitted date; any country for which all facilities were removed from the study record are listed under removed location countries .</li>
<li>Location terms<br>In the search feature, the Location terms field is used to narrow a search by location-related terms other than Country, State, and City or distance. For example, you may enter a specific facility name (such as National Institutes of Health Clinical Center) or a part of a facility name (such as Veteran for studies listing Veterans Hospital or Veteran Affairs in the facility name). Note: Not all study records include this level of detail about locations.</li>
<li>Masking<br>A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions. Types of masking include: open label, single blind masking, and double-blind masking.</li>
<li>NCT number<br>A unique identification code given to each clinical study record registered on ClinicalTrials.gov. The format is “NCT” followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier .</li>
<li>No intervention arm<br>An arm type in which a group of participants does not receive any intervention/treatment during the clinical trial.</li>
<li>Observational study<br>A type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific interventions/treatment .</li>
</ul>
<p>A patient registry is a type of observational study.</p>
<ul>
<li>Observational study model<br>The general design of the strategy for identifying and following up with participants during an observational study . Types of observational study models include cohort, case-control, case-only, case-cross-over, ecologic or community studies, family-based, and other.</li>
<li>Other adverse event<br>An adverse event that is not a serious adverse event , meaning that it does not result in death, is not life-threatening, does not require inpatient hospitalization or extend a current hospital stay, does not result in an ongoing or significant incapacity or interfere substantially with normal life functions, and does not cause a congenital anomaly or birth defect; it also does not put the participant in danger and does not require medical or surgical intervention to prevent one of the results listed above.</li>
<li>Other study IDs<br>Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study’s sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.</li>
<li>Other terms<br>In the search feature, the Other terms field is used to narrow a search. For example, you may enter the name of a drug or the NCT number of a clinical study to limit the search to study records that contain these words.</li>
<li>Outcome measure<br>For clinical trials , a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies , a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure .</li>
<li>Parallel assignment<br>A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A “in parallel” to participants in the other group, who receive drug B.</li>
<li>Participant flow<br>A summary of the progress of participants through each stage of a clinical study, by study arm or group/cohort . This includes the number of participants who started, completed, and dropped out of the study.</li>
<li>Patient registry<br>A type of observational study that collects information about patients’ medical conditions and/or treatments to better understand how a condition or treatment affects patients in the real world.</li>
<li>Phase<br>The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA) . The phase is based on the study’s objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0) , Phase 1 , Phase 2 , Phase 3 , and Phase 4 . Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.</li>
<li>Phase 1<br>A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug’s most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.</li>
<li>Phase 2<br>A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug’s effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo ) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.</li>
<li>Phase 3<br>A phase of research to describe clinical trials that gather more information about a drug’s safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.</li>
<li>Phase 4<br>A phase of research to describe clinical trials occurring after FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug’s safety, efficacy, or optimal use.</li>
<li>Phase Not Applicable<br>Describes trials without FDA-defined phases , including trials of devices or behavioral interventions.</li>
<li>Placebo<br>An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.</li>
<li>Placebo comparator arm<br>An arm type in which a group of participants receives a placebo during a clinical trial.</li>
<li>Primary completion date<br>The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure . Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The “estimated” primary completion date is the date that the researchers think will be the primary completion date for the study. </li>
<li>Primary outcome measure<br>In a clinical study’s protocol , the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment . Most clinical studies have one primary outcome measure, but some have more than one.</li>
<li>Primary purpose<br>The main reason for the clinical trial . The types of primary purpose are: treatment, prevention, diagnostic, supportive care, screening, health services research, basic science, and other.</li>
<li>Principal investigator (PI)<br>The person who is responsible for the scientific and technical direction of the entire clinical study.</li>
<li>Protocol<br>The written description of a clinical study. It includes the study’s objectives, design, and methods. It may also include relevant scientific background and statistical information.</li>
<li>Quality control (QC) review<br>National Library of Medicine (NLM) staff perform a limited review of submitted study records for apparent errors, deficiencies, or inconsistencies. NLM staff identify potential major and advisory issues and provide comments directly to the study sponsor or investigator. Major issues identified in QC review must be addressed or corrected (see First submitted that met QC criteria and Results first submitted that met QC criteria ). Advisory issues are suggestions to help improve the clarity of the record. NLM staff do not verify the scientific validity or relevance of the submitted information. The study sponsor or investigator is responsible for ensuring that the studies follow all applicable laws and regulations.</li>
<li>Randomized allocation<br>A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.</li>
<li>Recruitment status<ul>
<li><strong>Not yet recruiting:</strong> The study has not started recruiting participants.</li>
<li><strong>Recruiting:</strong> The study is currently recruiting participants.</li>
<li><strong>Enrolling by invitation:</strong> The study is selecting its participants from a population, or group of people, decided on by the researchers in advance. These studies are not open to everyone who meets the eligibility criteria but only to people in that particular population, who are specifically invited to participate.</li>
<li><strong>Active, not recruiting:</strong> The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.</li>
<li><strong>Suspended:</strong> The study has stopped early but may start again.</li>
<li><strong>Terminated:</strong> The study has stopped early and will not start again. Participants are no longer being examined or treated.</li>
<li><strong>Completed:</strong> The study has ended normally, and participants are no longer being examined or treated (that is, the last participant’s last visit has occurred).</li>
<li><strong>Withdrawn:</strong> The study stopped early, before enrolling its first participant.</li>
<li><strong>Unknown:</strong> A study on ClinicalTrials.gov whose last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been last verified within the past 2 years.</li>
</ul>
</li>
<li>Registration<br>The process of submitting and updating summary information about a clinical study and its protocol , from its beginning to end, to a structured, public Web-based study registry that is accessible to the public, such as ClinicalTrials.gov.</li>
<li>Removed location countries<br>Countries that appeared under listed location countries but were removed from the study record by the sponsor or investigator.</li>
<li>Reporting group<br>A grouping of participants in a clinical study that is used for summarizing the data collected during the study. This grouping may be the same as or different from a study arm or group.</li>
<li>Responsible party<br>The person responsible for submitting information about a clinical study to ClinicalTrials.gov and updating that information. Usually the study sponsor or investigator.</li>
<li>Results database<br>A structured online system, such as the ClinicalTrials.gov results database, that provides the public with access to registration and summary results information for completed or terminated clinical studies. A study with results available on ClinicalTrials.gov is described as having the results “posted.” </li>
</ul>
<p><strong>Note:</strong> The ClinicalTrials.gov results database became available in September 2008. Older studies are unlikely to have results available in the database.</p>
<ul>
<li>Results delayed<br>Indicates that the sponsor or investigator submitted a certification or extension request .</li>
<li>Results first posted<br>The date on which summary results information was first available on ClinicalTrials.gov. There is typically a delay between the date the study sponsor or investigator first submits summary results information (the results first submitted date) and the results first posted date.</li>
<li>Results first submitted<br>The date on which the study sponsor or investigator first submits a study record with summary results information. There is typically a delay between the results first submitted date and when summary results information becomes available on ClinicalTrials.gov (the results first posted date).</li>
<li>Results first submitted that met QC criteria<br>The date on which the study sponsor or investigator first submits a study record with summary results information that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit results information one or more times before NLM’s QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.</li>
<li>Results returned after quality control review<br>The date on which the National Library of Medicine provided quality control (QC) review comments to the study sponsor or investigator. The sponsor or investigator must address major issues identified in the review comments. If there is a date listed for results returned after quality control review, but there is not a subsequent date listed for results submitted to ClinicalTrials.gov , this means that the submission is pending changes by the sponsor or investigator.</li>
<li>Results submitted to ClinicalTrials.gov<br>Indicates that the study sponsor or investigator has submitted summary results information for a clinical study to ClinicalTrials.gov but the quality control (QC) review process has not concluded.</li>
</ul>
<p>The results submitted date indicates when the study sponsor or investigator first submitted summary results information or submitted changes to summary results information. Submissions with changes are typically in response to QC review comments from the National Library of Medicine (NLM). If there is a date listed for results submitted to ClinicalTrials.gov, but there is not a subsequent date listed for results returned after quality control review , this means that the submission is pending review by NLM.</p>
<ul>
<li>Secondary outcome measure<br>In a clinical study’s protocol , a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.</li>
<li>Serious adverse event<br>An adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above.</li>
<li>Sex<br>A type of eligibility criteria that indicates the sex of people who may participate in a clinical study (all, female, male). Sex is a person’s classification as female or male based on biological distinctions. Sex is distinct from gender-based eligibility .</li>
<li>Sham comparator arm<br>An arm type in which a group of participants receives a procedure or device that appears to be the same as the actual procedure or device being studied but does not contain active processes or components.</li>
<li>Single group assignment<br>A type of intervention model describing a clinical trial in which all participants receive the same intervention/treatment.</li>
<li>Sort studies by<br>In Advanced Search, the Sort studies by option is used to change the order of studies listed on the Search Results page. You can sort by Relevance or Newest First: <ul>
<li>Relevance: Studies that best match your search terms appear higher in the search results list. This is the default display for all searches.</li>
<li>Newest First: Studies with the most recent First posted dates appear higher in the search results list.</li>
</ul>
</li>
<li>Sponsor<br>The organization or person who initiates the study and who has authority and control over the study.</li>
<li>State<br>In the search feature, the State field is used to find clinical studies with locations in a specific state within the United States. If you choose United States in the Country field, you can search for studies with locations in a specific state.</li>
<li>Statistical analysis plan (SAP)<br>The written description of the statistical considerations and methods for analyzing the data collected in the clinical study .</li>
<li>Status<br>Indicates the current recruitment status or the expanded access status .</li>
<li>Study completion date<br>The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures , secondary outcome measures , and adverse events (that is, the last participant’s last visit). The “estimated” study completion date is the date that the researchers think will be the study completion date.</li>
<li>Study design<br>The investigative methods and strategies used in the clinical study.</li>
<li>Study documents<br>Refers to the type of documents that the study sponsor or principal investigator may add to their study record . These include a study protocol , statistical analysis plan , and informed consent form .</li>
<li>Study IDs<br>Identifiers that are assigned to a clinical study by the study’s sponsor , funders, or others. They include unique identifiers from other trial study registries and National Institutes of Health grant numbers. Note: ClinicalTrials.gov assigns a unique identification code to each clinical study registered on ClinicalTrials.gov. Also called the NCT number , the format is “NCT” followed by an 8-digit number (for example, NCT00000419).</li>
<li>Study record<br>An entry on ClinicalTrials.gov that contains a summary of a clinical study’s protocol information, including the recruitment status ; eligibility criteria; contact information; and, in some cases, summary results. Each study record is assigned a ClinicalTrials.gov identifier, or NCT number .</li>
<li>Study registry<br>A structured online system, such as ClinicalTrials.gov, that provides the public with access to summary information about ongoing and completed clinical studies.</li>
<li>Study results<br>A study record that includes the summary results posted in the ClinicalTrials.gov results database . Summary results information includes participant flow , baseline characteristics , outcome measures , and adverse events (including serious adverse events ).</li>
<li>Study start date<br>The actual date on which the first participant was enrolled in a clinical study. The “estimated” study start date is the date that the researchers think will be the study start date.</li>
<li>Study type<br>Describes the nature of a clinical study . Study types include interventional studies (also called clinical trials), observational studies (including patient registries ), and expanded access .</li>
<li>Submitted date<br>The date on which the study sponsor or investigator submitted a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria.</li>
<li>Title<br>The official title of a protocol used to identify a clinical study or a short title written in language intended for the lay public.</li>
<li>Title acronym<br>The acronym or initials used to identify a clinical study (not all studies have one). For example, the title acronym for the Women’s Health Initiative is “WHI.”</li>
<li>U.S. Agency for Healthcare Research and Quality (AHRQ)<br>An agency within the U.S. Department of Health and Human Services. AHRQ’s mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used.</li>
<li>U.S. Food and Drug Administration (FDA)<br>An agency within the U.S. Department of Health and Human Services. The FDA is responsible for protecting the public health by making sure that human and veterinary drugs, vaccines and other biological products, medical devices, the Nation’s food supply, cosmetics, dietary supplements, and products that give off radiation are safe, effective, and secure.</li>
<li>Unknown<br>A type of recruitment status . It identifies a study on ClinicalTrials.gov whose last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been verified within the past 2 years. Studies with an unknown status are considered closed studies.</li>
</ul>
<h2 id="Downloading-Content-for-Analysis-ClinicalTrials-gov"><a href="#Downloading-Content-for-Analysis-ClinicalTrials-gov" class="headerlink" title="Downloading Content for Analysis - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/resources/download#DownloadAllData">Downloading Content for Analysis - ClinicalTrials.gov</a></h2><h1 id="Web-Log"><a href="#Web-Log" class="headerlink" title="Web Log"></a>Web Log</h1><h2 id="Search-of-COVID-19-List-Results-ClinicalTrials-gov"><a href="#Search-of-COVID-19-List-Results-ClinicalTrials-gov" class="headerlink" title="Search of: COVID-19 - List Results - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/results?cond=COVID-19">Search of: COVID-19 - List Results - ClinicalTrials.gov</a></h2><h2 id="URL-in-mermaid"><a href="#URL-in-mermaid" class="headerlink" title="URL in mermaid"></a>URL in <code>mermaid</code></h2><ul>
<li><a target="_blank" rel="noopener" href="https://www.google.com/search?q=mermaid+clickable&oq=mermaid+clickable&aqs=chrome..69i57j0l2j0i20i263j0l6.5820j0j4&sourceid=chrome&ie=UTF-8">mermaid clickable - Google Search</a></li>
<li><a target="_blank" rel="noopener" href="https://stackoverflow.com/questions/41960529/how-to-add-a-link-in-a-mermaid-node-description">javascript - How to add a link in a mermaid node description? - Stack Overflow</a></li>
<li><a target="_blank" rel="noopener" href="https://developercommunity.visualstudio.com/t/mermaid-gantt-diagrams-clickable/921637">Mermaid Gantt diagrams, clickable - Visual Studio Feedback</a></li>
<li><a target="_blank" rel="noopener" href="https://forum.gitlab.com/t/using-url-link-in-mermaid-node-description/29855/2">Using url-link in mermaid node description - How to Use GitLab - GitLab Forum</a></li>
<li><a target="_blank" rel="noopener" href="https://gitlab.com/gitlab-org/gitlab/-/blob/4799db3b5ddafceefef99427c6b4f5128d2ce087/app/assets/javascripts/behaviors/markdown/render_mermaid.js">app/assets/javascripts/behaviors/markdown/render_mermaid.js · 4799db3b5ddafceefef99427c6b4f5128d2ce087 · GitLab.org / GitLab · GitLab</a></li>
</ul>
<h1 id="Download"><a href="#Download" class="headerlink" title="Download"></a>Download</h1><ul>
<li><a href="/home/ht/Downloads/COVID-19_ClinicalTrials.tsv">COVID-19_ClinicalTrials.tsv</a></li>
<li><a href="/home/ht/Downloads/HIV_ClinicalTrials.tsv">HIV_ClinicalTrials.tsv</a></li>
</ul>
<h1 id="HIV-treatment"><a href="#HIV-treatment" class="headerlink" title="HIV treatment"></a>HIV treatment</h1><ul>
<li><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/results?cond=hiv&term=treatment&cntry=&state=&city=&dist=">Search of: treatment | hiv - List Results - ClinicalTrials.gov</a></li>
</ul>
<figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br></pre></td><td class="code"><pre><span class="line">cat HIV_ClinicalTrials.tsv | awk -F&#39;\t&#39; &#39;&#123;print $5&#125;&#39; | sort | uniq</span><br><span class="line">#</span><br><span class="line">cat HIV_ClinicalTrials.tsv | awk -F&#39;\t&#39; &#39;&#123;print $5&#125;&#39; | grep -n Completed | wc -l # output 4518</span><br><span class="line">#</span><br><span class="line">cat HIV_ClinicalTrials.tsv | ag -i &#39;Traditional Chinese Medicine&#39;</span><br><span class="line"># NCT00974454</span><br><span class="line"># NCT00974519</span><br><span class="line"></span><br></pre></td></tr></table></figure>
<h2 id="Selected-clinical-trials"><a href="#Selected-clinical-trials" class="headerlink" title="Selected clinical trials"></a>Selected clinical trials</h2><ul>
<li><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/results?term=treatment&cond=hiv&flds=aby&Search=Apply&recrs=e&age_v=&gndr=&type=&rslt=">Search of: treatment | Completed Studies | hiv - List Results - ClinicalTrials.gov</a></li>
</ul>
<hr>
<h3 id="Early-and-Intermittent-Antiretroviral-Therapy-in-Naive-HIV-Infected-Adults-Full-Text-View-ClinicalTrials-gov"><a href="#Early-and-Intermittent-Antiretroviral-Therapy-in-Naive-HIV-Infected-Adults-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT00820118?term=treatment&recrs=e&cond=hiv&draw=2&rank=3">Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults - Full Text View - ClinicalTrials.gov</a></h3><h3 id="Effectiveness-of-Antiretroviral-Therapy-During-Acute-HIV-Infection-Full-Text-View-ClinicalTrials-gov"><a href="#Effectiveness-of-Antiretroviral-Therapy-During-Acute-HIV-Infection-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="Effectiveness of Antiretroviral Therapy During Acute HIV Infection - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT00705926?term=treatment&recrs=e&cond=hiv&draw=2&rank=5">Effectiveness of Antiretroviral Therapy During Acute HIV Infection - Full Text View - ClinicalTrials.gov</a></h3><p><strong>Effectiveness of Antiretroviral Therapy During Acute HIV Infection</strong></p>
<p>The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.</p>
<p>ClinicalTrials.gov Identifier: NCT00705926</p>
<p>Recruitment Status  : Completed</p>
<p>First Posted  : June 27, 2008</p>
<p>Last Update Posted  : August 31, 2017</p>
<p>Sponsor:</p>
<p>Massachusetts General Hospital</p>
<p>Collaborator:</p>
<p>National Institute of Allergy and Infectious Diseases (NIAID)</p>
<p>Information provided by (Responsible Party):</p>
<p>Eric Rosenberg, MD, Massachusetts General Hospital</p>
<ul>
<li>  Study Details</li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/record/NCT00705926?term=treatment&recrs=e&cond=hiv&draw=2&rank=5">Tabular View</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/results/NCT00705926?term=treatment&recrs=e&cond=hiv&draw=2&rank=5">No Results Posted</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" title="Disclaimer - opens new window">Disclaimer</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/help/how-read-study" title="How to Read a Study Record - opens new window">How to Read a Study Record</a></li>
</ul>
<p>Study Description</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Brief Summary:</p>
<p>This study will determine whether HIV treatment that is initiated during the acute phase of HIV infection, followed by discontinuation of treatment, is effective in reducing the amount of HIV and an increasing the amount of CD4 cells in the blood of people with HIV, compared to the amounts of HIV and CD4 cells in people who do not receive treatment at this stage.</p>
<p>Condition or disease </p>
<p>Intervention/treatment </p>
<p>Phase </p>
<p>HIV Infections</p>
<p>Drug: Highly Active Antiretroviral Therapy (HAART)Other: No treatment</p>
<p>Phase 1</p>
<p>Detailed Description:</p>
<p>Antiretroviral (ARV) therapy for the treatment of HIV infection has been remarkably successful in reducing morbidity and mortality in HIV infected people. This treatment still has its shortcomings, however. Individuals receiving ARV treatment are at risk of toxicity, developing drug resistance, and unknown long-term side effects. Therefore, development of alternative treatment strategies is important. A short course of ARV treatment that is initiated during the acute period of HIV infection, followed by treatment cessation may have a substantial impact on controlling infection and delaying the need for lifelong potent ARV therapy. The purpose of this study is to investigate whether treatment initiated during acute HIV infection and followed by a terminal treatment interruption is effective in lowering the viral load set point and raising CD4 cell counts in people with HIV, as compared to those measures in people with HIV who have received no treatment.</p>
<p>Participants in this study will be randomly assigned to one of three groups. Participants in Group A1 will receive ARV therapy for 12 weeks. Participants in Group A2 will receive ARV therapy for 32 weeks. Participants in Group B will not receive any treatment. This study will not provide medications to any of the groups. All groups will be followed for a total of 72 weeks following study entry. Participants will attend between 30 and 36 study visits over the course of the 72 weeks, depending on their study group. Study visits will occur every week for the first 12 weeks and then every 1 to 6 weeks for the remainder of the study. Tests occurring at study visits may include blood tests, investigational immune system tests, and pregnancy tests. Participants will also undergo a complete physical exam and will be asked to provide information about their medical and medication histories.</p>
<p>Study Design</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Study Type  :</p>
<p>Interventional  (Clinical Trial)</p>
<p>Actual Enrollment  :</p>
<p>25 participants</p>
<p>Allocation:</p>
<p>Randomized</p>
<p>Intervention Model:</p>
<p>Parallel Assignment</p>
<p>Masking:</p>
<p>None (Open Label)</p>
<p>Primary Purpose:</p>
<p>Treatment</p>
<p>Official Title:</p>
<p>A Phase 1 Clinical Trial to Evaluate the Initiation of Treatment Versus no Treatment During Acute HIV-1 Infection</p>
<p>Study Start Date  :</p>
<p>October 2008</p>
<p>Actual Primary Completion Date  :</p>
<p>February 7, 2013</p>
<p>Actual Study Completion Date  :</p>
<p>July 16, 2017</p>
<p><strong>Resource links provided by the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><a target="_blank" rel="noopener" href="https://medlineplus.gov/" title="MedlinePlus">MedlinePlus</a> related topics: <a target="_blank" rel="noopener" href="https://medlineplus.gov/hivaids.html" title="HIV/AIDS at MedlinePlus">HIV/AIDS</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/info/fdalinks" title="Show FDA resources page">U.S. FDA Resources</a></p>
<p>Arms and Interventions</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Arm </p>
<p>Intervention/treatment </p>
<p>Experimental: A1</p>
<p>Antiretroviral therapy followed by discontinuation at Week 12.</p>
<p>Drug: Highly Active Antiretroviral Therapy (HAART)</p>
<p>Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.</p>
<p>Experimental: A2</p>
<p>Antiretroviral therapy followed by discontinuation at Week 32.</p>
<p>Drug: Highly Active Antiretroviral Therapy (HAART)</p>
<p>Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.</p>
<p>Placebo Comparator: B</p>
<p>No treatment.</p>
<p>Other: No treatment</p>
<p>Participants in this group will not receive treatment at this stage of their infection.</p>
<p>Outcome Measures</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Primary Outcome Measures  :</p>
<ol>
<li> Difference in the level of HIV RNA at viral load set point if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment [ Time Frame: Week 72 ]  </li>
</ol>
<p>Secondary Outcome Measures  :</p>
<ol>
<li><p> Difference in the level of CD4 cells if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment [ Time Frame: Week 72 ]  </p>
</li>
<li><p> Difference in the level of HIV RNA and CD4 cell numbers between therapy initiated during acute HIV infection followed by terminal treatment interruption after at least 12 weeks of treatment and no therapy at 16 weeks after discontinuation of treatment [ Time Frame: Weeks 12 and 16 ]  </p>
</li>
<li><p> Difference in the level of HIV at viral load set point and CD4 cell number at 72 weeks after study entry if therapy is initiated during acute HIV infection followed by terminal treatment interruption at 12 weeks versus at 32 weeks [ Time Frame: Week 72 ]  </p>
</li>
</ol>
<p>Eligibility Criteria</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn" title="Learn About Clinical Studies">Learn About Clinical Studies.</a></em></p>
<p>Ages Eligible for Study:  </p>
<p>18 Years to 65 Years   (Adult, Older Adult)</p>
<p>Sexes Eligible for Study:  </p>
<p>All</p>
<p>Accepts Healthy Volunteers:  </p>
<p>No</p>
<p>Criteria</p>
<p>Inclusion Criteria:</p>
<ul>
<li>  Acute HIV infection as determined by a positive HIV viral load (at least 5,000 copies of RNA per ml of plasma) and a negative or indeterminate Western Blot test</li>
<li>  Certain laboratory values. More information about this criterion can be found in the protocol.</li>
<li>  Agrees to use an approved form of contraception</li>
</ul>
<p>Exclusion Criteria:</p>
<ul>
<li>  Presence of opportunistic infections or AIDS-defining illnesses, unless they are directly attributable to the acute seroconversion illness</li>
<li>  Receipt of investigational research agents within 30 days prior to study entry</li>
<li>  Receipt of prior experimental HIV vaccines. Individuals who received a saline placebo in a prior HIV vaccine trial are not excluded, provided that they did not receive a sham vector or an adjuvant.</li>
<li>  Receipt of immunosuppressive medications or immunomodulators (e.g., cytokine therapy) within the past 6 months. Participants taking corticosteroid nasal spray for allergic rhinitis; topical corticosteroids for acute, uncomplicated dermatitis; or over the counter medications for acute, uncomplicated dermatitis for a period not longer than 14 days will not be excluded.</li>
<li>  Current use of prohibited concomitant medications</li>
<li>  Current anti-tuberculosis prophylaxis or therapy</li>
<li>  Serious illness other than acute HIV infection requiring systemic treatment or hospitalization until either therapy is completed or patient is clinically stable on therapy</li>
<li>  Hepatitis B surface antigen positivity within 21 days prior to study entry</li>
<li>  Pregnant or breastfeeding</li>
</ul>
<p>Contacts and Locations</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.</em></p>
<p><em>Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT00705926</strong></em></p>
<p>Locations</p>
<p>United States, Massachusetts</p>
<p>Massachusetts General Hospital</p>
<p>Boston, Massachusetts, United States, 02114</p>
<p>Sponsors and Collaborators</p>
<p>Massachusetts General Hospital</p>
<p>National Institute of Allergy and Infectious Diseases (NIAID)</p>
<p>Investigators</p>
<p>Study Chair:</p>
<p>Eric S. Rosenberg, MD</p>
<p>Massachusetts General Hospital, Division of Infectious Diseases</p>
<p>Principal Investigator:</p>
<p>H.T. Banks, PhD</p>
<p>North Carolina State University, College of Physical and Mathematical Sciences</p>
<p>Principal Investigator:</p>
<p>Marie Davidian, PhD</p>
<p>North Carolina State University, Department of Statistics</p>
<p>More Information</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Publications:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCBLRCj-gFjA6h9Ei4L3BUgWwNG0it." title="Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D&#39;agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 1;42(7):1024-31. Epub 2006 Feb 27.">Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D’agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 1;42(7):1024-31. Epub 2006 Feb 27.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRC8xR4tcRF8A6h9Ei4L3BUgWwNG0it." title="Kassutto S, Rosenberg ES. Editorial comment: treatment of acute HIV infection--uncertainties about best practice. AIDS Read. 2005 May;15(5):250-1.">Kassutto S, Rosenberg ES. Editorial comment: treatment of acute HIV infection–uncertainties about best practice. AIDS Read. 2005 May;15(5):250-1.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRC8agCBWK4VA6h9Ei4L3BUgWwNG0it." title="Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis. 2004 May 15;38(10):1447-53. Epub 2004 Apr 30.">Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis. 2004 May 15;38(10):1447-53. Epub 2004 Apr 30.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCnLKC5Eg4JA6h9Ei4L3BUgWwNG0it." title="Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis. 2003 Mar 1;187(5):748-57. Epub 2003 Feb 18.">Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis. 2003 Mar 1;187(5):748-57. Epub 2003 Feb 18.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCtcR4J-gCJA6h9Ei4L3BUgWwNG0it." title="Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, Musey L, Schacker T, Corey L, McElrath MJ. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000 Jan;181(1):121-31.">Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, Musey L, Schacker T, Corey L, McElrath MJ. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000 Jan;181(1):121-31.</a></p>
<p>Responsible Party:</p>
<p>Eric Rosenberg, MD, Investigator of Record, Massachusetts General Hospital</p>
<p>ClinicalTrials.gov Identifier:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/show/NCT00705926" title="Current version of study NCT00705926 on ClinicalTrials.gov">NCT00705926</a>     <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/history/NCT00705926" title="Historical versions of study NCT00705926 on ClinicalTrials.gov Archive Site">History of Changes</a></p>
<p>Other Study ID Numbers:</p>
<p><a target="_blank" rel="noopener" href="https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01AI071915&Fy=all" title="Additional information available on NIH RePORTER">R01AI071915 ( U.S. NIH Grant/Contract )</a><br>RO1AIO71915 ( Other Grant/Funding Number: NIAID )  </p>
<p>First Posted:</p>
<p>June 27, 2008    <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/keydates/NCT00705926" title="View key record dates for NCT00705926">Key Record Dates</a></p>
<p>Last Update Posted:</p>
<p>August 31, 2017</p>
<p>Last Verified:</p>
<p>August 2017</p>
<p>Keywords provided by Eric Rosenberg, MD, Massachusetts General Hospital:</p>
<p>Acute Infection<br>HIV<br>HAART<br>Treatment Naive  </p>
<p>Additional relevant MeSH terms:</p>
<p>HIV Infections<br>Acquired Immunodeficiency Syndrome<br>Infection<br>Communicable Diseases<br>Lentivirus Infections<br>Retroviridae Infections<br>RNA Virus Infections<br>Virus Diseases  </p>
<p>Sexually Transmitted Diseases, Viral<br>Sexually Transmitted Diseases<br>Immunologic Deficiency Syndromes<br>Immune System Diseases<br>Slow Virus Diseases<br>Anti-Retroviral Agents<br>Antiviral Agents<br>Anti-Infective Agents</p>
<h3 id="Study-to-Evaluate-the-Activity-and-Tolerability-of-Lopinavir-Ritonavir-and-Lamivudine-Bitherapy-in-HIV-Patients-With-Viral-Suppression-Full-Text-View-ClinicalTrials-gov"><a href="#Study-to-Evaluate-the-Activity-and-Tolerability-of-Lopinavir-Ritonavir-and-Lamivudine-Bitherapy-in-HIV-Patients-With-Viral-Suppression-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT01471821?term=treatment&recrs=e&cond=hiv&draw=2&rank=9">Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression - Full Text View - ClinicalTrials.gov</a></h3><h3 id="Research-on-Effect-of-Traditional-Chinese-Medicine-TCM-on-Immune-Reconstitution-of-HIV-AIDS-Patients-After-Highly-Active-Antiretroviral-Therapy-HAART-Full-Text-View-ClinicalTrials-gov"><a href="#Research-on-Effect-of-Traditional-Chinese-Medicine-TCM-on-Immune-Reconstitution-of-HIV-AIDS-Patients-After-Highly-Active-Antiretroviral-Therapy-HAART-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART) - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT00974454?term=NCT00974454&draw=2&rank=1">Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART) - Full Text View - ClinicalTrials.gov</a></h3><p><strong>Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)</strong></p>
<p>The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.</p>
<p>ClinicalTrials.gov Identifier: NCT00974454</p>
<p>Recruitment Status  : Unknown</p>
<p>Verified September 2009 by Guang’anmen Hospital of China Academy of Chinese Medical Sciences.<br>Recruitment status was:  Recruiting</p>
<p>First Posted  : September 10, 2009</p>
<p>Last Update Posted  : October 29, 2009</p>
<p>Sponsor:</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>Information provided by:</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<ul>
<li>  Study Details</li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/record/NCT00974454?term=NCT00974454&draw=2&rank=1">Tabular View</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/results/NCT00974454?term=NCT00974454&draw=2&rank=1">No Results Posted</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" title="Disclaimer - opens new window">Disclaimer</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/help/how-read-study" title="How to Read a Study Record - opens new window">How to Read a Study Record</a></li>
</ul>
<p>Study Description</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Brief Summary:</p>
<p>Chinese prescriptions can inhibit viral replication according to the course of viral replication, and the effects is similar to the effect of HAART, and even better than the anti-viral and immune reconstitution of HAART due to its effect on improve immune system function. Over the past decades, many researchers have screened the effective Chinese medicines to treat AIDS.</p>
<p>Condition or disease </p>
<p>Intervention/treatment </p>
<p>Phase </p>
<p>Acquired Immune Deficiency Syndrome VirusHIV Infections</p>
<p>Drug: Fuzheng 2Drug: Placebo</p>
<p>Not Applicable</p>
<p>Detailed Description:</p>
<ul>
<li>  There is no record of AIDS in Chinese medicine, modern clinicians hold that AIDS is linked to TCM theory according to its pathogenesis, character of onset and clinical manifestations. As early as more than 2000 years ago, there were records of immune function in TCM. 2 TCM books recorded that “keep vital Qi, the evil will not invade the body “and” the invasion of evil is caused by the deficiency of vital Qi. Vital Qi summarizes the normal immune system function. Vital Qi is the basic material and physiological function which can eliminate the evil, regulating yin and yang and protect the body.</li>
<li>  And this is in accordance with defense, homeostasis and surveillance of immune system in western medicine. The knowledge of immunology has guided medical practice in China for more than two thousand years. In response to a variety of immune diseases, there are various immunotherapy such as Yiqi Fuzheng immunotherapy, reinforce kidney therapy, huoxuehuayu therapy and heat-clearing and detoxifying therapy. Throughout the course of AIDS, the evil (HIV) exists and the vital Qi is turning weak gradually. If we adopted a number of intervention measures to assist the body’s Vital Qi, Vital Qi will be strengthened and the evil will be weakened. Therefore, TCM will play an important role in improving immune function.</li>
<li>  Chinese prescriptions can inhibit viral replication according to the course of viral replication, and the effects is similar to the effect of HAART, and even better than the anti-viral and immune reconstitution of HAART due to its effect on improve immune system function. Over the past decades, many researchers have screened the effective Chinese medicines to treat AIDS.</li>
</ul>
<p>Researchers screened single Chinese herbs, some extract and the effective components of Chinese medicine and prescriptions. Some study the role of its anti-HIV, some study the role of its regulating immunization function. The former studies have shown that immunization 2 (Fuzheng 2) has wide effect on immune system and it can activate the reticuloendothelial system, macrophage phagocytes and lymphocyte transformation. And it can relieve disorders, imbalance of the immune system caused by HIV infection.</p>
<ul>
<li>  In addition, this prescription can inhibit HIV reverse transcription polymerase enzyme and virus-induced syncytium formation, protect virus-infected cells, and inhibit virus replication in HIV-1 infected cells.</li>
<li>  Through the clinical trials, we will evaluate the effect of immune 2 (Fuzheng 2) on immune reconstitution of adult HIV/AIDS patients who have received HAART.</li>
</ul>
<p>Study Design</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Study Type  :</p>
<p>Interventional  (Clinical Trial)</p>
<p>Estimated Enrollment  :</p>
<p>180 participants</p>
<p>Allocation:</p>
<p>Randomized</p>
<p>Intervention Model:</p>
<p>Parallel Assignment</p>
<p>Masking:</p>
<p>Double (Participant, Investigator)</p>
<p>Primary Purpose:</p>
<p>Treatment</p>
<p>Official Title:</p>
<p>Research on Effect of TCM on Immune Reconstitution of HIV/AIDS Patients After HAART</p>
<p>Study Start Date  :</p>
<p>September 2009</p>
<p>Estimated Primary Completion Date  :</p>
<p>April 2010</p>
<p>Estimated Study Completion Date  :</p>
<p>December 2010</p>
<p><strong>Resource links provided by the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><a target="_blank" rel="noopener" href="https://medlineplus.gov/" title="MedlinePlus">MedlinePlus</a> related topics: <a target="_blank" rel="noopener" href="https://medlineplus.gov/hivaids.html" title="HIV/AIDS at MedlinePlus">HIV/AIDS</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/info/fdalinks" title="Show FDA resources page">U.S. FDA Resources</a></p>
<p>Arms and Interventions</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Arm </p>
<p>Intervention/treatment </p>
<p>Active Comparator: Fuzheng 2</p>
<p>Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Drug: Fuzheng 2</p>
<p>Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Placebo Comparator: Placebo</p>
<p>Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Drug: Placebo</p>
<p>Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Outcome Measures</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Primary Outcome Measures  :</p>
<ol>
<li> Peripheral blood CD3+ CD4+ counts [ Time Frame: 6 months ]  </li>
</ol>
<p>Secondary Outcome Measures  :</p>
<ol>
<li><p> Immune reconstitution efficiency [ Time Frame: 6 months ]  </p>
</li>
<li><p> Viral load [ Time Frame: 6 months ]  </p>
</li>
<li><p> Clinical symptoms and signs [ Time Frame: 6 months ]  </p>
</li>
<li><p> KPS score [ Time Frame: 6 months ]  </p>
</li>
<li><p> Quality of life score [ Time Frame: 6 months ]  </p>
</li>
<li><p> Side effects of HAART [ Time Frame: 6 months ]  </p>
</li>
<li><p> Safety evaluation [ Time Frame: 6 months ]  </p>
</li>
<li><p> Economic evaluation [ Time Frame: 6 months ]  </p>
</li>
</ol>
<p>Eligibility Criteria</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn" title="Learn About Clinical Studies">Learn About Clinical Studies.</a></em></p>
<p>Ages Eligible for Study:  </p>
<p>18 Years to 70 Years   (Adult, Older Adult)</p>
<p>Sexes Eligible for Study:  </p>
<p>All</p>
<p>Accepts Healthy Volunteers:  </p>
<p>No</p>
<p>Criteria</p>
<p>Inclusion Criteria:</p>
<ul>
<li>  HIV antibody-positive, confirmed by Western Blot test</li>
<li>  HIV antibody-positive, confirmed by Western Blot test</li>
<li>  HAART ≥ 12 months</li>
<li>  CD 4 count increased by &lt;100 cells / ul</li>
<li>  HIV RNA &lt;50 c / ml (bDNA);</li>
<li>  Age ≥ 18 years old and ≤ 70 years old</li>
<li>  Voluntary participated in this study, signed informed consent form, and could be followed-up</li>
</ul>
<p>Exclusion Criteria:</p>
<ul>
<li>  Serious opportunistic infections were not brought under control (Pneumocystis carinii pneumonia, meningitis, esophageal candidiasis, lymphoma, toxoplasma encephalopathy, tuberculosis, etc.) before the experiment</li>
<li>  Participated in clinical trials of other drugs within one month before the experiment</li>
<li>  Received immunomodulatory treatment within one month before the experiment</li>
<li>  WBC &lt;2 × 10 9 / L, N &lt;1.0 × 10 9 / L, Hb &lt;90g / L, PLT &lt;75 × 10 9 / L,liver and kidney dysfunction (AST, ALT, T-BIL ≥2 times of upper limit of the reference value or creatinine ≥ 2 times of the upper limit of reference value)</li>
<li>  Patients with pancreatitis or active gastric ulcer</li>
<li>  Patients with obvious active diseases in respiratory system, digestive system, circulatory system, blood system, neuroendocrine system, or genitourinary system diseases</li>
<li>  Persons suffering from autoimmune diseases</li>
<li>  Cancer patients which need chemotherapy</li>
<li>  Pregnant or lactating women, and did not use safe contraceptive measures for women of child-bearing age, as well as the male that can not take a reasonable method of contraception in trial period</li>
<li>  Hypersensitive people</li>
<li>  Patients with dysgnosia or language barriers, which can not fully understand the test or cooperate well</li>
</ul>
<p>Contacts and Locations</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.</em></p>
<p><em>Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT00974454</strong></em></p>
<p>Contacts</p>
<p>Contact: Jie Liu, MD</p>
<p>8610-88001381</p>
<p><a href="mailto:dr.liujie%40163.com?subject=NCT00974454,%2009.07.16-1,%20Research%20on%20Effect%20of%20Traditional%20Chinese%20Medicine%20(TCM)%20on%20Immune%20Reconstitution%20of%20HIV/AIDS%20Patients%20After%20Highly%20Active%20Antiretroviral%20Therapy%20(HAART)">dr.liujie@163.com</a></p>
<p>Locations</p>
<p>China, Beijing</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>Recruiting</p>
<p>Beijing, Beijing, China, 100053</p>
<p>Contact: Jie WANG, MD    8610-88001381    <a href="mailto:dr.liujie%40163.com?subject=NCT00974454,%2009.07.16-1,%20Research%20on%20Effect%20of%20Traditional%20Chinese%20Medicine%20(TCM)%20on%20Immune%20Reconstitution%20of%20HIV/AIDS%20Patients%20After%20Highly%20Active%20Antiretroviral%20Therapy%20(HAART)">dr.liujie@163.com</a>   </p>
<p>Sponsors and Collaborators</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>Investigators</p>
<p>Study Chair:</p>
<p>Jie WANG, MD</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>More Information</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Responsible Party:</p>
<p>WANG, Jie/Professor, Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>ClinicalTrials.gov Identifier:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/show/NCT00974454" title="Current version of study NCT00974454 on ClinicalTrials.gov">NCT00974454</a>     <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/history/NCT00974454" title="Historical versions of study NCT00974454 on ClinicalTrials.gov Archive Site">History of Changes</a></p>
<p>Other Study ID Numbers:</p>
<p>09.07.16-1  </p>
<p>First Posted:</p>
<p>September 10, 2009    <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/keydates/NCT00974454" title="View key record dates for NCT00974454">Key Record Dates</a></p>
<p>Last Update Posted:</p>
<p>October 29, 2009</p>
<p>Last Verified:</p>
<p>September 2009</p>
<p>Keywords provided by Guang’anmen Hospital of China Academy of Chinese Medical Sciences:</p>
<p>AIDS<br>complementary therapies<br>treatment experienced  </p>
<p>Additional relevant MeSH terms:</p>
<p>HIV Infections<br>Acquired Immunodeficiency Syndrome<br>Immunologic Deficiency Syndromes<br>Lentivirus Infections<br>Retroviridae Infections<br>RNA Virus Infections</p>
<h3 id="The-Effect-of-Combination-of-Traditional-Chinese-Medicine-TCM-and-Highly-Active-Antiretroviral-Therapy-HAART-on-Immune-Reconstitution-of-HIV-AIDS-Patients-Full-Text-View-ClinicalTrials-gov"><a href="#The-Effect-of-Combination-of-Traditional-Chinese-Medicine-TCM-and-Highly-Active-Antiretroviral-Therapy-HAART-on-Immune-Reconstitution-of-HIV-AIDS-Patients-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT00974519?term=NCT00974519&draw=2&rank=1">The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients - Full Text View - ClinicalTrials.gov</a></h3><p><strong>The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients</strong></p>
<p>The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.</p>
<p>ClinicalTrials.gov Identifier: NCT00974519</p>
<p>Recruitment Status  : Unknown</p>
<p>Verified September 2009 by Guang’anmen Hospital of China Academy of Chinese Medical Sciences.<br>Recruitment status was:  Recruiting</p>
<p>First Posted  : September 10, 2009</p>
<p>Last Update Posted  : October 29, 2009</p>
<p>Sponsor:</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>Information provided by:</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<ul>
<li>  Study Details</li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/record/NCT00974519?term=NCT00974519&draw=2&rank=1">Tabular View</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/results/NCT00974519?term=NCT00974519&draw=2&rank=1">No Results Posted</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" title="Disclaimer - opens new window">Disclaimer</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/help/how-read-study" title="How to Read a Study Record - opens new window">How to Read a Study Record</a></li>
</ul>
<p>Study Description</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Brief Summary:</p>
<p>Immunity 1 (Fuzheng 1) is composed of herbs which have tonic and detoxific function. The long-term clinical application has proved the safety and effect. It can improve the symptoms and signs in AIDS patients with the effective rate of 70% and can significantly improve the quality of life. It can also improve and stabilize immune function and inhibit viral replication. The basis study have shown that Immunity 1 (Fuzheng 1) can inhibit viral replication from multi-target, multi-link, enhance immune function, increase the secretion of IL-2, IFN-γ, participate in immune regulation effect, enhance NK cell activity, promote CD3+CD4+T cell proliferation and increase macrophage phagocytes capacity.</p>
<p>Condition or disease </p>
<p>Intervention/treatment </p>
<p>Phase </p>
<p>Acquired Immune Deficiency Syndrome VirusHIV Infections</p>
<p>Drug: Fuzheng 3Drug: Fuzheng 1Drug: Placebo</p>
<p>Not Applicable</p>
<p>Detailed Description:</p>
<ul>
<li>  Meng Kun found that Joint application of Chuankezhi can enhance the number of CD4 cells and reduce side-effects of HAART compared with HAART alone. in order to verify the long-term efficacy of combination therapy, they carried out an clinical observations of three cases of patients who received combination therapy for over a period of 3 years, through the observation of three cases of patients, they found that CD3+CD4+T lymphocyte count were significantly increased and HIV-RNA viral load were below 50copies for long-term, and without the occurrence of drug resistance. And the patient’s symptoms and signs have also been significantly improved.</li>
<li>  Duan Cheng Yu analyses 334 cases of AIDS patients’ clinical symptoms, signs and Karnofsky score, and CD3+CD4+ T lymphocyte count before and after treatment. The patients all take “kang ai bao sheng” capsules for 3 months. The results showed that 334 cases of patients receiving traditional Chinese and western medicine treatment shows improvement in symptoms and signs, increase in CD3+CD4+ T lymphocyte count. They proposed that combination of traditional Chinese and western medicine can improve symptoms, enhance immunity function and improve the quality of life of AIDS patients.</li>
<li>  In order to observe the effect of combination of TCM and HAART on HIV/AIDS patients, ZHANG Ai-min divided 63 cases of AIDS into 3 groups. 20 cases received TCM treatment and 22 cases received combination of TCM and HAART, 21 cases received western medicine. The patients’ symptoms, signs, Karnofsky score points, CD3+CD4+T lymphocyte counts and HIV-RNA viral load were recorded and compare the difference between the 3 groups. The results showed that combination treatment can more effectively improve the immune function of HIV/AIDS patients, reduce HIV-RNA viral load, and improve the patients’ symptoms, signs and the quality of life.</li>
<li>  Immunity 1 (Fuzheng 1) is composed of herbs which have tonic and detoxific function. The long-term clinical application has proved the safety and effect. It can improve the symptoms and signs in AIDS patients with the effective rate of 70% and can significantly improve the quality of life. It can also improve and stabilize immune function and inhibit viral replication. The basis study have shown that Immunity 1 (Fuzheng 1) can inhibit viral replication from multi-target, multi-link, enhance immune function, increase the secretion of IL-2, IFN-γ, participate in immune regulation effect, enhance NK cell activity, promote CD3+CD4+T cell proliferation and increase macrophage phagocytes capacity.</li>
<li>  Through the clinical trials, we are going to evaluate the efficacy and safety of combination of TCM and HAART on immune reconstitution of HIV/AIDS patients.</li>
</ul>
<p>Study Design</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Study Type  :</p>
<p>Interventional  (Clinical Trial)</p>
<p>Estimated Enrollment  :</p>
<p>180 participants</p>
<p>Allocation:</p>
<p>Randomized</p>
<p>Intervention Model:</p>
<p>Parallel Assignment</p>
<p>Masking:</p>
<p>Double (Participant, Investigator)</p>
<p>Primary Purpose:</p>
<p>Treatment</p>
<p>Official Title:</p>
<p>Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Combination of TCM and HAART on Immune Reconstitution of HIV/AIDS Patients</p>
<p>Study Start Date  :</p>
<p>September 2009</p>
<p>Estimated Primary Completion Date  :</p>
<p>June 2010</p>
<p>Estimated Study Completion Date  :</p>
<p>December 2010</p>
<p><strong>Resource links provided by the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><a target="_blank" rel="noopener" href="https://medlineplus.gov/" title="MedlinePlus">MedlinePlus</a> related topics: <a target="_blank" rel="noopener" href="https://medlineplus.gov/hivaids.html" title="HIV/AIDS at MedlinePlus">HIV/AIDS</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/info/fdalinks" title="Show FDA resources page">U.S. FDA Resources</a></p>
<p>Arms and Interventions</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Arm </p>
<p>Intervention/treatment </p>
<p>Active Comparator: Fuzheng 3</p>
<p>Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Drug: Fuzheng 3</p>
<p>Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Active Comparator: Fuzheng 1</p>
<p>Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Drug: Fuzheng 1</p>
<p>Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Placebo Comparator: Placebo</p>
<p>Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Drug: Placebo</p>
<p>Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.</p>
<p>Outcome Measures</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Primary Outcome Measures  :</p>
<ol>
<li> Peripheral blood CD3+ CD4+ counts [ Time Frame: 6 months ]  </li>
</ol>
<p>Secondary Outcome Measures  :</p>
<ol>
<li><p> Immune reconstitution efficiency [ Time Frame: 6 months ]  </p>
</li>
<li><p> Viral load [ Time Frame: 6 months ]  </p>
</li>
<li><p> Clinical symptoms and signs [ Time Frame: 6 months ]  </p>
</li>
<li><p> KPS score [ Time Frame: 6 months ]  </p>
</li>
<li><p> Quality of life score [ Time Frame: 6 months ]  </p>
</li>
<li><p> Side effect of HAART [ Time Frame: 6 months ]  </p>
</li>
<li><p> Safety evaluation [ Time Frame: 6 months ]  </p>
</li>
<li><p> Economic evaluation [ Time Frame: 6 months ]  </p>
</li>
</ol>
<p>Eligibility Criteria</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn" title="Learn About Clinical Studies">Learn About Clinical Studies.</a></em></p>
<p>Ages Eligible for Study:  </p>
<p>18 Years to 70 Years   (Adult, Older Adult)</p>
<p>Sexes Eligible for Study:  </p>
<p>All</p>
<p>Accepts Healthy Volunteers:  </p>
<p>No</p>
<p>Criteria</p>
<p>Inclusion Criteria:</p>
<ul>
<li>  HIV antibody-positive, confirmed by Western Blot test</li>
<li>  CD 4 count ≤ 350 cells / ul</li>
<li>  Age ≥ 18 years old and ≤ 70 years old</li>
<li>  Voluntary participated in this study, signed informed consent form, and could be followed-up</li>
</ul>
<p>Exclusion Criteria:</p>
<ul>
<li>  Serious opportunistic infections were not brought under control (Pneumocystis carinii pneumonia, meningitis, esophageal candidiasis, lymphoma, toxoplasma encephalopathy, tuberculosis, etc.) before the experiment</li>
<li>  Participated in clinical trials of other drugs within one month before the experiment</li>
<li>  Received antiretroviral therapy or are anti-HIV drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) and fusion-inhibiting agent (FIs), integrase inhibitors, inhibitors penetration within one month before the experiment</li>
<li>  Received immunomodulatory treatment within one month before the experiment WBC &lt;2 × 10 9 / L, N &lt;1.0 × 10 9 / L, Hb &lt;90g / L, PLT &lt;75 × 10 9 / L, liver and kidney dysfunction (AST, ALT, T-BIL ≥2 times of upper limit of the reference value or creatinine ≥ 2 times of the upper limit of reference value)</li>
<li>  Patients with pancreatitis or active gastric ulcer</li>
<li>  Patients with obvious active diseases in respiratory system, digestive system, circulatory system, blood system, neuroendocrine system, or genitourinary system diseases</li>
<li>  Persons suffering from autoimmune diseases</li>
<li>  Cancer patients which need chemotherapy</li>
<li>  Pregnant or lactating women, and did not use safe contraceptive measures for women of child-bearing age, as well as the male that can not take a reasonable method of contraception in trial period</li>
<li>  Hypersensitive people</li>
<li>  Patients with dysgnosia or language barriers, which can not fully understand the test or cooperate well</li>
</ul>
<p>Contacts and Locations</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.</em></p>
<p><em>Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT00974519</strong></em></p>
<p>Contacts</p>
<p>Contact: Jie Liu, MD</p>
<p>8610-88001381</p>
<p><a href="mailto:dr.liujie%40163.com?subject=NCT00974519,%2009.07.16-2,%20The%20Effect%20of%20Combination%20of%20Traditional%20Chinese%20Medicine%20(TCM)%20and%20Highly%20Active%20Antiretroviral%20Therapy%20(HAART)%20on%20Immune%20Reconstitution%20of%20HIV/AIDS%20Patients">dr.liujie@163.com</a></p>
<p>Locations</p>
<p>China, Beijing</p>
<p>Jie, WANG</p>
<p>Recruiting</p>
<p>Beijing, Beijing, China, 100053</p>
<p>Contact: Jie WANG, MD    8610-88001381    <a href="mailto:dr.liujie%40163.com?subject=NCT00974519,%2009.07.16-2,%20The%20Effect%20of%20Combination%20of%20Traditional%20Chinese%20Medicine%20(TCM)%20and%20Highly%20Active%20Antiretroviral%20Therapy%20(HAART)%20on%20Immune%20Reconstitution%20of%20HIV/AIDS%20Patients">dr.liujie@163.com</a>   </p>
<p>Sponsors and Collaborators</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>Investigators</p>
<p>Study Chair:</p>
<p>Jie WANG, MD</p>
<p>Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>More Information</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Responsible Party:</p>
<p>WANG, Jie/Professor, Guang’anmen Hospital of China Academy of Chinese Medical Sciences</p>
<p>ClinicalTrials.gov Identifier:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/show/NCT00974519" title="Current version of study NCT00974519 on ClinicalTrials.gov">NCT00974519</a>     <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/history/NCT00974519" title="Historical versions of study NCT00974519 on ClinicalTrials.gov Archive Site">History of Changes</a></p>
<p>Other Study ID Numbers:</p>
<p>09.07.16-2  </p>
<p>First Posted:</p>
<p>September 10, 2009    <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/keydates/NCT00974519" title="View key record dates for NCT00974519">Key Record Dates</a></p>
<p>Last Update Posted:</p>
<p>October 29, 2009</p>
<p>Last Verified:</p>
<p>September 2009</p>
<p>Keywords provided by Guang’anmen Hospital of China Academy of Chinese Medical Sciences:</p>
<p>ADIS<br>complementary therapies  </p>
<p>Additional relevant MeSH terms:</p>
<p>HIV Infections<br>Acquired Immunodeficiency Syndrome<br>Immunologic Deficiency Syndromes<br>Lentivirus Infections<br>Retroviridae Infections<br>RNA Virus Infections</p>
<h3 id="Lactoferrin-Treatment-in-HIV-Patients-Full-Text-View-ClinicalTrials-gov"><a href="#Lactoferrin-Treatment-in-HIV-Patients-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="Lactoferrin Treatment in HIV Patients - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT01830595?recrs=e&cond=hiv&u_prot=Yes&draw=2&rank=13">Lactoferrin Treatment in HIV Patients - Full Text View - ClinicalTrials.gov</a></h3><ul>
<li><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ProvidedDocs/95/NCT01830595/Prot_SAP_ICF_000.pdf">Microsoft Word - LactoferrinProtocol_v2.0_CLEAN_25March2015.doc</a></li>
</ul>
<p><strong>Lactoferrin Treatment in HIV Patients</strong></p>
<p>The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.</p>
<p>ClinicalTrials.gov Identifier: NCT01830595</p>
<p>Recruitment Status  : Completed</p>
<p>First Posted  : April 12, 2013</p>
<p>Results First Posted  : September 18, 2018</p>
<p>Last Update Posted  : October 18, 2018</p>
<p>Sponsor:</p>
<p>Jason Baker</p>
<p>Collaborator:</p>
<p>Ventria Bioscience</p>
<p>Information provided by (Responsible Party):</p>
<p>Jason Baker, Hennepin Healthcare Research Institute</p>
<ul>
<li>  Study Details</li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/record/NCT01830595?recrs=e&cond=hiv&u_prot=Yes&draw=2&rank=13">Tabular View</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/results/NCT01830595?recrs=e&cond=hiv&u_prot=Yes&draw=2&rank=13">Study Results</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" title="Disclaimer - opens new window">Disclaimer</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/help/how-read-study" title="How to Read a Study Record - opens new window">How to Read a Study Record</a></li>
</ul>
<p>Study Description</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Brief Summary:</p>
<p>Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.</p>
<p>Condition or disease </p>
<p>Intervention/treatment </p>
<p>Phase </p>
<p>HIV Infection</p>
<p>Drug: Recombinant LactoferrinDrug: Placebo</p>
<p>Phase 2</p>
<p>Study Design</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Study Type  :</p>
<p>Interventional  (Clinical Trial)</p>
<p>Actual Enrollment  :</p>
<p>55 participants</p>
<p>Allocation:</p>
<p>Randomized</p>
<p>Intervention Model:</p>
<p>Crossover Assignment</p>
<p>Masking:</p>
<p>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</p>
<p>Primary Purpose:</p>
<p>Treatment</p>
<p>Official Title:</p>
<p>Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients</p>
<p>Actual Study Start Date  :</p>
<p>September 2014</p>
<p>Actual Primary Completion Date  :</p>
<p>July 2017</p>
<p>Actual Study Completion Date  :</p>
<p>January 2018</p>
<p><strong>Resource links provided by the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><a target="_blank" rel="noopener" href="https://medlineplus.gov/" title="MedlinePlus">MedlinePlus</a> related topics: <a target="_blank" rel="noopener" href="https://medlineplus.gov/hivaids.html" title="HIV/AIDS at MedlinePlus">HIV/AIDS</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/info/fdalinks" title="Show FDA resources page">U.S. FDA Resources</a></p>
<p>Arms and Interventions</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Arm </p>
<p>Intervention/treatment </p>
<p>Active Comparator: Recombinant Lactoferrin</p>
<p>Recombinant lactoferrin will be administered by mouth twice daily</p>
<p>Drug: Recombinant Lactoferrin  </p>
<p>Placebo Comparator: Placebo</p>
<p>Matched placebo will be administered by mouth twice daily</p>
<p>Drug: Placebo  </p>
<p>Outcome Measures</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Primary Outcome Measures  :</p>
<ol>
<li><p>Number of Participants With at Least One Side Effect, Adverse Event, and Serious Adverse Event [ Time Frame: During 3 months on Lactoferrin or Placebo (and following washout period) ]</p>
<p> Self reported side effects and/or Division of AIDS (DAIDS) criteria will be used for grading adverse events (serious and non-serious)</p>
</li>
</ol>
<ol start="2">
<li><p>IL-6 &amp; D-dimer Score Changes From Baseline to 3 Months (or Month 5 to Month 8) [ Time Frame: 3 months (Baseline to Month 3 or Month 5 to Month 8) ]</p>
<p> The IL-6 &amp; D-dimer score is defined as: 0. 33*log2 IL-6 + 0.16*log2 D-dimer, where IL-6 is measured in pg/mL and D-dimer in ug/mL. Since the biomarkers are on the log2 scale, associations of risk with the IL-6 &amp; D-dimer score are interpreted as “HR(event) per doubling of IL-6 and D-dimer”, or “HR(event) per 20% increase in IL-6 and D-dimer”; the score itself is unitless.</p>
<p> Among the 3766 study participants for whom the score was developed, the min was -1.7, the max was 2.5.</p>
<p> Higher scores are worse.</p>
</li>
</ol>
<ol start="3">
<li><p>Number of Participants Taking Medication as Assigned [ Time Frame: 3 months ]</p>
<p> Number of participants taking medication as assigned at 3 months</p>
</li>
</ol>
<p>Other Outcome Measures:</p>
<ol>
<li><p>Activated Monocyte Phenotype (CD16+) [ Time Frame: 3 months ]</p>
<p> The change in CD16+ monocyte subsets will be compared between active and placebo treatment phases. During both the active and placebo treatment phase, all relevant time points are used in calculation of change (i.e., baseline, month 1 and month 3 for phase 1; and similarly months 5, 6 and 8 for phase 2).</p>
</li>
</ol>
<ol start="2">
<li><p>sCD163 [ Time Frame: 3 months ]</p>
<p> The change in blood levels of sCD163 will be compared between active and placebo treatment phases. During both the active and placebo treatment phase, all relevant time points are used in calculation of change (i.e., baseline, month 1 and month 3 for phase 1; and similarly months 5, 6 and 8 for phase 2).</p>
</li>
</ol>
<p>Eligibility Criteria</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn" title="Learn About Clinical Studies">Learn About Clinical Studies.</a></em></p>
<p>Ages Eligible for Study:  </p>
<p>40 Years and older   (Adult, Older Adult)</p>
<p>Sexes Eligible for Study:  </p>
<p>All</p>
<p>Accepts Healthy Volunteers:  </p>
<p>No</p>
<p>Criteria</p>
<p>Inclusion Criteria:</p>
<ol>
<li> HIV-positive participants receiving Antiretroviral Therapy (ART) for &gt;1 year</li>
<li> HIV RNA level &lt;200 copies/mL for at least 6 months (≥2 separate values)</li>
<li> Age &gt;40 years</li>
</ol>
<p>Exclusion Criteria:</p>
<ol>
<li> Prior cardiovascular disease or stroke</li>
<li> Diabetes</li>
<li> Rheumatologic Diseases</li>
<li> Pregnancy</li>
<li> Chronic kidney disease, stage IV or V (creatinine clearance &lt;30 mL/min/1.73m2)</li>
<li> Cirrhosis or end-stage liver disease</li>
</ol>
<p>Contacts and Locations</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.</em></p>
<p><em>Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT01830595</strong></em></p>
<p>Locations</p>
<p>United States, Minnesota</p>
<p>Hennepin County Medical Center</p>
<p>Minneapolis, Minnesota, United States, 55415</p>
<p>Sponsors and Collaborators</p>
<p>Jason Baker</p>
<p>Ventria Bioscience</p>
<p>Investigators</p>
<p>Principal Investigator:</p>
<p>Jason V Baker, MD, MS</p>
<p>Hennepin Healthcare Research Institute</p>
<p> Study Documents (Full-Text)</p>
<p>Documents provided by Jason Baker, Hennepin Healthcare Research Institute:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ProvidedDocs/95/NCT01830595/Prot_SAP_ICF_000.pdf" title="Study Protocol, Statistical Analysis Plan, and Informed Consent Form">Study Protocol, Statistical Analysis Plan, and Informed Consent Form</a>  [PDF] March 25, 2015</p>
<p>More Information</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFt-R0jxKCwA6h9Ei4L3BUgWwNG0it." title="Sortino O, Hullsiek KH, Richards E, Rupert A, Schminke A, Tetekpor N, Quinones M, Prosser R, Schacker T, Sereti I, Baker JV. The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy. J Infect Dis. 2019 May 24;219(12):1963-1968. doi: 10.1093/infdis/jiz042.">Sortino O, Hullsiek KH, Richards E, Rupert A, Schminke A, Tetekpor N, Quinones M, Prosser R, Schacker T, Sereti I, Baker JV. The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy. J Infect Dis. 2019 May 24;219(12):1963-1968. doi: 10.1093/infdis/jiz042.</a></p>
<p>Responsible Party:</p>
<p>Jason Baker, Associate Professor of Medicine, Hennepin Healthcare Research Institute</p>
<p>ClinicalTrials.gov Identifier:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/show/NCT01830595" title="Current version of study NCT01830595 on ClinicalTrials.gov">NCT01830595</a>     <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/history/NCT01830595" title="Historical versions of study NCT01830595 on ClinicalTrials.gov Archive Site">History of Changes</a></p>
<p>Other Study ID Numbers:</p>
<p>PCC-006  </p>
<p>First Posted:</p>
<p>April 12, 2013    <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/keydates/NCT01830595" title="View key record dates for NCT01830595">Key Record Dates</a></p>
<p>Results First Posted:</p>
<p>September 18, 2018</p>
<p>Last Update Posted:</p>
<p>October 18, 2018</p>
<p>Last Verified:</p>
<p>September 2018</p>
<p>Additional relevant MeSH terms:</p>
<p>HIV Infections<br>Lentivirus Infections<br>Retroviridae Infections<br>RNA Virus Infections<br>Virus Diseases<br>Sexually Transmitted Diseases, Viral  </p>
<p>Sexually Transmitted Diseases<br>Immunologic Deficiency Syndromes<br>Immune System Diseases<br>Lactoferrin<br>Anti-Infective Agents</p>
<h3 id="New-Era-Study-Treatment-With-Multi-Drug-Class-MDC-HAART-in-HIV-Infected-Patients-Full-Text-View-ClinicalTrials-gov"><a href="#New-Era-Study-Treatment-With-Multi-Drug-Class-MDC-HAART-in-HIV-Infected-Patients-Full-Text-View-ClinicalTrials-gov" class="headerlink" title="New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients - Full Text View - ClinicalTrials.gov"></a><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/NCT00908544?recrs=e&cond=hiv&u_prot=Yes&draw=2&rank=18">New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients - Full Text View - ClinicalTrials.gov</a></h3><ul>
<li><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ProvidedDocs/44/NCT00908544/Prot_SAP_000.pdf">New Era Prüfplan v3.2.2 final</a></li>
</ul>
<p><strong>New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients (NewEra)</strong></p>
<p>The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.</p>
<p>ClinicalTrials.gov Identifier: NCT00908544</p>
<p>Recruitment Status  : Completed</p>
<p>First Posted  : May 27, 2009</p>
<p>Results First Posted  : August 28, 2019</p>
<p>Last Update Posted  : August 28, 2019</p>
<p>Sponsor:</p>
<p>MUC Research GmbH</p>
<p>Collaborators:</p>
<p>Merck Sharp &amp; Dohme Corp.</p>
<p>AbbVie</p>
<p>Pfizer</p>
<p>German Center for Infection Research</p>
<p>Information provided by (Responsible Party):</p>
<p>MUC Research GmbH</p>
<ul>
<li>  Study Details</li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/record/NCT00908544?recrs=e&cond=hiv&u_prot=Yes&draw=2&rank=18">Tabular View</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/show/results/NCT00908544?recrs=e&cond=hiv&u_prot=Yes&draw=2&rank=18">Study Results</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" title="Disclaimer - opens new window">Disclaimer</a></li>
<li>  <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/help/how-read-study" title="How to Read a Study Record - opens new window">How to Read a Study Record</a></li>
</ul>
<p>Study Description</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Brief Summary:</p>
<p>This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr. Johannes Bogner are planning to perform an IIT (investigator initiated trial) with the goal to eradicate HIV in N=40 HIV-infected patients with either primary infection or chronic infection and successful HAART (Highly Active Antiretroviral Treatment) of several years.</p>
<p>All patients will be started on a multi-drug HAART including two Nucleoside-Reverse-Transcriptase-Inhibitors (NRTI´s), one Protease-Inhibitor (PI), a CCR5-inhibitor and an Integrase-Inhibitor (INI). Decay of viral reservoirs like latently HIV-infected CD4+ T-cells will be monitored over time.</p>
<p>Condition or disease </p>
<p>Intervention/treatment </p>
<p>Phase </p>
<p>HIV Infections</p>
<p>Other: PHI-patientsOther: CHI-patients</p>
<p>Not Applicable</p>
<p><img src="https://clinicaltrials.gov/ct2/html/images/expand.png" alt="Show"> Show detailed description</p>
<p>Study Design</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Study Type  :</p>
<p>Interventional  (Clinical Trial)</p>
<p>Actual Enrollment  :</p>
<p>47 participants</p>
<p>Allocation:</p>
<p>Non-Randomized</p>
<p>Intervention Model:</p>
<p>Parallel Assignment</p>
<p>Masking:</p>
<p>None (Open Label)</p>
<p>Primary Purpose:</p>
<p>Treatment</p>
<p>Official Title:</p>
<p>NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0</p>
<p>Actual Study Start Date  :</p>
<p>May 15, 2009</p>
<p>Actual Primary Completion Date  :</p>
<p>April 3, 2018</p>
<p>Actual Study Completion Date  :</p>
<p>May 2018</p>
<p><strong>Resource links provided by the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><a target="_blank" rel="noopener" href="https://medlineplus.gov/" title="MedlinePlus">MedlinePlus</a> related topics: <a target="_blank" rel="noopener" href="https://medlineplus.gov/hivaids.html" title="HIV/AIDS at MedlinePlus">HIV/AIDS</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/info/fdalinks" title="Show FDA resources page">U.S. FDA Resources</a></p>
<p>Arms and Interventions</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Arm </p>
<p>Intervention/treatment </p>
<p>Experimental: PHI-patients</p>
<p>Patients with primary HIV infection (PHI) (see also “Eligibility”) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir</p>
<p>Other: PHI-patients</p>
<p>Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir</p>
<p>Experimental: CHI-patients</p>
<p>Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also “Eligibility”) intensified by Maraviroc + Raltegravir</p>
<p>Other: CHI-patients</p>
<p>Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir</p>
<p>Outcome Measures</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Primary Outcome Measures  :</p>
<ol>
<li><p>Combined Endpoint Including HIV RNA and HIV DNA [ Time Frame: Screening, month -3 (= pre-baseline only for CHI-patients), baseline, months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> The primary outcome measure (i.e. achievement of ‘eradication’) is a combined endpoint including cell-associated proviral DNA and plasma HIV RNA and is defined as undetectable cell-associated HIV DNA (copies per 10exp6 PBMC (peripheral blood mononuclear cells) and per 10exp6 CD4 cells) for at least 2 years (measurement by the French ANRS Group) combined with plasma viral load &lt; 50 copies/ml for at least 5 years and undetectable plasma viral load (HIV RNA &lt; 1 copy/ml, 1-copy assay) for at least 2 years.</p>
</li>
</ol>
<p>Secondary Outcome Measures  :</p>
<ol>
<li><p>Mean Change in HIV DNA in PBMC (Month 36 and Month 84) [ Time Frame: Change from baseline at months 36 and 84 ]</p>
<p> Mean change (CI=95% Confidence Intervall) in HIV DNA copies/10exp6 PBMC (= peripheral blood mononuclear cells) from baseline, to evaluate the decay rates of latently infected cell reservoir.</p>
</li>
</ol>
<ol start="2">
<li><p>Mean Change in HIV DNA in CD4+T Cells (Month 36 and Month 84) [ Time Frame: Change from baseline at months 36 and 84 ]</p>
<p> Mean change (CI=95% Confidence Intervall) in HIV DNA copies/10exp6 CD4+T cells from baseline, to evaluate the decay rates of latently infected cell reservoir.</p>
</li>
</ol>
<ol start="3">
<li><p>HIV RNA &lt;50 Copies/ml (Proportion) [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Percentage of patients with Plasma HIV RNA &lt;50 copies/ml at baseline and during follow-up</p>
</li>
</ol>
<ol start="4">
<li><p>Median Change in HIV DNA in PBMC Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Median Change from baseline (IQR, interquartile range) in HIV DNA copies/10exp6 PBMC (= peripheral blood mononuclear cells), to evaluate the decay rates of latently infected cell reservoir.</p>
</li>
</ol>
<ol start="5">
<li><p>Median Change in HIV DNA in CD4+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Median Change from baseline (IQR, interquartile range) in HIV DNA in CD4+T cells, to evaluate the decay rates of latently infected cell reservoir.</p>
</li>
</ol>
<ol start="6">
<li><p>Median Change in CD4+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Median Change from baseline (IQR, interquartile range) in CD4+T cells/µl.</p>
</li>
</ol>
<ol start="7">
<li><p>Median Change in Relative CD4+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Median Change from baseline (IQR, interquartile range) in relative CD4+T cells/µl.</p>
</li>
</ol>
<ol start="8">
<li><p>Median Change in CD4+/CD8+ Ratio Over Time [ Time Frame: Change form Baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Median change in CD4+/ CD8+ ratio at baseline (IQR, interquartile range) and during follow-up</p>
</li>
</ol>
<ol start="9">
<li><p>Median Change in CD8+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p> Median Change from baseline (IQR, interquartile range) in CD8+T cells/µl.</p>
</li>
</ol>
<ol start="10">
<li><p>Median Change in CD8+CD38+T Cells Over Time [ Time Frame: Change from baseline at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Median Change from baseline (IQR, interquartile range) in CD8+CD38+T cells/µl.</p>
</li>
</ol>
<ol start="11">
<li><p>Absolute HIV DNA in PBMC [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Absolute HIV DNA in PBMC (= peripheral blood mononuclear cells) from baseline (Median; IQR, interquartile range), to quantify the cell-associated latently infected reservoir size by visit and treatment Group.</p>
</li>
</ol>
<ol start="12">
<li><p>Absolute HIV DNA in CD4+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Absolute HIV DNA in CD4+T cells from baseline (Median; IQR, interquartile range), to quantify the cell-associated latently infected reservoir size by visit and treatment Group.</p>
</li>
</ol>
<ol start="13">
<li><p>Absolute CD4+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Median CD4+T cells/µl at baseline (IQR, interquartile range) and during follow-up</p>
</li>
</ol>
<ol start="14">
<li><p>Relative CD4+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Median relative CD4+T cells/µl at baseline (IQR, interquartile range) and during follow-up</p>
</li>
</ol>
<ol start="15">
<li><p>CD4+/CD8+ Ratio [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Median CD4+/CD8+ ratio at baseline (IQR, interquartile range) and during follow-up</p>
</li>
</ol>
<ol start="16">
<li><p>Absolute CD8+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Median CD8+T cells/µl at baseline (IQR, interquartile range) and during follow-up</p>
</li>
</ol>
<ol start="17">
<li><p>Absolute CD8+CD38+T Cells [ Time Frame: Baseline and at months 1, 3, 6 and then every 6 months until month 84 ]</p>
<p>Median CD8+CD38+T cells/µl at baseline (IQR, interquartile range) and during follow-up</p>
</li>
</ol>
<p>Eligibility Criteria</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/about-studies/learn" title="Learn About Clinical Studies">Learn About Clinical Studies.</a></em></p>
<p>Ages Eligible for Study:  </p>
<p>18 Years to 70 Years   (Adult, Older Adult)</p>
<p>Sexes Eligible for Study:  </p>
<p>All</p>
<p>Accepts Healthy Volunteers:  </p>
<p>No</p>
<p>Criteria</p>
<ol>
<li><p>Inclusion Criteria:</p>
<p> For all patients:</p>
<ul>
<li><p>  HIV-infected patient</p>
</li>
<li><p>  Age greater 18 years</p>
</li>
<li><p>  No acute AIDS-defining disease or history of AIDS- defining disease</p>
</li>
<li><p>  CD4-cell nadir above or equal 200 cells/µL</p>
</li>
<li><p>  Hemoglobin greater 8 g/dl</p>
</li>
<li><p>  Neutrophil count greater 750 cells/µL</p>
</li>
<li><p>  Platelet count greater 50.000 cells/µL</p>
</li>
<li><p>  AST/ALT below 5x upper limit of normal range</p>
</li>
<li><p>  No evidence for drug intolerability</p>
</li>
<li><p>  No prior use of an HIV integrase inhibitor or CCR5 antagonist</p>
</li>
<li><p>  No presence of malignancy (requiring active treatment and malignancy within 5 years prior to enrolment (even if in complete remission)</p>
</li>
<li><p>  No significant underlying disease (non-HIV) that might impinge upon disease progression or death</p>
</li>
<li><p>  No history of alcohol or other substance abuse or other condition which in the opinion of the investigator would interfere with the patient compliance or safety.</p>
</li>
<li><p>  Written informed consent</p>
</li>
<li><p>  For males and premenopausal females use of acceptable methods of birth control during the entire study and for 6 weeks thereafter</p>
</li>
<li><p>  No pregnancy (for premenopausal women: negative serum or urine pregnancy test within 48 hours prior to initiating study medications)</p>
</li>
<li><p>No breastfeeding</p>
<p>For chronically HIV-infected patients (CHI):</p>
</li>
<li><p>  Continuous plasma viral load below 50 copies/ml for the preceding 36 months under HAART (two or less single viral load blips up to 500 copies/ml are allowed)</p>
</li>
<li><p>  Stable HAART (for at least 3 months) prior to the Screening visit consisting of 2 NRTI + 1 PI</p>
</li>
<li><p>  No history of virological failure</p>
</li>
<li><p>  No documented resistance to PI and NRTI</p>
</li>
<li><p>CCR5-tropic virus</p>
<p>For patients with primary HIV infection (PHI):</p>
</li>
<li><p>  Detectable plasma viral load</p>
</li>
<li><p>  ELISA positive or negative and Western Blot negative or positive with less or equal 2 bands at screening visit</p>
</li>
<li><p>  No primary resistance to PI´s and NRTI´s</p>
</li>
<li><p>  CCR5-tropic virus</p>
</li>
</ul>
</li>
<li><p> Exclusion criteria:</p>
</li>
</ol>
<p>Evidence for drug intolerability or contraindication concerning any drug foreseen for MDC HAART</p>
<ul>
<li><p>  Documented HIV-1 resistance to PI and/or NRTI.</p>
</li>
<li><p>  CD4 nadir &lt;200/µL</p>
</li>
<li><p>  Acute AIDS-defining disease or history of AIDS-defining disease</p>
</li>
<li><p>  CHI: preceding virological failure</p>
</li>
<li><p>  History of alcohol or other substance abuse or other condition which in the opinion of the investigator would interfere with the patient compliance or safety.</p>
</li>
<li><p>Any of the following abnormal laboratory test results in screening:</p>
<ol>
<li> Hemoglobin &lt; 8 g/dL</li>
<li> Neutrophil count &lt; 750 cells/µL</li>
<li> Platelet count &lt; 50,000 cells/µL</li>
<li> AST or ALT &gt; 5x the upper limit of normal</li>
</ol>
</li>
<li><p>  Presence of malignancy (requiring active treatment and malignancy within 5 years prior to enrolment (even if in complete remission)</p>
</li>
<li><p>  Significant underlying disease (non-HIV) that might impinge upon disease progression or death</p>
</li>
<li><p>  Prior use of any experimental HIV- Integrase-Inhibitor or CCR5-antagonist.</p>
</li>
<li><p>  Patient is pregnant or breastfeeding, or expecting to conceive (within the duration of the study). Patient is expecting to donate eggs (within the duration of the study). Patient is expecting to donate sperm (within the duration of the study).</p>
</li>
<li><p>  Contraindications for Maraviroc (Celsentri®) or Raltegravir (Isentress®) according to the respective summary of product characteristics (see also product informations attached to the protocol) (Hypersensitivity to the active substances or any of the excipients).</p>
</li>
</ul>
<p>Contacts and Locations</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p><strong>Information from the National Library of Medicine</strong><img src="https://clinicaltrials.gov/ct2/html/images/NIH_NLM_ABRV_BLK_4.png"></p>
<p><em>To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.</em></p>
<p><em>Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT00908544</strong></em></p>
<p>Locations</p>
<p>Germany</p>
<p>Onkology Karlsruhe</p>
<p>Karlsruhe, Baden-Wuerttemberg, Germany, 76135</p>
<p>Private Practice for Internal Medicine, Hematology and Oncology</p>
<p>Mannheim, Baden-Wuerttemberg, Germany, 68161</p>
<p>Private Practice Drs Ulmer/Frietsch/Mueller</p>
<p>Stuttgart, Baden-Wuerttemberg, Germany, 70197</p>
<p>Practice Dr. med. Lothar Schneider</p>
<p>Fürth, Bavaria, Germany, 90762</p>
<p>Private Practice Drs Pauli/Becker</p>
<p>Munich, Bavaria, Germany, 80331</p>
<p>MVZ Karlsplatz</p>
<p>Munich, Bavaria, Germany, 80335</p>
<p>University Munich University Hospital, Dept. of Infectious Diseases</p>
<p>Munich, Bavaria, Germany, 80336</p>
<p>ICH Study Center</p>
<p>Hamburg, Germany, 20354</p>
<p>Sponsors and Collaborators</p>
<p>MUC Research GmbH</p>
<p>Merck Sharp &amp; Dohme Corp.</p>
<p>AbbVie</p>
<p>Pfizer</p>
<p>German Center for Infection Research</p>
<p>Investigators</p>
<p>Study Chair:</p>
<p>Hans Jaeger, MD</p>
<p>MUC Research GmbH</p>
<p>Study Chair:</p>
<p>Johannes Bogner, Prof., MD</p>
<p>University Munich, University Hospital, Dept. of Infectious Diseases,</p>
<p> Study Documents (Full-Text)</p>
<p>Documents provided by MUC Research GmbH:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ProvidedDocs/44/NCT00908544/Prot_SAP_000.pdf" title="Study Protocol and Statistical Analysis Plan">Study Protocol and Statistical Analysis Plan</a>  [PDF] November 6, 2014</p>
<p>More Information</p>
<p>Go to  <img src="https://clinicaltrials.gov/ct2/html/images/pulldown.png" alt="sections"></p>
<p>Publications of Results:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR05-g0tcKCRA6h9Ei4L3BUgWwNG0it." title="Grützner EM, Hoffmann T, Wolf E, Gersbacher E, Neizert A, Stirner R, Pauli R, Ulmer A, Brust J, Bogner JR, Jaeger H, Draenert R. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells. Front Immunol. 2018 Apr 30;9:811. doi: 10.3389/fimmu.2018.00811. eCollection 2018.">Grützner EM, Hoffmann T, Wolf E, Gersbacher E, Neizert A, Stirner R, Pauli R, Ulmer A, Brust J, Bogner JR, Jaeger H, Draenert R. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells. Front Immunol. 2018 Apr 30;9:811. doi: 10.3389/fimmu.2018.00811. eCollection 2018.</a></p>
<p>Other Publications:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCnLR08cg0VA6h9Ei4L3BUgWwNG0it." title="Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, Pomerantz RJ, Perelson AS. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to &lt;5 copies per milliliter, with a half-life of 6 months. J Virol. 2003 Feb;77(3):2271-5.">Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, Pomerantz RJ, Perelson AS. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to &lt;5 copies per milliliter, with a half-life of 6 months. J Virol. 2003 Feb;77(3):2271-5.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCBEKC5SKCtA6h9Ei4L3BUgWwNG0it." title="Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19;366(9485):549-55.">Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19;366(9485):549-55.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCtcRCROR05A6h9Ei4L3BUgWwNG0it." title="Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000 Jan;6(1):82-5.">Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000 Jan;6(1):82-5.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCw-K4V-K4BA6h9Ei4L3BUgWwNG0it." title="Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog. 2007 Aug 31;3(8):e122.">Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog. 2007 Aug 31;3(8):e122.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCJagFjWgF8A6h9Ei4L3BUgWwNG0it." title="Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis. 2008 Jan 2;8:2. doi: 10.1186/1471-2334-8-2.">Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis. 2008 Jan 2;8:2. doi: 10.1186/1471-2334-8-2.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCn-gCVLR4VA6h9Ei4L3BUgWwNG0it." title="Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Jun;9(6):727-8. Epub 2003 May 18.">Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Jun;9(6):727-8. Epub 2003 May 18.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRCtFg4jSgFnA6h9Ei4L3BUgWwNG0it." title="Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999 May 27;340(21):1605-13.">Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999 May 27;340(21):1605-13.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08Eg4wLgFwA6h9Ei4L3BUgWwNG0it." title="Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 2;161(5):319-27. doi: 10.7326/M14-1027.">Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 2;161(5):319-27. doi: 10.7326/M14-1027.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0jLgCn-gFnA6h9Ei4L3BUgWwNG0it." title="Hütter G, Ganepola S. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells. ScientificWorldJournal. 2011 May 5;11:1068-76. doi: 10.1100/tsw.2011.102.">Hütter G, Ganepola S. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells. ScientificWorldJournal. 2011 May 5;11:1068-76. doi: 10.1100/tsw.2011.102.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0VagCnSRFRA6h9Ei4L3BUgWwNG0it." title="Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, Strain M, Richman D, Luzuriaga K. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013 Nov 7;369(19):1828-35. doi: 10.1056/NEJMoa1302976. Epub 2013 Oct 23.">Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, Strain M, Richman D, Luzuriaga K. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013 Nov 7;369(19):1828-35. doi: 10.1056/NEJMoa1302976. Epub 2013 Oct 23.</a></p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0RLRCBFg0tA6h9Ei4L3BUgWwNG0it." title="Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.">Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.</a></p>
<p>Responsible Party:</p>
<p>MUC Research GmbH</p>
<p>ClinicalTrials.gov Identifier:</p>
<p><a target="_blank" rel="noopener" href="https://clinicaltrials.gov/show/NCT00908544" title="Current version of study NCT00908544 on ClinicalTrials.gov">NCT00908544</a>     <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/history/NCT00908544" title="Historical versions of study NCT00908544 on ClinicalTrials.gov Archive Site">History of Changes</a></p>
<p>Other Study ID Numbers:</p>
<p>MUC_NewEra_3.3<br>2008-002070-35 ( EudraCT Number )<br>4034932 ( Other Identifier: BfArM )<br>08101 ( Other Identifier: Bayerische Landesärztekammer )<br>ID 8879 ( Other Grant/Funding Number: Pfizer )<br>IISP #35576 ( Other Grant/Funding Number: MSD )  </p>
<p>First Posted:</p>
<p>May 27, 2009    <a target="_blank" rel="noopener" href="https://clinicaltrials.gov/ct2/keydates/NCT00908544" title="View key record dates for NCT00908544">Key Record Dates</a></p>
<p>Results First Posted:</p>
<p>August 28, 2019</p>
<p>Last Update Posted:</p>
<p>August 28, 2019</p>
<p>Last Verified:</p>
<p>August 2019</p>
<p>Individual Participant Data (IPD) Sharing Statement:</p>
<p>Plan to Share IPD:</p>
<p>No</p>
<p>Keywords provided by MUC Research GmbH:</p>
<p>HIV-infection<br>Primary HIV-infection<br>Proviral DNA<br>Eradication<br>Multi drug class HAART  </p>
<p>Additional relevant MeSH terms:</p>
<p>HIV Infections<br>Acquired Immunodeficiency Syndrome<br>Infection<br>Lentivirus Infections<br>Retroviridae Infections<br>RNA Virus Infections  </p>
<p>Virus Diseases<br>Sexually Transmitted Diseases, Viral<br>Sexually Transmitted Diseases<br>Immunologic Deficiency Syndromes<br>Immune System Diseases<br>Slow Virus Diseases</p>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
	<div class="article-tag tagcloud">
		<i class="icon-price-tags icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color2">Qv2ray</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color4">HIV</a>
        		</li>
      		
		</ul>
	</div>

      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/20/20210520/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210517" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/17/20210517/">20210517</a>
    </h1>
  

        
        <a href="/2021/05/17/20210517/" class="archive-article-date">
  	<time datetime="2021-05-16T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210517</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Useful-App"><span class="toc-number">1.1.</span> <span class="toc-text">Useful App</span></a></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#%E7%A7%BB%E5%8A%A8%E7%AB%AFApp%E7%9A%84%E8%87%AA%E5%8A%A8%E5%8C%96"><span class="toc-number">2.</span> <span class="toc-text">移动端App的自动化</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Shortcuts-iOS"><span class="toc-number">2.1.</span> <span class="toc-text">Shortcuts&#x2F;iOS</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#Android"><span class="toc-number">2.2.</span> <span class="toc-text">Android</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#Automate"><span class="toc-number">2.2.1.</span> <span class="toc-text">Automate</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Tasker"><span class="toc-number">2.2.2.</span> <span class="toc-text">Tasker</span></a></li></ol></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Tasker-Android"><span class="toc-number">3.</span> <span class="toc-text">Tasker&#x2F;Android</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#%E8%AE%A9%E6%89%8B%E6%9C%BA%E8%87%AA%E5%8A%A8%E5%B8%AE%E4%BD%A0%E5%81%9A%E4%BA%8B%EF%BC%8C%E7%A5%9E%E5%99%A8-Tasker-%E8%AE%BE%E7%BD%AE%E6%95%99%E7%A8%8B-%E9%A2%86%E5%AE%A2%E4%B8%93%E6%A0%8F-%C2%B7-%E9%9B%BB%E8%85%A6%E7%8E%A9%E7%89%A9"><span class="toc-number">3.1.</span> <span class="toc-text">让手机自动帮你做事，神器 Tasker 设置教程 | 领客专栏 · 電腦玩物</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#%E3%80%8CTasker%E3%80%8D%E6%98%AF%E4%B8%80%E6%AC%BE%E6%80%8E%E4%B9%88%E6%A0%B7%E7%9A%84%E5%B7%A5%E5%85%B7%EF%BC%9F"><span class="toc-number">3.1.1.</span> <span class="toc-text">「Tasker」是一款怎么样的工具？</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E5%A6%82%E4%BD%95%E4%B8%8B%E8%BD%BD%E3%80%8CTasker%E3%80%8D%E5%85%8D%E8%B4%B9%E8%AF%95%E7%94%A8%E7%89%88%EF%BC%9F"><span class="toc-number">3.1.2.</span> <span class="toc-text">如何下载「Tasker」免费试用版？</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E3%80%8CTasker%E3%80%8D%E4%BC%9A%E4%B8%8D%E4%BC%9A%E5%BE%88%E9%9A%BE%E7%94%A8%EF%BC%9F%E5%85%B6%E5%AE%9E%E5%BE%88%E7%AE%80%E5%8D%95%EF%BC%81"><span class="toc-number">3.1.3.</span> <span class="toc-text">「Tasker」会不会很难用？其实很简单！</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%AD%A5%E9%AA%A4%E4%B8%80%EF%BC%9A%E9%85%8D%E7%BD%AE%EF%BC%8C%E8%AE%BE%E5%AE%9A%E4%BD%A0%E7%9A%84%E6%83%85%E5%A2%83%E6%9D%A1%E4%BB%B6"><span class="toc-number">3.1.4.</span> <span class="toc-text">步骤一：配置，设定你的情境条件</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%AD%A5%E9%AA%A4%E4%BA%8C%EF%BC%9A%E4%BB%BB%E5%8A%A1%EF%BC%8C%E8%AE%BE%E5%AE%9A%E8%A6%81%E8%A7%A6%E5%8F%91%E7%9A%84%E5%8A%A8%E4%BD%9C"><span class="toc-number">3.1.5.</span> <span class="toc-text">步骤二：任务，设定要触发的动作</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%AD%A5%E9%AA%A4%E4%B8%89%EF%BC%9A%E6%8A%8A%E9%85%8D%E7%BD%AE%E4%B8%8E%E4%BB%BB%E5%8A%A1%E8%BF%9E%E7%BB%93%E5%9C%A8%E4%B8%80%E8%B5%B7"><span class="toc-number">3.1.6.</span> <span class="toc-text">步骤三：把配置与任务连结在一起</span></a></li></ol></li><li class="toc-item toc-level-2"><a class="toc-link" href="#%E8%A2%AB%E8%AA%89%E4%B8%BA-Android-%E6%95%88%E7%8E%87%E5%88%A9%E5%99%A8%E7%9A%84-Tasker%EF%BC%8C%E7%94%9F%E6%B4%BB%E4%B8%AD%E7%A9%B6%E7%AB%9F%E5%8F%AF%E4%BB%A5%E6%80%8E%E4%B9%88%E7%94%A8%EF%BC%9F"><span class="toc-number">3.2.</span> <span class="toc-text">被誉为 Android 效率利器的 Tasker，生活中究竟可以怎么用？</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#Daha%EF%BC%9A%E8%A7%A3%E6%94%BE%E7%94%9F%E6%B4%BB%E9%87%8C%E7%9A%84%E3%80%8C%E4%B8%8D%E8%87%AA%E7%94%B1%E3%80%8D"><span class="toc-number">3.2.1.</span> <span class="toc-text">@Daha：解放生活里的「不自由」</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#%E6%92%AD%E6%94%BE%E9%9F%B3%E4%B9%90"><span class="toc-number">3.2.1.1.</span> <span class="toc-text">播放音乐</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#%E7%9D%A1%E7%9C%A0%E8%AE%B0%E5%BD%95"><span class="toc-number">3.2.1.2.</span> <span class="toc-text">睡眠记录</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#%E7%AD%BE%E5%88%B0%E6%89%93%E5%8D%A1"><span class="toc-number">3.2.1.3.</span> <span class="toc-text">签到打卡</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Fairyex%EF%BC%9A%E8%87%AA%E5%8A%A8%E5%8C%96%E4%B9%9F%E8%83%BD%E5%BE%88%E3%80%8C%E5%A5%BD%E7%9C%8B%E3%80%8D"><span class="toc-number">3.2.2.</span> <span class="toc-text">@Fairyex：自动化也能很「好看」</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Clyde%EF%BC%9A%E5%9C%A8%E6%91%B8%E7%B4%A2%E5%92%8C%E8%AF%95%E9%94%99%E4%B8%AD%E4%B8%8A%E6%89%8B"><span class="toc-number">3.2.3.</span> <span class="toc-text">@Clyde：在摸索和试错中上手</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#PeggyLv%EF%BC%9A%E4%B8%93%E6%B3%A8%E9%9C%80%E6%B1%82%EF%BC%8C%E5%8F%AF%E7%B9%81%E5%8F%AF%E7%AE%80"><span class="toc-number">3.2.4.</span> <span class="toc-text">@PeggyLv：专注需求，可繁可简</span></a></li></ol></li></ol></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Agent-%E5%85%8D%E8%A8%AD%E5%AE%9A%E8%81%B0%E6%98%8E%E6%89%8B%E6%A9%9F%E8%87%AA%E5%8B%95%E9%96%8B%E6%9C%83%E9%9D%9C%E9%9F%B3%E3%80%81%E7%9D%A1%E7%9C%A0%E5%8B%BF%E6%93%BE%E3%80%81%E5%81%9C%E8%BB%8A%E5%AE%9A%E4%BD%8D%EF%BC%81"><span class="toc-number">4.</span> <span class="toc-text">Agent 免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#AutomateIt-%E8%87%AA%E5%8B%95%E6%8E%A7%E5%88%B6-Android-%E7%9C%81%E6%99%82%E5%85%8D%E5%8B%95%E6%89%8B%EF%BC%8C%E6%99%BA%E6%85%A7%E6%89%8B%E6%A9%9F%E6%9B%B4%E8%81%B0%E6%98%8E"><span class="toc-number">5.</span> <span class="toc-text">AutomateIt 自動控制 Android 省時免動手，智慧手機更聰明</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#IFTTT-Android-iOS-%E5%85%A5%E9%96%80%E6%95%99%E5%AD%B8%EF%BC%9A%E5%A6%82%E6%9E%9C%E6%98%8E%E5%A4%A9%E4%B8%8B%E9%9B%A8%E8%AB%8B%E4%BB%8A%E6%97%A5%E6%8F%90%E9%86%92%E6%88%91"><span class="toc-number">6.</span> <span class="toc-text">IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Zapier-%E6%95%99%E5%AD%B8%EF%BC%9A%E8%AE%93-Evernote-%E7%AD%86%E8%A8%98%E8%88%87-Google-%E6%97%A5%E6%9B%86%E8%87%AA%E5%8B%95%E9%80%A3%E5%8B%95%E5%A5%BD%E6%96%B9%E6%B3%95"><span class="toc-number">7.</span> <span class="toc-text">Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%96%B9%E6%B3%95%E4%B8%80%EF%BC%9A%E8%AE%93%E9%9C%80%E8%A6%81%E6%99%82%E9%96%93%E6%8F%90%E9%86%92%E7%9A%84-Evernote-%E7%AD%86%E8%A8%98%EF%BC%8C%E4%B9%9F%E5%8C%AF%E5%85%A5-Google-%E6%97%A5%E6%9B%86%E8%A1%8C%E7%A8%8B"><span class="toc-number">7.0.1.</span> <span class="toc-text">方法一：讓需要時間提醒的 Evernote 筆記，也匯入 Google 日曆行程</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%96%B9%E6%B3%95%E4%BA%8C%EF%BC%9A%E8%AE%93%E6%96%B0%E7%9A%84-Google-%E8%A1%8C%E4%BA%8B%E6%9B%86%E8%A1%8C%E7%A8%8B%EF%BC%8C%E8%87%AA%E5%8B%95%E6%96%B0%E5%A2%9E-Evernote-%E7%AD%86%E8%A8%98"><span class="toc-number">7.0.2.</span> <span class="toc-text">方法二：讓新的 Google 行事曆行程，自動新增 Evernote 筆記</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#%E6%96%B9%E6%B3%95%E4%B8%89%EF%BC%9A%E5%AE%8C%E5%85%A8%E8%87%AA%E8%A8%82"><span class="toc-number">7.0.3.</span> <span class="toc-text">方法三：完全自訂</span></a></li></ol></li></ol></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><h2 id="Useful-App"><a href="#Useful-App" class="headerlink" title="Useful App"></a>Useful App</h2><ol>
<li>Shortcuts：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa1RMcnFDX18zLU9LaEExcjFmQjJhT1BydWVTd3xBQ3Jtc0tuOFBkYVlkNEtvclpCSkhKVmhmRVVZMjYzWUx3djV1dzJPWG5IdTlDM1JZcDViMXdiN1kyUThOUFczN09qVFhoMzRCMlktR2RlQm10UzNKRkdyd0FFa05CM2VUUWNQdnBOVHVSdTBZRWNMTk1vTGhpUQ&q=https://apps.apple.com/us/app/shortcuts/id915249334">https://apps.apple.com/us/app/shortcu…</a> </li>
<li>Zenly（iOS版）：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbXljX19zUFp0WGxaWXJKTTY4V3ZUUnBRcWFFUXxBQ3Jtc0ttZFVtUjJFUlZ6SmZyWkpMeXh3bmd2TlRNS3hrdEM0ZnBDaF9EcjFQeHE4bWNmMkpkUzl6eTJiWEY4R0gzOHNodl9wNFZCMklYM21SYVF4ZC04SFJacm5OUzRtS2dmdVlYdkhIeEhINENNR2diQjVoSQ&q=https://apps.apple.com/us/app/zenly-your-map-your-people/id838848566">https://apps.apple.com/us/app/zenly-y…</a> </li>
<li>Zenly（安卓版）：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbHFkY0ZMcW9wR05pWmx5eUhsb0FmSW51cVVtd3xBQ3Jtc0ttUjNjSmJlbF9wRFpMcnhiMVFBd3lhLUxDd0xJcDRsNDFEOEROWGFjYWVld2tPc1psYmhRV1dxMWdvOXY3UTBuV1hSYWVfR2JPYVJpbDByeUlCbmIxbWlwa1NDQzFKTlNQRG1xVkxNSkZ4d21CRWt0TQ&q=https://play.google.com/store/apps/details?id=app.zenly.locator&hl=zh&gl=US">https://play.google.com/store/apps/de…</a> </li>
<li>Picsew：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa3JpMW1NTTRJMGQyQTV1VGwzeWlUOVpwem1TQXxBQ3Jtc0tsRnZDWDF2NjNwakE5N09pVV9ZTXhlSVlSWktjVGsxSF9iVnJ1VnFUd3FmNzJmUHRhNHo2MUQxb3lnek04T1BlZTlJbUZIeGQ1bEp5czhNV2NFR0dtZmlPbXJZRE9CTUdHOWN6Y01DTkFSVUtRbTZqZw&q=https://apps.apple.com/us/app/picsew-screenshot-stitching/id1208145167">https://apps.apple.com/us/app/picsew-…</a> </li>
<li>Vellum：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbERwNGo1YjhPeTBQcUxsRG14NFZZeGFaY2pZQXxBQ3Jtc0tsd01tSU9yQlo5YkI5ZXNYQzdQdUg0dmVVcVFraXV4dndGWUdURXQxaGVYYUNsenJSY3N6bElmQ096U3RqVU5RMEpTTFAwN01td1JuZHBCWWRram8yRWdRbDJYdHVPdUppS2lHejVrU3dGbzJaWUpWbw&q=https://apps.apple.com/us/app/vellum-wallpapers/id1095068317">https://apps.apple.com/us/app/vellum-…</a> </li>
<li>Call of Duty：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbVljbl9DTUw1MGJpbzlmX3JDbmJLdTBnS3EyUXxBQ3Jtc0trY2VTdE1DdnNGTTltc1NEUm1FRUljNkVXOWNFYkxtMHMySGpLSm9YcG1hM1lsYmIzSGxiNWF5dHVPMWlRZkQtM2ZVaTBTekJFNHpLOC1jSEpGbVhfMHgzQXhNc2VIcEpzaUlRRDNxVm1wYzRmZkMxdw&q=https://apps.apple.com/us/app/call-of-duty-companion-app/id1405837628">https://apps.apple.com/us/app/call-of…</a> </li>
<li>Snapseed：<br>  （iOS版）<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbC1sdHl6VmJUWnpUeFRaUGF4aTRrX2x3NGMwd3xBQ3Jtc0ttbk5nUzIteWpBUDdseExNdC03X3doajJIZTVMSkZDRXozMTVrUEJSQVp6VXBYVE03XzlaamFLN0tUV3hPRk1FeUdaNnduTmpOWkpaNFkzMVRPYy1hbjFvTy1UZ0YtUF85UzlHdFpWdmgwREFJYmx4WQ&q=https://apps.apple.com/us/app/snapseed/id439438619">https://apps.apple.com/us/app/snapsee…</a><br>  （安卓版） <a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqblZSalEtUHZhTE9GV1R1YWZVWFM3ekY4N2laQXxBQ3Jtc0tteXNHd3BXTWpQdjZzNWNmQ1FmdXpwbWVuQUN6UWFTQXB6a1poRnZFa1dnZFZ0S2taT3p1QU85OU5nYkRoZE5aT0EtTGpQNURZUDlJUExURFU4R1BLTGVfX2JXZUNadlJmUEhYSGY0R1VQaU5FSUpRZw&q=https://play.google.com/store/apps/details?id=com.niksoftware.snapseed&hl=zh&gl=US">https://play.google.com/store/apps/de…</a> </li>
<li>Shazam ：<a target="_blank" rel="noopener" href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbVJIMFAyT3hreDBJemJNX0pOZGM0R1ZVZEhJQXxBQ3Jtc0trY1JocF9McGFZUnRHTVhPTnQ4UW0tZlF1QjlnVFJfTjc3YkJFa3VqUXZIYXJzZ2lQdFVTeTFkTGU3WC1IX01hVXlBazJqcG1nMEZEN2hhLWVwX1lmSGowOHdFVURaSVRlbk84MkhMbm1vWk84MDlkWQ&q=https://www.shazam.com">https://www.shazam.com</a></li>
</ol>
<h1 id="移动端App的自动化"><a href="#移动端App的自动化" class="headerlink" title="移动端App的自动化"></a>移动端App的自动化</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2014/02/agent-app.html">Agent 免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！</a></li>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2013/06/automateit-android.html">AutomateIt 自動控制 Android 省時免動手，智慧手機更聰明</a></li>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2014/04/ifttt-android-ios.html">IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我</a></li>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2017/06/zapier-evernote-google-calendar.html">Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法</a></li>
</ul>
<h2 id="Shortcuts-iOS"><a href="#Shortcuts-iOS" class="headerlink" title="Shortcuts/iOS"></a>Shortcuts/iOS</h2><h2 id="Android"><a href="#Android" class="headerlink" title="Android"></a>Android</h2><h3 id="Automate"><a href="#Automate" class="headerlink" title="Automate"></a>Automate</h3><h3 id="Tasker"><a href="#Tasker" class="headerlink" title="Tasker"></a>Tasker</h3><h1 id="Tasker-Android"><a href="#Tasker-Android" class="headerlink" title="Tasker/Android"></a>Tasker/Android</h1><h2 id="让手机自动帮你做事，神器-Tasker-设置教程-领客专栏-·-電腦玩物"><a href="#让手机自动帮你做事，神器-Tasker-设置教程-领客专栏-·-電腦玩物" class="headerlink" title="让手机自动帮你做事，神器 Tasker 设置教程 | 领客专栏 · 電腦玩物"></a>让手机自动帮你做事，神器 Tasker 设置教程 | 领客专栏 · 電腦玩物</h2><ul>
<li><a target="_blank" rel="noopener" href="https://www.ifanr.com/app/879709">让手机自动帮你做事，神器 Tasker 设置教程 | 领客专栏 · 電腦玩物 | 爱范儿</a></li>
</ul>
<p><a target="_blank" rel="noopener" href="https://www.ifanr.com/app/">AppSo</a></p>
<p>2017-07-28 14:21</p>
<p>前几年，我在电脑玩物介绍过不少 Android 上的自动化工具，其中目前仍持续更新，还值得推荐的有：</p>
<ul>
<li>对一般人来说最好上手的：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/02/agent-app.html">Agent 免设定聪明手机自动开会静音、睡眠勿扰、停车定位</a>；</li>
<li>功能设定很丰富的：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/06/automateit-android.html">AutomateIt 自动控制 Android 省时免动手，智能手机更聪明</a>。</li>
</ul>
<p>但那时我独独漏掉 Tasker，而 Tasker 却是许多人心中最强大的 Android 自动化工具。</p>
<p>最近，看到「Tasker 5.0」推出，新版本有了焕然一新的界面，于是我便想说趁此机会来写一篇上手教学。</p>
<h3 id="「Tasker」是一款怎么样的工具？"><a href="#「Tasker」是一款怎么样的工具？" class="headerlink" title="「Tasker」是一款怎么样的工具？"></a>「Tasker」是一款怎么样的工具？</h3><p>近年比较流行「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/04/ifttt-android-ios.html">IFTTT</a>」或「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/06/zapier-evernote-google-calendar.html">Zapier</a>」这类网络服务自动串连工具。或许熟悉网络服务的朋友，有看过我介绍：</p>
<ul>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/04/ifttt-android-ios.html">IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我</a></li>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/06/zapier-evernote-google-calendar.html">Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法</a></li>
</ul>
<p>它们的功能是当 A 服务出现什么资讯时，自动在 B 服务也加入同类资讯，例如自动把 Facebook 贴文导入 Evernote。</p>
<p>不过 Tasker 和 Agent、AutomateIt，不是上面那类工具，只是概念一样，就是「<strong>当 A 条件发生时，就触发 B 动作</strong>」。</p>
<blockquote>
<p><strong>「Tasker」主要是针对手机内置功能的自动化。</strong>例如它可以帮你在睡觉时自动手机静音，回到家里不再锁定手机，开车时自动启动导航地图，还能用内置功能自动开启省电模式等等，就看你要使用到什么程度。</p>
</blockquote>
<p>尤其特别适合「<strong>常常会一直调整手机设定</strong>」的 Android 手机使用者，你只要利用「Tasker」设定好条件，那么它以后就能帮你在不同情况，自动调整你需要的设定，或是开启你需要的功能。</p>
<p>那 iOS 用户呢？有没有类似工具，也有，你可以试试看我之前介绍过的<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2015/01/workflow-ios-app.html">Workflow 史上最強 iOS App 自動化機器人上手教學與免費下載</a>。</p>
<h3 id="如何下载「Tasker」免费试用版？"><a href="#如何下载「Tasker」免费试用版？" class="headerlink" title="如何下载「Tasker」免费试用版？"></a>如何下载「Tasker」免费试用版？</h3><p>「Tasker」是付费软件，可以在 Google Play 上直接购买，以它强大的功能来说，价格不贵，只要新台币 100 元左右（约合人民币 22 元）。但如果你没用过，还不确定自己是否需要这个工具。那么你可以试试免费的试用版。</p>
<p>「Tasker」开发者在其<a target="_blank" rel="noopener" href="http://tasker.dinglisch.net/">官方网站</a>上，有提供<a target="_blank" rel="noopener" href="http://tasker.dinglisch.net/download.html">7 天试用版可直接下载</a>。</p>
<h3 id="「Tasker」会不会很难用？其实很简单！"><a href="#「Tasker」会不会很难用？其实很简单！" class="headerlink" title="「Tasker」会不会很难用？其实很简单！"></a>「Tasker」会不会很难用？其实很简单！</h3><p>乍看之下「Tasker」好像很复杂，是不是会很难用呢？其实它的上手逻辑是很简单的，困难点主要在于你可不可以想出「真正实用而有创意」的自动化流程。</p>
<p>要如何上手「Tasker」？只要思考一个问题就好：</p>
<blockquote>
<p>你想在什么情境条件下，自动触发什么动作？</p>
</blockquote>
<p>我就举个例子来示范，例如我最近开车都用「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/04/google-maps-navigation-app.html">Google 地图导航</a>」，但是我平常手机喜欢开静音（不要有任何干扰，也不要不小心干扰别人），所以我很需要一个自动化流程：「每次我打开 Google 地图时打开媒体音量，让导航有声音。但是我跳出 Google 地图时就关静音，避免干扰。」</p>
<p>这时候就可以利用「Tasker」解决上述需求，只要三个步骤！</p>
<h3 id="步骤一：配置，设定你的情境条件"><a href="#步骤一：配置，设定你的情境条件" class="headerlink" title="步骤一：配置，设定你的情境条件"></a><strong>步骤一：配置，设定你的情境条件</strong></h3><p>首先一进入「Tasker」，会看到有一个「配置文件」的页面，这里其实就是让你「建立（要触发自动反应的）情境条件」。可以设定手机感应器、特殊时间点、插上特殊装置、电池状态等等各种条件。</p>
<p><img src="https://s3.ifanr.com/wp-content/uploads/2017/07/tasker-2.jpg!720"></p>
<p>例如以我前面所举的例子为例，我的条件就是：「当 Google 地图启动时」要触发某些行为。这时候我就点右下角的「+」，选择「应用程式」，选择「Google 地图」。</p>
<p>这样就在「配置文件」中加入了我要的「情境条件」，也就是「启动 Google 地图时」。</p>
<p><img src="https://s3.ifanr.com/wp-content/uploads/2017/07/tasker-3.jpg!720"></p>
<h3 id="步骤二：任务，设定要触发的动作"><a href="#步骤二：任务，设定要触发的动作" class="headerlink" title="步骤二：任务，设定要触发的动作"></a><strong>步骤二：任务，设定要触发的动作</strong></h3><p>接着，我可以在第二个页面「任务」，加入我想触发的各种动作。<strong>「Tasker」之所以被认为很强大，就是因为它几乎可以触发手机上所有的装置功能，从音量、网络到各种设定。</strong></p>
<p>回到我前面的例子，我想要触发的动作是「开启媒体音量」，于是我就在「任务」页面右下角点击「+」，加入「把媒体音量调整到 11」的动作。</p>
<p><img src="https://s3.ifanr.com/wp-content/uploads/2017/07/tasker-4.jpg!720"></p>
<h3 id="步骤三：把配置与任务连结在一起"><a href="#步骤三：把配置与任务连结在一起" class="headerlink" title="步骤三：把配置与任务连结在一起"></a><strong>步骤三：把配置与任务连结在一起</strong></h3><p>有了「情境条件」，也有了「要触发的动作」，接着就把两个连在一起即可。</p>
<p>让「启动地图」这个配置，去连结刚刚建立的「开启媒体音量」任务。下图中则是我另外一个使用例子，当我开启<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/02/ted-talk-ted-android-ios-app.html">TED 影片 app</a>时，也自动触发开启媒体音量功能。</p>
<p><img src="https://s3.ifanr.com/wp-content/uploads/2017/07/tasker-5.jpg!720"></p>
<p>在「Tasker」中建立好上述条件与动作，实际执行的效果如下。</p>
<p>当我在手机上打开 Google 地图，媒体音量自动调整到 11，让我可以听到导航语音。当我跳出 Google 地图，媒体音量自动回到原本的静音状态。</p>
<p>这样就完成自动化流程，我就不用再自己动手调整了。</p>
<p><img src="https://s3.ifanr.com/wp-content/uploads/2017/07/tasker-6.jpg!720"></p>
<p>最后，为了让「Tasker」可以触发自动反应，你可能必须允许「Tasker」在后台运行，这样每次的条件触发才会顺利启动。</p>
<p>今天这篇文章，是「Tasker」的上手教学，我想用最简单的方法，让要试试看的朋友，知道「Tasker」这款工具并不难。当然，当你要进一步研究时，「Tasker」还有很多更进阶的设定，这就留待之后讨论了。</p>
<p>文章授权转自電腦玩物，原文链接：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/07/tasker-android.html">Tasker：Android 最强大自动化工具，最简单三步骤上手教学</a></p>
<p><strong>本文由让手机更好用的 AppSo 精选推荐，关注公众号 AppSo，回复「效率神器」，获取为你精选的<a target="_blank" rel="noopener" href="https://www.ifanr.com/app/676943">实用触发方案，让你轻松入门自动化神器 IFTTT</a>。</strong></p>
<h2 id="被誉为-Android-效率利器的-Tasker，生活中究竟可以怎么用？"><a href="#被誉为-Android-效率利器的-Tasker，生活中究竟可以怎么用？" class="headerlink" title="被誉为 Android 效率利器的 Tasker，生活中究竟可以怎么用？"></a>被誉为 Android 效率利器的 Tasker，生活中究竟可以怎么用？</h2><p><a target="_blank" rel="noopener" href="https://sspai.com/u/mp9rwx7n/updates"><img src="https://cdn.sspai.com/2017/08/22/8d043e41c293457fe00aa0fc9e4ccc58.png?imageMogr2/auto-orient/quality/95/thumbnail/!64x64r/gravity/Center/crop/64x64/interlace/1" alt="Android 派小队"></a></p>
<ul>
<li><a target="_blank" rel="noopener" href="https://sspai.com/post/58457">被誉为 Android 效率利器的 Tasker，生活中究竟可以怎么用？ - 少数派</a></li>
</ul>
<p><a target="_blank" rel="noopener" href="https://sspai.com/u/mp9rwx7n/updates">Android 派小队</a></p>
<p>2020年01月15日</p>
<p>在 2019 年的少数派<a target="_blank" rel="noopener" href="https://sspai.com/page/2019">年度盘点</a>中，我们将「学会自动化魔法，少做无用功」作为一条能够帮你提高效率的年度建议。去年我们做了不少与自动化相关的内容和选题，但自动化对大多数用户而言依然有着不小的距离感。</p>
<p>因此在这篇文章中，我们请来少数派的作者和编辑分享他们的 Tasker 使用经验，希望能够消除你对 Tasker 这款自动化工具的抵触，更好地拥抱效率生活。</p>
<h3 id="Daha：解放生活里的「不自由」"><a href="#Daha：解放生活里的「不自由」" class="headerlink" title="@Daha：解放生活里的「不自由」"></a>@Daha：解放生活里的「不自由」</h3><p>🔗<a target="_blank" rel="noopener" href="https://sspai.com/u/6aqo224h/posts">查看 TA 的作品</a></p>
<p>任务自动化最迷人的一点在于，当一切配置安顿好之后，只需要少许触发条件，「机器人」就悄悄地帮你完成了一切。你可能甚至意识不到它们的发生，自然而美好。</p>
<p>Tasker 作为 Android 平台上最优秀的任务自动化软件之一，可以帮助我们充分利用手机潜能（比如各类传感器），检测当前所处的状态并判断我们的意图，从而完成任务。从使用者的角度出发，我们甚至无需编写程序就能直接通过内置的交互界面做好任务配置。</p>
<p>下面展开讲讲我自己在用的几个常用配置：</p>
<h4 id="播放音乐"><a href="#播放音乐" class="headerlink" title="播放音乐"></a>播放音乐</h4><p>非常简单也令人愉悦的配置：「当连接上指定的蓝牙设备时，开始播放音乐」。我主要使用的音乐播放设备是 Airpods 和蓝牙小音箱。戴上 AirPods、AirBattery 检测到后帮它连上蓝牙、音乐自然地流淌出来，音量正合适。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/69d2185ca0aee2ff147ea39c3c921ae5.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>媒体音量调节</p>
<p>我有睡前戴耳机聆听音乐入睡的习惯，因为夜深人静，这个时候只需要很低的音量。所以我引入了这样的 Tasker 配置：「到了睡觉时间，调低媒体音量，30分钟后静音、终止音乐软件播放」。</p>
<h4 id="睡眠记录"><a href="#睡眠记录" class="headerlink" title="睡眠记录"></a>睡眠记录</h4><p>说到睡眠，睡眠时间记录也是一个常用的场景。这里配合了 NFC 标签的使用，我把 NFC 标签贴在床头，每当到了睡觉时间 Tasker 唤起 NFC ，将手机靠近标签，这时 Tasker 里提前定义好的「入睡时间」变量便会记录下此刻的时间；早上清醒之后，再打一次卡，记录「起床时间」变量，后台计算出睡眠时间后，告诉我晚上睡了多久，是否满 8 个小时。同时添加一条记录到「睡眠记录」文件，每个周五的时候提醒我查看这周的睡眠状况。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/d99daf1eda8de480d098b78cfbaddc7a.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>睡眠记录与睡眠报告</p>
<p>仅仅使用了一些变量，就可以轻松记录睡眠。最重要的是，配合 NFC 标签这一物理打卡器，一般不会出现忘记的情况。</p>
<h4 id="签到打卡"><a href="#签到打卡" class="headerlink" title="签到打卡"></a>签到打卡</h4><p>这个功能需要配合 <a target="_blank" rel="noopener" href="https://sspai.com/app/Nova%20Launcher">Nova Launcher</a> 启动器的 Swipe Up 和 <a target="_blank" rel="noopener" href="https://play.google.com/store/apps/details?id=com.joaomgcd.autoinput&hl=en_US">AutoInput</a> 软件。Nova Launcher 的 Swipe Up 支持软件图标上滑触发 Tasker 任务。所以我配置了上滑图标自动签到相关软件，Tasker 负责打开软件，AutoInput 负责自动完成点击任务。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/9167883be543fc43e796a60a1638fe23.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>网易云自动签到</p>
<p>还有一些简单的小任务：步数达到一个阈值时，晚些时候提醒拉伸放松；到家离家时问候以及提醒待办事项；电源不足提醒充电，充满电时提醒完成；打开 Instapaper 时启动横屏支持（本人的阅读习惯）；话费不足时打开充值界面……</p>
<p><img src="https://cdn.sspai.com/2020/01/15/016a151f7d0ebcc0e4e600cdeecf6a30.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>Instapaper 的自动横屏支持</p>
<p><img src="https://cdn.sspai.com/2020/01/15/de66f6a40d268ef40bd31ed2e3a14d25.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>步数统计提醒</p>
<p>总之，Tasker 解放了一切不自由，发挥你的想象力使用它吧！</p>
<p><a target="_blank" rel="noopener" href="https://sspai.com/app/AutoInput">AutoInput</a></p>
<p><a target="_blank" rel="noopener" href="https://sspai.com/app/AutoInput">相关文章</a><a target="_blank" rel="noopener" href="https://sspai.com/d/nMA6bn"></a></p>
<h3 id="Fairyex：自动化也能很「好看」"><a href="#Fairyex：自动化也能很「好看」" class="headerlink" title="@Fairyex：自动化也能很「好看」"></a>@Fairyex：自动化也能很「好看」</h3><p>🔗<a target="_blank" rel="noopener" href="https://sspai.com/u/hmy9ayji/posts">查看 TA 的作品</a></p>
<p>我从很早之前就开始使用 Tasker 了，在少数派的首篇文章也正是我自己使用 Tasker 一天的分享。</p>
<p><strong>关联阅读：</strong><a target="_blank" rel="noopener" href="https://sspai.com/post/39792">Tasker - 我与拥有它的生活方式</a></p>
<p><img src="https://cdn.sspai.com/fairyex/20200109/QfCQmhi1dz6y.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>当时的文章截图</p>
<p>之后工作和学习上的需求不断新增，我在手机上制作的 Tasker 任务数量越来越多，复杂程度也越来越高。对比上一篇文章发表的时候，我惊奇地发现我制作的任务不仅拥有了更好看的 UI，而且已经能够完全覆盖生活和工作的方方面面。</p>
<p>于是在今年的 Power+ 中我用多篇文章给大家分享了自己探索的包括如何使用网络 API 来实现自动记录时间、如何利用读取 NFC 来实现物品管理等各种 Tasker 高级技巧与 Tasker 不断更新新版本后带来的新玩法，也在《<a target="_blank" rel="noopener" href="https://sspai.com/post/56730">Power+ 奏折 40</a>》的桌面分享栏目中分享了自己目前任务的 UI 变化与新的任务，感兴趣的朋友也可以看看这篇文章。</p>
<p><img src="https://cdn.sspai.com/fairyex/20200109/q8dFevcKU0ea.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>更新的任务</p>
<p>上面提到我所制作的任务已经能够覆盖到生活工作的各种方面，其实主要是以下 6 个方面：</p>
<ol>
<li> 日常生活信息获取展示：天气、新闻、股票贵金属价格等实时信息获取，自己的快递、话费流量、单词本单词、每月收入支出等记账数据，应用使用时间等数据显示。</li>
<li> 日常生活记录：时间自动记录、物品收纳管理、快速自动记账、习惯打卡自动记录、与 NFC 芯片联动等。</li>
<li> 社交与工作信息的获取展示：自动获取各平台粉丝、文章阅读量点赞数、视频播放量等数据并展示，自动过滤每周自己不需要阅读的 RSS 文章，遇到感兴趣的文章自动分享到 Trello/Notion 等。</li>
<li> 工作信息的处理：每次开会前将所有人的选题都集中通过 Tasker 处理一遍，自动生成负责人标签等数据并导入到 Notion 里。对本周文章用 Tasker 自动收集阅读量点赞数等数据，并结合所有人的评分来给出最终每篇文章的分数，方便大家文章互评。</li>
<li> 文章处理：我在 Tasker 里面专门创建了一个项目，用来存放文章处理相关的任务，这些任务帮助我写文章的时候飞速提升效率。比如可以自动拼接图片并上传到特定的图床，自动将文章里面特定的图片或者其他类型的占位符替换成上传完成的图床链接和其他的 HTML 代码等，甚至现在正在做能够检查文章拼写错误和语法的 Tasker 任务。</li>
<li> 其他高级任务：今年我还在 Tasker 上尝试了更加复杂的任务类型，如涉及到人工智能或者自然语言处理（NLP）的任务，比如利用自然语言处理结合地图快递 API 实现快递到达时间预估，利用人工智能综合开奖数据以及热门数字来预测彩票下一期结果等。</li>
</ol>
<p>除此以外，我还帮助很多人制作了不同行业上使用的 Tasker 任务，比如营销行业的消息通知过滤提取与舆情邮件通知、房地产行业的房地产信息筛选报表，和特定房产推送通知甚至自动营销等都可以通过 Tasker 更加方便快捷实现。</p>
<p><img src="https://cdn.sspai.com/fairyex/20200109/MoetyjQ30p4L.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>部分任务列表</p>
<p>总而言之，限制 Tasker 能力的只有我们自己的想象力。</p>
<p>从上面相关文章的图片中大家可能也会发现，我制作自动化任务的时候非常注重 UI（或者说用户体验）——的确有很多任务，我在设计制作界面上花的时间比实现功能更多，既然 Tasker 给了我们创造自己界面的自由，那么我们就要好好利用它。</p>
<p><img src="https://cdn.sspai.com/fairyex/20190920/HTDxG7op2drI.gif"></p>
<p>快递预测</p>
<p>我建议大家在开始接触 Tasker 了解简单功能的同时也可以接触一下应用本身提供的「场景」功能，用户创建场景后，可以使用 Tasker 提供的高自由度与丰富的组件类型来打造自己的界面，也可以给组件联动展示变量数据或者添加点击等触发事件，拥有自己打造的漂亮界面的成就感与体验是一个个操作叠起来最后单纯的靠对话框或者提示输出结果所比不了的。</p>
<p>所有的自动化应用都是为了解决你的设备在你满足设定的条件时自动运行你想要的动作这个需求的，而我可以说 Tasker 是其中的佼佼者，<strong>因为它最大的优点是拥有不同能力和不同级别需求的人群都能够在上面找到合适自己的入手角度和难度曲线</strong>。</p>
<p>为了某个小功能即装即用、直接导入别人做好的配置、不 Root 的情况下打造自己的任务、Root 设备之后打造自己的任务、甚至 Root 之后加上插件、本身不会编程和本身会编程……这些人群都能使用 Tasker 在自己的能力内，通过短时间学习找到制作符合自己需求任务的途径。这主要得益于 Android 开放的系统与热情的开发者们（虽然 Android 最近几个版本权限已经收紧到能和 iOS 一较高下的程度， Google 还是在 Play 日益严格的审核条件下给 Tasker 开了小灶以保持它的开放性），无论你只是想要在插入耳机时自动播放音乐，还是想要每天定时用 Python 结合机器学习分析预测黄金涨跌然后自动在支付宝上买入卖出，都能利用 Tasker 轻便地完成。</p>
<p><img src="https://cdn.sspai.com/fairyex/20200109/FV4QRg6RaUJr.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>Tasker 场景搭建和利用本地网页构建场景</p>
<p>最后已经有很多人询问我付费教程的问题，为了解决大家不知道怎么轻松快速上手 Tasker，同时给大家分享更多我玩过用过的高级技巧，最近我会在少数派推出 Tasker 的入门与提高教程（起了个名字《Tasker 从入门到精通：打造真正的智能手机》，大家有更好听的也可以评论分享下），拥有教你如何快速上手和了解 Tasker 的基本内容操作，如何思考与实现常用的任务，又是如何利用 Tasker 实现更多高级操作等内容，包括：</p>
<ul>
<li>各种插件的使用</li>
<li>有编程基础的人如何在 Tasker 上运行各种语言</li>
<li>Tasker 如何与软（自己编写的应用、第三方工具）、硬（电脑，智能穿戴设备）件设备交互</li>
<li>……</li>
</ul>
<p>感兴趣的朋友可以持续关注我的主页。</p>
<h3 id="Clyde：在摸索和试错中上手"><a href="#Clyde：在摸索和试错中上手" class="headerlink" title="@Clyde：在摸索和试错中上手"></a>@Clyde：在摸索和试错中上手</h3><p>🔗<a target="_blank" rel="noopener" href="https://sspai.com/u/clyde/posts">查看 TA 的作品</a></p>
<p>因为 Tasker 相对复杂、看上去有些距离的交互界面，我在使用 Android 设备的这几年时间里曾经好几次想要尝试这款自动化工具，但每次都在下载、安装后对着「熟悉而陌生」的主界面茫然无措。</p>
<p>2019 年发布的 Android 10 成为了一次契机。当时下定决心入坑 Tasker 的目的很简单：我想要一个更智能的自动暗色主题，弥补原生 Android 10 还没有这一设置的缺憾。好在在 Tasker 更新加入暗色主题支持的同时开发者也放出了一套近乎无脑的配置方案，直接导入即可使用。</p>
<p>借着这套导入的方案，我第一次认真研究起了 Tasker 这款工具：配置文件、任务、场景和变量分别对应了「触发条件」与「执行任务」中的哪些要素？如何在定制 ROM 中找到特定设置所对应的数值变化？任务编辑的过程中又是如何对变量进行赋值的？</p>
<p>在对开发者给出的模板配置进行拆解、调整和试错后，我算是完成了此前一直都没有勇气迈出的第一步。基于这套配置，我将自己的自动化暗色主题配置过程分享在了<a target="_blank" rel="noopener" href="https://sspai.com/post/56905">这篇文章</a>里。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/43c634715968f37d2c149ff17c237ad1.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>根据日落、日出时间自动开启、关闭的暗色主题</p>
<p>有了探索自动暗色主题切换的经验，我在之后的时间里也越来越多地尝试用 Tasker 解决日常生活中遇到的实际需求和问题，比如每天都要「走一遍」的睡前流程：</p>
<blockquote>
<p>手机连上充电器放在枕边、关闭睡觉期间用不上的息屏显示（AOD）、开启飞行模式、打开蓝牙和 Wi-Fi、启动 Sleep as Android 开始睡眠追踪……</p>
</blockquote>
<p>接触 Tasker 前我日复一日地重复着上面这个流程，从来没有思考过如何让它变得更简单：在我目前在用的配置方案中，我将<strong>时间段</strong>（每天晚上 12:00 至次日凌晨 3:00）和<strong>充电器状态</strong>（AC 交流充电）这两种状态作为睡眠追踪的触发条件，两个条件同时满足的前提下自动触发一系列后续任务，包括关闭息屏显示、开启飞行模式但保留 Wi-Fi 和蓝牙连接、将勿扰模式设定为「仅限闹钟」等等，最后借助 Sleep as Android 内建的 Tasker 接入，开始使用手环辅助进行睡眠追踪。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/36c73238cd8ac2bd68e23f56e2e82e0e.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>睡眠追踪配置方案</p>
<p>除了睡眠追踪，很多生活中需要重复、机械地进行手动切换的操作我都交给了 Tasker，比如网络切换：在连接到家里 Wi-Fi 时关闭某个「网络加速器」，在离开家、与家里的 Wi-Fi 断开后则自动启用这个「网络加速器」。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/360ce97fd40a2db30ad931e8007b8abe.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>这种简单的小配置可以省下不少时间</p>
<p>而这些简单却实用的配置几乎都来源于最初对 Android 10 自动暗色主题的探索：理清自己的需求，分离触发条件与具体任务，然后通过对 Tasker 和第三方工具提供的接口进行摸索、试错，调校出一套适合自己的配置方案。有了实际要解决的问题之后，Tasker 显然没有我想象中的那么遥远。</p>
<h3 id="PeggyLv：专注需求，可繁可简"><a href="#PeggyLv：专注需求，可繁可简" class="headerlink" title="@PeggyLv：专注需求，可繁可简"></a>@PeggyLv：专注需求，可繁可简</h3><p>🔗<a target="_blank" rel="noopener" href="https://sspai.com/u/5isr02uh/posts">查看 TA 的作品</a></p>
<p>我接触 Tasker 的时间已经有四年了，说来惭愧，时至今日我还是一个彻头彻尾的小白。</p>
<p>初识 Tasker 时，我也曾绞尽脑汁地设想过哪些场景能够自动化，甚至一度沉迷于在网络上搜索各种 Tasker 教程。当然最后教程看了不少，付诸实施的却没有几个，究其原因无非是没有发现自己的需求是什么，以至于教程看不懂也缺乏动力学习。</p>
<p>好在 Tasker 对于新手还算友好，内置的大部分触发条件摸索一下也能理解其含义，找到自己的真实需求后，便可以一步一步上手。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/f0b850926fce48ef7494e10bd02c83cc.png?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>我的配置文件与任务</p>
<p><strong>这里不妨从最简单的夜间模式说起</strong>：几年前的 Android 系统尚且不能实现自动开启夜间模式，于是「晚上自动调整亮度到最低，次日恢复」便成了我的第一个需求。围绕这一需求，我在 Tasker 当中设置了以固定时间点为触发条件的动作：晚上 10 点自动调整亮度到最低，次日 7 点恢复。接着，我又发现晚上的时候各类通知铃声过于扰人，因此，这个动作加长到了「<strong>晚上 10 点亮度最低+手机开启静音模式+媒体音量调整为两格</strong>」。</p>
<p>在 Google 为 Android 带来暗色模式后，我的动作也随之进行了扩展，Tasker 的优秀之处就在于开发者会不断地为它加入适应当前系统的新特性，以满足使用者不断增长的需求。当然，比起 <a target="_blank" rel="noopener" href="https://sspai.com/post/56905">这篇文章</a> 当中的实现方式，我的思路还是过于简单了，有需要的朋友可以尝试一下文章当中更为高阶的方式。</p>
<p><strong>对于系统相对原生的用户而言，短信验证码复制也是个颇为实际的需求</strong>。如果你和我一样对于自动化一窍不通，听到「正则表达式」、「脚本」等名词一头雾水，也不必要担心玩不转 Tasker。Tasker 允许用户分享已经设置好的配置，我们可以通过他人分享的文件乃至链接下载现成的配置。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/457b2df8c9d30db564a4c9fff0df6fa7.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>短信验证码复制</p>
<p>通过酷安的评论区，我下载了热心网友分享的「短信验证码自动复制」这一配置，当短信当中含有验证码时，Tasker 会自动识别并复制验证码到剪切板，这对于使用类原生系统的我来说省事不少。</p>
<p>最后，由于在实际的手机使用过程中我经常会遇到插上耳机后还要特意去翻找音乐或视频应用的情况，因此为了省去翻找这一步骤，<strong>我利用 Tasker 内置的场景功能制作了一个小弹框</strong>。</p>
<p>当检测到插入耳机或者连接到我的蓝牙耳机就自动弹出选择框，方便我从常用的影音应用中选择自己想要的一个，单击 Spotify 图标打开 Spotify，长按则打开自带的音乐应用聆听本地音乐；单击 Netflix 图标打开 Netflix，长按则打开 Bilibili。当然，有时候我在插入耳机之前可能就已经打开了相应的应用，那么点击弹框的中间空白部分即可让弹框消失。事实上我们还可以为相应的图标位置添加双击操作，不过考虑到我实际上没有那么多应用需要用到耳机，也就不必要徒增记忆负担。</p>
<p><img src="https://cdn.sspai.com/2020/01/15/67b7e35a78a9ab0767297de20ee08a80.jpg?imageView2/2/w/1120/q/90/interlace/1/ignore-error/1"></p>
<p>自制的媒体服务选择弹窗</p>
<p>这一弹框现在也变成了我检测自己耳机有没有插好或者连接成功的标志。那么这一土制的场景有没有缺陷呢？当然有，并且很大——横屏必崩，相信 Tasker 内一定有设置的方法，但是正如前文所说：我是小白，够用就好。</p>
<p>打开我手机上的 Tasker 后，只有寥寥几个动作，但是诸如插入耳机自动降低音量、回到家中自动连接自家 WiFi 这些细碎的事情都不再需要手动进行，我也渐渐习以为常，不必担心晚上粗心忘记开启静音被通知吵醒，也不必担心早上忘记打开 WiFi 而错过重要通知。</p>
<p>得益于 Tasker 的可繁可简，我们可以动动手就制造出实用的自动化动作，如今我已经不再执着于要将 Tasker 发挥出最大的价值，也不再艳羡大佬们各式各样的神奇操作。明白自己的需求是什么，动手调一调去实现就够了。</p>
<hr>
<p>你是如何使用 Tasker 的，它又为你的生活带来了哪些改变？如果你在尝试 Tasker 的过程中遇到了问题，也欢迎在这篇文章的评论区留言交流。</p>
<p>题图来自<a target="_blank" rel="noopener" href="https://pixabay.com/illustrations/developer-programmer-technology-3461405/">Pixabay</a></p>
<p><a target="_blank" rel="noopener" href="https://sspai.com/app/Tasker">Tasker</a></p>
<p><a target="_blank" rel="noopener" href="https://sspai.com/app/Tasker">相关文章</a><a target="_blank" rel="noopener" href="https://sspai.com/d/KWq8En"></a></p>
<p><strong>关联阅读：</strong></p>
<ul>
<li><p><a target="_blank" rel="noopener" href="https://sspai.com/post/57683">Tasker 的新「杀手锏」功能：Logcat Entry</a></p>
</li>
<li><p><a target="_blank" rel="noopener" href="https://sspai.com/post/45759">Tasker：Android 上的自动化标杆</a></p>
</li>
<li><p><a target="_blank" rel="noopener" href="https://sspai.com/post/56905">如何让 Android 10 拥有不输 iOS 的暗色模式体验？</a>  </p>
</li>
</ul>
<blockquote>
<p>下载少数派<a target="_blank" rel="noopener" href="https://sspai.com/page/client">客户端</a>、关注<a target="_blank" rel="noopener" href="https://sspai.com/s/J71e">少数派公众号</a>，玩转 Tasker 没那么难 🐱‍🏍</p>
</blockquote>
<blockquote>
<p>特惠、好用的硬件产品，尽在<a target="_blank" rel="noopener" href="https://shop549593764.taobao.com/?spm=a230r.7195193.1997079397.2.2ddc7e0bPqKQHc">少数派sspai官方店铺</a>🛒</p>
</blockquote>
<h1 id="Agent-免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！"><a href="#Agent-免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！" class="headerlink" title="Agent 免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！"></a>Agent 免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2014/02/agent-app.html">Agent 免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！</a></li>
</ul>
<p>作者：<a target="_blank" rel="noopener" href="https://www.blogger.com/profile/10426807330996372963" title="author profile">Esor Huang</a><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2014/02/agent-app.html" title="permanent link">2月 12, 2014</a></p>
<p>Android 上最有趣的獨特 App 類型之一就是各式各樣的「自動化情境管理」工具。例如「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/02/myprofiles-android.html">MyProfiles 我的情境模式 Android 自動控制音量螢幕網路</a>」可以偵測你的各種場所情境，讓 Android 手機自動在你開會時靜音、回家時開啟無線網路等等，省去一直手動重複調整相同設定，而可以讓手機更聰明的自動改變設定。  </p>
<p>而最近發現一款<strong>更聰明、更簡單的免費自動化 Android App：「 Agent - do not disturb &amp; more 」，這款 App目前可以做到：</strong>電池快沒電時自動開啟省電、睡覺時自動開啟勿擾模式、開會時自動關靜音、停車時自動記住停車位置、開車時開啟手機自動接通模式。  </p>
<p>雖然「 Agent 」可能沒有其他自動化管理 App 的功能那麼多，但是相對的，「 Agent 」完全不需要設定，一安裝就有用，保證一般用戶也能上手，而其提供的上述自動化功能，也都是最切合大家日常需要的，非常值得試試看。  </p>
<ul>
<li><strong>1.完全不需設定，立即自動化</strong></li>
</ul>
<p>只要在 Android 手機上安裝這款「 Agent 」，預設就會啟動下面五個自動化功能，並且基本設定都已經調整好，大多數時候我們就能直接開始使用：  </p>
<ul>
<li>Battery：電池快沒電時自動開啟省電，充電時自動回復正常</li>
<li>Sleep：睡覺時自動開啟勿擾模式，但可以設定不錯過重要電話</li>
<li>Parking：停車時自動記住停車位置，還能導航找到停車處</li>
<li>Meeting：開會時手機自動關靜音</li>
<li>Drive：開車時開啟手機自動接通模式</li>
</ul>
<p>對於想要讓 Android 手機聰明完成自動化調整，<strong>但是懶得研究設定方法的朋友，這款「 Agent 」會是一個好選擇。</strong>  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-tvwhxoj01VM/Uvt9spFls4I/AAAAAAADPpE/h7MULMLNDfY/s1600/Agent+-+do+not+disturb+&+more-01.png"><img src="https://1.bp.blogspot.com/-tvwhxoj01VM/Uvt9spFls4I/AAAAAAADPpE/h7MULMLNDfY/s1600/Agent+-+do+not+disturb+&+more-01.png"></a><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-VluPKTq3Y9A/Uvt9P3ra8RI/AAAAAAADPng/NM7I2pxvTzU/s1600/Agent+-+do+not+disturb+%2526+more-02.png"><img src="https://4.bp.blogspot.com/-VluPKTq3Y9A/Uvt9P3ra8RI/AAAAAAADPng/NM7I2pxvTzU/s1600/Agent+-+do+not+disturb+%2526+more-02.png"></a></p>
<ul>
<li><strong>2.Battery：電池快沒電時自動開啟省電</strong></li>
</ul>
<p>像是我目前使用的 HTC New One 有內建自動開啟省電模式，會在手機的電池電力過低時，自動關閉一些耗電的功能（延伸參考：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/12/app-android.html">不需安裝優化App， Android 新手機推薦用內建設定搞定優化</a>）。  </p>
<p>如果你的手機沒有這樣的自動省電設定，那麼「 Agent 」的自動省電會預設在電力剩下 10% 時，自動關閉你的同步、藍芽、無線網路，以及調暗你的螢幕。而當你手機開始充電時，就幫你自動回覆正常使用狀態。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-0ZIzIIdZT7Y/Uvt9P8HbrQI/AAAAAAADPnk/4Xx-9MQE3wc/s1600/Agent+-+do+not+disturb+%2526+more-03.png"><img src="https://3.bp.blogspot.com/-0ZIzIIdZT7Y/Uvt9P8HbrQI/AAAAAAADPnk/4Xx-9MQE3wc/s1600/Agent+-+do+not+disturb+%2526+more-03.png"></a><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-v1ZgrzU09Dc/Uvt9P92rQ_I/AAAAAAADPns/S4A8EPC7Pwg/s1600/Agent+-+do+not+disturb+%2526+more-04.png"><img src="https://3.bp.blogspot.com/-v1ZgrzU09Dc/Uvt9P92rQ_I/AAAAAAADPns/S4A8EPC7Pwg/s1600/Agent+-+do+not+disturb+%2526+more-04.png"></a></p>
<ul>
<li><strong>3.Sleep：睡覺時自動開啟勿擾模式</strong></li>
</ul>
<p>「 Agent 」也幫我們預設好睡眠時自動開啟勿擾的功能，預設情況下會把每天下午 11 點到第二天早上 7 點當作睡覺時間，如果你的睡眠時間和預設不符合，也可以在這裡手動調整。  </p>
<p>一旦睡覺時間到，「 Agent 」會自動把手機關靜音，並且拒絕任何來電、簡訊、通知鈴聲，讓我們可以好好睡覺，一直到起床時間，「 Agent 」才會自動還原手機原本的模式。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-LuIjkJAnfHY/Uvt9Q9zDYcI/AAAAAAADPoY/S1uQ2bGLON0/s1600/Agent+-+do+not+disturb+%2526+more-05.png"><img src="https://3.bp.blogspot.com/-LuIjkJAnfHY/Uvt9Q9zDYcI/AAAAAAADPoY/S1uQ2bGLON0/s1600/Agent+-+do+not+disturb+%2526+more-05.png"></a></p>
<p>當然，<strong>有時候可能睡覺時我們也不能漏接一些重要的電話。</strong>  </p>
<p>這時候「 Agent 」也提供了手動進階設定功能，我們可以指定「哪些人打來的電話」會有來電鈴聲，或者是對方如果在 5 分鐘內連續打來兩次電話（可能真的有急事），那麼就想起來電鈴聲。  </p>
<p>是不是很聰明？  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-Mk37JtvUAc8/Uvt9RYPZk0I/AAAAAAADPn8/s9p3X1FulDk/s1600/Agent+-+do+not+disturb+%2526+more-07.png"><img src="https://1.bp.blogspot.com/-Mk37JtvUAc8/Uvt9RYPZk0I/AAAAAAADPn8/s9p3X1FulDk/s1600/Agent+-+do+not+disturb+%2526+more-07.png"></a></p>
<ul>
<li><strong>4.Parking：停車時自動記住停車位置</strong></li>
</ul>
<p>「 Agent 」還可以在「 Parking 」模式中自動記住你停車的位置，更棒的是，我們什麼都不需要設定，只要你的手機有正常的定位功能即可（參考：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/08/gps-wifi.html">手機 GPS定位 WiFi定位 怎樣省電精準？地圖實測比較心得</a>）。  </p>
<p>「 Agent 」會自動偵測我們的移動速度，判斷我們什麼時候在開車、什麼時候停車、什麼時候改成走路，<strong>於是「 Agent 」就能偵測出我們「停車下車」的位置，並且自動在地圖上標註出我們把車子停在哪裡。</strong>  </p>
<p>在清單中可以看到幾點幾分的停車定位，如果後來找不到之前停車的地方，利用這個清單，就能開啟地圖幫你導航到停車處！  </p>
<p>我測試這個功能好幾次，每次都很準確，不輸「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2012/09/google_22.html">Google 定位紀錄帶你解鎖世界地圖，回想一生旅行記憶</a>」，很值得試試看。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-w1_mSvWfpoI/Uvt9SAefszI/AAAAAAADPoM/a6Zn1FpKSm8/s1600/Agent+-+do+not+disturb+%2526+more-08.png"><img src="https://3.bp.blogspot.com/-w1_mSvWfpoI/Uvt9SAefszI/AAAAAAADPoM/a6Zn1FpKSm8/s1600/Agent+-+do+not+disturb+%2526+more-08.png"></a><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-dWer-muR5b8/Uvt9S9Szn6I/AAAAAAADPoc/Kw5QBIEX-MA/s1600/Agent+-+do+not+disturb+%2526+more-09.png"><img src="https://4.bp.blogspot.com/-dWer-muR5b8/Uvt9S9Szn6I/AAAAAAADPoc/Kw5QBIEX-MA/s1600/Agent+-+do+not+disturb+%2526+more-09.png"></a></p>
<ul>
<li><strong>5.Meeting：開會時自動關靜音</strong></li>
</ul>
<p>「 Agent 」預設會讀你 Android 手機上的行事曆，判斷出裡面設定為忙碌狀態的會議行程，並且在會議時間到達時，自動把手機切換到靜音模式，讓你不會在開會時被干擾到，也讓你不會忘記在開會前關手機。  </p>
<p>而會議時間結束後，就會幫你自動還原。  </p>
<p>更進一步的，在「 Agent 」的進階設定中，還可以指定幾點到幾點、一週內的哪幾天，要開啟這個開會靜音的行事曆自動偵測功能。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-rFTv4Hb5T9w/Uvt9TWVR1FI/AAAAAAADPog/-Q_yyIv0mR4/s1600/Agent+-+do+not+disturb+%2526+more-11.png"><img src="https://3.bp.blogspot.com/-rFTv4Hb5T9w/Uvt9TWVR1FI/AAAAAAADPog/-Q_yyIv0mR4/s1600/Agent+-+do+not+disturb+%2526+more-11.png"></a><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-PRM6j-V08U8/Uvt9Tk3YjXI/AAAAAAADPo8/IXmA87XG_bo/s1600/Agent+-+do+not+disturb+%2526+more-12.png"><img src="https://4.bp.blogspot.com/-PRM6j-V08U8/Uvt9Tk3YjXI/AAAAAAADPo8/IXmA87XG_bo/s1600/Agent+-+do+not+disturb+%2526+more-12.png"></a></p>
<ul>
<li><strong>6.Drive：開車時開啟手機自動接通模式</strong></li>
</ul>
<p>最後一個「 Agent 」的神奇自動設定，就是偵測到妳開車時，會幫你把手機調整成自動接通的模式，但是這個模式只有對真正的開車族有用，而且需要藍芽設定會比較準確，<strong>「 Agent 」可以在偵測、連結到車上的藍芽設備時，自動判斷你開始開車了，才開啟開車模式。</strong>  </p>
<p>不過這個模式對我來講不需要，所以我將這個模式關閉，而使用「 Agent 」的其他四種模式。  </p>
<p>「 Agent 」提供的開會靜音、睡眠勿擾、停車定位、自動省電，都是一般用戶常常會用到的功能，將這些動作自動化，讓我們省下許多麻煩，而且「 Agent 」還完全不需要設定，一安裝就能自動啟動這些功能，對一般用戶來說非常好上手，值得試試看。  </p>
<ul>
<li><strong>「 Agent 」 Android App：<a target="_blank" rel="noopener" href="https://play.google.com/store/apps/details?id=com.tryagent">https://play.google.com/store/apps/details?id=com.tryagent</a></strong></li>
</ul>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-KMO6t6LOIQo/Uvt9Uu0-6xI/AAAAAAADPo4/qk_GCuRK-EE/s1600/Agent+-+do+not+disturb+%2526+more-14.png"><img src="https://1.bp.blogspot.com/-KMO6t6LOIQo/Uvt9Uu0-6xI/AAAAAAADPo4/qk_GCuRK-EE/s1600/Agent+-+do+not+disturb+%2526+more-14.png"></a><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-iug5f5gdaKA/Uvt9VZ3-goI/AAAAAAADPpA/WdUs_ESVFss/s1600/Agent+-+do+not+disturb+%2526+more-15.png"><img src="https://2.bp.blogspot.com/-iug5f5gdaKA/Uvt9VZ3-goI/AAAAAAADPpA/WdUs_ESVFss/s1600/Agent+-+do+not+disturb+%2526+more-15.png"></a></p>
<h1 id="AutomateIt-自動控制-Android-省時免動手，智慧手機更聰明"><a href="#AutomateIt-自動控制-Android-省時免動手，智慧手機更聰明" class="headerlink" title="AutomateIt 自動控制 Android 省時免動手，智慧手機更聰明"></a>AutomateIt 自動控制 Android 省時免動手，智慧手機更聰明</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2013/06/automateit-android.html">AutomateIt 自動控制 Android 省時免動手，智慧手機更聰明</a></li>
</ul>
<p>作者：<a target="_blank" rel="noopener" href="https://www.blogger.com/profile/10426807330996372963" title="author profile">Esor Huang</a><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2013/06/automateit-android.html" title="permanent link">6月 03, 2013</a></p>
<p>我對於 Android 上的各種「<strong>自動化 App</strong>」很有興趣。回想我們自己的智慧型手機使用情況，你會不會常常需要進行重複的手機操作，例如：</p>
<ul>
<li>晚上睡覺前把手機關閉靜音，早上起床後回復正常。</li>
<li>插上耳機後音量調到適當大小並打開音樂播放器。</li>
<li>要查地圖時打開 GPS 但平常又想關閉。</li>
</ul>
<p>如果要一直「自己手動」切換開關，智慧型手機似乎就不夠智慧了。<strong>所以像是「 AutomateIt 」這樣的 App 就能大量節省反覆進行相同操作的時間</strong>，透過建立自動規則，手機就會在特定情況自動調整或啟動功能。而且「 AutomateIt 」還擁有中文介面與免費版本。</p>
<p>「 AutomateIt 」有區分付費和免費版本，<strong>一開始用戶可以先試試看免費版</strong>，如果覺得適合自己，或是需要進階功能，再購買付費版即可。</p>
<p>進入「 AutomateIt 」 App，可以看到主畫面上有「我的規則」儲存你自己建立的自動化規則，以及「規則市集」查看別人建立的規則。若是一開始你不知道建立什麼樣的規則對自己有幫助，可以到「規則市集」參考。</p>
<p><a target="_blank" rel="noopener" href="https://lh5.ggpht.com/-rpUQ2flzoY8/UawTeykVA5I/AAAAAAACohA/d3lVwAkmY3A/s1600-h/AutomateIt-01%25255B6%25255D.png"><img src="https://lh4.ggpht.com/-T1DopcTtA6U/UawTh4cU1zI/AAAAAAACohI/wlF0Dy_p3q0/AutomateIt-01_thumb%25255B2%25255D.png?imgmax=800" alt="AutomateIt-01" title="AutomateIt-01"></a><a target="_blank" rel="noopener" href="https://lh4.ggpht.com/-WIjT_9GNzcM/UawTkFW_uUI/AAAAAAACohQ/sNvj71B54Uk/s1600-h/AutomateIt-02%25255B6%25255D.png"><img src="https://lh6.ggpht.com/-3fxE3ZY9rZs/UawTmgsfHrI/AAAAAAACohY/yBw10ZFebBM/AutomateIt-02_thumb%25255B2%25255D.png?imgmax=800" alt="AutomateIt-02" title="AutomateIt-02"></a></p>
<p><strong>在「規則市集」中除了可以查看別人怎麼建立規則，也可以將別人想到的好規則下載到「 AutomateIt 」中使用</strong>。這是我覺得「 AutomateIt 」很不錯的一點，增加了使用上的方便性，不用自己去想規則要怎麼建立比較好，直接使用熱門、常用規則即可。</p>
<p><a target="_blank" rel="noopener" href="https://lh6.ggpht.com/-7_H7kw2LU-4/UawTpgqLy0I/AAAAAAACohg/0xMCRSJBINE/s1600-h/AutomateIt-03%25255B2%25255D.png"><img src="https://lh6.ggpht.com/-RpdbtbycDqY/UawTr81-yQI/AAAAAAACoho/19DybhGyHhY/AutomateIt-03_thumb.png?imgmax=800" alt="AutomateIt-03" title="AutomateIt-03"></a><a target="_blank" rel="noopener" href="https://lh6.ggpht.com/-ZZAJtzzhJCE/UawTuNNZCVI/AAAAAAACohw/xgY8zY242l8/s1600-h/AutomateIt-04%25255B2%25255D.png"><img src="https://lh3.ggpht.com/-esQzXYUUjAA/UawTwb_Z4tI/AAAAAAACoh4/F51VAAphRFo/AutomateIt-04_thumb.png?imgmax=800" alt="AutomateIt-04" title="AutomateIt-04"></a></p>
<p>例如我喜歡別人建好的：「打開地圖就開 GPS」、「關掉地圖就關閉 GPS 」自動規則，直接下載規則。</p>
<p>這樣一來就只有真的需要定位的 Google 地圖打開時才會開啟 GPS，關閉地圖後也會自動把 GPS 關閉，而像是打開臉書等社群 App 就不會浪費不必要的 GPS 電力了。</p>
<p><a target="_blank" rel="noopener" href="https://lh3.ggpht.com/-hlGv18S4KQM/UawTyJSaOTI/AAAAAAACoiA/rKljkF7J6Yo/s1600-h/AutomateIt-05%25255B2%25255D.png"><img src="https://lh5.ggpht.com/-ALbhuzuXhAg/UawT013da7I/AAAAAAACoiI/FmGyDtEkP1w/AutomateIt-05_thumb.png?imgmax=800" alt="AutomateIt-05" title="AutomateIt-05"></a><a target="_blank" rel="noopener" href="https://lh6.ggpht.com/-Kge_z4TF5bg/UawT39KGGjI/AAAAAAACoiQ/P-ZDZpJJTUA/s1600-h/AutomateIt-06%25255B2%25255D.png"><img src="https://lh5.ggpht.com/-gLmUYRldlgM/UawT6IiwlHI/AAAAAAACoiY/eY3aluTg_gY/AutomateIt-06_thumb.png?imgmax=800" alt="AutomateIt-06" title="AutomateIt-06"></a></p>
<p>你也可以自己在「 AutomateIt 」中建立規則，過程很直覺：</p>
<ul>
<li><strong>1.選擇一個觸發的條件（何時？何地？）。</strong></li>
<li><strong>2.選擇要執行什麼動作。</strong></li>
</ul>
<p>這樣就能建立一個「每當 XXX 發生時」，就讓手機「自動執行 XXX」，一些瑣碎但可能會重複執行的動作，都可以用這類自動化工具來完成，讓我們不用再自己動手操作，就能節省大量時間了！</p>
<p><a target="_blank" rel="noopener" href="https://lh6.ggpht.com/-RSooijssfPs/UawT7-S-EtI/AAAAAAACoig/dusuHaQUF74/s1600-h/AutomateIt-07%25255B2%25255D.png"><img src="https://lh5.ggpht.com/-nM7OHEiKII0/UawT-H-McjI/AAAAAAACoio/xdSdllwWiEE/AutomateIt-07_thumb.png?imgmax=800" alt="AutomateIt-07" title="AutomateIt-07"></a><a target="_blank" rel="noopener" href="https://lh3.ggpht.com/-e46LtCkHoTk/UawT_R0NzJI/AAAAAAACoiw/Tl1__NVjOJY/s1600-h/AutomateIt-08%25255B2%25255D.png"><img src="https://lh3.ggpht.com/-eoXje72c8NE/UawUBcFZ2ZI/AAAAAAACoi4/Up7-k90cwZU/AutomateIt-08_thumb.png?imgmax=800" alt="AutomateIt-08" title="AutomateIt-08"></a></p>
<ul>
<li><p><strong>「 AutomateIt 」 Android App：</strong><a target="_blank" rel="noopener" href="https://play.google.com/store/apps/details?id=AutomateIt.mainPackage">https://play.google.com/store/apps/details?id=AutomateIt.mainPackage</a></p>
</li>
<li><p><strong>類似工具推薦：</strong></p>
</li>
<li><p><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/02/myprofiles-android.html">MyProfiles 我的情境模式 Android 自動控制音量螢幕網路</a></p>
</li>
<li><p>為什麼你會想要重複切換不同手機設定？可以參考：</p>
</li>
<li><p><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2012/01/andorid.html">增加 Andorid手機電池續航力 ，一定有效的省電心得</a></p>
</li>
<li><p><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/02/android-app_17.html">如何解決讓 Android 效能慢、耗電多、佔空間問題 App？</a></p>
</li>
</ul>
<h1 id="IFTTT-Android-iOS-入門教學：如果明天下雨請今日提醒我"><a href="#IFTTT-Android-iOS-入門教學：如果明天下雨請今日提醒我" class="headerlink" title="IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我"></a>IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2014/04/ifttt-android-ios.html">IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我</a></li>
</ul>
<p>作者：<a target="_blank" rel="noopener" href="https://www.blogger.com/profile/10426807330996372963" title="author profile">Esor Huang</a><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2014/04/ifttt-android-ios.html" title="permanent link">4月 27, 2014</a></p>
<p><strong>「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/04/ifttt-android-ios.html">IFTTT</a>」是一個頗受好評的「網路自動連結」服務</strong>，什麼是網路自動連結？例如我自己在 IFTTT 上使用了一份「配方（菜單、 Recipes ）」，內容是「只要我在 Facebook 發表圖文訊息，那麼這份圖文訊息就會自動轉存到我的 Evernote 筆記」，這滿足了我把 A 服務內容串連到 B 服務的需求，並且我不用自己轉貼， IFTTT 可以自動幫我完成上述動作。  </p>
<blockquote>
<p>IFTTT 讓各個網路服務之間不再靜態分佈，可以把不同網路串連成「行動」，「如果」 A 服務發生什麼事情，「那麼」 B 服務就做出什麼反應。</p>
</blockquote>
<p>從一方面來看 IFTTT 讓「不會寫程式」的一般用戶也可以完成上面那樣神乎其技的配套，但另一方面來說 IFTTT 博大精深，仔細玩下去會發現很多可以自訂的細節，可是畢竟這是國外服務，有些自動串連的機制不一定那麼適合台灣用戶（例如對中文支援不完美）。  </p>
<p>幸好，最近 IFTTT 開始朝行動裝置邁進，<strong>接連推出了 IFTTT 的 iPhone、 iPad、 Android 版本，讓網路服務也可以去觸發我們身邊行動裝置上的反應</strong>（或是反過來），而這樣的演進我覺得更貼近個人的生活層面應用，所以我決定分成幾篇來好好介紹 IFTTT 這個的服務。今天這篇就先從以 App 來入門開始。  </p>
<ul>
<li><strong>IFTTT App 介面概觀：</strong></li>
</ul>
<ol>
<li>IFTTT 目前有 Android 、 iOS 和網頁版，分別如下：  </li>
</ol>
<ul>
<li>IFTTT Android：<a target="_blank" rel="noopener" href="https://play.google.com/store/apps/details?id=com.ifttt.ifttt">https://play.google.com/store/apps/details?id=com.ifttt.ifttt</a>t</li>
<li>IFTTT iOS：<a target="_blank" rel="noopener" href="https://itunes.apple.com/tw/app/ifttt/id660944635?l=zh&mt=8">https://itunes.apple.com/tw/app/ifttt/id660944635?l=zh&amp;mt=8</a></li>
<li>IFTTT 網站：<a target="_blank" rel="noopener" href="https://ifttt.com/">https://ifttt.com/</a></li>
</ul>
<p>這邊我以 IFTTT 的 Android 版介面作為介紹，因為 App 版本的介面更直覺，可以讓我們更快了解 IFTTT 的使用概念，其他版本的用法也大同小異，大家可以延伸參照。  </p>
<p>第一次打開 IFTTT App ，可以看到這個服務的簡單介紹，在 IFTTT 中給予用戶一個創造「如果怎樣就會怎樣」的能力，<strong>我們只要填入自己需要的服務，就可以創造「連鎖反應」。</strong>  </p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-i1PIEBM13j4/U1xRk-G1o8I/AAAAAAADbsw/YiSxlQTwgkg/s1600/IFTTT+Android+iOS-01.png"><img src="https://4.bp.blogspot.com/-i1PIEBM13j4/U1xRk-G1o8I/AAAAAAADbsw/YiSxlQTwgkg/s1600/IFTTT+Android+iOS-01.png"></a><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-syJRqx6KpBg/U1xRk93dnJI/AAAAAAADbs4/h7_271vK7qU/s1600/IFTTT+Android+iOS-02.png"><img src="https://2.bp.blogspot.com/-syJRqx6KpBg/U1xRk93dnJI/AAAAAAADbs4/h7_271vK7qU/s1600/IFTTT+Android+iOS-02.png"></a></p>
<ol start="2">
<li>登入或註冊一個 IFTTT 帳戶，進入主畫面，在主畫面中，可以看到啟動過的各種配方記錄。  </li>
</ol>
<p><strong>「配方（菜單、 Recipes ）」，就如同它的名字所表示的一樣</strong>，是「料理」不同網路服務的「別人提供的方法」，在 Android 版中點擊右上方的「料理」按鈕，就可以看到自己已經啟動的「配方（ Recipes ）」，繼續點擊右上方的「眼鏡」按鈕，可以查看他人提供的配方。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-0-Crtgr6U6c/U1xRk6tJspI/AAAAAAADbtE/Z0ob2cjYP-s/s1600/IFTTT+Android+iOS-03.png"><img src="https://3.bp.blogspot.com/-0-Crtgr6U6c/U1xRk6tJspI/AAAAAAADbtE/Z0ob2cjYP-s/s1600/IFTTT+Android+iOS-03.png"></a><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-C2z2q9QRsEY/U1xRlSyRqmI/AAAAAAADbtA/8BAHmuv3H8A/s1600/IFTTT+Android+iOS-04.png"><img src="https://2.bp.blogspot.com/-C2z2q9QRsEY/U1xRlSyRqmI/AAAAAAADbtA/8BAHmuv3H8A/s1600/IFTTT+Android+iOS-04.png"></a></p>
<ol start="3">
<li></li>
</ol>
<blockquote>
<p>如果我拍了一張新照片就自動換成手機桌布。<br>如果我在Facebook上張貼照片就自動把照片存入 Evernote。</p>
</blockquote>
<p>這些都可以在「 Browse 」中找到他人提供的固定配方，而我們只要在 IFTTT 裡啟動這些配方，就能完成配方裡設定好的自動化流程。  </p>
<p>而在瀏覽這些「配方（菜單、 Recipes ）」時，可以依據特色配方、熱門配方等排行榜，讓出學者快速找到好用的配方，直接試試看效果。  </p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-df3pFADo1Ks/U1xRlzJzRDI/AAAAAAADbtQ/ndv4tG1qT1Q/s1600/IFTTT+Android+iOS-05.png"><img src="https://4.bp.blogspot.com/-df3pFADo1Ks/U1xRlzJzRDI/AAAAAAADbtQ/ndv4tG1qT1Q/s1600/IFTTT+Android+iOS-05.png"></a><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-vh4FRrialuk/U1xRl8GdZ5I/AAAAAAADbt4/RVesp0ccNHQ/s1600/IFTTT+Android+iOS-06.png"><img src="https://2.bp.blogspot.com/-vh4FRrialuk/U1xRl8GdZ5I/AAAAAAADbt4/RVesp0ccNHQ/s1600/IFTTT+Android+iOS-06.png"></a></p>
<ul>
<li><strong>啟動一份配方：如果下雨，那麼就？</strong></li>
</ul>
<ol>
<li>那麼，不如就讓我們來啟動一份別人提供的配方（ Recipe ）試試看？  </li>
</ol>
<ul>
<li><strong>如果明天下雨，請在Android上通知我</strong>（Rain tomorrow? Get an Android Notification）：<a target="_blank" rel="noopener" href="https://ifttt.com/recipes/165139-rain-tomorrow-get-an-android-notification">https://ifttt.com/recipes/165139-rain-tomorrow-get-an-android-notification</a></li>
<li><strong>如果明天下雨，請在iOS上通知我</strong>（Rain tomorrow? Get an iOS Notification）：<a target="_blank" rel="noopener" href="https://ifttt.com/recipes/153667-rain-tomorrow-get-an-ios-notification">https://ifttt.com/recipes/153667-rain-tomorrow-get-an-ios-notification</a></li>
</ul>
<p>你可以在 IFTTT App 中搜尋上述對應的配方名稱（看你使用 Android 或 iOS ），或是直接點擊配方的網址來啟動。  </p>
<p>打開這份配方（ Recipe ）後，可以看到配方的功能描述，確認後按下〔 Use Recipe 〕。  </p>
<p>因應這份配方是要達成「如果明天下雨，請在今天提醒我」，所以首先會要求我們設定好自己想要偵測的城市地點，輸入地點並找到地點後，在天氣設定畫面按下〔 Activate 〕。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-GsXat9nTwpI/U1xRmenO2_I/AAAAAAADbtU/OBZVcNQ7TjI/s1600/IFTTT+Android+iOS-07.png"><img src="https://3.bp.blogspot.com/-GsXat9nTwpI/U1xRmenO2_I/AAAAAAADbtU/OBZVcNQ7TjI/s1600/IFTTT+Android+iOS-07.png"></a><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-6BEihsYjiR8/U1xRmvg4CWI/AAAAAAADbtc/0lfmtMnnZGU/s1600/IFTTT+Android+iOS-08.png"><img src="https://1.bp.blogspot.com/-6BEihsYjiR8/U1xRmvg4CWI/AAAAAAADbtc/0lfmtMnnZGU/s1600/IFTTT+Android+iOS-08.png"></a></p>
<ol start="2">
<li>這樣就在你的 IFTTT 中啟動這份下雨提醒配方了，一旦遇到明天要下雨的天氣預報時，今天我的 Android 或 iOS 手機上就會彈出提醒。  </li>
</ol>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-CpWtj2fuoo8/U1xRnIMlpUI/AAAAAAADbuE/VM-sQ4QybjU/s1600/IFTTT+Android+iOS-09.png"><img src="https://4.bp.blogspot.com/-CpWtj2fuoo8/U1xRnIMlpUI/AAAAAAADbuE/VM-sQ4QybjU/s1600/IFTTT+Android+iOS-09.png"></a></p>
<ul>
<li><strong>建立一份配方：如果怎樣，那就如何？</strong></li>
</ul>
<ol>
<li>在 IFTTT 中，我們當然可以不使用別人的配方，而自己來當廚師，自己料理自己需要的網路服務串連。  </li>
</ol>
<p>這邊就做一個簡單的示範，同樣在配方（ Recipe ）頁面中點擊「+」，進入自訂配方的畫面，這時候會看到 IFTTT 的基礎命令「<strong>如果（if）怎樣，那麼就會（then）如何</strong>」，我們只要自己在「如果」、「就會」的後面加上自己設定的行動即可。  </p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-GJhpLtzA6Uw/U1xRoR3-vkI/AAAAAAADbuA/XmGrTCWjQH4/s1600/IFTTT+Android+iOS-12.png"><img src="https://4.bp.blogspot.com/-GJhpLtzA6Uw/U1xRoR3-vkI/AAAAAAADbuA/XmGrTCWjQH4/s1600/IFTTT+Android+iOS-12.png"></a></p>
<ol start="2">
<li>例如，我們來建立一個「如果每天到了晚上 11 點，就會關閉手機鈴聲」的自動設定吧！  </li>
</ol>
<p>在「 if 」後面點擊「 + 」，設定「如果」的條件，這裡可以看到所有可以當作條件的網路服務、手機功能，在其中選擇「 Date &amp; Time 」，點擊「 Every day at 」。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-k_B6l7YNb74/U1xRq0mubII/AAAAAAADbus/yiAstziVhtY/s1600/IFTTT+Android+iOS-13.png"><img src="https://3.bp.blogspot.com/-k_B6l7YNb74/U1xRq0mubII/AAAAAAADbus/yiAstziVhtY/s1600/IFTTT+Android+iOS-13.png"></a></p>
<ol start="3">
<li>也就是如果每天到了幾點鐘，當作我們的命令條件。  </li>
</ol>
<p>第一次啟動時間功能時，會要求啟動查詢時間的權限，按下繼續後，會要求我們設定一個命令的時間，這裡調整成晚上 11 點即可。  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-3lRogTe-3Xw/U1xRoq8SzOI/AAAAAAADbuQ/yn49nzDV5xc/s1600/IFTTT+Android+iOS-14.png"><img src="https://1.bp.blogspot.com/-3lRogTe-3Xw/U1xRoq8SzOI/AAAAAAADbuQ/yn49nzDV5xc/s1600/IFTTT+Android+iOS-14.png"></a><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-80YilpLZyCY/U1xRpIarCfI/AAAAAAADbuU/gnJdY4H2WHQ/s1600/IFTTT+Android+iOS-15.png"><img src="https://4.bp.blogspot.com/-80YilpLZyCY/U1xRpIarCfI/AAAAAAADbuU/gnJdY4H2WHQ/s1600/IFTTT+Android+iOS-15.png"></a></p>
<ol start="4">
<li>設定好命令裡的「如果」條件後，接著點擊「就會（ then ）」後面的「+」，設定那麼要怎麼做的觸發反應。  </li>
</ol>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-elTPGbhF-YA/U1xRpcOBgMI/AAAAAAADbuc/aNYj2_hxjQM/s1600/IFTTT+Android+iOS-16.png"><img src="https://4.bp.blogspot.com/-elTPGbhF-YA/U1xRpcOBgMI/AAAAAAADbuc/aNYj2_hxjQM/s1600/IFTTT+Android+iOS-16.png"></a></p>
<ol start="5">
<li>在觸發反應中也可以看到所有能夠當作反應動作的服務、功能，找到「 Android Device 」裡的「 Mute ringtone 」，點擊「+」，添加為觸發反應。  </li>
</ol>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-sAoL-7rZyrA/U1xRpx24qvI/AAAAAAADbuk/MArp6eBeB1I/s1600/IFTTT+Android+iOS-18.png"><img src="https://1.bp.blogspot.com/-sAoL-7rZyrA/U1xRpx24qvI/AAAAAAADbuk/MArp6eBeB1I/s1600/IFTTT+Android+iOS-18.png"></a></p>
<ol start="6">
<li>這樣一來，就完成我們自己製作的一份 IFTTT Recipe（配方）了！以後只要到晚上 11 點，就會觸發把手機關靜音的反應（反應時間可能會慢個幾分鐘，因為 IFTTT 是定期定時檢查條件的方式，而非即時檢查條件）。  </li>
</ol>
<p>透過上面的 IFTTT 基本介面、添加別人製作好的配方、自己設定一份新配方，我們就可以快速練習 IFTTT 的基本功能，有興趣的朋友，則可以繼續深入研究看看，會發現有很多有趣強大的應用，尤其發揮創意想像力，說不一定你可以讓網路更聰明自動化喔！  </p>
<p>延伸閱讀，<strong>Android 其他自動化工具</strong>：  </p>
<ul>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/02/agent-app.html">Agent 免設定聰明手機自動開會靜音、睡眠勿擾、停車定位！</a></li>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/06/automateit-android.html">AutomateIt 自動控制 Android 省時免動手，智慧手機更聰明</a></li>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/11/android.html">我的 Android 手機自動化攻略：聽音樂上班旅行自動切換設定</a></li>
</ul>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-wLS8tUlknNU/U1xRqMYCdyI/AAAAAAADbuw/wR0By0ckYoA/s1600/IFTTT+Android+iOS-19.png"><img src="https://4.bp.blogspot.com/-wLS8tUlknNU/U1xRqMYCdyI/AAAAAAADbuw/wR0By0ckYoA/s1600/IFTTT+Android+iOS-19.png"></a></p>
<h1 id="Zapier-教學：讓-Evernote-筆記與-Google-日曆自動連動好方法"><a href="#Zapier-教學：讓-Evernote-筆記與-Google-日曆自動連動好方法" class="headerlink" title="Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法"></a>Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2017/06/zapier-evernote-google-calendar.html">Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法</a></li>
</ul>
<p>作者：<a target="_blank" rel="noopener" href="https://www.blogger.com/profile/10426807330996372963" title="author profile">Esor Huang</a><a target="_blank" rel="noopener" href="https://www.playpcesor.com/2017/06/zapier-evernote-google-calendar.html" title="permanent link">6月 08, 2017</a></p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-qHpoEi8G2XY/WTlQr0dicaI/AAAAAAAFY3w/SyFgrhgFT2s8v9rQb9NkeAOdyNmX7Hj9ACLcB/s1600/%25E8%259E%25A2%25E5%25B9%2595%25E5%25BF%25AB%25E7%2585%25A7%2B2017-06-08%2B%25E4%25B8%258B%25E5%258D%25889.26.30.png"><img src="https://4.bp.blogspot.com/-qHpoEi8G2XY/WTlQr0dicaI/AAAAAAAFY3w/SyFgrhgFT2s8v9rQb9NkeAOdyNmX7Hj9ACLcB/s640/%25E8%259E%25A2%25E5%25B9%2595%25E5%25BF%25AB%25E7%2585%25A7%2B2017-06-08%2B%25E4%25B8%258B%25E5%258D%25889.26.30.png"></a></p>
<p>我在電腦玩物曾經介紹過一個叫做「 IFTTT 」的服務，他的功能是在兩個不同的雲端服務之間創造自動化工作，例如「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/04/ifttt-android-ios.html">IFTTT Android iOS 入門教學：如果明天下雨請今日提醒我</a>」、「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/05/line-RSS.html">用 LINE 即時通訂閱對你最有價值的網站新文章</a>」。  </p>
<p>而這幾年在國外還有另一個更進階的知名服務叫做：「<strong>Zapier</strong>」，他可以創造出許多生產力工具之間更複雜的連動，例如像是：  </p>
<ul>
<li>當「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2015/01/evernote-10.html">Evernote 筆記</a>」加上時間提醒後，把這則筆記內容自動加入相應日期的「 Google 日曆」。</li>
<li>當「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2016/06/google-calendar-10-example.html">Google 日曆</a>」新增會議行程時，把這個行程內容自動加入「 Evernote 筆記」。</li>
</ul>
<p>跟我一樣使用 Evernote 與 Google 日曆做任務管理的朋友，可以試試看用「 Zapier 」來滿足<strong>兩個服務之間自動連動</strong>的需求，而且經過我一段時間的測試，這樣的自動連動頗為穩定，這篇文章我也把設定步驟寫成一篇教學。  </p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-uZbA2ef3q5w/WTk-i3BEs8I/AAAAAAAFY2c/CJFIaHet1KMZfq1kXGXVbdXz2O069ftmQCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-01.png"><img src="https://4.bp.blogspot.com/-uZbA2ef3q5w/WTk-i3BEs8I/AAAAAAAFY2c/CJFIaHet1KMZfq1kXGXVbdXz2O069ftmQCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-01.png"></a></p>
<h3 id="方法一：讓需要時間提醒的-Evernote-筆記，也匯入-Google-日曆行程"><a href="#方法一：讓需要時間提醒的-Evernote-筆記，也匯入-Google-日曆行程" class="headerlink" title="方法一：讓需要時間提醒的 Evernote 筆記，也匯入 Google 日曆行程"></a>方法一：讓需要時間提醒的 Evernote 筆記，也匯入 Google 日曆行程</h3><p>不用擔心會很難，雖然「 Zapier 」比較專業，但設定步驟其實也非常簡單，甚至套用基本模板後，只要跟著下一步完成設定即可。</p>
<p>那麼先讓我介紹第一個方法：</p>
<blockquote>
<p>假如我準備好了一個「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/p/blog-page_15.html">Esor的時間管理課程</a>」的 Evernote 筆記，上課日期是 6/24 ，於是我在筆記加上 6/24 的時間提醒，這時候，「 Zapier 」將會在 Google 日曆的 6/24 上新增這個筆記的行程，附上筆記的連結。</p>
</blockquote>
<p>怎麼做到？首先請你先申請一個「<a target="_blank" rel="noopener" href="https://zapier.com/">Zapier</a>」帳號，然後你可以搜尋要建立 Evernote 與 Google 日曆兩種服務之間的自動化工具，並找到別人已經建立好的模板來套用，這邊我已經幫大家找到可以使用這個模板：「<a target="_blank" rel="noopener" href="https://zapier.com/app/editor/template/1313">當 Evernote 筆記加上時間提醒，就自動匯入成 Google 日曆新行程</a>」。</p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-UlCFGSOwD1k/WTk-iyH6zvI/AAAAAAAFY2k/-15X__xAiPEe3lNYlMep58995jXxAwM1gCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-02.png"><img src="https://1.bp.blogspot.com/-UlCFGSOwD1k/WTk-iyH6zvI/AAAAAAAFY2k/-15X__xAiPEe3lNYlMep58995jXxAwM1gCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-02.png"></a></p>
<p>點開我前面提供的模板網址，然後在最下方按下「 Create this Zap 」。  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-5nmx2Oj_Xo4/WTk-jAt5oJI/AAAAAAAFY2g/Wye1muvIxVs1VR4NAYMfvxreFkHmFuPzwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-03.png"><img src="https://1.bp.blogspot.com/-5nmx2Oj_Xo4/WTk-jAt5oJI/AAAAAAAFY2g/Wye1muvIxVs1VR4NAYMfvxreFkHmFuPzwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-03.png"></a></p>
<p>接著按照預設，勾選當 Evernote 筆記有加上時間提醒就啟動功能，按下「 Continue 」繼續。  </p>
<p><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-U_wHtOaDeAI/WTk-j1JL3bI/AAAAAAAFY2o/_Y86teMw7GIf6RaMqGkDW9tT24NcHxtLwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-04.png"><img src="https://2.bp.blogspot.com/-U_wHtOaDeAI/WTk-j1JL3bI/AAAAAAAFY2o/_Y86teMw7GIf6RaMqGkDW9tT24NcHxtLwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-04.png"></a></p>
<p>當然，下一步我們要認證自己的 Evernote 帳號後繼續。  </p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-xPhWccdoCSA/WTk-kNFOjKI/AAAAAAAFY2s/xkxvaO7LCg0x1vXVSajd9utJYDkXE9o1ACEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-05.png"><img src="https://4.bp.blogspot.com/-xPhWccdoCSA/WTk-kNFOjKI/AAAAAAAFY2s/xkxvaO7LCg0x1vXVSajd9utJYDkXE9o1ACEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-05.png"></a></p>
<p>接著選擇在哪個記事本裡的 Evernote 筆記加上時間提醒後，會觸動功能。  </p>
<p>如果不選，就是所有筆記都會觸動。  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-zK34BH4xHv4/WTk-kT23MmI/AAAAAAAFY2w/fk_17Ke3028dsI0N6Zv_tRpBJBfz6G8TACEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-06.png"><img src="https://1.bp.blogspot.com/-zK34BH4xHv4/WTk-kT23MmI/AAAAAAAFY2w/fk_17Ke3028dsI0N6Zv_tRpBJBfz6G8TACEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-06.png"></a></p>
<p>下一步，就換成認證 Google 日曆帳號。  </p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-v0Xs6xYxwvs/WTk-k80sKSI/AAAAAAAFY20/SLgiuM429eo9xkbIpqGED17R78eWb4WwwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-07.png"><img src="https://3.bp.blogspot.com/-v0Xs6xYxwvs/WTk-k80sKSI/AAAAAAAFY20/SLgiuM429eo9xkbIpqGED17R78eWb4WwwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-07.png"></a></p>
<p>認證好 Google 日曆，接著就要設定如何把 Evernote 筆記的內容，匯入到 Google 日曆行程。</p>
<p>首先在「 Calendar」 ，選擇加上提醒的筆記要匯入哪一個行事曆。</p>
<p>接著在「 Start Date &amp; Time 」，選擇根據 Evernote 的時間提醒，在 Google 日曆的相應時間加上行程。</p>
<p>還要在「 End Date &amp; Time 」，選擇行程的結束時間，這時候要使用語法，例如在 Evernote 提醒時間後面「 +1h」（記得要空一格），就表示這個行程一個小時後結束。</p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-IdhjkNL7IDE/WTk-lGqy_TI/AAAAAAAFY24/qUYvBxgehf4YzkN9e2WKnlO27htmhEdnwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-08.png"><img src="https://3.bp.blogspot.com/-IdhjkNL7IDE/WTk-lGqy_TI/AAAAAAAFY24/qUYvBxgehf4YzkN9e2WKnlO27htmhEdnwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-08.png"></a></p>
<p>下方還可以做更多進階設定，例如用筆記標題當作 Google 日曆行程的名稱，以及要在 Google 行程的「說明（ Desciption ）」裡插入哪些筆記內容，我建議可以選下面兩個：  </p>
<ul>
<li>「 URL 」：也就是插入 Evernote 筆記的私密網址，這樣我可以點連結打開筆記。</li>
<li>「 Content no HTML 」：把筆記內容插入 Google 日曆行程說明。</li>
</ul>
<p><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-iv5tdiaUwMI/WTk-lvGjhoI/AAAAAAAFY28/fD8m1bktC4YOTNCtusfy84NQDFBEZFc3gCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-09.png"><img src="https://2.bp.blogspot.com/-iv5tdiaUwMI/WTk-lvGjhoI/AAAAAAAFY28/fD8m1bktC4YOTNCtusfy84NQDFBEZFc3gCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-09.png"></a></p>
<p>很簡單，一步一步來，這樣就設定完成了！「 Zapier 」預設每 15 分鐘會自動檢查一次，如果有發現新的加上提醒的筆記，就會在日曆新增行程。  </p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-pskh_wcq7_Q/WTk-l4LYStI/AAAAAAAFY3A/IdsFlUXo00gY2Ce1myYyTUDjvQpLP2nPwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-10.png"><img src="https://4.bp.blogspot.com/-pskh_wcq7_Q/WTk-l4LYStI/AAAAAAAFY3A/IdsFlUXo00gY2Ce1myYyTUDjvQpLP2nPwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-10.png"></a></p>
<p>回到「 Zapier 」的控制台，你可以看到自己目前啟動的所有自動工作菜單。  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-OTSDul6xBuc/WTk-mFYHn_I/AAAAAAAFY3E/byHwmQ3swssrB2-a2p6jvfBBpiD-WjXbwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-11.png"><img src="https://1.bp.blogspot.com/-OTSDul6xBuc/WTk-mFYHn_I/AAAAAAAFY3E/byHwmQ3swssrB2-a2p6jvfBBpiD-WjXbwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-11.png"></a></p>
<p>實際測試，我在 Evernote 某一則已經建立一段時間的筆記加上新的「時間提醒」（參考教學：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/05/evernote_27.html">Evernote 活用「提醒事項」教學，解決七大時間管理問題</a>），等個十幾分鐘，就看到 Google 日曆上的那一個時間，出現我要的行程囉！</p>
<p><a target="_blank" rel="noopener" href="https://4.bp.blogspot.com/-XIKqgYIzz6I/WTk-nHrKuJI/AAAAAAAFY3M/ktDZKBCLgyoYJAwoQoucn73S6v43ei9GwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-13.png"><img src="https://4.bp.blogspot.com/-XIKqgYIzz6I/WTk-nHrKuJI/AAAAAAAFY3M/ktDZKBCLgyoYJAwoQoucn73S6v43ei9GwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-13.png"></a></p>
<h3 id="方法二：讓新的-Google-行事曆行程，自動新增-Evernote-筆記"><a href="#方法二：讓新的-Google-行事曆行程，自動新增-Evernote-筆記" class="headerlink" title="方法二：讓新的 Google 行事曆行程，自動新增 Evernote 筆記"></a>方法二：讓新的 Google 行事曆行程，自動新增 Evernote 筆記</h3><p>另一個方法，則是反過來，如果我在 Google 行事曆上建立一個新的行程，就讓這個行程自動在 Evernote 建立一則筆記，例如：</p>
<blockquote>
<p>我下週五有一個會議，在 Google 日曆上建立會議行程，於是自動在 Evernote 新增這一次會議的會議筆記，筆記裡有相關的時間地點與說明資訊。（參考：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2013/04/evernote_29.html">如何建立有效會議記錄？ Evernote 會議筆記範本格式心得</a>）</p>
</blockquote>
<p>如何做到？利用「 Zapier 」的「<a target="_blank" rel="noopener" href="https://zapier.com/app/editor/template/10031">把新的 Google 日曆行程匯入到新 Evernote 筆記</a>」模板即可。</p>
<p>同樣的先認證 Google 日曆帳號，並指定要用哪一個行事曆的行程。（可參考：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/06/google-calendar-family.html">用 Google 日曆和家人一起管好家庭計劃，強化感情的7個技巧</a>）</p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-6-fBxdj-rYA/WTk-mgrDomI/AAAAAAAFY3I/xZFb03jRi-IAF6ncfLpPDQFknDoyq6ISQCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-12.png"><img src="https://3.bp.blogspot.com/-6-fBxdj-rYA/WTk-mgrDomI/AAAAAAAFY3I/xZFb03jRi-IAF6ncfLpPDQFknDoyq6ISQCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-12.png"></a></p>
<p>接著認證 Evernote 帳號，然後指定新的行程筆記要匯入哪一個記事本。  </p>
<p>其他大致上維持預設即可，也就是用行程名稱當做筆記標題，把行程的時間地點與說明匯入成筆記內文。  </p>
<p><a target="_blank" rel="noopener" href="https://2.bp.blogspot.com/-bIHMlnTS-tY/WTk-nTt5HkI/AAAAAAAFY3Q/9UHvFn69jbE5dZCIiTZl_A01We4lniMFgCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-14.png"><img src="https://2.bp.blogspot.com/-bIHMlnTS-tY/WTk-nTt5HkI/AAAAAAAFY3Q/9UHvFn69jbE5dZCIiTZl_A01We4lniMFgCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-14.png"></a></p>
<p>下面就是從 Google 日曆自動匯入的 Evernote 筆記。  </p>
<p>最近， Evernote 官方也在「<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2015/08/evernote-web.html">Evernote 網頁版</a>」測試一個「把 Google 日曆匯入成會議筆記」的新功能，有興趣的朋友也可以去網頁版試試看。  </p>
<p><a target="_blank" rel="noopener" href="https://1.bp.blogspot.com/-Ug9id5-o6vQ/WTk-n-Ue2aI/AAAAAAAFY3U/tZ3a8uUEDIw1s7lj__N9Xy5_osO3vg6QwCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-15.png"><img src="https://1.bp.blogspot.com/-Ug9id5-o6vQ/WTk-n-Ue2aI/AAAAAAAFY3U/tZ3a8uUEDIw1s7lj__N9Xy5_osO3vg6QwCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-15.png"></a></p>
<h3 id="方法三：完全自訂"><a href="#方法三：完全自訂" class="headerlink" title="方法三：完全自訂"></a>方法三：完全自訂</h3><p>熟練上述的方法後，如果覺得預設模板沒有自己想要的，也可以在「 Zapier 」中利用「 Make A ZAPI 」，來建立自己全新的自動化菜單。</p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-OKqIkAcob0g/WTk-oMtVs6I/AAAAAAAFY3Y/wxJl7vI9b8gAbmwmKzRBHPgh98gghLAZQCEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-16.png"><img src="https://3.bp.blogspot.com/-OKqIkAcob0g/WTk-oMtVs6I/AAAAAAAFY3Y/wxJl7vI9b8gAbmwmKzRBHPgh98gghLAZQCEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-16.png"></a></p>
<p>當然除了 Evernote 和 Google 日曆的連動，還有許多服務可以設定，有興趣的朋友可以好好研究看看「 Zapier 」。  </p>
<p>最後要注意的是，如果是使用「 Zapier 」<strong>免費版</strong>，最多可以規劃「五個」自動化工作流程，每個月「最多觸發 100 次的自動化連動」。  </p>
<p>延伸閱讀相關文章：  </p>
<ul>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2016/06/google-calendar-evernote.html">如何在 Google 日曆整合 Evernote 筆記？實用笨方法</a></li>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2016/03/evernote-google-calendar-sync.html">[實測教學] 直接雙向同步 Evernote 與 Google 行事曆</a></li>
<li><a target="_blank" rel="noopener" href="http://www.playpcesor.com/2014/11/10-automated-app-android.html">Android 的 10 種聰明 App 把這十個煩人步驟自動化</a></li>
</ul>
<p>「 <a target="_blank" rel="noopener" href="https://zapier.com/">Zapier</a> 」網站</p>
<p>轉貼本文時禁止修改，禁止商業使用，並且必須註明來自電腦玩物原創作者 esor huang（異塵行者），及附上原文連結：<a target="_blank" rel="noopener" href="http://www.playpcesor.com/2017/06/zapier-evernote-google-calendar.html">Zapier 教學：讓 Evernote 筆記與 Google 日曆自動連動好方法</a></p>
<p><a target="_blank" rel="noopener" href="https://3.bp.blogspot.com/-Z9YDSPl3qtM/WTk-okfrLRI/AAAAAAAFY3c/oJQHu-qWbrMfs_Vp_ifZnCjkdQrD02cwACEw/s1600/Zapier%2BEvernote%2BGoogle%2BCalendar-17.png"><img src="https://3.bp.blogspot.com/-Z9YDSPl3qtM/WTk-okfrLRI/AAAAAAAFY3c/oJQHu-qWbrMfs_Vp_ifZnCjkdQrD02cwACEw/s640/Zapier%2BEvernote%2BGoogle%2BCalendar-17.png"></a></p>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
	<div class="article-tag tagcloud">
		<i class="icon-price-tags icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color2">Tasker</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color5">Shortcuts</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color1">Agent</a>
        		</li>
      		
		</ul>
	</div>

      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/17/20210517/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210514" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/14/20210514/">20210514</a>
    </h1>
  

        
        <a href="/2021/05/14/20210514/" class="archive-article-date">
  	<time datetime="2021-05-13T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210514</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Margarine"><span class="toc-number">2.</span> <span class="toc-text">Margarine</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#Butter-vs-Margarine-Which-Is-Healthier"><span class="toc-number">2.1.</span> <span class="toc-text">Butter vs. Margarine: Which Is Healthier?</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#What-Are-Butter-and-Margarine"><span class="toc-number">2.1.1.</span> <span class="toc-text">What Are Butter and Margarine?</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Health-Benefits-of-Butter"><span class="toc-number">2.1.2.</span> <span class="toc-text">Health Benefits of Butter</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#Grass-Fed-Butter-is-Nutritious"><span class="toc-number">2.1.2.1.</span> <span class="toc-text">Grass-Fed Butter is Nutritious</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Risks-of-Eating-Butter"><span class="toc-number">2.1.3.</span> <span class="toc-text">Risks of Eating Butter</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#High-in-Saturated-Fat"><span class="toc-number">2.1.3.1.</span> <span class="toc-text">High in Saturated Fat</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#High-in-Cholesterol"><span class="toc-number">2.1.3.2.</span> <span class="toc-text">High in Cholesterol</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Health-Benefits-of-Margarine"><span class="toc-number">2.1.4.</span> <span class="toc-text">Health Benefits of Margarine</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#May-Be-High-in-Polyunsaturated-Fat"><span class="toc-number">2.1.4.1.</span> <span class="toc-text">May Be High in Polyunsaturated Fat</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#May-Contain-Plant-Sterols-and-Stanols"><span class="toc-number">2.1.4.2.</span> <span class="toc-text">May Contain Plant Sterols and Stanols</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Risks-of-Eating-Margarine"><span class="toc-number">2.1.5.</span> <span class="toc-text">Risks of Eating Margarine</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#May-Be-High-in-Trans-Fats"><span class="toc-number">2.1.5.1.</span> <span class="toc-text">May Be High in Trans Fats</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#May-Be-High-in-Omega-6-Fat"><span class="toc-number">2.1.5.2.</span> <span class="toc-text">May Be High in Omega-6 Fat</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#The-Bottom-Line"><span class="toc-number">2.1.6.</span> <span class="toc-text">The Bottom Line</span></a></li></ol></li><li class="toc-item toc-level-2"><a class="toc-link" href="#How-Does-Butter-Affect-My-Cholesterol-Levels"><span class="toc-number">2.2.</span> <span class="toc-text">How Does Butter Affect My Cholesterol Levels?</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#What-does-the-research-say"><span class="toc-number">2.2.1.</span> <span class="toc-text">What does the research say?</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#How-much-cholesterol-is-in-butter"><span class="toc-number">2.2.2.</span> <span class="toc-text">How much cholesterol is in butter?</span></a></li></ol></li><li class="toc-item toc-level-2"><a class="toc-link" href="#IS-MARGARINE-HARMFUL-6-SECRETS-THEY-DON%E2%80%99T-TELL-YOU"><span class="toc-number">2.3.</span> <span class="toc-text">IS MARGARINE HARMFUL? 6 SECRETS THEY DON’T TELL YOU!</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#IS-MARGARINE-GOOD-OR-BAD"><span class="toc-number">2.3.1.</span> <span class="toc-text">IS MARGARINE GOOD OR BAD?</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#WHAT-IS-MARGARINE"><span class="toc-number">2.3.2.</span> <span class="toc-text">WHAT IS MARGARINE?</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#THE-HISTORY-OF-MARGARINE"><span class="toc-number">2.3.3.</span> <span class="toc-text">THE HISTORY OF MARGARINE</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#LOW-FAT-MYTH"><span class="toc-number">2.3.4.</span> <span class="toc-text">LOW-FAT MYTH</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#QUALITY-OF-FAT-IS-IMPORTANT"><span class="toc-number">2.3.5.</span> <span class="toc-text">QUALITY OF FAT IS IMPORTANT</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#IS-MARGARINE-HARMFUL-6-SECRETS-ABOUT-MARGARINE-%E2%80%9CTHEY%E2%80%9D-DON%E2%80%99T-TELL-YOU"><span class="toc-number">2.3.6.</span> <span class="toc-text">IS MARGARINE HARMFUL - 6 SECRETS ABOUT MARGARINE  “THEY” DON’T TELL YOU:</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#1-MARGARINE-IS-HIGH-IN-TRANS-FATTY-ACIDS"><span class="toc-number">2.3.6.1.</span> <span class="toc-text">1. MARGARINE IS HIGH IN TRANS FATTY ACIDS.</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#2-MARGARINE-ACTUALLY-CONTRIBUTES-TO-HEART-ATTACKS"><span class="toc-number">2.3.6.2.</span> <span class="toc-text">2. MARGARINE ACTUALLY CONTRIBUTES TO HEART ATTACKS.</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#3-MARGARINE-INCREASES-CHOLESTEROL"><span class="toc-number">2.3.6.3.</span> <span class="toc-text">3. MARGARINE INCREASES CHOLESTEROL.</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#4-MARGARINE-LOWERS-QUALITY-OF-BREAST-MILK"><span class="toc-number">2.3.6.4.</span> <span class="toc-text">4. MARGARINE LOWERS QUALITY OF BREAST MILK.</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#5-MARGARINE-DECREASES-IMMUNE-RESPONSE"><span class="toc-number">2.3.6.5.</span> <span class="toc-text">5. MARGARINE DECREASES IMMUNE RESPONSE.</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#6-DECREASES-INSULIN-RESPONSE"><span class="toc-number">2.3.6.6.</span> <span class="toc-text">6. DECREASES INSULIN RESPONSE.</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#MARGARINE-DISADVANTAGES"><span class="toc-number">2.3.7.</span> <span class="toc-text">MARGARINE DISADVANTAGES</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#MISTAKE-IN-RESEARCH"><span class="toc-number">2.3.8.</span> <span class="toc-text">MISTAKE IN RESEARCH</span></a><ol class="toc-child"><li class="toc-item toc-level-5"><a class="toc-link" href="#THESE-%E2%80%9CMINOR%E2%80%9D-DIFFERENCE-HOWEVER-MADE-ALL-THE-DIFFERENCE-IN-THE-WORLD-TO-THE-CONCLUSION-OF-THE-RESEARCH"><span class="toc-number">2.3.8.0.1.</span> <span class="toc-text">THESE “MINOR” DIFFERENCE, HOWEVER, MADE ALL THE DIFFERENCE IN THE WORLD TO THE CONCLUSION OF THE RESEARCH.</span></a></li></ol></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#WHAT-ABOUT-%E2%80%9CHEART-HEALTHY%E2%80%9D-SUBSTITUTES"><span class="toc-number">2.3.9.</span> <span class="toc-text">WHAT ABOUT “HEART HEALTHY” SUBSTITUTES?</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#PIN-IT"><span class="toc-number">2.3.10.</span> <span class="toc-text">PIN IT!</span></a></li></ol></li><li class="toc-item toc-level-2"><a class="toc-link" href="#The-truth-about-fats-the-good-the-bad-and-the-in-between"><span class="toc-number">2.4.</span> <span class="toc-text">The truth about fats: the good, the bad, and the in-between</span></a><ol class="toc-child"><li class="toc-item toc-level-3"><a class="toc-link" href="#Avoid-the-trans-fats-limit-the-saturated-fats-and-replace-with-essential-polyunsaturated-fats"><span class="toc-number">2.4.1.</span> <span class="toc-text">Avoid the trans fats, limit the saturated fats, and replace with essential polyunsaturated fats</span></a></li></ol></li></ol></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><ul>
<li><a target="_blank" rel="noopener" href="https://www.linuxadictos.com/zh-TW/crear-distribucion-linux.html">如何創建自己的自定義Linux發行版。 Linux成癮者</a></li>
<li><a target="_blank" rel="noopener" href="https://sites.google.com/site/nationinsky/seraphim-2/live-usb">linux live-usb的终极制作 - 天国神族</a></li>
<li><a target="_blank" rel="noopener" href="https://linuxtoy.org/archives/ubuntu_live_cd_custom.html">Ubuntu Live CD 个性化定制全程图解 · LinuxTOY</a></li>
<li><a target="_blank" rel="noopener" href="https://blog.csdn.net/weixin_30363981/article/details/95445508">定制个性化Live CD_weixin_30363981的博客-CSDN博客</a></li>
</ul>
<figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br><span class="line">17</span><br><span class="line">18</span><br><span class="line">19</span><br><span class="line">20</span><br></pre></td><td class="code"><pre><span class="line">also installing the dependencies </span><br><span class="line">&quot;clipr&quot;, &quot;viridisLite&quot;, &quot;ggplot2&quot;, &quot;gridExtra&quot;, &quot;downloader&quot;, &quot;igraph&quot;, &quot;influenceR&quot;, &quot;readr&quot;, &quot;tidyr&quot;, &quot;viridis&quot;, &quot;visNetwork&quot;</span><br><span class="line"></span><br><span class="line">尊敬的项目办领导，</span><br><span class="line"></span><br><span class="line">按照要求提交文件，请查收并批评指正。</span><br><span class="line"></span><br><span class="line">zdzx10_2016@vip.126.com</span><br><span class="line"></span><br><span class="line">刘宏图-课题进展-2018ZX10201002</span><br><span class="line"></span><br><span class="line">2021 National Trade Estimate Report on</span><br><span class="line">FOREIGN TRADE</span><br><span class="line">BARRIERS</span><br><span class="line"></span><br><span class="line">World Trade Statistical Review 2020</span><br><span class="line"></span><br><span class="line">2021 Trade Policy Agenda and 2020 Annual Report OF THE PRESIDENT OF THE UNITED STATES ON THE TRADE AGREEMENTS PROGRAM</span><br><span class="line"></span><br><span class="line">World Trade Statistical Review 2020</span><br></pre></td></tr></table></figure>
<h1 id="Margarine"><a href="#Margarine" class="headerlink" title="Margarine"></a>Margarine</h1><p>人造黄油的迷思</p>
<p>首先是针对黄油的传说。基本逻辑是，由于脂肪不是好东西，饱含脂肪的黄油肯定不是好东西。不过，最近的观察表明，单独的黄油对于人体健康的影响，说不上正面，也说不上负面。甚至，动物脂肪对于人体健康的影响也是充满着矛盾。</p>
<p>人造黄油(Margarine)被人诟病的有4点：</p>
<ol>
<li>含有不饱和脂肪酸</li>
<li>含有反式脂肪酸</li>
<li>含有人工添加的维生素</li>
<li>含有人工色素</li>
</ol>
<p>分别说明一下：</p>
<ol>
<li>含有不饱和脂肪酸：黄油中是饱和脂肪酸。人造黄油中的不饱和脂肪酸占比不到20%。因此食用等量的黄油和人造黄油，饱和脂肪酸的摄入量差别没有想象的大。</li>
<li>含有反式脂肪酸：早期的合成方式，可以想成反式脂肪酸，同时，反式脂肪酸不能被人吸收，被吹成减肥神品。FDA曾经发文禁止反式脂肪酸，但接近一半的美国生产商可以申请继续生产含有反式脂肪酸的人造黄油。最新的合成方式已经避免了反式脂肪酸的产生，因此反式脂肪酸已经不是新式人造黄油的痛点。</li>
<li>含有人工添加的维生素：维生素以及其他添加剂曾经是人造黄油的另一个神话。近来的研究已经否认了这些添加的健康因素。</li>
<li>含有人工色素：曾经是被诟病的痛点。但，大量食品中也含有该类添加剂，不能说一定有害。</li>
</ol>
<h2 id="Butter-vs-Margarine-Which-Is-Healthier"><a href="#Butter-vs-Margarine-Which-Is-Healthier" class="headerlink" title="Butter vs. Margarine: Which Is Healthier?"></a>Butter vs. Margarine: Which Is Healthier?</h2><p><img src="https://i0.wp.com/post.healthline.com/wp-content/uploads/2020/06/kris3.png?w=105&h=105"></p>
<ul>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/butter-vs-margarine">Butter vs. Margarine: Which Is Healthier?</a></li>
</ul>
<p>Written by<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition-team">Kris Gunnars, BSc</a>—Updated on April 17, 2018</p>
<ul>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#what-are-butter-and-margarine">What Are Butter and Margarine?</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#benefits-of-butter">Benefits of Butter</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#risks-of-eating-butter">Risks of Eating Butter</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#benefits-of-margarine">Benefits of Margarine</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#risks-of-eating-margarine">Risks of Eating Margarine</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#bottom-line">Bottom Line</a></li>
</ul>
<p>A massive amount of nutrition misinformation exists on the internet.</p>
<p>Some of it is based on poor research or incomplete evidence, while other information may simply be outdated.</p>
<p>The professionals themselves may even tell you things that seem to directly contradict something you read the other day.</p>
<p>A good example of a subject no one seems to agree upon are the health effects of butter and margarine.</p>
<p>This article compares the two, looking at both sides of the debate.</p>
<h3 id="What-Are-Butter-and-Margarine"><a href="#What-Are-Butter-and-Margarine" class="headerlink" title="What Are Butter and Margarine?"></a>What Are Butter and Margarine?</h3><p>Butter is a traditional dietary staple made by churning cream.</p>
<p>It’s mainly used as a frying fat, spread or component of sauces, cakes and pastries.</p>
<p>As a concentrated source of milk fat, it’s mostly composed of saturated fat.</p>
<p>Because of studies associating a high intake of saturated fat with an increased risk of heart disease, public health authorities started recommending that people limit their consumption of butter in the 1970s.</p>
<p>Margarine is a processed food that is designed to taste and look similar to butter. It is often recommended as a heart-healthy replacement.</p>
<p>Modern types of margarine are made from vegetable oils, which contain polyunsaturated fats that can lower the “bad” LDL cholesterol when used instead of saturated fat.</p>
<p>Since<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/11-serious-concerns-about-vegetable-oils">vegetable oils</a>are liquid at room temperature, food scientists change their chemical structure to make them solid like butter.</p>
<p>For the past few decades, a process known as hydrogenation has been used to harden the vegetable oils in margarine.</p>
<p>Hydrogenation increases the oil’s saturated fat content, but unhealthy trans fats are formed as a side product (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26268692">1Trusted Source</a>).</p>
<p>A more recent process called interesterification achieves similar results without forming any trans fats (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28729812">2Trusted Source</a>).</p>
<p>In addition to hydrogenated or interesterified vegetable oils, modern margarine may contain several food additives, including emulsifiers and colorants.</p>
<p>Put simply, modern margarine is a highly processed food product made from vegetable oils, while butter is basically concentrated dairy fat.</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Butter is a dairy product made by churning cream. Conversely, margarine is a product designed to imitate butter. While butter is mainly composed of dairy fat, margarine is typically produced from vegetable oils.</p>
</blockquote>
<h3 id="Health-Benefits-of-Butter"><a href="#Health-Benefits-of-Butter" class="headerlink" title="Health Benefits of Butter"></a>Health Benefits of Butter</h3><p><a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/7-reasons-why-butter-is-good-for-you">Butter</a>may contain several nutrients not found in many other foods.</p>
<p>For example, butter from grass-fed cows may provide some vitamin K2, which has been associated with improved bone health (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/23858094">3Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26770129">4Trusted Source</a>).</p>
<p>In fact, butter from grass-fed cows appears to be a better source of many nutrients than butter from cows fed grains.</p>
<h4 id="Grass-Fed-Butter-is-Nutritious"><a href="#Grass-Fed-Butter-is-Nutritious" class="headerlink" title="Grass-Fed Butter is Nutritious"></a>Grass-Fed Butter is Nutritious</h4><p>The health effects of butter largely depend on the diet of the cows it came from.</p>
<p>Cows eat grass in their natural environment, but in many countries, their menu is largely based on grain-based feeds.</p>
<p><a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/grass-fed-butter-superfood-for-the-heart">Butter from grass-fed cows</a>is much more nutritious. It contains more:</p>
<ul>
<li>**Vitamin K2:**This little known vitamin may help prevent many serious diseases, including cancer, osteoporosis and heart disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/19179058">5Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/18400723">6Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/16801507">7Trusted Source</a>).</li>
<li>**Conjugated Linoleic Acid (CLA):**Studies suggest that this fatty acid can have anti-cancer properties and help lower your body fat percentage (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/11110851">8Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/19266226">9Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/16475675">10Trusted Source</a>).</li>
<li>**Butyrate:**A short-chain fatty acid found in butter that’s also produced by bacteria in the intestine. It can fight inflammation, improve digestive health and may help prevent weight gain (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/1612357">11Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/11989838">12Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699871/">13Trusted Source</a>).</li>
<li>**Omega-3:**Grass-fed butter has less omega-6 and more omega-3, which is important because most people are already eating way too much omega-6 fat (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/12442909">14Trusted Source</a>).</li>
</ul>
<p>Nonetheless, butter is generally consumed in small amounts, and its contribution to the total dietary intake of these nutrients is low.</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Butter from grass-fed cows contains much greater amounts of heart-healthy nutrients than butter from grain-fed cows.</p>
</blockquote>
<p>HEALTHLINE NEWSLETTER</p>
<p>Sign up for daily nutrition tips and tricks</p>
<p>Healthier eating shouldn’t be a hassle. We’ll send you our evidence-based tips on meal planning and nutrition</p>
<p>Enter your email</p>
<p>GET STARTED</p>
<p>Your<a target="_blank" rel="noopener" href="https://www.healthline.com/privacy-policy">privacy</a>is important to us. Any information you provide to us via this website may be placed by us on servers located in countries outside of the EU. If you do not agree to such placement, do not provide the information.</p>
<h3 id="Risks-of-Eating-Butter"><a href="#Risks-of-Eating-Butter" class="headerlink" title="Risks of Eating Butter"></a>Risks of Eating Butter</h3><p>Some experts are worried about the large amounts of saturated fat and cholesterol in butter and advise people to limit their intake.</p>
<h4 id="High-in-Saturated-Fat"><a href="#High-in-Saturated-Fat" class="headerlink" title="High in Saturated Fat"></a>High in Saturated Fat</h4><p>For decades, butter has been demonized for its high<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/saturated-fat-good-or-bad">saturated fat</a>content.</p>
<p>It’s composed of around 50% saturated fat, while the rest is mainly water and unsaturated fat.</p>
<p>Observational studies investigating the association between saturated fat and heart disease have provided mixed results (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26268692">1Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/20071648">15Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/17921367">16Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/20372173">17Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22810464">18Trusted Source</a>).</p>
<p>A recent review of studies concluded that eating less saturated fat is linked to a 17% reduced risk of heart disease when it’s replaced with polyunsaturated fat (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26068959">19Trusted Source</a>).</p>
<p>Conversely, switching saturated fat out for carbs or protein appears to have no effects (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26068959">19Trusted Source</a>).</p>
<p>As a result, some experts doubt that saturated fat intake is really a cause for concern. Others are still convinced that excessive saturated fat intake is a risk factor for heart disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28125802">20Trusted Source</a>).</p>
<p>In fact, health authorities have advised people to limit their saturated fat intake for decades.</p>
<p>Proponents of this popular opinion often point to studies showing that saturated fat increases levels of “bad” LDL cholesterol.</p>
<p>While it’s true that saturated fat promotes higher levels of LDL cholesterol, the story is a bit more complex (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28166253">21Trusted Source</a>).</p>
<p>Interestingly, some scientists believe that eating saturated fat may actually have<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/top-8-reasons-not-to-fear-saturated-fats">some benefits</a>, including improving the blood lipid profile.</p>
<p>It may raise “good” HDL cholesterol and change LDL cholesterol particle size from small and dense to large, which is considered more benign (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28572872">22Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/9583838">23Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/23627975">24Trusted Source</a>).</p>
<p>No strong evidence supports claims that a high intake of butter or other dietary sources of saturated fat are directly responsible for heart disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/27355649">25Trusted Source</a>).</p>
<p>However, more high-quality research is needed before scientists can fully understand saturated fat metabolism and its relevance to heart health.</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>High intake of saturated fat has been linked to an increased risk of heart disease, but the evidence is inconsistent. The issue is one of the most controversial in nutrition science.</p>
</blockquote>
<h4 id="High-in-Cholesterol"><a href="#High-in-Cholesterol" class="headerlink" title="High in Cholesterol"></a>High in Cholesterol</h4><p>Butter is also high in cholesterol.</p>
<p>A high intake of cholesterol was<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/top-9-biggest-lies-about-dietary-fat-and-cholesterol">once thought</a>to be a major risk factor for heart disease.</p>
<p>This concern was based on studies showing that high blood levels of cholesterol were associated with an increased risk of heart disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/27016614">26Trusted Source</a>).</p>
<p>However, it’s now clear that getting moderate amounts of cholesterol from the diet doesn’t raise its blood levels in most people. The body compensates by producing less.</p>
<p>Normally, this keeps its blood levels in the normal range, although a very high intake may still cause a moderate rise in blood cholesterol levels (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/18726564">27Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/19343078">28Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/27739004">29Trusted Source</a>).</p>
<p>Public health authorities have advocated low-cholesterol diets for decades.</p>
<p>These guidelines especially apply to people with familial hypercholesterolemia, a genetic condition that causes abnormally high blood cholesterol levels (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/21762914">30Trusted Source</a>).</p>
<p>Nevertheless, dietary strategies seem to have a limited effect in this group (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/20091526">31Trusted Source</a>).</p>
<p>Scientists continue to debate the role of dietary cholesterol in heart disease, but the concerns have been decreasing in recent years (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/27739004">29Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26109578">32Trusted Source</a>).</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Butter is high in cholesterol. However, it has limited effects on blood cholesterol levels in most people.</p>
</blockquote>
<p><a target="_blank" rel="noopener" href="https://rubiconproject.com/?utm_source=ad%20unit&utm_campaign=outstream">powered by Rubicon Project</a></p>
<h3 id="Health-Benefits-of-Margarine"><a href="#Health-Benefits-of-Margarine" class="headerlink" title="Health Benefits of Margarine"></a>Health Benefits of Margarine</h3><p>The health benefits of margarine depend on what kind of vegetable oils it contains and how it is processed.</p>
<h4 id="May-Be-High-in-Polyunsaturated-Fat"><a href="#May-Be-High-in-Polyunsaturated-Fat" class="headerlink" title="May Be High in Polyunsaturated Fat"></a>May Be High in Polyunsaturated Fat</h4><p>Most types of margarine are high in polyunsaturated fat. The exact amount depends on what vegetable oils were used to produce it.</p>
<p>For example, soybean oil-based margarine may contain approximately 20% polyunsaturated fat (<a target="_blank" rel="noopener" href="https://ndb.nal.usda.gov/ndb/">33Trusted Source</a>).</p>
<p>Polyunsaturated fat is generally considered healthy. It may even have benefits for heart health when compared to saturated fat.</p>
<p>Case in point, replacing saturated fat with polyunsaturated fat has been associated with a 17% reduced risk of heart problems, but no significant effect on the risk of death from heart disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/19211817">34Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26068959">35Trusted Source</a>).</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Margarine is often rich in polyunsaturated fat. Studies show that eating polyunsaturated fat instead of saturated fat may reduce the risk of heart problems.</p>
</blockquote>
<h4 id="May-Contain-Plant-Sterols-and-Stanols"><a href="#May-Contain-Plant-Sterols-and-Stanols" class="headerlink" title="May Contain Plant Sterols and Stanols"></a>May Contain Plant Sterols and Stanols</h4><p>Some margarines are enriched with<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/phytosterols-good-or-bad">phytosterols</a>or stanols. Vegetable oils are also naturally rich in these compounds.</p>
<p>Phytosterol-enriched margarines lower total and “bad” LDL cholesterol, at least in the short term, but they may also decrease ”good” HDL cholesterol (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/25497967">36Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26393644">37Trusted Source</a>).</p>
<p>However, most studies haven’t detected a significant association between total phytosterol intake and heart disease risk (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22334625">38Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/25305273">39Trusted Source</a>).</p>
<p>It’s important to stress the difference between risk factors and hard outcomes.</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Vegetable oil-based margarine is often rich in phytosterols. While phytosterols may reduce the levels of LDL cholesterol, they don’t seem to affect heart disease risk.</p>
</blockquote>
<h3 id="Risks-of-Eating-Margarine"><a href="#Risks-of-Eating-Margarine" class="headerlink" title="Risks of Eating Margarine"></a>Risks of Eating Margarine</h3><p>Although margarine may contain some heart-friendly nutrients, it often contains trans fat, which has been associated with an increased risk of heart disease and other chronic health issues (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26268692">1Trusted Source</a>).</p>
<h4 id="May-Be-High-in-Trans-Fats"><a href="#May-Be-High-in-Trans-Fats" class="headerlink" title="May Be High in Trans Fats"></a>May Be High in Trans Fats</h4><p>Vegetable oils are not solid at room temperature like butter.</p>
<p>To make them solid for use in margarine, food scientists chemically change their structure using a process known as hydrogenation.</p>
<p>This involves exposing the oils to high heat, high pressure, hydrogen gas and a metal catalyst.</p>
<p>Hydrogenation changes some of the unsaturated fat into saturated fat, which is solid at room temperature, and also increases the product’s shelf life.</p>
<p>Unfortunately,<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/why-trans-fats-are-bad">trans fat</a>is formed as a side product. A high intake of industrial trans fats has been linked to an increased risk of chronic disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26268692">1Trusted Source</a>).</p>
<p>For this reason, health authorities strongly advise people to limit their consumption of it.</p>
<p>Additionally, the FDA is implementing a ban on trans fat in all processed foods, although food producers can apply for an exception.</p>
<p>As a result, many food producers have started using a new technique to harden the vegetable oils in margarine.</p>
<p>This method is called interesterification. It replaces some of the unsaturated fats in the oil with saturated fat (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28729812">2Trusted Source</a>).</p>
<p>Interesterified vegetable oils are considered healthier than hydrogenated oils because they contain no trans fats.</p>
<p>If you prefer margarine over butter, try to select trans-fat-free varieties. If it says “hydrogenated” anywhere on the ingredients list, avoid it.</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Many margarines are high in trans fat, which is linked to an increased risk of chronic disease. However, because of negative publicity and new laws, trans-fat-free margarines are becoming increasingly common.</p>
</blockquote>
<h4 id="May-Be-High-in-Omega-6-Fat"><a href="#May-Be-High-in-Omega-6-Fat" class="headerlink" title="May Be High in Omega-6 Fat"></a>May Be High in Omega-6 Fat</h4><p>Many types of polyunsaturated fats exist.</p>
<p>They are often divided into categories based on their chemical structure. Two of the most common are omega-3 and omega-6 fats.</p>
<p><a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/17-health-benefits-of-omega-3">Omega-3 fats</a>are considered anti-inflammatory, meaning they act against inflammation. Conversely, eating too much omega-6 fat may promote chronic inflammation.</p>
<p>Based on ancestral diets, the<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/optimize-omega-6-omega-3-ratio">optimal ratio of omega-6 to omega-3</a>is estimated to be around 1:1.</p>
<p>If this ratio has any health relevance, people are eating far too much omega-6 fat today. In fact, the ratio is estimated to be as high as 20:1 in developed countries (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26950145">40Trusted Source</a>).</p>
<p>Observational studies have linked a high intake of omega-6 fat to an increased risk of obesity and chronic diseases, such as heart disease and inflammatory bowel disease (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22570770">41Trusted Source</a>).</p>
<p>However, analyses of controlled studies conclude that linoleic acid — the most common omega-6 fat — doesn’t affect blood levels of inflammatory markers (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28752873">42Trusted Source</a>,<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22889633">43Trusted Source</a>).</p>
<p>Because of this inconsistency, it’s unclear whether a high intake of omega-6 fats is really a cause for concern. More research is needed.</p>
<p>Vegetable oils that are especially high in omega-6 fat include sunflower, corn, soybean and cottonseed oils.</p>
<p>If you are worried about eating too much omega-6 fat, avoid eating margarine containing these oils.</p>
<blockquote>
<p><strong>SUMMARY</strong></p>
<p>Margarine is often very high in polyunsaturated omega-6 fatty acids. Some scientists believe excessive omega-6 intake may promote inflammation, but controlled studies do not support this theory.</p>
</blockquote>
<h3 id="The-Bottom-Line"><a href="#The-Bottom-Line" class="headerlink" title="The Bottom Line"></a>The Bottom Line</h3><p>Butter and margarine look similar and are used for the same purpose in the kitchen.</p>
<p>However, their nutritional profiles differ. While butter is high in saturated fat, margarine is rich in unsaturated fat and sometimes trans fat.</p>
<p>The health effects of saturated fat are highly controversial, and its role in heart disease has been downplayed in recent years.</p>
<p>Conversely, scientists agree that trans fats, which are found in some margarines, raise the risk of chronic disease. For this reason, trans-fat-free margarines are becoming increasingly common.</p>
<p>If you prefer margarine over butter, make sure to choose trans-fat-free brands and select products made with healthy oils, such as olive oil.</p>
<p>If butter is your favorite, consider buying products made from grass-fed cow’s milk.</p>
<p>In the end, there is no clear winner, but I personally prefer foods that are less processed, like butter.</p>
<p>Whatever you choose, consume these products in moderation.</p>
<p><a target="_blank" rel="noopener" href="https://activation.healthline.com/api/member-offers/2487/redirect?lp=328&tc=120226&subid2=/nutrition/butter-vs-margarine&subid=noom_hl_othernutrition_bot_3074&correlationId=01311ea6-2b66-4272-901d-fe38b1408484"><img src="https://i0.wp.com/healthline-activation-prod.healthline.com/driver-images/Noom%20IMAGE57.jpg?w=1155" alt="LEARN MORE"></a></p>
<p>ADVERTISEMENT</p>
<p><img src="https://i0.wp.com/healthline-activation-prod.healthline.com/driver-images/Noom%20LOGO15.png?h=63" alt="Noom"></p>
<p>Start a custom weight loss program</p>
<p>Noom helps you adopt healthy habits so you can lose weight and keep it off. Your program is customized to your goals and fitness needs. Just take a quick assessment and get started today.</p>
<p><a target="_blank" rel="noopener" href="https://activation.healthline.com/api/member-offers/2487/redirect?lp=328&tc=120226&subid2=/nutrition/butter-vs-margarine&subid=noom_hl_othernutrition_bot_3074&correlationId=01311ea6-2b66-4272-901d-fe38b1408484">LEARN MORE</a></p>
<p>FEEDBACK:</p>
<h2 id="How-Does-Butter-Affect-My-Cholesterol-Levels"><a href="#How-Does-Butter-Affect-My-Cholesterol-Levels" class="headerlink" title="How Does Butter Affect My Cholesterol Levels?"></a>How Does Butter Affect My Cholesterol Levels?</h2><p><img src="https://i0.wp.com/post.healthline.com/wp-content/uploads/2018/09/NatalieButler.png?w=105&h=105"></p>
<p>Medically reviewed by<a target="_blank" rel="noopener" href="https://www.healthline.com/reviewers/natalie-butler-rd-ld">Natalie Butler, R.D., L.D.</a>—Written by Annette McDermott—Updated on February 14, 2017</p>
<ul>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#research">Research</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#cholesterol-in-butter">Cholesterol in butter</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#butter-substitutes">Butter substitutes</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#symptoms">Symptoms</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#outlook">Outlook</a></li>
<li><a target="_blank" rel="noopener" href="https://www.healthline.com/health/butter-cholesterol#management">Management</a></li>
</ul>
<p>Overview</p>
<p>If you’re concerned about high cholesterol, you may wonder if eating butter will have a negative impact on your cholesterol. Butter is a dairy product made primarily from milk fat. It also contains small amounts of water and milk solids. Most of the fat in butter is saturated fat.</p>
<p>At one time, people with high cholesterol were told to avoid butter since it’s high in saturated fat. Saturated fat has been linked to an increase in low-density lipoprotein (LDL). LDL cholesterol is sometimes called bad cholesterol, and can increase risk of heart disease and stroke. The other type of cholesterol is high-density lipoprotein (HDL), and it’s sometimes called good cholesterol.</p>
<p>Recent<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943062/">researchTrusted Source</a>, however, has caused medical experts to re-evaluate their previous stance on the impact of saturated fat and butter on cholesterol and heart health.</p>
<p><strong><a target="_blank" rel="noopener" href="https://www.healthline.com/health/cholesterol-and-heart-disease">Learn more: Does high cholesterol cause heart disease? »</a></strong></p>
<h3 id="What-does-the-research-say"><a href="#What-does-the-research-say" class="headerlink" title="What does the research say?"></a>What does the research say?</h3><p>Products such as butter that contain saturated fat have historically been linked to high LDL cholesterol, high total cholesterol, and heart disease. But according to a<a target="_blank" rel="noopener" href="http://annals.org/aim/article/1846638/association-dietary-circulating-supplement-fatty-acids-coronary-risk-systematic-review">2014 systematic review and meta-analysisTrusted Source</a>, research doesn’t support a definite link between saturated fat and an increased risk of heart disease and stroke. Instead, your ratio of LDL and HDL levels may be more important than your total cholesterol number or your LDL level alone.</p>
<p>That doesn’t mean you should eat all the saturated fat you want. The<a target="_blank" rel="noopener" href="http://www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Know-Your-Fats_UCM_305628_Article.jsp#.WIKEkfkrLIU">AHA</a>still recommends people concerned about their LDL cholesterol keep their saturated fat intake to no more than 5 to 6 percent of total calories. Other organizations recommend less than 10 percent. The AHA also supports replacing butter with healthy plant fats, such as avocados and olive oil, instead of refined carbohydrates, which can worsen heart health.</p>
<h3 id="How-much-cholesterol-is-in-butter"><a href="#How-much-cholesterol-is-in-butter" class="headerlink" title="How much cholesterol is in butter?"></a>How much cholesterol is in butter?</h3><p>One tablespoon of<a target="_blank" rel="noopener" href="https://ndb.nal.usda.gov/ndb/foods/show/132?manu=&fgcd=&ds=">unsalted butterTrusted Source</a>has 31 milligrams (mg) of cholesterol. To put this in perspective, the United States Department of Agriculture’s previous recommendation was to consume between<a target="_blank" rel="noopener" href="https://www.choosemyplate.gov/2015-2020-dietary-guidelines-answers-your-questions">100 – 300 mg</a>of cholesterol a day. Evidence doesn’t support that dietary cholesterol in food plays a significant role in blood cholesterol levels, however.</p>
<h2 id="IS-MARGARINE-HARMFUL-6-SECRETS-THEY-DON’T-TELL-YOU"><a href="#IS-MARGARINE-HARMFUL-6-SECRETS-THEY-DON’T-TELL-YOU" class="headerlink" title="IS MARGARINE HARMFUL? 6 SECRETS THEY DON’T TELL YOU!"></a>IS MARGARINE HARMFUL? 6 SECRETS THEY DON’T TELL YOU!</h2><p><a target="_blank" rel="noopener" href="https://www.facebook.com/sharer/sharer.php?u=https://myculturedpalate.com/is-margarine-harmful-6-secrets-they-dont-tell-you/&display=popup&ref=plugin&src=share_button" title="Share on Facebook">Facebook</a><a target="_blank" rel="noopener" href="https://twitter.com/share?url=https://myculturedpalate.com/is-margarine-harmful-6-secrets-they-dont-tell-you/&text=Is%20Margarine%20Harmful?%206%20Secrets%20They%20Don%27t%20Tell%20You!" title="Share on Twitter">Tweet</a><a target="_blank" rel="noopener" href="https://pinterest.com/pin/create/button/?url=https://myculturedpalate.com/is-margarine-harmful-6-secrets-they-dont-tell-you/&media=https://myculturedpalate.com/wp-content/uploads/2012/12/Is-Margarine-Bad.jpg&description=Is%20Margarine%20Harmful?%206%20Secrets%20They%20Don%27t%20Tell%20You!" title="Share on Pinterest">Pin</a>SHARES1.1k</p>
<ul>
<li><a target="_blank" rel="noopener" href="https://myculturedpalate.com/is-margarine-harmful-6-secrets-they-dont-tell-you/">Is Margarine Harmful? - 6 Secrets They Don’t Tell You!</a></li>
</ul>
<p>Is Margarine Harmful? Or, to put it another way, is margarine bad for you?</p>
<p>Let’s take a look at what margarine is, the side effects of margarine, and the disadvantages of margarine.</p>
<p><img src="https://myculturedpalate.com/wp-content/uploads/2012/12/Is-Margarine-Bad.jpg" alt="Closeup of a knife in margarine from the post, Is Margarine Harmful?"></p>
<p>My mother had a mild heart attack the week before Thanksgiving and was found to have an 85% blockage in one of her coronary arteries.</p>
<p>She was put on a low-fat diet which contained margarine.</p>
<h3 id="IS-MARGARINE-GOOD-OR-BAD"><a href="#IS-MARGARINE-GOOD-OR-BAD" class="headerlink" title="IS MARGARINE GOOD OR BAD?"></a>IS MARGARINE GOOD OR BAD?</h3><p>What food do you think of as being full fat? For me, it is butter, rich creamy butter. Unfortunately, butter is a big no-no on a heart healthy diet.</p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<p>So, when looking for a “heart healthy” alternative to butter, margarine is recommended - according to the doctors!</p>
<p>After all, who would want butter, full of fat and saturated fats at that!  At the risk of being politically incorrect,  saturated fats are good for you! But margarine …</p>
<p>According to the<a target="_blank" rel="noopener" href="http://www.thefreedictionary.com/margarine">Free Dictionary</a>:</p>
<blockquote>
<p>A fatty solid butter substitute consisting of a blend of hydrogenated vegetable oils mixed with emulsifiers, vitamins, coloring matter, and other ingredients.<br>[French, from Greek margaron, <em>pearl</em>] And…A substitute for butter, prepared from vegetable and animal fats by emulsifying them with water and adding small amounts of milk, salt, vitamins, colouring matter, etc</p>
</blockquote>
<h3 id="WHAT-IS-MARGARINE"><a href="#WHAT-IS-MARGARINE" class="headerlink" title="WHAT IS MARGARINE?"></a>WHAT IS MARGARINE?</h3><p>From the above quote, we see that margarine is made up of the following:</p>
<ul>
<li>Hydrogenated vegetable oils and possibly some animal fats mixed with emulsifiers</li>
<li>Salt</li>
<li>Vitamins</li>
<li>Coloring</li>
<li>Other ingredients</li>
</ul>
<p>Hydrogenation is the process used to make liquid vegetables oil solid.</p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<p>Hydrogenation increases the oil’s saturated fat content, but unhealthy trans fats are formed as a side product. (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26268692">1</a>)</p>
<h3 id="THE-HISTORY-OF-MARGARINE"><a href="#THE-HISTORY-OF-MARGARINE" class="headerlink" title="THE HISTORY OF MARGARINE"></a>THE HISTORY OF MARGARINE</h3><p>Margarine was created in 1870 by a Frenchman from Provence, France – Hippolyte Mège-Mouriez – in response to an offer by the Emperor Louis Napoleon III for the production of a satisfactory substitute for butter.</p>
<p>He used margaric acid, a fatty acid component isolated in 1813 by Michael Chevreul and named because of the lustrous pearly drops that reminded him of the Greek word for pearl, margarites  - and - he claimed the Emperor’s prize.</p>
<p>Margarine has had a colorful history to say the least!</p>
<p>In fact, at different points in history:</p>
<ul>
<li>27 states prohibited the manufacture or sale of colored margarine</li>
<li>24 imposed some kind of consumer tax</li>
<li>26 required licenses or otherwise restricted margarine sales</li>
</ul>
<p>But, with advertising and new packaging, it reached consumers who eagerly devoured the fake stuff.</p>
<p>1998 marked the 125th anniversary of the U.S. patent for margarine.</p>
<h3 id="LOW-FAT-MYTH"><a href="#LOW-FAT-MYTH" class="headerlink" title="LOW-FAT MYTH"></a>LOW-FAT MYTH</h3><p>Everywhere we turn we hear how good a low-fat diet is for us - from television commercials to the American Heart Association.</p>
<p>But, looking at the nation as a whole shows a different picture than what the medical community proports.</p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<p>In the 1960s, fats and oils supplied Americans with about 45 percent of calories - about 13 percent of adults were obese and under 1 percent had type 2 diabetes.</p>
<p>Today, Americans take in less fat, getting about 33 percent of calories from fats and oils - yet 34 percent of adults are obese and 11 percent have diabetes, most with type 2 diabetes.</p>
<p>It is time to expose the myth that a low-fat diet is good for you!</p>
<p>Low-fat is<strong>not</strong>what the human body needs - In fact it is harmful!</p>
<h3 id="QUALITY-OF-FAT-IS-IMPORTANT"><a href="#QUALITY-OF-FAT-IS-IMPORTANT" class="headerlink" title="QUALITY OF FAT IS IMPORTANT"></a>QUALITY OF FAT IS IMPORTANT</h3><p>Not all fats are created equal as is the case with butter made from the milk of grass fed cows vs the butter made from grain fed cows.</p>
<p>According to<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/butter-vs-margarine#benefits-of-butter">Healthline</a>:</p>
<blockquote>
<p>Butter from grass-fed cows contains much greater amounts of heart-healthy nutrients than butter from grain-fed cows.</p>
</blockquote>
<h3 id="IS-MARGARINE-HARMFUL-6-SECRETS-ABOUT-MARGARINE-“THEY”-DON’T-TELL-YOU"><a href="#IS-MARGARINE-HARMFUL-6-SECRETS-ABOUT-MARGARINE-“THEY”-DON’T-TELL-YOU" class="headerlink" title="IS MARGARINE HARMFUL - 6 SECRETS ABOUT MARGARINE  “THEY” DON’T TELL YOU:"></a>IS MARGARINE HARMFUL - 6 SECRETS ABOUT MARGARINE  “THEY” DON’T TELL YOU:</h3><h4 id="1-MARGARINE-IS-HIGH-IN-TRANS-FATTY-ACIDS"><a href="#1-MARGARINE-IS-HIGH-IN-TRANS-FATTY-ACIDS" class="headerlink" title="1. MARGARINE IS HIGH IN TRANS FATTY ACIDS."></a><strong>1. MARGARINE IS HIGH IN TRANS FATTY ACIDS.</strong></h4><p>The disadvantage of true margarine is the trans fat level. (<a target="_blank" rel="noopener" href="https://www.healthline.com/nutrition/butter-vs-margarine#benefits-of-butter">butter vs. margarine</a>)</p>
<p>A study done in Boston, at the Harvard School of Public Health showed that trans-fatty acids do increase the risk of heart attack.</p>
<p>In fact, the risk of heart attack<strong>more than doubled</strong>between those who ate the most and those who ate the least foods containing vegetable oil trans-fatty acids.</p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<p>The more solid a margarine is at room temperature, the more trans fat it contains, as much as 3 grams per tablespoon.</p>
<p>Even the improved brands, such as Smart Balance, are full of:</p>
<ul>
<li>artificial ingredients</li>
<li>synthetic vitamins - which do nothing to boost your immune system (as those found in real butter do)</li>
<li>artificial colors - because without them the products don’t appeal to customers</li>
</ul>
<h4 id="2-MARGARINE-ACTUALLY-CONTRIBUTES-TO-HEART-ATTACKS"><a href="#2-MARGARINE-ACTUALLY-CONTRIBUTES-TO-HEART-ATTACKS" class="headerlink" title="2. MARGARINE ACTUALLY CONTRIBUTES TO HEART ATTACKS."></a><strong>2. MARGARINE ACTUALLY CONTRIBUTES TO HEART ATTACKS</strong>.</h4><p>Another study done by the Harvard School of Public Health asked people how much margarine they ate.</p>
<p>Once the answers were recorded they waited to see what they died from.</p>
<p>Amazingly, people who ate as little as three pats of margarine a day had twice the heart-attack rate of those who ate less than a pat a day,<strong>far worse than those who ate lard or butter</strong>. (<a target="_blank" rel="noopener" href="https://www.news24.com/You/Archive/shocking-facts-about-margarine-20170728-2">3</a>)</p>
<h4 id="3-MARGARINE-INCREASES-CHOLESTEROL"><a href="#3-MARGARINE-INCREASES-CHOLESTEROL" class="headerlink" title="3. MARGARINE INCREASES CHOLESTEROL."></a><strong>3. MARGARINE INCREASES CHOLESTEROL.</strong></h4><p>Not only does margarine increase total cholesterol, it also increases the LDL (the bad cholesterol). Source:<a target="_blank" rel="noopener" href="https://www.health.harvard.edu/staying-healthy/butter-vs-margarine">butter versus margarine (harvard.edu)</a></p>
<p>If that were not enough, margarine lowers the HDL which is the good cholesterol!</p>
<p><img src="https://myculturedpalate.com/wp-content/uploads/2012/12/is-margarine-harmful-sh-pn.png" alt="Close up of margarine with knife in it and text overlay."></p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<h4 id="4-MARGARINE-LOWERS-QUALITY-OF-BREAST-MILK"><a href="#4-MARGARINE-LOWERS-QUALITY-OF-BREAST-MILK" class="headerlink" title="4. MARGARINE LOWERS QUALITY OF BREAST MILK."></a><strong>4. MARGARINE LOWERS QUALITY OF BREAST MILK</strong>.</h4><p>Studies show how a mother’s eating of trans fats affects the level of trans fats in her milk.</p>
<p>One study, for example, comparing Canadian breast milk to Chinese breast milk found that Canadian mothers had 33 more trans fats in their milk than the Chinese mothers.</p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<p>So trans fats consumptions may affect the quality of breast milk. (<a target="_blank" rel="noopener" href="https://www.alexfergus.com/blog/11-reasons-to-avoid-margarine">5</a>)</p>
<h4 id="5-MARGARINE-DECREASES-IMMUNE-RESPONSE"><a href="#5-MARGARINE-DECREASES-IMMUNE-RESPONSE" class="headerlink" title="5. MARGARINE DECREASES IMMUNE RESPONSE."></a><strong>5. MARGARINE DECREASES IMMUNE RESPONSE.</strong></h4><p><img src="http://www.assoc-amazon.com/e/ir?t=culturedpalate-20&l=as2&o=1&a=0967812607"></p>
<p>According to Dr. Mary Enig, author of<a target="_blank" rel="noopener" href="http://www.amazon.com/gp/product/0967812607/ref=as_li_ss_tl?ie=UTF8&camp=1789&creative=390957&creativeASIN=0967812607&linkCode=as2&tag=culturedpalate-20">Know Your Fats</a> (affiliate link), consuming trans fatty acids</p>
<blockquote>
<p>Affects immune response by lowering efficiency of B cell response and increasing proliferation of T cells.</p>
</blockquote>
<p>This decreases the body’s immune response.</p>
<h4 id="6-DECREASES-INSULIN-RESPONSE"><a href="#6-DECREASES-INSULIN-RESPONSE" class="headerlink" title="6. DECREASES INSULIN RESPONSE."></a>6. DECREASES INSULIN RESPONSE.</h4><p>Actually, the trans fats can increase blood insulin levels, which increases the risk for diabetes. (<a target="_blank" rel="noopener" href="https://sciencebasedmedicine.org/fake-news-about-margarine/">6</a>)</p>
<h3 id="MARGARINE-DISADVANTAGES"><a href="#MARGARINE-DISADVANTAGES" class="headerlink" title="MARGARINE DISADVANTAGES"></a>MARGARINE DISADVANTAGES</h3><p>So, let’s summarize the disadvantages of margarin that help us decide if margarine is good or bad.</p>
<p>Margarine:</p>
<ol>
<li> Is high in trans fatty acids.</li>
<li> Contributes to heart attacks.</li>
<li> Increases cholesterol.</li>
<li> Lowers quality of breast milk.</li>
<li> Decreases immune response.</li>
<li> Decreases insulin response.</li>
</ol>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<h3 id="MISTAKE-IN-RESEARCH"><a href="#MISTAKE-IN-RESEARCH" class="headerlink" title="MISTAKE IN RESEARCH"></a>MISTAKE IN RESEARCH</h3><p>So, if margarine is actually bad for us, how did it get to be so popular?  Pure and simple - money!</p>
<p>Margarine gained popularity beginning with America’s entry into World War I when there was a shortage of fats and cost of living was high.</p>
<p>Therefore, a cheaper alternative to the more expensive butter was quickly received by the uninformed public.</p>
<p>Dr. Mary Enig discovered during her research that  the studies linking saturated fat to heart disease were wrong.</p>
<p>Saturated fats along with trans fats (partially hydrogenated fats) had been grouped together because of there similar chemical structure. This was done for analytical purposes.</p>
<h5 id="THESE-“MINOR”-DIFFERENCE-HOWEVER-MADE-ALL-THE-DIFFERENCE-IN-THE-WORLD-TO-THE-CONCLUSION-OF-THE-RESEARCH"><a href="#THESE-“MINOR”-DIFFERENCE-HOWEVER-MADE-ALL-THE-DIFFERENCE-IN-THE-WORLD-TO-THE-CONCLUSION-OF-THE-RESEARCH" class="headerlink" title="THESE “MINOR” DIFFERENCE, HOWEVER, MADE ALL THE DIFFERENCE IN THE WORLD TO THE CONCLUSION OF THE RESEARCH."></a>THESE “MINOR” DIFFERENCE, HOWEVER, MADE ALL THE DIFFERENCE IN THE WORLD TO THE CONCLUSION OF THE RESEARCH.</h5><p>Dr. Enig found that when separated into different groups,<strong>saturated fats were found to have NO LINK to heart disease</strong>while<strong>trans fats were found to have a very strong link</strong>!</p>
<p><a target="_blank" rel="noopener" href="https://www.mediavine.com/"><img src="data:image/png;base64,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"></a></p>
<p>Unfortunately, when Dr. Enig tried to make others aware of the mistake, she was cast out.</p>
<p>Naturally the edible oil industry whose profits she so threatened opposed her findings and she found herself unable to get grants, funding, or even a job.</p>
<p>Fortunately for us, she has continued her research quietly and is now on the board of the Weston A. Price Foundation.</p>
<h3 id="WHAT-ABOUT-“HEART-HEALTHY”-SUBSTITUTES"><a href="#WHAT-ABOUT-“HEART-HEALTHY”-SUBSTITUTES" class="headerlink" title="WHAT ABOUT “HEART HEALTHY” SUBSTITUTES?"></a>WHAT ABOUT “HEART HEALTHY” SUBSTITUTES?</h3><p>You might be tempted to compromise with heart healthy oil blends. But, think again!</p>
<p>The word “Smart” should be taken out of Smart Balance!</p>
<p>As mentioned earlier not only is it:</p>
<ul>
<li>full of artificial ingredients</li>
<li>synthetic vitamins which do nothing to boost your immune system (as those found in real butter do)</li>
<li>artificial colors</li>
</ul>
<p>But, the process to make them is called “interesterification” which may be even more dangerous to health than trans fats!</p>
<p>Source:<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497165/">what are interestified fats</a></p>
<p>You can read more about the process at<a target="_blank" rel="noopener" href="http://www.westonaprice.org/know-your-fats/556-interesterification.html">what is interestification</a>.</p>
<p>So, back to my question - is margarine harmful?</p>
<p><strong>Personally, I’m sticking with the natural stuff from now on! How about you?</strong></p>
<h3 id="PIN-IT"><a href="#PIN-IT" class="headerlink" title="PIN IT!"></a>PIN IT!</h3><p><img src="https://myculturedpalate.com/wp-content/uploads/2012/12/is-margarine-bad-lg-pn.jpg" alt="Margarine shown in two images with text overlay - one being cut with a knife and the other on wooden table with knife and bread."></p>
<ul>
<li><a target="_blank" rel="noopener" href="https://www.health.harvard.edu/staying-healthy/the-truth-about-fats-bad-and-good">The truth about fats: the good, the bad, and the in-between - Harvard Health</a></li>
</ul>
<h2 id="The-truth-about-fats-the-good-the-bad-and-the-in-between"><a href="#The-truth-about-fats-the-good-the-bad-and-the-in-between" class="headerlink" title="The truth about fats: the good, the bad, and the in-between"></a>The truth about fats: the good, the bad, and the in-between</h2><p>Updated: December 11, 2019</p>
<h3 id="Avoid-the-trans-fats-limit-the-saturated-fats-and-replace-with-essential-polyunsaturated-fats"><a href="#Avoid-the-trans-fats-limit-the-saturated-fats-and-replace-with-essential-polyunsaturated-fats" class="headerlink" title="Avoid the trans fats, limit the saturated fats, and replace with essential polyunsaturated fats"></a>Avoid the trans fats, limit the saturated fats, and replace with essential polyunsaturated fats</h3><p><img src="https://domf5oio6qrcr.cloudfront.net/medialibrary/7113/fats.jpg" alt="fats"></p>
<p><strong>Image: vasata/Getty Images</strong></p>
<p>Why are trans fats bad for you, polyunsaturated and monounsaturated fats good for you, and saturated fats somewhere in-between? For years, fat was a four-letter word. We were urged to banish it from our diets whenever possible. We switched to low-fat foods. But the shift didn’t make us healthier, probably because we cut back on<a target="_blank" rel="noopener" href="https://www.health.harvard.edu/staying-healthy/mediterranean-style-the-healthy-fats-and-healthy-carbs-diet">healthy fats</a>as well as harmful ones.</p>
<p>You may wonder isn’t fat bad for you, but your body needs some fat from food. It’s a major source of energy. It helps you absorb some vitamins and minerals. Fat is needed to build cell membranes, the vital exterior of each cell, and the sheaths surrounding nerves. It is essential for blood clotting, muscle movement, and<a target="_blank" rel="noopener" href="https://www.health.harvard.edu/staying-healthy/playing-with-the-fire-of-inflammation">inflammation</a>. For long-term health, some fats are better than others. Good fats include monounsaturated and polyunsaturated fats. Bad ones include industrial-made trans fats. Saturated fats fall somewhere in the middle.</p>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
	<div class="article-tag tagcloud">
		<i class="icon-price-tags icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="javascript:void(0)" class="js-tag article-tag-list-link color5">Margarine</a>
        		</li>
      		
		</ul>
	</div>

      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log/Computing//" class="article-tag-list-link color5">Computing</a>
        		</li>
      		 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log/Computing/Margarine//" class="article-tag-list-link color5">Margarine</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/14/20210514/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210513" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/13/20210513/">20210513</a>
    </h1>
  

        
        <a href="/2021/05/13/20210513/" class="archive-article-date">
  	<time datetime="2021-05-12T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210513</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#%E5%8F%82%E5%B1%95%E5%95%86%E5%90%8D%E5%8D%95-2021%E5%B9%B4%E4%B8%AD%E5%9B%BD%E5%9B%BD%E9%99%85%E6%B6%88%E8%B4%B9%E5%93%81%E5%8D%9A%E8%A7%88%E4%BC%9A"><span class="toc-number">1.1.</span> <span class="toc-text">参展商名单 - 2021年中国国际消费品博览会</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#CI5"><span class="toc-number">1.2.</span> <span class="toc-text">CI5</span></a></li></ol></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">i&#x3D;&#39;&#x2F;media&#x2F;ht&#x2F;ht_5T&#x2F;Work&#x2F;Projects&#x2F;苏州CDC&#x2F;慢病中心&#39;; cd $&#123;i&#125;</span><br><span class="line">#</span><br><span class="line">wget https:&#x2F;&#x2F;cdn.who.int&#x2F;media&#x2F;docs&#x2F;default-source&#x2F;immunization&#x2F;sage&#x2F;2021&#x2F;april&#x2F;5_sage29apr2021_critical-evidence_sinovac.pdf</span><br></pre></td></tr></table></figure>
<h2 id="参展商名单-2021年中国国际消费品博览会"><a href="#参展商名单-2021年中国国际消费品博览会" class="headerlink" title="参展商名单 - 2021年中国国际消费品博览会"></a><a target="_blank" rel="noopener" href="https://www.hainanexpo.org.cn/ExhibitorList.html">参展商名单 - 2021年中国国际消费品博览会</a></h2><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">wget &#39;https:&#x2F;&#x2F;www.hainanexpo.org.cn&#x2F;upload&#x2F;default&#x2F;20210507&#x2F;efb3abd145741aaa826bf03b62d5c25c.pdf&#39;</span><br></pre></td></tr></table></figure>
<h2 id="CI5"><a href="#CI5" class="headerlink" title="CI5"></a>CI5</h2><ul>
<li><a target="_blank" rel="noopener" href="https://ci5.iarc.fr/CI5I-X/Pages/download.aspx">CI5 I-X - Download</a></li>
<li><a target="_blank" rel="noopener" href="https://ci5.iarc.fr/CI5-XI/Default.aspx">CI5 XI - Home</a></li>
<li><a target="_blank" rel="noopener" href="https://publications.iarc.fr/Book-And-Report-Series/Iarc-Scientific-Publications/Cancer-Incidence-In-Five-Continents%C2%A0Volume-XI-2021">IARC Publications Website - Cancer Incidence in Five Continents Volume XI</a></li>
<li><a href="file:///home/ht/Downloads/125-book.pdf">125-book.pdf</a></li>
</ul>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/13/20210513/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
    <article id="post-20210508" class="article article-type-post  article-index" itemscope itemprop="blogPost">
  <div class="article-inner">
    
      <header class="article-header">
        
  
    <h1 itemprop="name">
      <a class="article-title" href="/2021/05/08/20210508/">20210508</a>
    </h1>
  

        
        <a href="/2021/05/08/20210508/" class="archive-article-date">
  	<time datetime="2021-05-07T16:00:00.000Z" itemprop="datePublished"><i class="icon-calendar icon"></i>20210508</time>
</a>
        
      </header>
    
    <div class="article-entry" itemprop="articleBody">
    

      
<div id="toc" class="toc-article">
  <strong class="toc-title">Contents</strong>
  <ol class="toc"><li class="toc-item toc-level-1"><a class="toc-link" href="#Working-directories"><span class="toc-number">1.</span> <span class="toc-text">Working directories</span></a></li><li class="toc-item toc-level-1"><a class="toc-link" href="#Faster-alternatives-to-%E2%80%9Cfind%E2%80%9D-and-%E2%80%9Clocate%E2%80%9D"><span class="toc-number">2.</span> <span class="toc-text">Faster alternatives to “find” and “locate”?</span></a><ol class="toc-child"><li class="toc-item toc-level-2"><a class="toc-link" href="#locate-likes-using-indices"><span class="toc-number">2.1.</span> <span class="toc-text">locate-likes (using indices)</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#find-likes-directory-traversal"><span class="toc-number">2.2.</span> <span class="toc-text">find-likes (directory traversal)</span></a></li><li class="toc-item toc-level-2"><a class="toc-link" href="#grep-likes-looking-at-content"><span class="toc-number">2.3.</span> <span class="toc-text">grep-likes (looking at content)</span></a></li></ol></li></ol>
</div>

        <h1 id="Working-directories"><a href="#Working-directories" class="headerlink" title="Working directories"></a>Working directories</h1><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br><span class="line">17</span><br><span class="line">18</span><br></pre></td><td class="code"><pre><span class="line">also installing the dependencies </span><br><span class="line">&quot;clipr&quot;, &quot;viridisLite&quot;, &quot;ggplot2&quot;, &quot;gridExtra&quot;, &quot;downloader&quot;, &quot;igraph&quot;, &quot;influenceR&quot;, &quot;readr&quot;, &quot;tidyr&quot;, &quot;viridis&quot;, &quot;visNetwork&quot;</span><br><span class="line"></span><br><span class="line">尊敬的项目办领导，</span><br><span class="line"></span><br><span class="line">按照要求提交文件，请查收并批评指正。</span><br><span class="line"></span><br><span class="line">zdzx10_2016@vip.126.com</span><br><span class="line"></span><br><span class="line">刘宏图-课题进展-2018ZX10201002</span><br><span class="line"></span><br><span class="line">2021 National Trade Estimate Report on</span><br><span class="line">FOREIGN TRADE</span><br><span class="line">BARRIERS</span><br><span class="line"></span><br><span class="line">World Trade Statistical Review 2020</span><br><span class="line"></span><br><span class="line">2021 Trade Policy Agenda and 2020 Annual Report OF THE PRESIDENT OF THE UNITED STATES ON THE TRADE AGREEMENTS PROGRAM</span><br></pre></td></tr></table></figure>
<h1 id="Faster-alternatives-to-“find”-and-“locate”"><a href="#Faster-alternatives-to-“find”-and-“locate”" class="headerlink" title="Faster alternatives to “find” and “locate”?"></a><a target="_blank" rel="noopener" href="https://superuser.com/questions/341232/faster-alternatives-to-find-and-locate">Faster alternatives to “find” and “locate”?</a></h1><ul>
<li><a target="_blank" rel="noopener" href="https://superuser.com/questions/341232/faster-alternatives-to-find-and-locate">linux - Faster alternatives to “find” and “locate”? - Super User</a></li>
</ul>
<p>As of early 2021 I evaluated a few tools for similar use cases and integration with <a target="_blank" rel="noopener" href="https://github.com/junegunn/fzf">fzf</a>:</p>
<p><strong>tl;dr:</strong> <strong><code>plocate</code></strong> is a <em>very</em> fast alternative to <code>mlocate</code> in most cases. (GNU) <strong><code>find</code></strong> often still seems to be hard to beat for tools which don’t require an index.</p>
<h2 id="locate-likes-using-indices"><a href="#locate-likes-using-indices" class="headerlink" title="locate-likes (using indices)"></a><code>locate</code>-likes (using indices)</h2><p>I compared the commonly used <code>mlocate</code> and <a target="_blank" rel="noopener" href="https://plocate.sesse.net/"><code>plocate</code></a>. In a database of about 61 million files <code>plocate</code> answers specific queries (a couple of hundred results) in the order of 0.01 to 0.2 seconds and only becomes much slower (&gt; 100 seconds) for very unspecific queries with millions of results. <code>mlocate</code> takes an almost constant 35 to 40 seconds to query the same database in all tested cases. Most of the time <strong><code>plocate</code> is multiple orders of magnitude faster than <code>mlocate</code>.</strong></p>
<h2 id="find-likes-directory-traversal"><a href="#find-likes-directory-traversal" class="headerlink" title="find-likes (directory traversal)"></a><code>find</code>-likes (directory traversal)</h2><p>It’s harder to - sorry - locate a good find alternative and the result very much depends on the specific queries. Here are some results for just trying to find all files in a sample directory (~200.000 files) in descending speed order:</p>
<ul>
<li>  GNU find (<code>find -type f</code>): Surprisingly, <strong><code>find</code> is often the fastest tool</strong> (~ 0.01 seconds)</li>
<li>  plocate (<code>plocate --regexp &quot;^$PWD&quot;</code>) (&lt; 0.1 seconds)</li>
<li>  mlocate (<code>mlocate --regexp &quot;^$PWD&quot;</code>): Interestingly faster than the non-regexp queries (~ 5 seconds)</li>
<li>  ripgrep (<code>rg --files --no-ignore --hidden</code>): A good bit faster, but still very slow (~0.5 seconds)</li>
<li>  fd (<code>fdfind --type f</code> on Debian): Not as fast as expected (~0.7 seconds)</li>
<li>  <code>zsh</code> globs (<code>**/*</code> and extended versions): Generally very slow, but can be elegant in scripts (~3 seconds)</li>
</ul>
<p>With directory structures not cached in RAM, <code>plocate</code> probably beats <code>find</code>, especially on disks with high seek times (HDDs), but does of course require an up-to-date database.</p>
<p>A parallelized <code>find</code> might give better results on systems which profit from command queuing and can request data in parallel. Depending on use case, this can be implemented in scripts, too, by running multiple instances of <code>find</code> on different subtrees, but performance characteristics depend on a lot of factors there.</p>
<h2 id="grep-likes-looking-at-content"><a href="#grep-likes-looking-at-content" class="headerlink" title="grep-likes (looking at content)"></a><code>grep</code>-likes (looking at content)</h2><p>There’s a whole lot of recursive <code>grep</code>-like tools with different features, but most offer very limited features for finding files based on their metadata instead of their contents. Even if they are fast like <code>ag</code> (silversurfer), <code>rg</code> (ripgrep) or <code>ugrep</code>, they are not necessarily fast if just looking at file names.</p>

      

      
    </div>
    <div class="article-info article-info-index">
      
      
      
	<div class="article-category tagcloud">
		<i class="icon-book icon"></i>
		<ul class="article-tag-list">
			 
        		<li class="article-tag-list-item">
        			<a href="/categories/Log//" class="article-tag-list-link color4">Log</a>
        		</li>
      		
		</ul>
	</div>


      
        <p class="article-more-link">
          <a class="article-more-a" href="/2021/05/08/20210508/">Expand all items >></a>
        </p>
      

      
      <div class="clearfix"></div>
    </div>
  </div>
</article>

<aside class="wrap-side-operation">
    <div class="mod-side-operation">
        
        <div class="jump-container" id="js-jump-container" style="display:none;">
            <a href="javascript:void(0)" class="mod-side-operation__jump-to-top">
                <i class="icon-font icon-back"></i>
            </a>
            <div id="js-jump-plan-container" class="jump-plan-container" style="top: -11px;">
                <i class="icon-font icon-plane jump-plane"></i>
            </div>
        </div>
        
        
    </div>
</aside>




  
  
    <nav id="page-nav">
      <a class="extend prev" rel="prev" href="/page/6/">&amp;laquo; Prev</a><a class="page-number" href="/">1</a><span class="space">&hellip;</span><a class="page-number" href="/page/5/">5</a><a class="page-number" href="/page/6/">6</a><span class="page-number current">7</span><a class="page-number" href="/page/8/">8</a><a class="page-number" href="/page/9/">9</a><span class="space">&hellip;</span><a class="page-number" href="/page/17/">17</a><a class="extend next" rel="next" href="/page/8/">Next &amp;raquo;</a>
    </nav>
  


          </div>
        </div>
      </div>
      <footer id="footer">
  <div class="outer">
    <div id="footer-info">
    	<div class="footer-left">
    		&copy; 2022 Hongtu Liu
    	</div>
      	<div class="footer-right">
      		<a href="http://hexo.io/" target="_blank">Hexo</a>  Theme <a href="https://github.com/litten/hexo-theme-yilia" target="_blank">Yilia</a> by Litten
      	</div>
    </div>
  </div>
</footer>



<script src='https://unpkg.com/mermaid@7.1.2/dist/mermaid.min.js'></script>

<script>
    if (window.mermaid) {
        mermaid.initialize({"startOnload":true});
    }
</script>


    </div>
    <script>
	var yiliaConfig = {
		mathjax: false,
		isHome: true,
		isPost: false,
		isArchive: false,
		isTag: false,
		isCategory: false,
		open_in_new: false,
		toc_hide_index: true,
		root: "/",
		innerArchive: true,
		showTags: false
	}
</script>

<script>!function(t){function n(e){if(r[e])return r[e].exports;var i=r[e]={exports:{},id:e,loaded:!1};return t[e].call(i.exports,i,i.exports,n),i.loaded=!0,i.exports}var r={};n.m=t,n.c=r,n.p="./",n(0)}([function(t,n,r){r(195),t.exports=r(191)},function(t,n,r){var e=r(3),i=r(52),o=r(27),u=r(28),c=r(53),f="prototype",a=function(t,n,r){var s,l,h,v,p=t&a.F,d=t&a.G,y=t&a.S,g=t&a.P,b=t&a.B,m=d?e:y?e[n]||(e[n]={}):(e[n]||{})[f],x=d?i:i[n]||(i[n]={}),w=x[f]||(x[f]={});d&&(r=n);for(s in r)l=!p&&m&&void 0!==m[s],h=(l?m:r)[s],v=b&&l?c(h,e):g&&"function"==typeof h?c(Function.call,h):h,m&&u(m,s,h,t&a.U),x[s]!=h&&o(x,s,v),g&&w[s]!=h&&(w[s]=h)};e.core=i,a.F=1,a.G=2,a.S=4,a.P=8,a.B=16,a.W=32,a.U=64,a.R=128,t.exports=a},function(t,n,r){var e=r(6);t.exports=function(t){if(!e(t))throw TypeError(t+" is not an object!");return t}},function(t,n){var r=t.exports="undefined"!=typeof window&&window.Math==Math?window:"undefined"!=typeof self&&self.Math==Math?self:Function("return this")();"number"==typeof __g&&(__g=r)},function(t,n){t.exports=function(t){try{return!!t()}catch(t){return!0}}},function(t,n){var r=t.exports="undefined"!=typeof window&&window.Math==Math?window:"undefined"!=typeof self&&self.Math==Math?self:Function("return this")();"number"==typeof __g&&(__g=r)},function(t,n){t.exports=function(t){return"object"==typeof t?null!==t:"function"==typeof t}},function(t,n,r){var e=r(126)("wks"),i=r(76),o=r(3).Symbol,u="function"==typeof o;(t.exports=function(t){return e[t]||(e[t]=u&&o[t]||(u?o:i)("Symbol."+t))}).store=e},function(t,n){var r={}.hasOwnProperty;t.exports=function(t,n){return r.call(t,n)}},function(t,n,r){var e=r(94),i=r(33);t.exports=function(t){return e(i(t))}},function(t,n,r){t.exports=!r(4)(function(){return 7!=Object.defineProperty({},"a",{get:function(){return 7}}).a})},function(t,n,r){var e=r(2),i=r(167),o=r(50),u=Object.defineProperty;n.f=r(10)?Object.defineProperty:function(t,n,r){if(e(t),n=o(n,!0),e(r),i)try{return u(t,n,r)}catch(t){}if("get"in r||"set"in r)throw TypeError("Accessors not supported!");return"value"in r&&(t[n]=r.value),t}},function(t,n,r){t.exports=!r(18)(function(){return 7!=Object.defineProperty({},"a",{get:function(){return 7}}).a})},function(t,n,r){var e=r(14),i=r(22);t.exports=r(12)?function(t,n,r){return e.f(t,n,i(1,r))}:function(t,n,r){return t[n]=r,t}},function(t,n,r){var e=r(20),i=r(58),o=r(42),u=Object.defineProperty;n.f=r(12)?Object.defineProperty:function(t,n,r){if(e(t),n=o(n,!0),e(r),i)try{return u(t,n,r)}catch(t){}if("get"in r||"set"in r)throw TypeError("Accessors not supported!");return"value"in r&&(t[n]=r.value),t}},function(t,n,r){var e=r(40)("wks"),i=r(23),o=r(5).Symbol,u="function"==typeof o;(t.exports=function(t){return e[t]||(e[t]=u&&o[t]||(u?o:i)("Symbol."+t))}).store=e},function(t,n,r){var e=r(67),i=Math.min;t.exports=function(t){return t>0?i(e(t),9007199254740991):0}},function(t,n,r){var e=r(46);t.exports=function(t){return Object(e(t))}},function(t,n){t.exports=function(t){try{return!!t()}catch(t){return!0}}},function(t,n,r){var e=r(63),i=r(34);t.exports=Object.keys||function(t){return e(t,i)}},function(t,n,r){var e=r(21);t.exports=function(t){if(!e(t))throw TypeError(t+" is not an object!");return t}},function(t,n){t.exports=function(t){return"object"==typeof t?null!==t:"function"==typeof t}},function(t,n){t.exports=function(t,n){return{enumerable:!(1&t),configurable:!(2&t),writable:!(4&t),value:n}}},function(t,n){var r=0,e=Math.random();t.exports=function(t){return"Symbol(".concat(void 0===t?"":t,")_",(++r+e).toString(36))}},function(t,n){var r={}.hasOwnProperty;t.exports=function(t,n){return r.call(t,n)}},function(t,n){var r=t.exports={version:"2.4.0"};"number"==typeof __e&&(__e=r)},function(t,n){t.exports=function(t){if("function"!=typeof t)throw TypeError(t+" is not a function!");return t}},function(t,n,r){var e=r(11),i=r(66);t.exports=r(10)?function(t,n,r){return e.f(t,n,i(1,r))}:function(t,n,r){return t[n]=r,t}},function(t,n,r){var e=r(3),i=r(27),o=r(24),u=r(76)("src"),c="toString",f=Function[c],a=(""+f).split(c);r(52).inspectSource=function(t){return f.call(t)},(t.exports=function(t,n,r,c){var f="function"==typeof r;f&&(o(r,"name")||i(r,"name",n)),t[n]!==r&&(f&&(o(r,u)||i(r,u,t[n]?""+t[n]:a.join(String(n)))),t===e?t[n]=r:c?t[n]?t[n]=r:i(t,n,r):(delete t[n],i(t,n,r)))})(Function.prototype,c,function(){return"function"==typeof this&&this[u]||f.call(this)})},function(t,n,r){var e=r(1),i=r(4),o=r(46),u=function(t,n,r,e){var i=String(o(t)),u="<"+n;return""!==r&&(u+=" "+r+'="'+String(e).replace(/"/g,"&quot;")+'"'),u+">"+i+"</"+n+">"};t.exports=function(t,n){var r={};r[t]=n(u),e(e.P+e.F*i(function(){var n=""[t]('"');return n!==n.toLowerCase()||n.split('"').length>3}),"String",r)}},function(t,n,r){var e=r(115),i=r(46);t.exports=function(t){return e(i(t))}},function(t,n,r){var e=r(116),i=r(66),o=r(30),u=r(50),c=r(24),f=r(167),a=Object.getOwnPropertyDescriptor;n.f=r(10)?a:function(t,n){if(t=o(t),n=u(n,!0),f)try{return a(t,n)}catch(t){}if(c(t,n))return i(!e.f.call(t,n),t[n])}},function(t,n,r){var e=r(24),i=r(17),o=r(145)("IE_PROTO"),u=Object.prototype;t.exports=Object.getPrototypeOf||function(t){return t=i(t),e(t,o)?t[o]:"function"==typeof t.constructor&&t instanceof t.constructor?t.constructor.prototype:t instanceof Object?u:null}},function(t,n){t.exports=function(t){if(void 0==t)throw TypeError("Can't call method on  "+t);return t}},function(t,n){t.exports="constructor,hasOwnProperty,isPrototypeOf,propertyIsEnumerable,toLocaleString,toString,valueOf".split(",")},function(t,n){t.exports={}},function(t,n){t.exports=!0},function(t,n){n.f={}.propertyIsEnumerable},function(t,n,r){var e=r(14).f,i=r(8),o=r(15)("toStringTag");t.exports=function(t,n,r){t&&!i(t=r?t:t.prototype,o)&&e(t,o,{configurable:!0,value:n})}},function(t,n,r){var e=r(40)("keys"),i=r(23);t.exports=function(t){return e[t]||(e[t]=i(t))}},function(t,n,r){var e=r(5),i="__core-js_shared__",o=e[i]||(e[i]={});t.exports=function(t){return o[t]||(o[t]={})}},function(t,n){var r=Math.ceil,e=Math.floor;t.exports=function(t){return isNaN(t=+t)?0:(t>0?e:r)(t)}},function(t,n,r){var e=r(21);t.exports=function(t,n){if(!e(t))return t;var r,i;if(n&&"function"==typeof(r=t.toString)&&!e(i=r.call(t)))return i;if("function"==typeof(r=t.valueOf)&&!e(i=r.call(t)))return i;if(!n&&"function"==typeof(r=t.toString)&&!e(i=r.call(t)))return i;throw TypeError("Can't convert object to primitive value")}},function(t,n,r){var e=r(5),i=r(25),o=r(36),u=r(44),c=r(14).f;t.exports=function(t){var n=i.Symbol||(i.Symbol=o?{}:e.Symbol||{});"_"==t.charAt(0)||t in n||c(n,t,{value:u.f(t)})}},function(t,n,r){n.f=r(15)},function(t,n){var r={}.toString;t.exports=function(t){return r.call(t).slice(8,-1)}},function(t,n){t.exports=function(t){if(void 0==t)throw TypeError("Can't call method on  "+t);return t}},function(t,n,r){var e=r(4);t.exports=function(t,n){return!!t&&e(function(){n?t.call(null,function(){},1):t.call(null)})}},function(t,n,r){var e=r(53),i=r(115),o=r(17),u=r(16),c=r(203);t.exports=function(t,n){var r=1==t,f=2==t,a=3==t,s=4==t,l=6==t,h=5==t||l,v=n||c;return function(n,c,p){for(var d,y,g=o(n),b=i(g),m=e(c,p,3),x=u(b.length),w=0,S=r?v(n,x):f?v(n,0):void 0;x>w;w++)if((h||w in b)&&(d=b[w],y=m(d,w,g),t))if(r)S[w]=y;else if(y)switch(t){case 3:return!0;case 5:return d;case 6:return w;case 2:S.push(d)}else if(s)return!1;return l?-1:a||s?s:S}}},function(t,n,r){var e=r(1),i=r(52),o=r(4);t.exports=function(t,n){var r=(i.Object||{})[t]||Object[t],u={};u[t]=n(r),e(e.S+e.F*o(function(){r(1)}),"Object",u)}},function(t,n,r){var e=r(6);t.exports=function(t,n){if(!e(t))return t;var r,i;if(n&&"function"==typeof(r=t.toString)&&!e(i=r.call(t)))return i;if("function"==typeof(r=t.valueOf)&&!e(i=r.call(t)))return i;if(!n&&"function"==typeof(r=t.toString)&&!e(i=r.call(t)))return i;throw TypeError("Can't convert object to primitive value")}},function(t,n,r){var e=r(5),i=r(25),o=r(91),u=r(13),c="prototype",f=function(t,n,r){var a,s,l,h=t&f.F,v=t&f.G,p=t&f.S,d=t&f.P,y=t&f.B,g=t&f.W,b=v?i:i[n]||(i[n]={}),m=b[c],x=v?e:p?e[n]:(e[n]||{})[c];v&&(r=n);for(a in r)(s=!h&&x&&void 0!==x[a])&&a in b||(l=s?x[a]:r[a],b[a]=v&&"function"!=typeof x[a]?r[a]:y&&s?o(l,e):g&&x[a]==l?function(t){var n=function(n,r,e){if(this instanceof t){switch(arguments.length){case 0:return new t;case 1:return new t(n);case 2:return new t(n,r)}return new t(n,r,e)}return t.apply(this,arguments)};return n[c]=t[c],n}(l):d&&"function"==typeof l?o(Function.call,l):l,d&&((b.virtual||(b.virtual={}))[a]=l,t&f.R&&m&&!m[a]&&u(m,a,l)))};f.F=1,f.G=2,f.S=4,f.P=8,f.B=16,f.W=32,f.U=64,f.R=128,t.exports=f},function(t,n){var r=t.exports={version:"2.4.0"};"number"==typeof __e&&(__e=r)},function(t,n,r){var e=r(26);t.exports=function(t,n,r){if(e(t),void 0===n)return t;switch(r){case 1:return function(r){return t.call(n,r)};case 2:return function(r,e){return t.call(n,r,e)};case 3:return function(r,e,i){return t.call(n,r,e,i)}}return function(){return t.apply(n,arguments)}}},function(t,n,r){var e=r(183),i=r(1),o=r(126)("metadata"),u=o.store||(o.store=new(r(186))),c=function(t,n,r){var i=u.get(t);if(!i){if(!r)return;u.set(t,i=new e)}var o=i.get(n);if(!o){if(!r)return;i.set(n,o=new e)}return o},f=function(t,n,r){var e=c(n,r,!1);return void 0!==e&&e.has(t)},a=function(t,n,r){var e=c(n,r,!1);return void 0===e?void 0:e.get(t)},s=function(t,n,r,e){c(r,e,!0).set(t,n)},l=function(t,n){var r=c(t,n,!1),e=[];return r&&r.forEach(function(t,n){e.push(n)}),e},h=function(t){return void 0===t||"symbol"==typeof t?t:String(t)},v=function(t){i(i.S,"Reflect",t)};t.exports={store:u,map:c,has:f,get:a,set:s,keys:l,key:h,exp:v}},function(t,n,r){"use strict";if(r(10)){var e=r(69),i=r(3),o=r(4),u=r(1),c=r(127),f=r(152),a=r(53),s=r(68),l=r(66),h=r(27),v=r(73),p=r(67),d=r(16),y=r(75),g=r(50),b=r(24),m=r(180),x=r(114),w=r(6),S=r(17),_=r(137),O=r(70),E=r(32),P=r(71).f,j=r(154),F=r(76),M=r(7),A=r(48),N=r(117),T=r(146),I=r(155),k=r(80),L=r(123),R=r(74),C=r(130),D=r(160),U=r(11),W=r(31),G=U.f,B=W.f,V=i.RangeError,z=i.TypeError,q=i.Uint8Array,K="ArrayBuffer",J="Shared"+K,Y="BYTES_PER_ELEMENT",H="prototype",$=Array[H],X=f.ArrayBuffer,Q=f.DataView,Z=A(0),tt=A(2),nt=A(3),rt=A(4),et=A(5),it=A(6),ot=N(!0),ut=N(!1),ct=I.values,ft=I.keys,at=I.entries,st=$.lastIndexOf,lt=$.reduce,ht=$.reduceRight,vt=$.join,pt=$.sort,dt=$.slice,yt=$.toString,gt=$.toLocaleString,bt=M("iterator"),mt=M("toStringTag"),xt=F("typed_constructor"),wt=F("def_constructor"),St=c.CONSTR,_t=c.TYPED,Ot=c.VIEW,Et="Wrong length!",Pt=A(1,function(t,n){return Tt(T(t,t[wt]),n)}),jt=o(function(){return 1===new q(new Uint16Array([1]).buffer)[0]}),Ft=!!q&&!!q[H].set&&o(function(){new q(1).set({})}),Mt=function(t,n){if(void 0===t)throw z(Et);var r=+t,e=d(t);if(n&&!m(r,e))throw V(Et);return e},At=function(t,n){var r=p(t);if(r<0||r%n)throw V("Wrong offset!");return r},Nt=function(t){if(w(t)&&_t in t)return t;throw z(t+" is not a typed array!")},Tt=function(t,n){if(!(w(t)&&xt in t))throw z("It is not a typed array constructor!");return new t(n)},It=function(t,n){return kt(T(t,t[wt]),n)},kt=function(t,n){for(var r=0,e=n.length,i=Tt(t,e);e>r;)i[r]=n[r++];return i},Lt=function(t,n,r){G(t,n,{get:function(){return this._d[r]}})},Rt=function(t){var n,r,e,i,o,u,c=S(t),f=arguments.length,s=f>1?arguments[1]:void 0,l=void 0!==s,h=j(c);if(void 0!=h&&!_(h)){for(u=h.call(c),e=[],n=0;!(o=u.next()).done;n++)e.push(o.value);c=e}for(l&&f>2&&(s=a(s,arguments[2],2)),n=0,r=d(c.length),i=Tt(this,r);r>n;n++)i[n]=l?s(c[n],n):c[n];return i},Ct=function(){for(var t=0,n=arguments.length,r=Tt(this,n);n>t;)r[t]=arguments[t++];return r},Dt=!!q&&o(function(){gt.call(new q(1))}),Ut=function(){return gt.apply(Dt?dt.call(Nt(this)):Nt(this),arguments)},Wt={copyWithin:function(t,n){return D.call(Nt(this),t,n,arguments.length>2?arguments[2]:void 0)},every:function(t){return rt(Nt(this),t,arguments.length>1?arguments[1]:void 0)},fill:function(t){return C.apply(Nt(this),arguments)},filter:function(t){return It(this,tt(Nt(this),t,arguments.length>1?arguments[1]:void 0))},find:function(t){return et(Nt(this),t,arguments.length>1?arguments[1]:void 0)},findIndex:function(t){return it(Nt(this),t,arguments.length>1?arguments[1]:void 0)},forEach:function(t){Z(Nt(this),t,arguments.length>1?arguments[1]:void 0)},indexOf:function(t){return ut(Nt(this),t,arguments.length>1?arguments[1]:void 0)},includes:function(t){return ot(Nt(this),t,arguments.length>1?arguments[1]:void 0)},join:function(t){return vt.apply(Nt(this),arguments)},lastIndexOf:function(t){return st.apply(Nt(this),arguments)},map:function(t){return Pt(Nt(this),t,arguments.length>1?arguments[1]:void 0)},reduce:function(t){return lt.apply(Nt(this),arguments)},reduceRight:function(t){return ht.apply(Nt(this),arguments)},reverse:function(){for(var t,n=this,r=Nt(n).length,e=Math.floor(r/2),i=0;i<e;)t=n[i],n[i++]=n[--r],n[r]=t;return n},some:function(t){return nt(Nt(this),t,arguments.length>1?arguments[1]:void 0)},sort:function(t){return pt.call(Nt(this),t)},subarray:function(t,n){var r=Nt(this),e=r.length,i=y(t,e);return new(T(r,r[wt]))(r.buffer,r.byteOffset+i*r.BYTES_PER_ELEMENT,d((void 0===n?e:y(n,e))-i))}},Gt=function(t,n){return It(this,dt.call(Nt(this),t,n))},Bt=function(t){Nt(this);var n=At(arguments[1],1),r=this.length,e=S(t),i=d(e.length),o=0;if(i+n>r)throw V(Et);for(;o<i;)this[n+o]=e[o++]},Vt={entries:function(){return at.call(Nt(this))},keys:function(){return ft.call(Nt(this))},values:function(){return ct.call(Nt(this))}},zt=function(t,n){return w(t)&&t[_t]&&"symbol"!=typeof n&&n in t&&String(+n)==String(n)},qt=function(t,n){return zt(t,n=g(n,!0))?l(2,t[n]):B(t,n)},Kt=function(t,n,r){return!(zt(t,n=g(n,!0))&&w(r)&&b(r,"value"))||b(r,"get")||b(r,"set")||r.configurable||b(r,"writable")&&!r.writable||b(r,"enumerable")&&!r.enumerable?G(t,n,r):(t[n]=r.value,t)};St||(W.f=qt,U.f=Kt),u(u.S+u.F*!St,"Object",{getOwnPropertyDescriptor:qt,defineProperty:Kt}),o(function(){yt.call({})})&&(yt=gt=function(){return vt.call(this)});var Jt=v({},Wt);v(Jt,Vt),h(Jt,bt,Vt.values),v(Jt,{slice:Gt,set:Bt,constructor:function(){},toString:yt,toLocaleString:Ut}),Lt(Jt,"buffer","b"),Lt(Jt,"byteOffset","o"),Lt(Jt,"byteLength","l"),Lt(Jt,"length","e"),G(Jt,mt,{get:function(){return this[_t]}}),t.exports=function(t,n,r,f){f=!!f;var a=t+(f?"Clamped":"")+"Array",l="Uint8Array"!=a,v="get"+t,p="set"+t,y=i[a],g=y||{},b=y&&E(y),m=!y||!c.ABV,S={},_=y&&y[H],j=function(t,r){var e=t._d;return e.v[v](r*n+e.o,jt)},F=function(t,r,e){var i=t._d;f&&(e=(e=Math.round(e))<0?0:e>255?255:255&e),i.v[p](r*n+i.o,e,jt)},M=function(t,n){G(t,n,{get:function(){return j(this,n)},set:function(t){return F(this,n,t)},enumerable:!0})};m?(y=r(function(t,r,e,i){s(t,y,a,"_d");var o,u,c,f,l=0,v=0;if(w(r)){if(!(r instanceof X||(f=x(r))==K||f==J))return _t in r?kt(y,r):Rt.call(y,r);o=r,v=At(e,n);var p=r.byteLength;if(void 0===i){if(p%n)throw V(Et);if((u=p-v)<0)throw V(Et)}else if((u=d(i)*n)+v>p)throw V(Et);c=u/n}else c=Mt(r,!0),u=c*n,o=new X(u);for(h(t,"_d",{b:o,o:v,l:u,e:c,v:new Q(o)});l<c;)M(t,l++)}),_=y[H]=O(Jt),h(_,"constructor",y)):L(function(t){new y(null),new y(t)},!0)||(y=r(function(t,r,e,i){s(t,y,a);var o;return w(r)?r instanceof X||(o=x(r))==K||o==J?void 0!==i?new g(r,At(e,n),i):void 0!==e?new g(r,At(e,n)):new g(r):_t in r?kt(y,r):Rt.call(y,r):new g(Mt(r,l))}),Z(b!==Function.prototype?P(g).concat(P(b)):P(g),function(t){t in y||h(y,t,g[t])}),y[H]=_,e||(_.constructor=y));var A=_[bt],N=!!A&&("values"==A.name||void 0==A.name),T=Vt.values;h(y,xt,!0),h(_,_t,a),h(_,Ot,!0),h(_,wt,y),(f?new y(1)[mt]==a:mt in _)||G(_,mt,{get:function(){return a}}),S[a]=y,u(u.G+u.W+u.F*(y!=g),S),u(u.S,a,{BYTES_PER_ELEMENT:n,from:Rt,of:Ct}),Y in _||h(_,Y,n),u(u.P,a,Wt),R(a),u(u.P+u.F*Ft,a,{set:Bt}),u(u.P+u.F*!N,a,Vt),u(u.P+u.F*(_.toString!=yt),a,{toString:yt}),u(u.P+u.F*o(function(){new y(1).slice()}),a,{slice:Gt}),u(u.P+u.F*(o(function(){return[1,2].toLocaleString()!=new y([1,2]).toLocaleString()})||!o(function(){_.toLocaleString.call([1,2])})),a,{toLocaleString:Ut}),k[a]=N?A:T,e||N||h(_,bt,T)}}else t.exports=function(){}},function(t,n){var r={}.toString;t.exports=function(t){return r.call(t).slice(8,-1)}},function(t,n,r){var e=r(21),i=r(5).document,o=e(i)&&e(i.createElement);t.exports=function(t){return o?i.createElement(t):{}}},function(t,n,r){t.exports=!r(12)&&!r(18)(function(){return 7!=Object.defineProperty(r(57)("div"),"a",{get:function(){return 7}}).a})},function(t,n,r){"use strict";var e=r(36),i=r(51),o=r(64),u=r(13),c=r(8),f=r(35),a=r(96),s=r(38),l=r(103),h=r(15)("iterator"),v=!([].keys&&"next"in[].keys()),p="keys",d="values",y=function(){return this};t.exports=function(t,n,r,g,b,m,x){a(r,n,g);var w,S,_,O=function(t){if(!v&&t in F)return F[t];switch(t){case p:case d:return function(){return new r(this,t)}}return function(){return new r(this,t)}},E=n+" Iterator",P=b==d,j=!1,F=t.prototype,M=F[h]||F["@@iterator"]||b&&F[b],A=M||O(b),N=b?P?O("entries"):A:void 0,T="Array"==n?F.entries||M:M;if(T&&(_=l(T.call(new t)))!==Object.prototype&&(s(_,E,!0),e||c(_,h)||u(_,h,y)),P&&M&&M.name!==d&&(j=!0,A=function(){return M.call(this)}),e&&!x||!v&&!j&&F[h]||u(F,h,A),f[n]=A,f[E]=y,b)if(w={values:P?A:O(d),keys:m?A:O(p),entries:N},x)for(S in w)S in F||o(F,S,w[S]);else i(i.P+i.F*(v||j),n,w);return w}},function(t,n,r){var e=r(20),i=r(100),o=r(34),u=r(39)("IE_PROTO"),c=function(){},f="prototype",a=function(){var t,n=r(57)("iframe"),e=o.length;for(n.style.display="none",r(93).appendChild(n),n.src="javascript:",t=n.contentWindow.document,t.open(),t.write("<script>document.F=Object<\/script>"),t.close(),a=t.F;e--;)delete a[f][o[e]];return a()};t.exports=Object.create||function(t,n){var r;return null!==t?(c[f]=e(t),r=new c,c[f]=null,r[u]=t):r=a(),void 0===n?r:i(r,n)}},function(t,n,r){var e=r(63),i=r(34).concat("length","prototype");n.f=Object.getOwnPropertyNames||function(t){return e(t,i)}},function(t,n){n.f=Object.getOwnPropertySymbols},function(t,n,r){var e=r(8),i=r(9),o=r(90)(!1),u=r(39)("IE_PROTO");t.exports=function(t,n){var r,c=i(t),f=0,a=[];for(r in c)r!=u&&e(c,r)&&a.push(r);for(;n.length>f;)e(c,r=n[f++])&&(~o(a,r)||a.push(r));return a}},function(t,n,r){t.exports=r(13)},function(t,n,r){var e=r(76)("meta"),i=r(6),o=r(24),u=r(11).f,c=0,f=Object.isExtensible||function(){return!0},a=!r(4)(function(){return f(Object.preventExtensions({}))}),s=function(t){u(t,e,{value:{i:"O"+ ++c,w:{}}})},l=function(t,n){if(!i(t))return"symbol"==typeof t?t:("string"==typeof t?"S":"P")+t;if(!o(t,e)){if(!f(t))return"F";if(!n)return"E";s(t)}return t[e].i},h=function(t,n){if(!o(t,e)){if(!f(t))return!0;if(!n)return!1;s(t)}return t[e].w},v=function(t){return a&&p.NEED&&f(t)&&!o(t,e)&&s(t),t},p=t.exports={KEY:e,NEED:!1,fastKey:l,getWeak:h,onFreeze:v}},function(t,n){t.exports=function(t,n){return{enumerable:!(1&t),configurable:!(2&t),writable:!(4&t),value:n}}},function(t,n){var r=Math.ceil,e=Math.floor;t.exports=function(t){return isNaN(t=+t)?0:(t>0?e:r)(t)}},function(t,n){t.exports=function(t,n,r,e){if(!(t instanceof n)||void 0!==e&&e in t)throw TypeError(r+": incorrect invocation!");return t}},function(t,n){t.exports=!1},function(t,n,r){var e=r(2),i=r(173),o=r(133),u=r(145)("IE_PROTO"),c=function(){},f="prototype",a=function(){var t,n=r(132)("iframe"),e=o.length;for(n.style.display="none",r(135).appendChild(n),n.src="javascript:",t=n.contentWindow.document,t.open(),t.write("<script>document.F=Object<\/script>"),t.close(),a=t.F;e--;)delete a[f][o[e]];return a()};t.exports=Object.create||function(t,n){var r;return null!==t?(c[f]=e(t),r=new c,c[f]=null,r[u]=t):r=a(),void 0===n?r:i(r,n)}},function(t,n,r){var e=r(175),i=r(133).concat("length","prototype");n.f=Object.getOwnPropertyNames||function(t){return e(t,i)}},function(t,n,r){var e=r(175),i=r(133);t.exports=Object.keys||function(t){return e(t,i)}},function(t,n,r){var e=r(28);t.exports=function(t,n,r){for(var i in n)e(t,i,n[i],r);return t}},function(t,n,r){"use strict";var e=r(3),i=r(11),o=r(10),u=r(7)("species");t.exports=function(t){var n=e[t];o&&n&&!n[u]&&i.f(n,u,{configurable:!0,get:function(){return this}})}},function(t,n,r){var e=r(67),i=Math.max,o=Math.min;t.exports=function(t,n){return t=e(t),t<0?i(t+n,0):o(t,n)}},function(t,n){var r=0,e=Math.random();t.exports=function(t){return"Symbol(".concat(void 0===t?"":t,")_",(++r+e).toString(36))}},function(t,n,r){var e=r(33);t.exports=function(t){return Object(e(t))}},function(t,n,r){var e=r(7)("unscopables"),i=Array.prototype;void 0==i[e]&&r(27)(i,e,{}),t.exports=function(t){i[e][t]=!0}},function(t,n,r){var e=r(53),i=r(169),o=r(137),u=r(2),c=r(16),f=r(154),a={},s={},n=t.exports=function(t,n,r,l,h){var v,p,d,y,g=h?function(){return t}:f(t),b=e(r,l,n?2:1),m=0;if("function"!=typeof g)throw TypeError(t+" is not iterable!");if(o(g)){for(v=c(t.length);v>m;m++)if((y=n?b(u(p=t[m])[0],p[1]):b(t[m]))===a||y===s)return y}else for(d=g.call(t);!(p=d.next()).done;)if((y=i(d,b,p.value,n))===a||y===s)return y};n.BREAK=a,n.RETURN=s},function(t,n){t.exports={}},function(t,n,r){var e=r(11).f,i=r(24),o=r(7)("toStringTag");t.exports=function(t,n,r){t&&!i(t=r?t:t.prototype,o)&&e(t,o,{configurable:!0,value:n})}},function(t,n,r){var e=r(1),i=r(46),o=r(4),u=r(150),c="["+u+"]",f="​",a=RegExp("^"+c+c+"*"),s=RegExp(c+c+"*$"),l=function(t,n,r){var i={},c=o(function(){return!!u[t]()||f[t]()!=f}),a=i[t]=c?n(h):u[t];r&&(i[r]=a),e(e.P+e.F*c,"String",i)},h=l.trim=function(t,n){return t=String(i(t)),1&n&&(t=t.replace(a,"")),2&n&&(t=t.replace(s,"")),t};t.exports=l},function(t,n,r){t.exports={default:r(86),__esModule:!0}},function(t,n,r){t.exports={default:r(87),__esModule:!0}},function(t,n,r){"use strict";function e(t){return t&&t.__esModule?t:{default:t}}n.__esModule=!0;var i=r(84),o=e(i),u=r(83),c=e(u),f="function"==typeof c.default&&"symbol"==typeof o.default?function(t){return typeof t}:function(t){return t&&"function"==typeof c.default&&t.constructor===c.default&&t!==c.default.prototype?"symbol":typeof t};n.default="function"==typeof c.default&&"symbol"===f(o.default)?function(t){return void 0===t?"undefined":f(t)}:function(t){return t&&"function"==typeof c.default&&t.constructor===c.default&&t!==c.default.prototype?"symbol":void 0===t?"undefined":f(t)}},function(t,n,r){r(110),r(108),r(111),r(112),t.exports=r(25).Symbol},function(t,n,r){r(109),r(113),t.exports=r(44).f("iterator")},function(t,n){t.exports=function(t){if("function"!=typeof t)throw TypeError(t+" is not a function!");return t}},function(t,n){t.exports=function(){}},function(t,n,r){var e=r(9),i=r(106),o=r(105);t.exports=function(t){return function(n,r,u){var c,f=e(n),a=i(f.length),s=o(u,a);if(t&&r!=r){for(;a>s;)if((c=f[s++])!=c)return!0}else for(;a>s;s++)if((t||s in f)&&f[s]===r)return t||s||0;return!t&&-1}}},function(t,n,r){var e=r(88);t.exports=function(t,n,r){if(e(t),void 0===n)return t;switch(r){case 1:return function(r){return t.call(n,r)};case 2:return function(r,e){return t.call(n,r,e)};case 3:return function(r,e,i){return t.call(n,r,e,i)}}return function(){return t.apply(n,arguments)}}},function(t,n,r){var e=r(19),i=r(62),o=r(37);t.exports=function(t){var n=e(t),r=i.f;if(r)for(var u,c=r(t),f=o.f,a=0;c.length>a;)f.call(t,u=c[a++])&&n.push(u);return n}},function(t,n,r){t.exports=r(5).document&&document.documentElement},function(t,n,r){var e=r(56);t.exports=Object("z").propertyIsEnumerable(0)?Object:function(t){return"String"==e(t)?t.split(""):Object(t)}},function(t,n,r){var e=r(56);t.exports=Array.isArray||function(t){return"Array"==e(t)}},function(t,n,r){"use strict";var e=r(60),i=r(22),o=r(38),u={};r(13)(u,r(15)("iterator"),function(){return this}),t.exports=function(t,n,r){t.prototype=e(u,{next:i(1,r)}),o(t,n+" Iterator")}},function(t,n){t.exports=function(t,n){return{value:n,done:!!t}}},function(t,n,r){var e=r(19),i=r(9);t.exports=function(t,n){for(var r,o=i(t),u=e(o),c=u.length,f=0;c>f;)if(o[r=u[f++]]===n)return r}},function(t,n,r){var e=r(23)("meta"),i=r(21),o=r(8),u=r(14).f,c=0,f=Object.isExtensible||function(){return!0},a=!r(18)(function(){return f(Object.preventExtensions({}))}),s=function(t){u(t,e,{value:{i:"O"+ ++c,w:{}}})},l=function(t,n){if(!i(t))return"symbol"==typeof t?t:("string"==typeof t?"S":"P")+t;if(!o(t,e)){if(!f(t))return"F";if(!n)return"E";s(t)}return t[e].i},h=function(t,n){if(!o(t,e)){if(!f(t))return!0;if(!n)return!1;s(t)}return t[e].w},v=function(t){return a&&p.NEED&&f(t)&&!o(t,e)&&s(t),t},p=t.exports={KEY:e,NEED:!1,fastKey:l,getWeak:h,onFreeze:v}},function(t,n,r){var e=r(14),i=r(20),o=r(19);t.exports=r(12)?Object.defineProperties:function(t,n){i(t);for(var r,u=o(n),c=u.length,f=0;c>f;)e.f(t,r=u[f++],n[r]);return t}},function(t,n,r){var e=r(37),i=r(22),o=r(9),u=r(42),c=r(8),f=r(58),a=Object.getOwnPropertyDescriptor;n.f=r(12)?a:function(t,n){if(t=o(t),n=u(n,!0),f)try{return a(t,n)}catch(t){}if(c(t,n))return i(!e.f.call(t,n),t[n])}},function(t,n,r){var e=r(9),i=r(61).f,o={}.toString,u="object"==typeof window&&window&&Object.getOwnPropertyNames?Object.getOwnPropertyNames(window):[],c=function(t){try{return i(t)}catch(t){return u.slice()}};t.exports.f=function(t){return u&&"[object Window]"==o.call(t)?c(t):i(e(t))}},function(t,n,r){var e=r(8),i=r(77),o=r(39)("IE_PROTO"),u=Object.prototype;t.exports=Object.getPrototypeOf||function(t){return t=i(t),e(t,o)?t[o]:"function"==typeof t.constructor&&t instanceof t.constructor?t.constructor.prototype:t instanceof Object?u:null}},function(t,n,r){var e=r(41),i=r(33);t.exports=function(t){return function(n,r){var o,u,c=String(i(n)),f=e(r),a=c.length;return f<0||f>=a?t?"":void 0:(o=c.charCodeAt(f),o<55296||o>56319||f+1===a||(u=c.charCodeAt(f+1))<56320||u>57343?t?c.charAt(f):o:t?c.slice(f,f+2):u-56320+(o-55296<<10)+65536)}}},function(t,n,r){var e=r(41),i=Math.max,o=Math.min;t.exports=function(t,n){return t=e(t),t<0?i(t+n,0):o(t,n)}},function(t,n,r){var e=r(41),i=Math.min;t.exports=function(t){return t>0?i(e(t),9007199254740991):0}},function(t,n,r){"use strict";var e=r(89),i=r(97),o=r(35),u=r(9);t.exports=r(59)(Array,"Array",function(t,n){this._t=u(t),this._i=0,this._k=n},function(){var t=this._t,n=this._k,r=this._i++;return!t||r>=t.length?(this._t=void 0,i(1)):"keys"==n?i(0,r):"values"==n?i(0,t[r]):i(0,[r,t[r]])},"values"),o.Arguments=o.Array,e("keys"),e("values"),e("entries")},function(t,n){},function(t,n,r){"use strict";var e=r(104)(!0);r(59)(String,"String",function(t){this._t=String(t),this._i=0},function(){var t,n=this._t,r=this._i;return r>=n.length?{value:void 0,done:!0}:(t=e(n,r),this._i+=t.length,{value:t,done:!1})})},function(t,n,r){"use strict";var e=r(5),i=r(8),o=r(12),u=r(51),c=r(64),f=r(99).KEY,a=r(18),s=r(40),l=r(38),h=r(23),v=r(15),p=r(44),d=r(43),y=r(98),g=r(92),b=r(95),m=r(20),x=r(9),w=r(42),S=r(22),_=r(60),O=r(102),E=r(101),P=r(14),j=r(19),F=E.f,M=P.f,A=O.f,N=e.Symbol,T=e.JSON,I=T&&T.stringify,k="prototype",L=v("_hidden"),R=v("toPrimitive"),C={}.propertyIsEnumerable,D=s("symbol-registry"),U=s("symbols"),W=s("op-symbols"),G=Object[k],B="function"==typeof N,V=e.QObject,z=!V||!V[k]||!V[k].findChild,q=o&&a(function(){return 7!=_(M({},"a",{get:function(){return M(this,"a",{value:7}).a}})).a})?function(t,n,r){var e=F(G,n);e&&delete G[n],M(t,n,r),e&&t!==G&&M(G,n,e)}:M,K=function(t){var n=U[t]=_(N[k]);return n._k=t,n},J=B&&"symbol"==typeof N.iterator?function(t){return"symbol"==typeof t}:function(t){return t instanceof N},Y=function(t,n,r){return t===G&&Y(W,n,r),m(t),n=w(n,!0),m(r),i(U,n)?(r.enumerable?(i(t,L)&&t[L][n]&&(t[L][n]=!1),r=_(r,{enumerable:S(0,!1)})):(i(t,L)||M(t,L,S(1,{})),t[L][n]=!0),q(t,n,r)):M(t,n,r)},H=function(t,n){m(t);for(var r,e=g(n=x(n)),i=0,o=e.length;o>i;)Y(t,r=e[i++],n[r]);return t},$=function(t,n){return void 0===n?_(t):H(_(t),n)},X=function(t){var n=C.call(this,t=w(t,!0));return!(this===G&&i(U,t)&&!i(W,t))&&(!(n||!i(this,t)||!i(U,t)||i(this,L)&&this[L][t])||n)},Q=function(t,n){if(t=x(t),n=w(n,!0),t!==G||!i(U,n)||i(W,n)){var r=F(t,n);return!r||!i(U,n)||i(t,L)&&t[L][n]||(r.enumerable=!0),r}},Z=function(t){for(var n,r=A(x(t)),e=[],o=0;r.length>o;)i(U,n=r[o++])||n==L||n==f||e.push(n);return e},tt=function(t){for(var n,r=t===G,e=A(r?W:x(t)),o=[],u=0;e.length>u;)!i(U,n=e[u++])||r&&!i(G,n)||o.push(U[n]);return o};B||(N=function(){if(this instanceof N)throw TypeError("Symbol is not a constructor!");var t=h(arguments.length>0?arguments[0]:void 0),n=function(r){this===G&&n.call(W,r),i(this,L)&&i(this[L],t)&&(this[L][t]=!1),q(this,t,S(1,r))};return o&&z&&q(G,t,{configurable:!0,set:n}),K(t)},c(N[k],"toString",function(){return this._k}),E.f=Q,P.f=Y,r(61).f=O.f=Z,r(37).f=X,r(62).f=tt,o&&!r(36)&&c(G,"propertyIsEnumerable",X,!0),p.f=function(t){return K(v(t))}),u(u.G+u.W+u.F*!B,{Symbol:N});for(var nt="hasInstance,isConcatSpreadable,iterator,match,replace,search,species,split,toPrimitive,toStringTag,unscopables".split(","),rt=0;nt.length>rt;)v(nt[rt++]);for(var nt=j(v.store),rt=0;nt.length>rt;)d(nt[rt++]);u(u.S+u.F*!B,"Symbol",{for:function(t){return i(D,t+="")?D[t]:D[t]=N(t)},keyFor:function(t){if(J(t))return y(D,t);throw TypeError(t+" is not a symbol!")},useSetter:function(){z=!0},useSimple:function(){z=!1}}),u(u.S+u.F*!B,"Object",{create:$,defineProperty:Y,defineProperties:H,getOwnPropertyDescriptor:Q,getOwnPropertyNames:Z,getOwnPropertySymbols:tt}),T&&u(u.S+u.F*(!B||a(function(){var t=N();return"[null]"!=I([t])||"{}"!=I({a:t})||"{}"!=I(Object(t))})),"JSON",{stringify:function(t){if(void 0!==t&&!J(t)){for(var n,r,e=[t],i=1;arguments.length>i;)e.push(arguments[i++]);return n=e[1],"function"==typeof n&&(r=n),!r&&b(n)||(n=function(t,n){if(r&&(n=r.call(this,t,n)),!J(n))return n}),e[1]=n,I.apply(T,e)}}}),N[k][R]||r(13)(N[k],R,N[k].valueOf),l(N,"Symbol"),l(Math,"Math",!0),l(e.JSON,"JSON",!0)},function(t,n,r){r(43)("asyncIterator")},function(t,n,r){r(43)("observable")},function(t,n,r){r(107);for(var e=r(5),i=r(13),o=r(35),u=r(15)("toStringTag"),c=["NodeList","DOMTokenList","MediaList","StyleSheetList","CSSRuleList"],f=0;f<5;f++){var a=c[f],s=e[a],l=s&&s.prototype;l&&!l[u]&&i(l,u,a),o[a]=o.Array}},function(t,n,r){var e=r(45),i=r(7)("toStringTag"),o="Arguments"==e(function(){return arguments}()),u=function(t,n){try{return t[n]}catch(t){}};t.exports=function(t){var n,r,c;return void 0===t?"Undefined":null===t?"Null":"string"==typeof(r=u(n=Object(t),i))?r:o?e(n):"Object"==(c=e(n))&&"function"==typeof n.callee?"Arguments":c}},function(t,n,r){var e=r(45);t.exports=Object("z").propertyIsEnumerable(0)?Object:function(t){return"String"==e(t)?t.split(""):Object(t)}},function(t,n){n.f={}.propertyIsEnumerable},function(t,n,r){var e=r(30),i=r(16),o=r(75);t.exports=function(t){return function(n,r,u){var c,f=e(n),a=i(f.length),s=o(u,a);if(t&&r!=r){for(;a>s;)if((c=f[s++])!=c)return!0}else for(;a>s;s++)if((t||s in f)&&f[s]===r)return t||s||0;return!t&&-1}}},function(t,n,r){"use strict";var e=r(3),i=r(1),o=r(28),u=r(73),c=r(65),f=r(79),a=r(68),s=r(6),l=r(4),h=r(123),v=r(81),p=r(136);t.exports=function(t,n,r,d,y,g){var b=e[t],m=b,x=y?"set":"add",w=m&&m.prototype,S={},_=function(t){var n=w[t];o(w,t,"delete"==t?function(t){return!(g&&!s(t))&&n.call(this,0===t?0:t)}:"has"==t?function(t){return!(g&&!s(t))&&n.call(this,0===t?0:t)}:"get"==t?function(t){return g&&!s(t)?void 0:n.call(this,0===t?0:t)}:"add"==t?function(t){return n.call(this,0===t?0:t),this}:function(t,r){return n.call(this,0===t?0:t,r),this})};if("function"==typeof m&&(g||w.forEach&&!l(function(){(new m).entries().next()}))){var O=new m,E=O[x](g?{}:-0,1)!=O,P=l(function(){O.has(1)}),j=h(function(t){new m(t)}),F=!g&&l(function(){for(var t=new m,n=5;n--;)t[x](n,n);return!t.has(-0)});j||(m=n(function(n,r){a(n,m,t);var e=p(new b,n,m);return void 0!=r&&f(r,y,e[x],e),e}),m.prototype=w,w.constructor=m),(P||F)&&(_("delete"),_("has"),y&&_("get")),(F||E)&&_(x),g&&w.clear&&delete w.clear}else m=d.getConstructor(n,t,y,x),u(m.prototype,r),c.NEED=!0;return v(m,t),S[t]=m,i(i.G+i.W+i.F*(m!=b),S),g||d.setStrong(m,t,y),m}},function(t,n,r){"use strict";var e=r(27),i=r(28),o=r(4),u=r(46),c=r(7);t.exports=function(t,n,r){var f=c(t),a=r(u,f,""[t]),s=a[0],l=a[1];o(function(){var n={};return n[f]=function(){return 7},7!=""[t](n)})&&(i(String.prototype,t,s),e(RegExp.prototype,f,2==n?function(t,n){return l.call(t,this,n)}:function(t){return l.call(t,this)}))}
},function(t,n,r){"use strict";var e=r(2);t.exports=function(){var t=e(this),n="";return t.global&&(n+="g"),t.ignoreCase&&(n+="i"),t.multiline&&(n+="m"),t.unicode&&(n+="u"),t.sticky&&(n+="y"),n}},function(t,n){t.exports=function(t,n,r){var e=void 0===r;switch(n.length){case 0:return e?t():t.call(r);case 1:return e?t(n[0]):t.call(r,n[0]);case 2:return e?t(n[0],n[1]):t.call(r,n[0],n[1]);case 3:return e?t(n[0],n[1],n[2]):t.call(r,n[0],n[1],n[2]);case 4:return e?t(n[0],n[1],n[2],n[3]):t.call(r,n[0],n[1],n[2],n[3])}return t.apply(r,n)}},function(t,n,r){var e=r(6),i=r(45),o=r(7)("match");t.exports=function(t){var n;return e(t)&&(void 0!==(n=t[o])?!!n:"RegExp"==i(t))}},function(t,n,r){var e=r(7)("iterator"),i=!1;try{var o=[7][e]();o.return=function(){i=!0},Array.from(o,function(){throw 2})}catch(t){}t.exports=function(t,n){if(!n&&!i)return!1;var r=!1;try{var o=[7],u=o[e]();u.next=function(){return{done:r=!0}},o[e]=function(){return u},t(o)}catch(t){}return r}},function(t,n,r){t.exports=r(69)||!r(4)(function(){var t=Math.random();__defineSetter__.call(null,t,function(){}),delete r(3)[t]})},function(t,n){n.f=Object.getOwnPropertySymbols},function(t,n,r){var e=r(3),i="__core-js_shared__",o=e[i]||(e[i]={});t.exports=function(t){return o[t]||(o[t]={})}},function(t,n,r){for(var e,i=r(3),o=r(27),u=r(76),c=u("typed_array"),f=u("view"),a=!(!i.ArrayBuffer||!i.DataView),s=a,l=0,h="Int8Array,Uint8Array,Uint8ClampedArray,Int16Array,Uint16Array,Int32Array,Uint32Array,Float32Array,Float64Array".split(",");l<9;)(e=i[h[l++]])?(o(e.prototype,c,!0),o(e.prototype,f,!0)):s=!1;t.exports={ABV:a,CONSTR:s,TYPED:c,VIEW:f}},function(t,n){"use strict";var r={versions:function(){var t=window.navigator.userAgent;return{trident:t.indexOf("Trident")>-1,presto:t.indexOf("Presto")>-1,webKit:t.indexOf("AppleWebKit")>-1,gecko:t.indexOf("Gecko")>-1&&-1==t.indexOf("KHTML"),mobile:!!t.match(/AppleWebKit.*Mobile.*/),ios:!!t.match(/\(i[^;]+;( U;)? CPU.+Mac OS X/),android:t.indexOf("Android")>-1||t.indexOf("Linux")>-1,iPhone:t.indexOf("iPhone")>-1||t.indexOf("Mac")>-1,iPad:t.indexOf("iPad")>-1,webApp:-1==t.indexOf("Safari"),weixin:-1==t.indexOf("MicroMessenger")}}()};t.exports=r},function(t,n,r){"use strict";var e=r(85),i=function(t){return t&&t.__esModule?t:{default:t}}(e),o=function(){function t(t,n,e){return n||e?String.fromCharCode(n||e):r[t]||t}function n(t){return e[t]}var r={"&quot;":'"',"&lt;":"<","&gt;":">","&amp;":"&","&nbsp;":" "},e={};for(var u in r)e[r[u]]=u;return r["&apos;"]="'",e["'"]="&#39;",{encode:function(t){return t?(""+t).replace(/['<> "&]/g,n).replace(/\r?\n/g,"<br/>").replace(/\s/g,"&nbsp;"):""},decode:function(n){return n?(""+n).replace(/<br\s*\/?>/gi,"\n").replace(/&quot;|&lt;|&gt;|&amp;|&nbsp;|&apos;|&#(\d+);|&#(\d+)/g,t).replace(/\u00a0/g," "):""},encodeBase16:function(t){if(!t)return t;t+="";for(var n=[],r=0,e=t.length;e>r;r++)n.push(t.charCodeAt(r).toString(16).toUpperCase());return n.join("")},encodeBase16forJSON:function(t){if(!t)return t;t=t.replace(/[\u4E00-\u9FBF]/gi,function(t){return escape(t).replace("%u","\\u")});for(var n=[],r=0,e=t.length;e>r;r++)n.push(t.charCodeAt(r).toString(16).toUpperCase());return n.join("")},decodeBase16:function(t){if(!t)return t;t+="";for(var n=[],r=0,e=t.length;e>r;r+=2)n.push(String.fromCharCode("0x"+t.slice(r,r+2)));return n.join("")},encodeObject:function(t){if(t instanceof Array)for(var n=0,r=t.length;r>n;n++)t[n]=o.encodeObject(t[n]);else if("object"==(void 0===t?"undefined":(0,i.default)(t)))for(var e in t)t[e]=o.encodeObject(t[e]);else if("string"==typeof t)return o.encode(t);return t},loadScript:function(t){var n=document.createElement("script");document.getElementsByTagName("body")[0].appendChild(n),n.setAttribute("src",t)},addLoadEvent:function(t){var n=window.onload;"function"!=typeof window.onload?window.onload=t:window.onload=function(){n(),t()}}}}();t.exports=o},function(t,n,r){"use strict";var e=r(17),i=r(75),o=r(16);t.exports=function(t){for(var n=e(this),r=o(n.length),u=arguments.length,c=i(u>1?arguments[1]:void 0,r),f=u>2?arguments[2]:void 0,a=void 0===f?r:i(f,r);a>c;)n[c++]=t;return n}},function(t,n,r){"use strict";var e=r(11),i=r(66);t.exports=function(t,n,r){n in t?e.f(t,n,i(0,r)):t[n]=r}},function(t,n,r){var e=r(6),i=r(3).document,o=e(i)&&e(i.createElement);t.exports=function(t){return o?i.createElement(t):{}}},function(t,n){t.exports="constructor,hasOwnProperty,isPrototypeOf,propertyIsEnumerable,toLocaleString,toString,valueOf".split(",")},function(t,n,r){var e=r(7)("match");t.exports=function(t){var n=/./;try{"/./"[t](n)}catch(r){try{return n[e]=!1,!"/./"[t](n)}catch(t){}}return!0}},function(t,n,r){t.exports=r(3).document&&document.documentElement},function(t,n,r){var e=r(6),i=r(144).set;t.exports=function(t,n,r){var o,u=n.constructor;return u!==r&&"function"==typeof u&&(o=u.prototype)!==r.prototype&&e(o)&&i&&i(t,o),t}},function(t,n,r){var e=r(80),i=r(7)("iterator"),o=Array.prototype;t.exports=function(t){return void 0!==t&&(e.Array===t||o[i]===t)}},function(t,n,r){var e=r(45);t.exports=Array.isArray||function(t){return"Array"==e(t)}},function(t,n,r){"use strict";var e=r(70),i=r(66),o=r(81),u={};r(27)(u,r(7)("iterator"),function(){return this}),t.exports=function(t,n,r){t.prototype=e(u,{next:i(1,r)}),o(t,n+" Iterator")}},function(t,n,r){"use strict";var e=r(69),i=r(1),o=r(28),u=r(27),c=r(24),f=r(80),a=r(139),s=r(81),l=r(32),h=r(7)("iterator"),v=!([].keys&&"next"in[].keys()),p="keys",d="values",y=function(){return this};t.exports=function(t,n,r,g,b,m,x){a(r,n,g);var w,S,_,O=function(t){if(!v&&t in F)return F[t];switch(t){case p:case d:return function(){return new r(this,t)}}return function(){return new r(this,t)}},E=n+" Iterator",P=b==d,j=!1,F=t.prototype,M=F[h]||F["@@iterator"]||b&&F[b],A=M||O(b),N=b?P?O("entries"):A:void 0,T="Array"==n?F.entries||M:M;if(T&&(_=l(T.call(new t)))!==Object.prototype&&(s(_,E,!0),e||c(_,h)||u(_,h,y)),P&&M&&M.name!==d&&(j=!0,A=function(){return M.call(this)}),e&&!x||!v&&!j&&F[h]||u(F,h,A),f[n]=A,f[E]=y,b)if(w={values:P?A:O(d),keys:m?A:O(p),entries:N},x)for(S in w)S in F||o(F,S,w[S]);else i(i.P+i.F*(v||j),n,w);return w}},function(t,n){var r=Math.expm1;t.exports=!r||r(10)>22025.465794806718||r(10)<22025.465794806718||-2e-17!=r(-2e-17)?function(t){return 0==(t=+t)?t:t>-1e-6&&t<1e-6?t+t*t/2:Math.exp(t)-1}:r},function(t,n){t.exports=Math.sign||function(t){return 0==(t=+t)||t!=t?t:t<0?-1:1}},function(t,n,r){var e=r(3),i=r(151).set,o=e.MutationObserver||e.WebKitMutationObserver,u=e.process,c=e.Promise,f="process"==r(45)(u);t.exports=function(){var t,n,r,a=function(){var e,i;for(f&&(e=u.domain)&&e.exit();t;){i=t.fn,t=t.next;try{i()}catch(e){throw t?r():n=void 0,e}}n=void 0,e&&e.enter()};if(f)r=function(){u.nextTick(a)};else if(o){var s=!0,l=document.createTextNode("");new o(a).observe(l,{characterData:!0}),r=function(){l.data=s=!s}}else if(c&&c.resolve){var h=c.resolve();r=function(){h.then(a)}}else r=function(){i.call(e,a)};return function(e){var i={fn:e,next:void 0};n&&(n.next=i),t||(t=i,r()),n=i}}},function(t,n,r){var e=r(6),i=r(2),o=function(t,n){if(i(t),!e(n)&&null!==n)throw TypeError(n+": can't set as prototype!")};t.exports={set:Object.setPrototypeOf||("__proto__"in{}?function(t,n,e){try{e=r(53)(Function.call,r(31).f(Object.prototype,"__proto__").set,2),e(t,[]),n=!(t instanceof Array)}catch(t){n=!0}return function(t,r){return o(t,r),n?t.__proto__=r:e(t,r),t}}({},!1):void 0),check:o}},function(t,n,r){var e=r(126)("keys"),i=r(76);t.exports=function(t){return e[t]||(e[t]=i(t))}},function(t,n,r){var e=r(2),i=r(26),o=r(7)("species");t.exports=function(t,n){var r,u=e(t).constructor;return void 0===u||void 0==(r=e(u)[o])?n:i(r)}},function(t,n,r){var e=r(67),i=r(46);t.exports=function(t){return function(n,r){var o,u,c=String(i(n)),f=e(r),a=c.length;return f<0||f>=a?t?"":void 0:(o=c.charCodeAt(f),o<55296||o>56319||f+1===a||(u=c.charCodeAt(f+1))<56320||u>57343?t?c.charAt(f):o:t?c.slice(f,f+2):u-56320+(o-55296<<10)+65536)}}},function(t,n,r){var e=r(122),i=r(46);t.exports=function(t,n,r){if(e(n))throw TypeError("String#"+r+" doesn't accept regex!");return String(i(t))}},function(t,n,r){"use strict";var e=r(67),i=r(46);t.exports=function(t){var n=String(i(this)),r="",o=e(t);if(o<0||o==1/0)throw RangeError("Count can't be negative");for(;o>0;(o>>>=1)&&(n+=n))1&o&&(r+=n);return r}},function(t,n){t.exports="\t\n\v\f\r   ᠎             　\u2028\u2029\ufeff"},function(t,n,r){var e,i,o,u=r(53),c=r(121),f=r(135),a=r(132),s=r(3),l=s.process,h=s.setImmediate,v=s.clearImmediate,p=s.MessageChannel,d=0,y={},g="onreadystatechange",b=function(){var t=+this;if(y.hasOwnProperty(t)){var n=y[t];delete y[t],n()}},m=function(t){b.call(t.data)};h&&v||(h=function(t){for(var n=[],r=1;arguments.length>r;)n.push(arguments[r++]);return y[++d]=function(){c("function"==typeof t?t:Function(t),n)},e(d),d},v=function(t){delete y[t]},"process"==r(45)(l)?e=function(t){l.nextTick(u(b,t,1))}:p?(i=new p,o=i.port2,i.port1.onmessage=m,e=u(o.postMessage,o,1)):s.addEventListener&&"function"==typeof postMessage&&!s.importScripts?(e=function(t){s.postMessage(t+"","*")},s.addEventListener("message",m,!1)):e=g in a("script")?function(t){f.appendChild(a("script"))[g]=function(){f.removeChild(this),b.call(t)}}:function(t){setTimeout(u(b,t,1),0)}),t.exports={set:h,clear:v}},function(t,n,r){"use strict";var e=r(3),i=r(10),o=r(69),u=r(127),c=r(27),f=r(73),a=r(4),s=r(68),l=r(67),h=r(16),v=r(71).f,p=r(11).f,d=r(130),y=r(81),g="ArrayBuffer",b="DataView",m="prototype",x="Wrong length!",w="Wrong index!",S=e[g],_=e[b],O=e.Math,E=e.RangeError,P=e.Infinity,j=S,F=O.abs,M=O.pow,A=O.floor,N=O.log,T=O.LN2,I="buffer",k="byteLength",L="byteOffset",R=i?"_b":I,C=i?"_l":k,D=i?"_o":L,U=function(t,n,r){var e,i,o,u=Array(r),c=8*r-n-1,f=(1<<c)-1,a=f>>1,s=23===n?M(2,-24)-M(2,-77):0,l=0,h=t<0||0===t&&1/t<0?1:0;for(t=F(t),t!=t||t===P?(i=t!=t?1:0,e=f):(e=A(N(t)/T),t*(o=M(2,-e))<1&&(e--,o*=2),t+=e+a>=1?s/o:s*M(2,1-a),t*o>=2&&(e++,o/=2),e+a>=f?(i=0,e=f):e+a>=1?(i=(t*o-1)*M(2,n),e+=a):(i=t*M(2,a-1)*M(2,n),e=0));n>=8;u[l++]=255&i,i/=256,n-=8);for(e=e<<n|i,c+=n;c>0;u[l++]=255&e,e/=256,c-=8);return u[--l]|=128*h,u},W=function(t,n,r){var e,i=8*r-n-1,o=(1<<i)-1,u=o>>1,c=i-7,f=r-1,a=t[f--],s=127&a;for(a>>=7;c>0;s=256*s+t[f],f--,c-=8);for(e=s&(1<<-c)-1,s>>=-c,c+=n;c>0;e=256*e+t[f],f--,c-=8);if(0===s)s=1-u;else{if(s===o)return e?NaN:a?-P:P;e+=M(2,n),s-=u}return(a?-1:1)*e*M(2,s-n)},G=function(t){return t[3]<<24|t[2]<<16|t[1]<<8|t[0]},B=function(t){return[255&t]},V=function(t){return[255&t,t>>8&255]},z=function(t){return[255&t,t>>8&255,t>>16&255,t>>24&255]},q=function(t){return U(t,52,8)},K=function(t){return U(t,23,4)},J=function(t,n,r){p(t[m],n,{get:function(){return this[r]}})},Y=function(t,n,r,e){var i=+r,o=l(i);if(i!=o||o<0||o+n>t[C])throw E(w);var u=t[R]._b,c=o+t[D],f=u.slice(c,c+n);return e?f:f.reverse()},H=function(t,n,r,e,i,o){var u=+r,c=l(u);if(u!=c||c<0||c+n>t[C])throw E(w);for(var f=t[R]._b,a=c+t[D],s=e(+i),h=0;h<n;h++)f[a+h]=s[o?h:n-h-1]},$=function(t,n){s(t,S,g);var r=+n,e=h(r);if(r!=e)throw E(x);return e};if(u.ABV){if(!a(function(){new S})||!a(function(){new S(.5)})){S=function(t){return new j($(this,t))};for(var X,Q=S[m]=j[m],Z=v(j),tt=0;Z.length>tt;)(X=Z[tt++])in S||c(S,X,j[X]);o||(Q.constructor=S)}var nt=new _(new S(2)),rt=_[m].setInt8;nt.setInt8(0,2147483648),nt.setInt8(1,2147483649),!nt.getInt8(0)&&nt.getInt8(1)||f(_[m],{setInt8:function(t,n){rt.call(this,t,n<<24>>24)},setUint8:function(t,n){rt.call(this,t,n<<24>>24)}},!0)}else S=function(t){var n=$(this,t);this._b=d.call(Array(n),0),this[C]=n},_=function(t,n,r){s(this,_,b),s(t,S,b);var e=t[C],i=l(n);if(i<0||i>e)throw E("Wrong offset!");if(r=void 0===r?e-i:h(r),i+r>e)throw E(x);this[R]=t,this[D]=i,this[C]=r},i&&(J(S,k,"_l"),J(_,I,"_b"),J(_,k,"_l"),J(_,L,"_o")),f(_[m],{getInt8:function(t){return Y(this,1,t)[0]<<24>>24},getUint8:function(t){return Y(this,1,t)[0]},getInt16:function(t){var n=Y(this,2,t,arguments[1]);return(n[1]<<8|n[0])<<16>>16},getUint16:function(t){var n=Y(this,2,t,arguments[1]);return n[1]<<8|n[0]},getInt32:function(t){return G(Y(this,4,t,arguments[1]))},getUint32:function(t){return G(Y(this,4,t,arguments[1]))>>>0},getFloat32:function(t){return W(Y(this,4,t,arguments[1]),23,4)},getFloat64:function(t){return W(Y(this,8,t,arguments[1]),52,8)},setInt8:function(t,n){H(this,1,t,B,n)},setUint8:function(t,n){H(this,1,t,B,n)},setInt16:function(t,n){H(this,2,t,V,n,arguments[2])},setUint16:function(t,n){H(this,2,t,V,n,arguments[2])},setInt32:function(t,n){H(this,4,t,z,n,arguments[2])},setUint32:function(t,n){H(this,4,t,z,n,arguments[2])},setFloat32:function(t,n){H(this,4,t,K,n,arguments[2])},setFloat64:function(t,n){H(this,8,t,q,n,arguments[2])}});y(S,g),y(_,b),c(_[m],u.VIEW,!0),n[g]=S,n[b]=_},function(t,n,r){var e=r(3),i=r(52),o=r(69),u=r(182),c=r(11).f;t.exports=function(t){var n=i.Symbol||(i.Symbol=o?{}:e.Symbol||{});"_"==t.charAt(0)||t in n||c(n,t,{value:u.f(t)})}},function(t,n,r){var e=r(114),i=r(7)("iterator"),o=r(80);t.exports=r(52).getIteratorMethod=function(t){if(void 0!=t)return t[i]||t["@@iterator"]||o[e(t)]}},function(t,n,r){"use strict";var e=r(78),i=r(170),o=r(80),u=r(30);t.exports=r(140)(Array,"Array",function(t,n){this._t=u(t),this._i=0,this._k=n},function(){var t=this._t,n=this._k,r=this._i++;return!t||r>=t.length?(this._t=void 0,i(1)):"keys"==n?i(0,r):"values"==n?i(0,t[r]):i(0,[r,t[r]])},"values"),o.Arguments=o.Array,e("keys"),e("values"),e("entries")},function(t,n){function r(t,n){t.classList?t.classList.add(n):t.className+=" "+n}t.exports=r},function(t,n){function r(t,n){if(t.classList)t.classList.remove(n);else{var r=new RegExp("(^|\\b)"+n.split(" ").join("|")+"(\\b|$)","gi");t.className=t.className.replace(r," ")}}t.exports=r},function(t,n){function r(){throw new Error("setTimeout has not been defined")}function e(){throw new Error("clearTimeout has not been defined")}function i(t){if(s===setTimeout)return setTimeout(t,0);if((s===r||!s)&&setTimeout)return s=setTimeout,setTimeout(t,0);try{return s(t,0)}catch(n){try{return s.call(null,t,0)}catch(n){return s.call(this,t,0)}}}function o(t){if(l===clearTimeout)return clearTimeout(t);if((l===e||!l)&&clearTimeout)return l=clearTimeout,clearTimeout(t);try{return l(t)}catch(n){try{return l.call(null,t)}catch(n){return l.call(this,t)}}}function u(){d&&v&&(d=!1,v.length?p=v.concat(p):y=-1,p.length&&c())}function c(){if(!d){var t=i(u);d=!0;for(var n=p.length;n;){for(v=p,p=[];++y<n;)v&&v[y].run();y=-1,n=p.length}v=null,d=!1,o(t)}}function f(t,n){this.fun=t,this.array=n}function a(){}var s,l,h=t.exports={};!function(){try{s="function"==typeof setTimeout?setTimeout:r}catch(t){s=r}try{l="function"==typeof clearTimeout?clearTimeout:e}catch(t){l=e}}();var v,p=[],d=!1,y=-1;h.nextTick=function(t){var n=new Array(arguments.length-1);if(arguments.length>1)for(var r=1;r<arguments.length;r++)n[r-1]=arguments[r];p.push(new f(t,n)),1!==p.length||d||i(c)},f.prototype.run=function(){this.fun.apply(null,this.array)},h.title="browser",h.browser=!0,h.env={},h.argv=[],h.version="",h.versions={},h.on=a,h.addListener=a,h.once=a,h.off=a,h.removeListener=a,h.removeAllListeners=a,h.emit=a,h.prependListener=a,h.prependOnceListener=a,h.listeners=function(t){return[]},h.binding=function(t){throw new Error("process.binding is not supported")},h.cwd=function(){return"/"},h.chdir=function(t){throw new Error("process.chdir is not supported")},h.umask=function(){return 0}},function(t,n,r){var e=r(45);t.exports=function(t,n){if("number"!=typeof t&&"Number"!=e(t))throw TypeError(n);return+t}},function(t,n,r){"use strict";var e=r(17),i=r(75),o=r(16);t.exports=[].copyWithin||function(t,n){var r=e(this),u=o(r.length),c=i(t,u),f=i(n,u),a=arguments.length>2?arguments[2]:void 0,s=Math.min((void 0===a?u:i(a,u))-f,u-c),l=1;for(f<c&&c<f+s&&(l=-1,f+=s-1,c+=s-1);s-- >0;)f in r?r[c]=r[f]:delete r[c],c+=l,f+=l;return r}},function(t,n,r){var e=r(79);t.exports=function(t,n){var r=[];return e(t,!1,r.push,r,n),r}},function(t,n,r){var e=r(26),i=r(17),o=r(115),u=r(16);t.exports=function(t,n,r,c,f){e(n);var a=i(t),s=o(a),l=u(a.length),h=f?l-1:0,v=f?-1:1;if(r<2)for(;;){if(h in s){c=s[h],h+=v;break}if(h+=v,f?h<0:l<=h)throw TypeError("Reduce of empty array with no initial value")}for(;f?h>=0:l>h;h+=v)h in s&&(c=n(c,s[h],h,a));return c}},function(t,n,r){"use strict";var e=r(26),i=r(6),o=r(121),u=[].slice,c={},f=function(t,n,r){if(!(n in c)){for(var e=[],i=0;i<n;i++)e[i]="a["+i+"]";c[n]=Function("F,a","return new F("+e.join(",")+")")}return c[n](t,r)};t.exports=Function.bind||function(t){var n=e(this),r=u.call(arguments,1),c=function(){var e=r.concat(u.call(arguments));return this instanceof c?f(n,e.length,e):o(n,e,t)};return i(n.prototype)&&(c.prototype=n.prototype),c}},function(t,n,r){"use strict";var e=r(11).f,i=r(70),o=r(73),u=r(53),c=r(68),f=r(46),a=r(79),s=r(140),l=r(170),h=r(74),v=r(10),p=r(65).fastKey,d=v?"_s":"size",y=function(t,n){var r,e=p(n);if("F"!==e)return t._i[e];for(r=t._f;r;r=r.n)if(r.k==n)return r};t.exports={getConstructor:function(t,n,r,s){var l=t(function(t,e){c(t,l,n,"_i"),t._i=i(null),t._f=void 0,t._l=void 0,t[d]=0,void 0!=e&&a(e,r,t[s],t)});return o(l.prototype,{clear:function(){for(var t=this,n=t._i,r=t._f;r;r=r.n)r.r=!0,r.p&&(r.p=r.p.n=void 0),delete n[r.i];t._f=t._l=void 0,t[d]=0},delete:function(t){var n=this,r=y(n,t);if(r){var e=r.n,i=r.p;delete n._i[r.i],r.r=!0,i&&(i.n=e),e&&(e.p=i),n._f==r&&(n._f=e),n._l==r&&(n._l=i),n[d]--}return!!r},forEach:function(t){c(this,l,"forEach");for(var n,r=u(t,arguments.length>1?arguments[1]:void 0,3);n=n?n.n:this._f;)for(r(n.v,n.k,this);n&&n.r;)n=n.p},has:function(t){return!!y(this,t)}}),v&&e(l.prototype,"size",{get:function(){return f(this[d])}}),l},def:function(t,n,r){var e,i,o=y(t,n);return o?o.v=r:(t._l=o={i:i=p(n,!0),k:n,v:r,p:e=t._l,n:void 0,r:!1},t._f||(t._f=o),e&&(e.n=o),t[d]++,"F"!==i&&(t._i[i]=o)),t},getEntry:y,setStrong:function(t,n,r){s(t,n,function(t,n){this._t=t,this._k=n,this._l=void 0},function(){for(var t=this,n=t._k,r=t._l;r&&r.r;)r=r.p;return t._t&&(t._l=r=r?r.n:t._t._f)?"keys"==n?l(0,r.k):"values"==n?l(0,r.v):l(0,[r.k,r.v]):(t._t=void 0,l(1))},r?"entries":"values",!r,!0),h(n)}}},function(t,n,r){var e=r(114),i=r(161);t.exports=function(t){return function(){if(e(this)!=t)throw TypeError(t+"#toJSON isn't generic");return i(this)}}},function(t,n,r){"use strict";var e=r(73),i=r(65).getWeak,o=r(2),u=r(6),c=r(68),f=r(79),a=r(48),s=r(24),l=a(5),h=a(6),v=0,p=function(t){return t._l||(t._l=new d)},d=function(){this.a=[]},y=function(t,n){return l(t.a,function(t){return t[0]===n})};d.prototype={get:function(t){var n=y(this,t);if(n)return n[1]},has:function(t){return!!y(this,t)},set:function(t,n){var r=y(this,t);r?r[1]=n:this.a.push([t,n])},delete:function(t){var n=h(this.a,function(n){return n[0]===t});return~n&&this.a.splice(n,1),!!~n}},t.exports={getConstructor:function(t,n,r,o){var a=t(function(t,e){c(t,a,n,"_i"),t._i=v++,t._l=void 0,void 0!=e&&f(e,r,t[o],t)});return e(a.prototype,{delete:function(t){if(!u(t))return!1;var n=i(t);return!0===n?p(this).delete(t):n&&s(n,this._i)&&delete n[this._i]},has:function(t){if(!u(t))return!1;var n=i(t);return!0===n?p(this).has(t):n&&s(n,this._i)}}),a},def:function(t,n,r){var e=i(o(n),!0);return!0===e?p(t).set(n,r):e[t._i]=r,t},ufstore:p}},function(t,n,r){t.exports=!r(10)&&!r(4)(function(){return 7!=Object.defineProperty(r(132)("div"),"a",{get:function(){return 7}}).a})},function(t,n,r){var e=r(6),i=Math.floor;t.exports=function(t){return!e(t)&&isFinite(t)&&i(t)===t}},function(t,n,r){var e=r(2);t.exports=function(t,n,r,i){try{return i?n(e(r)[0],r[1]):n(r)}catch(n){var o=t.return;throw void 0!==o&&e(o.call(t)),n}}},function(t,n){t.exports=function(t,n){return{value:n,done:!!t}}},function(t,n){t.exports=Math.log1p||function(t){return(t=+t)>-1e-8&&t<1e-8?t-t*t/2:Math.log(1+t)}},function(t,n,r){"use strict";var e=r(72),i=r(125),o=r(116),u=r(17),c=r(115),f=Object.assign;t.exports=!f||r(4)(function(){var t={},n={},r=Symbol(),e="abcdefghijklmnopqrst";return t[r]=7,e.split("").forEach(function(t){n[t]=t}),7!=f({},t)[r]||Object.keys(f({},n)).join("")!=e})?function(t,n){for(var r=u(t),f=arguments.length,a=1,s=i.f,l=o.f;f>a;)for(var h,v=c(arguments[a++]),p=s?e(v).concat(s(v)):e(v),d=p.length,y=0;d>y;)l.call(v,h=p[y++])&&(r[h]=v[h]);return r}:f},function(t,n,r){var e=r(11),i=r(2),o=r(72);t.exports=r(10)?Object.defineProperties:function(t,n){i(t);for(var r,u=o(n),c=u.length,f=0;c>f;)e.f(t,r=u[f++],n[r]);return t}},function(t,n,r){var e=r(30),i=r(71).f,o={}.toString,u="object"==typeof window&&window&&Object.getOwnPropertyNames?Object.getOwnPropertyNames(window):[],c=function(t){try{return i(t)}catch(t){return u.slice()}};t.exports.f=function(t){return u&&"[object Window]"==o.call(t)?c(t):i(e(t))}},function(t,n,r){var e=r(24),i=r(30),o=r(117)(!1),u=r(145)("IE_PROTO");t.exports=function(t,n){var r,c=i(t),f=0,a=[];for(r in c)r!=u&&e(c,r)&&a.push(r);for(;n.length>f;)e(c,r=n[f++])&&(~o(a,r)||a.push(r));return a}},function(t,n,r){var e=r(72),i=r(30),o=r(116).f;t.exports=function(t){return function(n){for(var r,u=i(n),c=e(u),f=c.length,a=0,s=[];f>a;)o.call(u,r=c[a++])&&s.push(t?[r,u[r]]:u[r]);return s}}},function(t,n,r){var e=r(71),i=r(125),o=r(2),u=r(3).Reflect;t.exports=u&&u.ownKeys||function(t){var n=e.f(o(t)),r=i.f;return r?n.concat(r(t)):n}},function(t,n,r){var e=r(3).parseFloat,i=r(82).trim;t.exports=1/e(r(150)+"-0")!=-1/0?function(t){var n=i(String(t),3),r=e(n);return 0===r&&"-"==n.charAt(0)?-0:r}:e},function(t,n,r){var e=r(3).parseInt,i=r(82).trim,o=r(150),u=/^[\-+]?0[xX]/;t.exports=8!==e(o+"08")||22!==e(o+"0x16")?function(t,n){var r=i(String(t),3);return e(r,n>>>0||(u.test(r)?16:10))}:e},function(t,n){t.exports=Object.is||function(t,n){return t===n?0!==t||1/t==1/n:t!=t&&n!=n}},function(t,n,r){var e=r(16),i=r(149),o=r(46);t.exports=function(t,n,r,u){var c=String(o(t)),f=c.length,a=void 0===r?" ":String(r),s=e(n);if(s<=f||""==a)return c;var l=s-f,h=i.call(a,Math.ceil(l/a.length));return h.length>l&&(h=h.slice(0,l)),u?h+c:c+h}},function(t,n,r){n.f=r(7)},function(t,n,r){"use strict";var e=r(164);t.exports=r(118)("Map",function(t){return function(){return t(this,arguments.length>0?arguments[0]:void 0)}},{get:function(t){var n=e.getEntry(this,t);return n&&n.v},set:function(t,n){return e.def(this,0===t?0:t,n)}},e,!0)},function(t,n,r){r(10)&&"g"!=/./g.flags&&r(11).f(RegExp.prototype,"flags",{configurable:!0,get:r(120)})},function(t,n,r){"use strict";var e=r(164);t.exports=r(118)("Set",function(t){return function(){return t(this,arguments.length>0?arguments[0]:void 0)}},{add:function(t){return e.def(this,t=0===t?0:t,t)}},e)},function(t,n,r){"use strict";var e,i=r(48)(0),o=r(28),u=r(65),c=r(172),f=r(166),a=r(6),s=u.getWeak,l=Object.isExtensible,h=f.ufstore,v={},p=function(t){return function(){return t(this,arguments.length>0?arguments[0]:void 0)}},d={get:function(t){if(a(t)){var n=s(t);return!0===n?h(this).get(t):n?n[this._i]:void 0}},set:function(t,n){return f.def(this,t,n)}},y=t.exports=r(118)("WeakMap",p,d,f,!0,!0);7!=(new y).set((Object.freeze||Object)(v),7).get(v)&&(e=f.getConstructor(p),c(e.prototype,d),u.NEED=!0,i(["delete","has","get","set"],function(t){var n=y.prototype,r=n[t];o(n,t,function(n,i){if(a(n)&&!l(n)){this._f||(this._f=new e);var o=this._f[t](n,i);return"set"==t?this:o}return r.call(this,n,i)})}))},,,,function(t,n){"use strict";function r(){var t=document.querySelector("#page-nav");if(t&&!document.querySelector("#page-nav .extend.prev")&&(t.innerHTML='<a class="extend prev disabled" rel="prev">&laquo; Prev</a>'+t.innerHTML),t&&!document.querySelector("#page-nav .extend.next")&&(t.innerHTML=t.innerHTML+'<a class="extend next disabled" rel="next">Next &raquo;</a>'),yiliaConfig&&yiliaConfig.open_in_new){document.querySelectorAll(".article-entry a:not(.article-more-a)").forEach(function(t){var n=t.getAttribute("target");n&&""!==n||t.setAttribute("target","_blank")})}if(yiliaConfig&&yiliaConfig.toc_hide_index){document.querySelectorAll(".toc-number").forEach(function(t){t.style.display="none"})}var n=document.querySelector("#js-aboutme");n&&0!==n.length&&(n.innerHTML=n.innerText)}t.exports={init:r}},function(t,n,r){"use strict";function e(t){return t&&t.__esModule?t:{default:t}}function i(t,n){var r=/\/|index.html/g;return t.replace(r,"")===n.replace(r,"")}function o(){for(var t=document.querySelectorAll(".js-header-menu li a"),n=window.location.pathname,r=0,e=t.length;r<e;r++){var o=t[r];i(n,o.getAttribute("href"))&&(0,h.default)(o,"active")}}function u(t){for(var n=t.offsetLeft,r=t.offsetParent;null!==r;)n+=r.offsetLeft,r=r.offsetParent;return n}function c(t){for(var n=t.offsetTop,r=t.offsetParent;null!==r;)n+=r.offsetTop,r=r.offsetParent;return n}function f(t,n,r,e,i){var o=u(t),f=c(t)-n;if(f-r<=i){var a=t.$newDom;a||(a=t.cloneNode(!0),(0,d.default)(t,a),t.$newDom=a,a.style.position="fixed",a.style.top=(r||f)+"px",a.style.left=o+"px",a.style.zIndex=e||2,a.style.width="100%",a.style.color="#fff"),a.style.visibility="visible",t.style.visibility="hidden"}else{t.style.visibility="visible";var s=t.$newDom;s&&(s.style.visibility="hidden")}}function a(){var t=document.querySelector(".js-overlay"),n=document.querySelector(".js-header-menu");f(t,document.body.scrollTop,-63,2,0),f(n,document.body.scrollTop,1,3,0)}function s(){document.querySelector("#container").addEventListener("scroll",function(t){a()}),window.addEventListener("scroll",function(t){a()}),a()}var l=r(156),h=e(l),v=r(157),p=(e(v),r(382)),d=e(p),y=r(128),g=e(y),b=r(190),m=e(b),x=r(129);(function(){g.default.versions.mobile&&window.screen.width<800&&(o(),s())})(),(0,x.addLoadEvent)(function(){m.default.init()}),t.exports={}},,,,function(t,n,r){(function(t){"use strict";function n(t,n,r){t[n]||Object[e](t,n,{writable:!0,configurable:!0,value:r})}if(r(381),r(391),r(198),t._babelPolyfill)throw new Error("only one instance of babel-polyfill is allowed");t._babelPolyfill=!0;var e="defineProperty";n(String.prototype,"padLeft","".padStart),n(String.prototype,"padRight","".padEnd),"pop,reverse,shift,keys,values,entries,indexOf,every,some,forEach,map,filter,find,findIndex,includes,join,slice,concat,push,splice,unshift,sort,lastIndexOf,reduce,reduceRight,copyWithin,fill".split(",").forEach(function(t){[][t]&&n(Array,t,Function.call.bind([][t]))})}).call(n,function(){return this}())},,,function(t,n,r){r(210),t.exports=r(52).RegExp.escape},,,,function(t,n,r){var e=r(6),i=r(138),o=r(7)("species");t.exports=function(t){var n;return i(t)&&(n=t.constructor,"function"!=typeof n||n!==Array&&!i(n.prototype)||(n=void 0),e(n)&&null===(n=n[o])&&(n=void 0)),void 0===n?Array:n}},function(t,n,r){var e=r(202);t.exports=function(t,n){return new(e(t))(n)}},function(t,n,r){"use strict";var e=r(2),i=r(50),o="number";t.exports=function(t){if("string"!==t&&t!==o&&"default"!==t)throw TypeError("Incorrect hint");return i(e(this),t!=o)}},function(t,n,r){var e=r(72),i=r(125),o=r(116);t.exports=function(t){var n=e(t),r=i.f;if(r)for(var u,c=r(t),f=o.f,a=0;c.length>a;)f.call(t,u=c[a++])&&n.push(u);return n}},function(t,n,r){var e=r(72),i=r(30);t.exports=function(t,n){for(var r,o=i(t),u=e(o),c=u.length,f=0;c>f;)if(o[r=u[f++]]===n)return r}},function(t,n,r){"use strict";var e=r(208),i=r(121),o=r(26);t.exports=function(){for(var t=o(this),n=arguments.length,r=Array(n),u=0,c=e._,f=!1;n>u;)(r[u]=arguments[u++])===c&&(f=!0);return function(){var e,o=this,u=arguments.length,a=0,s=0;if(!f&&!u)return i(t,r,o);if(e=r.slice(),f)for(;n>a;a++)e[a]===c&&(e[a]=arguments[s++]);for(;u>s;)e.push(arguments[s++]);return i(t,e,o)}}},function(t,n,r){t.exports=r(3)},function(t,n){t.exports=function(t,n){var r=n===Object(n)?function(t){return n[t]}:n;return function(n){return String(n).replace(t,r)}}},function(t,n,r){var e=r(1),i=r(209)(/[\\^$*+?.()|[\]{}]/g,"\\$&");e(e.S,"RegExp",{escape:function(t){return i(t)}})},function(t,n,r){var e=r(1);e(e.P,"Array",{copyWithin:r(160)}),r(78)("copyWithin")},function(t,n,r){"use strict";var e=r(1),i=r(48)(4);e(e.P+e.F*!r(47)([].every,!0),"Array",{every:function(t){return i(this,t,arguments[1])}})},function(t,n,r){var e=r(1);e(e.P,"Array",{fill:r(130)}),r(78)("fill")},function(t,n,r){"use strict";var e=r(1),i=r(48)(2);e(e.P+e.F*!r(47)([].filter,!0),"Array",{filter:function(t){return i(this,t,arguments[1])}})},function(t,n,r){"use strict";var e=r(1),i=r(48)(6),o="findIndex",u=!0;o in[]&&Array(1)[o](function(){u=!1}),e(e.P+e.F*u,"Array",{findIndex:function(t){return i(this,t,arguments.length>1?arguments[1]:void 0)}}),r(78)(o)},function(t,n,r){"use strict";var e=r(1),i=r(48)(5),o="find",u=!0;o in[]&&Array(1)[o](function(){u=!1}),e(e.P+e.F*u,"Array",{find:function(t){return i(this,t,arguments.length>1?arguments[1]:void 0)}}),r(78)(o)},function(t,n,r){"use strict";var e=r(1),i=r(48)(0),o=r(47)([].forEach,!0);e(e.P+e.F*!o,"Array",{forEach:function(t){return i(this,t,arguments[1])}})},function(t,n,r){"use strict";var e=r(53),i=r(1),o=r(17),u=r(169),c=r(137),f=r(16),a=r(131),s=r(154);i(i.S+i.F*!r(123)(function(t){Array.from(t)}),"Array",{from:function(t){var n,r,i,l,h=o(t),v="function"==typeof this?this:Array,p=arguments.length,d=p>1?arguments[1]:void 0,y=void 0!==d,g=0,b=s(h);if(y&&(d=e(d,p>2?arguments[2]:void 0,2)),void 0==b||v==Array&&c(b))for(n=f(h.length),r=new v(n);n>g;g++)a(r,g,y?d(h[g],g):h[g]);else for(l=b.call(h),r=new v;!(i=l.next()).done;g++)a(r,g,y?u(l,d,[i.value,g],!0):i.value);return r.length=g,r}})},function(t,n,r){"use strict";var e=r(1),i=r(117)(!1),o=[].indexOf,u=!!o&&1/[1].indexOf(1,-0)<0;e(e.P+e.F*(u||!r(47)(o)),"Array",{indexOf:function(t){return u?o.apply(this,arguments)||0:i(this,t,arguments[1])}})},function(t,n,r){var e=r(1);e(e.S,"Array",{isArray:r(138)})},function(t,n,r){"use strict";var e=r(1),i=r(30),o=[].join;e(e.P+e.F*(r(115)!=Object||!r(47)(o)),"Array",{join:function(t){return o.call(i(this),void 0===t?",":t)}})},function(t,n,r){"use strict";var e=r(1),i=r(30),o=r(67),u=r(16),c=[].lastIndexOf,f=!!c&&1/[1].lastIndexOf(1,-0)<0;e(e.P+e.F*(f||!r(47)(c)),"Array",{lastIndexOf:function(t){if(f)return c.apply(this,arguments)||0;var n=i(this),r=u(n.length),e=r-1;for(arguments.length>1&&(e=Math.min(e,o(arguments[1]))),e<0&&(e=r+e);e>=0;e--)if(e in n&&n[e]===t)return e||0;return-1}})},function(t,n,r){"use strict";var e=r(1),i=r(48)(1);e(e.P+e.F*!r(47)([].map,!0),"Array",{map:function(t){return i(this,t,arguments[1])}})},function(t,n,r){"use strict";var e=r(1),i=r(131);e(e.S+e.F*r(4)(function(){function t(){}return!(Array.of.call(t)instanceof t)}),"Array",{of:function(){for(var t=0,n=arguments.length,r=new("function"==typeof this?this:Array)(n);n>t;)i(r,t,arguments[t++]);return r.length=n,r}})},function(t,n,r){"use strict";var e=r(1),i=r(162);e(e.P+e.F*!r(47)([].reduceRight,!0),"Array",{reduceRight:function(t){return i(this,t,arguments.length,arguments[1],!0)}})},function(t,n,r){"use strict";var e=r(1),i=r(162);e(e.P+e.F*!r(47)([].reduce,!0),"Array",{reduce:function(t){return i(this,t,arguments.length,arguments[1],!1)}})},function(t,n,r){"use strict";var e=r(1),i=r(135),o=r(45),u=r(75),c=r(16),f=[].slice;e(e.P+e.F*r(4)(function(){i&&f.call(i)}),"Array",{slice:function(t,n){var r=c(this.length),e=o(this);if(n=void 0===n?r:n,"Array"==e)return f.call(this,t,n);for(var i=u(t,r),a=u(n,r),s=c(a-i),l=Array(s),h=0;h<s;h++)l[h]="String"==e?this.charAt(i+h):this[i+h];return l}})},function(t,n,r){"use strict";var e=r(1),i=r(48)(3);e(e.P+e.F*!r(47)([].some,!0),"Array",{some:function(t){return i(this,t,arguments[1])}})},function(t,n,r){"use strict";var e=r(1),i=r(26),o=r(17),u=r(4),c=[].sort,f=[1,2,3];e(e.P+e.F*(u(function(){f.sort(void 0)})||!u(function(){f.sort(null)})||!r(47)(c)),"Array",{sort:function(t){return void 0===t?c.call(o(this)):c.call(o(this),i(t))}})},function(t,n,r){r(74)("Array")},function(t,n,r){var e=r(1);e(e.S,"Date",{now:function(){return(new Date).getTime()}})},function(t,n,r){"use strict";var e=r(1),i=r(4),o=Date.prototype.getTime,u=function(t){return t>9?t:"0"+t};e(e.P+e.F*(i(function(){return"0385-07-25T07:06:39.999Z"!=new Date(-5e13-1).toISOString()})||!i(function(){new Date(NaN).toISOString()})),"Date",{toISOString:function(){
if(!isFinite(o.call(this)))throw RangeError("Invalid time value");var t=this,n=t.getUTCFullYear(),r=t.getUTCMilliseconds(),e=n<0?"-":n>9999?"+":"";return e+("00000"+Math.abs(n)).slice(e?-6:-4)+"-"+u(t.getUTCMonth()+1)+"-"+u(t.getUTCDate())+"T"+u(t.getUTCHours())+":"+u(t.getUTCMinutes())+":"+u(t.getUTCSeconds())+"."+(r>99?r:"0"+u(r))+"Z"}})},function(t,n,r){"use strict";var e=r(1),i=r(17),o=r(50);e(e.P+e.F*r(4)(function(){return null!==new Date(NaN).toJSON()||1!==Date.prototype.toJSON.call({toISOString:function(){return 1}})}),"Date",{toJSON:function(t){var n=i(this),r=o(n);return"number"!=typeof r||isFinite(r)?n.toISOString():null}})},function(t,n,r){var e=r(7)("toPrimitive"),i=Date.prototype;e in i||r(27)(i,e,r(204))},function(t,n,r){var e=Date.prototype,i="Invalid Date",o="toString",u=e[o],c=e.getTime;new Date(NaN)+""!=i&&r(28)(e,o,function(){var t=c.call(this);return t===t?u.call(this):i})},function(t,n,r){var e=r(1);e(e.P,"Function",{bind:r(163)})},function(t,n,r){"use strict";var e=r(6),i=r(32),o=r(7)("hasInstance"),u=Function.prototype;o in u||r(11).f(u,o,{value:function(t){if("function"!=typeof this||!e(t))return!1;if(!e(this.prototype))return t instanceof this;for(;t=i(t);)if(this.prototype===t)return!0;return!1}})},function(t,n,r){var e=r(11).f,i=r(66),o=r(24),u=Function.prototype,c="name",f=Object.isExtensible||function(){return!0};c in u||r(10)&&e(u,c,{configurable:!0,get:function(){try{var t=this,n=(""+t).match(/^\s*function ([^ (]*)/)[1];return o(t,c)||!f(t)||e(t,c,i(5,n)),n}catch(t){return""}}})},function(t,n,r){var e=r(1),i=r(171),o=Math.sqrt,u=Math.acosh;e(e.S+e.F*!(u&&710==Math.floor(u(Number.MAX_VALUE))&&u(1/0)==1/0),"Math",{acosh:function(t){return(t=+t)<1?NaN:t>94906265.62425156?Math.log(t)+Math.LN2:i(t-1+o(t-1)*o(t+1))}})},function(t,n,r){function e(t){return isFinite(t=+t)&&0!=t?t<0?-e(-t):Math.log(t+Math.sqrt(t*t+1)):t}var i=r(1),o=Math.asinh;i(i.S+i.F*!(o&&1/o(0)>0),"Math",{asinh:e})},function(t,n,r){var e=r(1),i=Math.atanh;e(e.S+e.F*!(i&&1/i(-0)<0),"Math",{atanh:function(t){return 0==(t=+t)?t:Math.log((1+t)/(1-t))/2}})},function(t,n,r){var e=r(1),i=r(142);e(e.S,"Math",{cbrt:function(t){return i(t=+t)*Math.pow(Math.abs(t),1/3)}})},function(t,n,r){var e=r(1);e(e.S,"Math",{clz32:function(t){return(t>>>=0)?31-Math.floor(Math.log(t+.5)*Math.LOG2E):32}})},function(t,n,r){var e=r(1),i=Math.exp;e(e.S,"Math",{cosh:function(t){return(i(t=+t)+i(-t))/2}})},function(t,n,r){var e=r(1),i=r(141);e(e.S+e.F*(i!=Math.expm1),"Math",{expm1:i})},function(t,n,r){var e=r(1),i=r(142),o=Math.pow,u=o(2,-52),c=o(2,-23),f=o(2,127)*(2-c),a=o(2,-126),s=function(t){return t+1/u-1/u};e(e.S,"Math",{fround:function(t){var n,r,e=Math.abs(t),o=i(t);return e<a?o*s(e/a/c)*a*c:(n=(1+c/u)*e,r=n-(n-e),r>f||r!=r?o*(1/0):o*r)}})},function(t,n,r){var e=r(1),i=Math.abs;e(e.S,"Math",{hypot:function(t,n){for(var r,e,o=0,u=0,c=arguments.length,f=0;u<c;)r=i(arguments[u++]),f<r?(e=f/r,o=o*e*e+1,f=r):r>0?(e=r/f,o+=e*e):o+=r;return f===1/0?1/0:f*Math.sqrt(o)}})},function(t,n,r){var e=r(1),i=Math.imul;e(e.S+e.F*r(4)(function(){return-5!=i(4294967295,5)||2!=i.length}),"Math",{imul:function(t,n){var r=65535,e=+t,i=+n,o=r&e,u=r&i;return 0|o*u+((r&e>>>16)*u+o*(r&i>>>16)<<16>>>0)}})},function(t,n,r){var e=r(1);e(e.S,"Math",{log10:function(t){return Math.log(t)/Math.LN10}})},function(t,n,r){var e=r(1);e(e.S,"Math",{log1p:r(171)})},function(t,n,r){var e=r(1);e(e.S,"Math",{log2:function(t){return Math.log(t)/Math.LN2}})},function(t,n,r){var e=r(1);e(e.S,"Math",{sign:r(142)})},function(t,n,r){var e=r(1),i=r(141),o=Math.exp;e(e.S+e.F*r(4)(function(){return-2e-17!=!Math.sinh(-2e-17)}),"Math",{sinh:function(t){return Math.abs(t=+t)<1?(i(t)-i(-t))/2:(o(t-1)-o(-t-1))*(Math.E/2)}})},function(t,n,r){var e=r(1),i=r(141),o=Math.exp;e(e.S,"Math",{tanh:function(t){var n=i(t=+t),r=i(-t);return n==1/0?1:r==1/0?-1:(n-r)/(o(t)+o(-t))}})},function(t,n,r){var e=r(1);e(e.S,"Math",{trunc:function(t){return(t>0?Math.floor:Math.ceil)(t)}})},function(t,n,r){"use strict";var e=r(3),i=r(24),o=r(45),u=r(136),c=r(50),f=r(4),a=r(71).f,s=r(31).f,l=r(11).f,h=r(82).trim,v="Number",p=e[v],d=p,y=p.prototype,g=o(r(70)(y))==v,b="trim"in String.prototype,m=function(t){var n=c(t,!1);if("string"==typeof n&&n.length>2){n=b?n.trim():h(n,3);var r,e,i,o=n.charCodeAt(0);if(43===o||45===o){if(88===(r=n.charCodeAt(2))||120===r)return NaN}else if(48===o){switch(n.charCodeAt(1)){case 66:case 98:e=2,i=49;break;case 79:case 111:e=8,i=55;break;default:return+n}for(var u,f=n.slice(2),a=0,s=f.length;a<s;a++)if((u=f.charCodeAt(a))<48||u>i)return NaN;return parseInt(f,e)}}return+n};if(!p(" 0o1")||!p("0b1")||p("+0x1")){p=function(t){var n=arguments.length<1?0:t,r=this;return r instanceof p&&(g?f(function(){y.valueOf.call(r)}):o(r)!=v)?u(new d(m(n)),r,p):m(n)};for(var x,w=r(10)?a(d):"MAX_VALUE,MIN_VALUE,NaN,NEGATIVE_INFINITY,POSITIVE_INFINITY,EPSILON,isFinite,isInteger,isNaN,isSafeInteger,MAX_SAFE_INTEGER,MIN_SAFE_INTEGER,parseFloat,parseInt,isInteger".split(","),S=0;w.length>S;S++)i(d,x=w[S])&&!i(p,x)&&l(p,x,s(d,x));p.prototype=y,y.constructor=p,r(28)(e,v,p)}},function(t,n,r){var e=r(1);e(e.S,"Number",{EPSILON:Math.pow(2,-52)})},function(t,n,r){var e=r(1),i=r(3).isFinite;e(e.S,"Number",{isFinite:function(t){return"number"==typeof t&&i(t)}})},function(t,n,r){var e=r(1);e(e.S,"Number",{isInteger:r(168)})},function(t,n,r){var e=r(1);e(e.S,"Number",{isNaN:function(t){return t!=t}})},function(t,n,r){var e=r(1),i=r(168),o=Math.abs;e(e.S,"Number",{isSafeInteger:function(t){return i(t)&&o(t)<=9007199254740991}})},function(t,n,r){var e=r(1);e(e.S,"Number",{MAX_SAFE_INTEGER:9007199254740991})},function(t,n,r){var e=r(1);e(e.S,"Number",{MIN_SAFE_INTEGER:-9007199254740991})},function(t,n,r){var e=r(1),i=r(178);e(e.S+e.F*(Number.parseFloat!=i),"Number",{parseFloat:i})},function(t,n,r){var e=r(1),i=r(179);e(e.S+e.F*(Number.parseInt!=i),"Number",{parseInt:i})},function(t,n,r){"use strict";var e=r(1),i=r(67),o=r(159),u=r(149),c=1..toFixed,f=Math.floor,a=[0,0,0,0,0,0],s="Number.toFixed: incorrect invocation!",l="0",h=function(t,n){for(var r=-1,e=n;++r<6;)e+=t*a[r],a[r]=e%1e7,e=f(e/1e7)},v=function(t){for(var n=6,r=0;--n>=0;)r+=a[n],a[n]=f(r/t),r=r%t*1e7},p=function(){for(var t=6,n="";--t>=0;)if(""!==n||0===t||0!==a[t]){var r=String(a[t]);n=""===n?r:n+u.call(l,7-r.length)+r}return n},d=function(t,n,r){return 0===n?r:n%2==1?d(t,n-1,r*t):d(t*t,n/2,r)},y=function(t){for(var n=0,r=t;r>=4096;)n+=12,r/=4096;for(;r>=2;)n+=1,r/=2;return n};e(e.P+e.F*(!!c&&("0.000"!==8e-5.toFixed(3)||"1"!==.9.toFixed(0)||"1.25"!==1.255.toFixed(2)||"1000000000000000128"!==(0xde0b6b3a7640080).toFixed(0))||!r(4)(function(){c.call({})})),"Number",{toFixed:function(t){var n,r,e,c,f=o(this,s),a=i(t),g="",b=l;if(a<0||a>20)throw RangeError(s);if(f!=f)return"NaN";if(f<=-1e21||f>=1e21)return String(f);if(f<0&&(g="-",f=-f),f>1e-21)if(n=y(f*d(2,69,1))-69,r=n<0?f*d(2,-n,1):f/d(2,n,1),r*=4503599627370496,(n=52-n)>0){for(h(0,r),e=a;e>=7;)h(1e7,0),e-=7;for(h(d(10,e,1),0),e=n-1;e>=23;)v(1<<23),e-=23;v(1<<e),h(1,1),v(2),b=p()}else h(0,r),h(1<<-n,0),b=p()+u.call(l,a);return a>0?(c=b.length,b=g+(c<=a?"0."+u.call(l,a-c)+b:b.slice(0,c-a)+"."+b.slice(c-a))):b=g+b,b}})},function(t,n,r){"use strict";var e=r(1),i=r(4),o=r(159),u=1..toPrecision;e(e.P+e.F*(i(function(){return"1"!==u.call(1,void 0)})||!i(function(){u.call({})})),"Number",{toPrecision:function(t){var n=o(this,"Number#toPrecision: incorrect invocation!");return void 0===t?u.call(n):u.call(n,t)}})},function(t,n,r){var e=r(1);e(e.S+e.F,"Object",{assign:r(172)})},function(t,n,r){var e=r(1);e(e.S,"Object",{create:r(70)})},function(t,n,r){var e=r(1);e(e.S+e.F*!r(10),"Object",{defineProperties:r(173)})},function(t,n,r){var e=r(1);e(e.S+e.F*!r(10),"Object",{defineProperty:r(11).f})},function(t,n,r){var e=r(6),i=r(65).onFreeze;r(49)("freeze",function(t){return function(n){return t&&e(n)?t(i(n)):n}})},function(t,n,r){var e=r(30),i=r(31).f;r(49)("getOwnPropertyDescriptor",function(){return function(t,n){return i(e(t),n)}})},function(t,n,r){r(49)("getOwnPropertyNames",function(){return r(174).f})},function(t,n,r){var e=r(17),i=r(32);r(49)("getPrototypeOf",function(){return function(t){return i(e(t))}})},function(t,n,r){var e=r(6);r(49)("isExtensible",function(t){return function(n){return!!e(n)&&(!t||t(n))}})},function(t,n,r){var e=r(6);r(49)("isFrozen",function(t){return function(n){return!e(n)||!!t&&t(n)}})},function(t,n,r){var e=r(6);r(49)("isSealed",function(t){return function(n){return!e(n)||!!t&&t(n)}})},function(t,n,r){var e=r(1);e(e.S,"Object",{is:r(180)})},function(t,n,r){var e=r(17),i=r(72);r(49)("keys",function(){return function(t){return i(e(t))}})},function(t,n,r){var e=r(6),i=r(65).onFreeze;r(49)("preventExtensions",function(t){return function(n){return t&&e(n)?t(i(n)):n}})},function(t,n,r){var e=r(6),i=r(65).onFreeze;r(49)("seal",function(t){return function(n){return t&&e(n)?t(i(n)):n}})},function(t,n,r){var e=r(1);e(e.S,"Object",{setPrototypeOf:r(144).set})},function(t,n,r){"use strict";var e=r(114),i={};i[r(7)("toStringTag")]="z",i+""!="[object z]"&&r(28)(Object.prototype,"toString",function(){return"[object "+e(this)+"]"},!0)},function(t,n,r){var e=r(1),i=r(178);e(e.G+e.F*(parseFloat!=i),{parseFloat:i})},function(t,n,r){var e=r(1),i=r(179);e(e.G+e.F*(parseInt!=i),{parseInt:i})},function(t,n,r){"use strict";var e,i,o,u=r(69),c=r(3),f=r(53),a=r(114),s=r(1),l=r(6),h=r(26),v=r(68),p=r(79),d=r(146),y=r(151).set,g=r(143)(),b="Promise",m=c.TypeError,x=c.process,w=c[b],x=c.process,S="process"==a(x),_=function(){},O=!!function(){try{var t=w.resolve(1),n=(t.constructor={})[r(7)("species")]=function(t){t(_,_)};return(S||"function"==typeof PromiseRejectionEvent)&&t.then(_)instanceof n}catch(t){}}(),E=function(t,n){return t===n||t===w&&n===o},P=function(t){var n;return!(!l(t)||"function"!=typeof(n=t.then))&&n},j=function(t){return E(w,t)?new F(t):new i(t)},F=i=function(t){var n,r;this.promise=new t(function(t,e){if(void 0!==n||void 0!==r)throw m("Bad Promise constructor");n=t,r=e}),this.resolve=h(n),this.reject=h(r)},M=function(t){try{t()}catch(t){return{error:t}}},A=function(t,n){if(!t._n){t._n=!0;var r=t._c;g(function(){for(var e=t._v,i=1==t._s,o=0;r.length>o;)!function(n){var r,o,u=i?n.ok:n.fail,c=n.resolve,f=n.reject,a=n.domain;try{u?(i||(2==t._h&&I(t),t._h=1),!0===u?r=e:(a&&a.enter(),r=u(e),a&&a.exit()),r===n.promise?f(m("Promise-chain cycle")):(o=P(r))?o.call(r,c,f):c(r)):f(e)}catch(t){f(t)}}(r[o++]);t._c=[],t._n=!1,n&&!t._h&&N(t)})}},N=function(t){y.call(c,function(){var n,r,e,i=t._v;if(T(t)&&(n=M(function(){S?x.emit("unhandledRejection",i,t):(r=c.onunhandledrejection)?r({promise:t,reason:i}):(e=c.console)&&e.error&&e.error("Unhandled promise rejection",i)}),t._h=S||T(t)?2:1),t._a=void 0,n)throw n.error})},T=function(t){if(1==t._h)return!1;for(var n,r=t._a||t._c,e=0;r.length>e;)if(n=r[e++],n.fail||!T(n.promise))return!1;return!0},I=function(t){y.call(c,function(){var n;S?x.emit("rejectionHandled",t):(n=c.onrejectionhandled)&&n({promise:t,reason:t._v})})},k=function(t){var n=this;n._d||(n._d=!0,n=n._w||n,n._v=t,n._s=2,n._a||(n._a=n._c.slice()),A(n,!0))},L=function(t){var n,r=this;if(!r._d){r._d=!0,r=r._w||r;try{if(r===t)throw m("Promise can't be resolved itself");(n=P(t))?g(function(){var e={_w:r,_d:!1};try{n.call(t,f(L,e,1),f(k,e,1))}catch(t){k.call(e,t)}}):(r._v=t,r._s=1,A(r,!1))}catch(t){k.call({_w:r,_d:!1},t)}}};O||(w=function(t){v(this,w,b,"_h"),h(t),e.call(this);try{t(f(L,this,1),f(k,this,1))}catch(t){k.call(this,t)}},e=function(t){this._c=[],this._a=void 0,this._s=0,this._d=!1,this._v=void 0,this._h=0,this._n=!1},e.prototype=r(73)(w.prototype,{then:function(t,n){var r=j(d(this,w));return r.ok="function"!=typeof t||t,r.fail="function"==typeof n&&n,r.domain=S?x.domain:void 0,this._c.push(r),this._a&&this._a.push(r),this._s&&A(this,!1),r.promise},catch:function(t){return this.then(void 0,t)}}),F=function(){var t=new e;this.promise=t,this.resolve=f(L,t,1),this.reject=f(k,t,1)}),s(s.G+s.W+s.F*!O,{Promise:w}),r(81)(w,b),r(74)(b),o=r(52)[b],s(s.S+s.F*!O,b,{reject:function(t){var n=j(this);return(0,n.reject)(t),n.promise}}),s(s.S+s.F*(u||!O),b,{resolve:function(t){if(t instanceof w&&E(t.constructor,this))return t;var n=j(this);return(0,n.resolve)(t),n.promise}}),s(s.S+s.F*!(O&&r(123)(function(t){w.all(t).catch(_)})),b,{all:function(t){var n=this,r=j(n),e=r.resolve,i=r.reject,o=M(function(){var r=[],o=0,u=1;p(t,!1,function(t){var c=o++,f=!1;r.push(void 0),u++,n.resolve(t).then(function(t){f||(f=!0,r[c]=t,--u||e(r))},i)}),--u||e(r)});return o&&i(o.error),r.promise},race:function(t){var n=this,r=j(n),e=r.reject,i=M(function(){p(t,!1,function(t){n.resolve(t).then(r.resolve,e)})});return i&&e(i.error),r.promise}})},function(t,n,r){var e=r(1),i=r(26),o=r(2),u=(r(3).Reflect||{}).apply,c=Function.apply;e(e.S+e.F*!r(4)(function(){u(function(){})}),"Reflect",{apply:function(t,n,r){var e=i(t),f=o(r);return u?u(e,n,f):c.call(e,n,f)}})},function(t,n,r){var e=r(1),i=r(70),o=r(26),u=r(2),c=r(6),f=r(4),a=r(163),s=(r(3).Reflect||{}).construct,l=f(function(){function t(){}return!(s(function(){},[],t)instanceof t)}),h=!f(function(){s(function(){})});e(e.S+e.F*(l||h),"Reflect",{construct:function(t,n){o(t),u(n);var r=arguments.length<3?t:o(arguments[2]);if(h&&!l)return s(t,n,r);if(t==r){switch(n.length){case 0:return new t;case 1:return new t(n[0]);case 2:return new t(n[0],n[1]);case 3:return new t(n[0],n[1],n[2]);case 4:return new t(n[0],n[1],n[2],n[3])}var e=[null];return e.push.apply(e,n),new(a.apply(t,e))}var f=r.prototype,v=i(c(f)?f:Object.prototype),p=Function.apply.call(t,v,n);return c(p)?p:v}})},function(t,n,r){var e=r(11),i=r(1),o=r(2),u=r(50);i(i.S+i.F*r(4)(function(){Reflect.defineProperty(e.f({},1,{value:1}),1,{value:2})}),"Reflect",{defineProperty:function(t,n,r){o(t),n=u(n,!0),o(r);try{return e.f(t,n,r),!0}catch(t){return!1}}})},function(t,n,r){var e=r(1),i=r(31).f,o=r(2);e(e.S,"Reflect",{deleteProperty:function(t,n){var r=i(o(t),n);return!(r&&!r.configurable)&&delete t[n]}})},function(t,n,r){"use strict";var e=r(1),i=r(2),o=function(t){this._t=i(t),this._i=0;var n,r=this._k=[];for(n in t)r.push(n)};r(139)(o,"Object",function(){var t,n=this,r=n._k;do{if(n._i>=r.length)return{value:void 0,done:!0}}while(!((t=r[n._i++])in n._t));return{value:t,done:!1}}),e(e.S,"Reflect",{enumerate:function(t){return new o(t)}})},function(t,n,r){var e=r(31),i=r(1),o=r(2);i(i.S,"Reflect",{getOwnPropertyDescriptor:function(t,n){return e.f(o(t),n)}})},function(t,n,r){var e=r(1),i=r(32),o=r(2);e(e.S,"Reflect",{getPrototypeOf:function(t){return i(o(t))}})},function(t,n,r){function e(t,n){var r,c,s=arguments.length<3?t:arguments[2];return a(t)===s?t[n]:(r=i.f(t,n))?u(r,"value")?r.value:void 0!==r.get?r.get.call(s):void 0:f(c=o(t))?e(c,n,s):void 0}var i=r(31),o=r(32),u=r(24),c=r(1),f=r(6),a=r(2);c(c.S,"Reflect",{get:e})},function(t,n,r){var e=r(1);e(e.S,"Reflect",{has:function(t,n){return n in t}})},function(t,n,r){var e=r(1),i=r(2),o=Object.isExtensible;e(e.S,"Reflect",{isExtensible:function(t){return i(t),!o||o(t)}})},function(t,n,r){var e=r(1);e(e.S,"Reflect",{ownKeys:r(177)})},function(t,n,r){var e=r(1),i=r(2),o=Object.preventExtensions;e(e.S,"Reflect",{preventExtensions:function(t){i(t);try{return o&&o(t),!0}catch(t){return!1}}})},function(t,n,r){var e=r(1),i=r(144);i&&e(e.S,"Reflect",{setPrototypeOf:function(t,n){i.check(t,n);try{return i.set(t,n),!0}catch(t){return!1}}})},function(t,n,r){function e(t,n,r){var f,h,v=arguments.length<4?t:arguments[3],p=o.f(s(t),n);if(!p){if(l(h=u(t)))return e(h,n,r,v);p=a(0)}return c(p,"value")?!(!1===p.writable||!l(v)||(f=o.f(v,n)||a(0),f.value=r,i.f(v,n,f),0)):void 0!==p.set&&(p.set.call(v,r),!0)}var i=r(11),o=r(31),u=r(32),c=r(24),f=r(1),a=r(66),s=r(2),l=r(6);f(f.S,"Reflect",{set:e})},function(t,n,r){var e=r(3),i=r(136),o=r(11).f,u=r(71).f,c=r(122),f=r(120),a=e.RegExp,s=a,l=a.prototype,h=/a/g,v=/a/g,p=new a(h)!==h;if(r(10)&&(!p||r(4)(function(){return v[r(7)("match")]=!1,a(h)!=h||a(v)==v||"/a/i"!=a(h,"i")}))){a=function(t,n){var r=this instanceof a,e=c(t),o=void 0===n;return!r&&e&&t.constructor===a&&o?t:i(p?new s(e&&!o?t.source:t,n):s((e=t instanceof a)?t.source:t,e&&o?f.call(t):n),r?this:l,a)};for(var d=u(s),y=0;d.length>y;)!function(t){t in a||o(a,t,{configurable:!0,get:function(){return s[t]},set:function(n){s[t]=n}})}(d[y++]);l.constructor=a,a.prototype=l,r(28)(e,"RegExp",a)}r(74)("RegExp")},function(t,n,r){r(119)("match",1,function(t,n,r){return[function(r){"use strict";var e=t(this),i=void 0==r?void 0:r[n];return void 0!==i?i.call(r,e):new RegExp(r)[n](String(e))},r]})},function(t,n,r){r(119)("replace",2,function(t,n,r){return[function(e,i){"use strict";var o=t(this),u=void 0==e?void 0:e[n];return void 0!==u?u.call(e,o,i):r.call(String(o),e,i)},r]})},function(t,n,r){r(119)("search",1,function(t,n,r){return[function(r){"use strict";var e=t(this),i=void 0==r?void 0:r[n];return void 0!==i?i.call(r,e):new RegExp(r)[n](String(e))},r]})},function(t,n,r){r(119)("split",2,function(t,n,e){"use strict";var i=r(122),o=e,u=[].push,c="split",f="length",a="lastIndex";if("c"=="abbc"[c](/(b)*/)[1]||4!="test"[c](/(?:)/,-1)[f]||2!="ab"[c](/(?:ab)*/)[f]||4!="."[c](/(.?)(.?)/)[f]||"."[c](/()()/)[f]>1||""[c](/.?/)[f]){var s=void 0===/()??/.exec("")[1];e=function(t,n){var r=String(this);if(void 0===t&&0===n)return[];if(!i(t))return o.call(r,t,n);var e,c,l,h,v,p=[],d=(t.ignoreCase?"i":"")+(t.multiline?"m":"")+(t.unicode?"u":"")+(t.sticky?"y":""),y=0,g=void 0===n?4294967295:n>>>0,b=new RegExp(t.source,d+"g");for(s||(e=new RegExp("^"+b.source+"$(?!\\s)",d));(c=b.exec(r))&&!((l=c.index+c[0][f])>y&&(p.push(r.slice(y,c.index)),!s&&c[f]>1&&c[0].replace(e,function(){for(v=1;v<arguments[f]-2;v++)void 0===arguments[v]&&(c[v]=void 0)}),c[f]>1&&c.index<r[f]&&u.apply(p,c.slice(1)),h=c[0][f],y=l,p[f]>=g));)b[a]===c.index&&b[a]++;return y===r[f]?!h&&b.test("")||p.push(""):p.push(r.slice(y)),p[f]>g?p.slice(0,g):p}}else"0"[c](void 0,0)[f]&&(e=function(t,n){return void 0===t&&0===n?[]:o.call(this,t,n)});return[function(r,i){var o=t(this),u=void 0==r?void 0:r[n];return void 0!==u?u.call(r,o,i):e.call(String(o),r,i)},e]})},function(t,n,r){"use strict";r(184);var e=r(2),i=r(120),o=r(10),u="toString",c=/./[u],f=function(t){r(28)(RegExp.prototype,u,t,!0)};r(4)(function(){return"/a/b"!=c.call({source:"a",flags:"b"})})?f(function(){var t=e(this);return"/".concat(t.source,"/","flags"in t?t.flags:!o&&t instanceof RegExp?i.call(t):void 0)}):c.name!=u&&f(function(){return c.call(this)})},function(t,n,r){"use strict";r(29)("anchor",function(t){return function(n){return t(this,"a","name",n)}})},function(t,n,r){"use strict";r(29)("big",function(t){return function(){return t(this,"big","","")}})},function(t,n,r){"use strict";r(29)("blink",function(t){return function(){return t(this,"blink","","")}})},function(t,n,r){"use strict";r(29)("bold",function(t){return function(){return t(this,"b","","")}})},function(t,n,r){"use strict";var e=r(1),i=r(147)(!1);e(e.P,"String",{codePointAt:function(t){return i(this,t)}})},function(t,n,r){"use strict";var e=r(1),i=r(16),o=r(148),u="endsWith",c=""[u];e(e.P+e.F*r(134)(u),"String",{endsWith:function(t){var n=o(this,t,u),r=arguments.length>1?arguments[1]:void 0,e=i(n.length),f=void 0===r?e:Math.min(i(r),e),a=String(t);return c?c.call(n,a,f):n.slice(f-a.length,f)===a}})},function(t,n,r){"use strict";r(29)("fixed",function(t){return function(){return t(this,"tt","","")}})},function(t,n,r){"use strict";r(29)("fontcolor",function(t){return function(n){return t(this,"font","color",n)}})},function(t,n,r){"use strict";r(29)("fontsize",function(t){return function(n){return t(this,"font","size",n)}})},function(t,n,r){var e=r(1),i=r(75),o=String.fromCharCode,u=String.fromCodePoint;e(e.S+e.F*(!!u&&1!=u.length),"String",{fromCodePoint:function(t){for(var n,r=[],e=arguments.length,u=0;e>u;){if(n=+arguments[u++],i(n,1114111)!==n)throw RangeError(n+" is not a valid code point");r.push(n<65536?o(n):o(55296+((n-=65536)>>10),n%1024+56320))}return r.join("")}})},function(t,n,r){"use strict";var e=r(1),i=r(148),o="includes";e(e.P+e.F*r(134)(o),"String",{includes:function(t){return!!~i(this,t,o).indexOf(t,arguments.length>1?arguments[1]:void 0)}})},function(t,n,r){"use strict";r(29)("italics",function(t){return function(){return t(this,"i","","")}})},function(t,n,r){"use strict";var e=r(147)(!0);r(140)(String,"String",function(t){this._t=String(t),this._i=0},function(){var t,n=this._t,r=this._i;return r>=n.length?{value:void 0,done:!0}:(t=e(n,r),this._i+=t.length,{value:t,done:!1})})},function(t,n,r){"use strict";r(29)("link",function(t){return function(n){return t(this,"a","href",n)}})},function(t,n,r){var e=r(1),i=r(30),o=r(16);e(e.S,"String",{raw:function(t){for(var n=i(t.raw),r=o(n.length),e=arguments.length,u=[],c=0;r>c;)u.push(String(n[c++])),c<e&&u.push(String(arguments[c]));return u.join("")}})},function(t,n,r){var e=r(1);e(e.P,"String",{repeat:r(149)})},function(t,n,r){"use strict";r(29)("small",function(t){return function(){return t(this,"small","","")}})},function(t,n,r){"use strict";var e=r(1),i=r(16),o=r(148),u="startsWith",c=""[u];e(e.P+e.F*r(134)(u),"String",{startsWith:function(t){var n=o(this,t,u),r=i(Math.min(arguments.length>1?arguments[1]:void 0,n.length)),e=String(t);return c?c.call(n,e,r):n.slice(r,r+e.length)===e}})},function(t,n,r){"use strict";r(29)("strike",function(t){return function(){return t(this,"strike","","")}})},function(t,n,r){"use strict";r(29)("sub",function(t){return function(){return t(this,"sub","","")}})},function(t,n,r){"use strict";r(29)("sup",function(t){return function(){return t(this,"sup","","")}})},function(t,n,r){"use strict";r(82)("trim",function(t){return function(){return t(this,3)}})},function(t,n,r){"use strict";var e=r(3),i=r(24),o=r(10),u=r(1),c=r(28),f=r(65).KEY,a=r(4),s=r(126),l=r(81),h=r(76),v=r(7),p=r(182),d=r(153),y=r(206),g=r(205),b=r(138),m=r(2),x=r(30),w=r(50),S=r(66),_=r(70),O=r(174),E=r(31),P=r(11),j=r(72),F=E.f,M=P.f,A=O.f,N=e.Symbol,T=e.JSON,I=T&&T.stringify,k="prototype",L=v("_hidden"),R=v("toPrimitive"),C={}.propertyIsEnumerable,D=s("symbol-registry"),U=s("symbols"),W=s("op-symbols"),G=Object[k],B="function"==typeof N,V=e.QObject,z=!V||!V[k]||!V[k].findChild,q=o&&a(function(){return 7!=_(M({},"a",{get:function(){return M(this,"a",{value:7}).a}})).a})?function(t,n,r){var e=F(G,n);e&&delete G[n],M(t,n,r),e&&t!==G&&M(G,n,e)}:M,K=function(t){var n=U[t]=_(N[k]);return n._k=t,n},J=B&&"symbol"==typeof N.iterator?function(t){return"symbol"==typeof t}:function(t){return t instanceof N},Y=function(t,n,r){return t===G&&Y(W,n,r),m(t),n=w(n,!0),m(r),i(U,n)?(r.enumerable?(i(t,L)&&t[L][n]&&(t[L][n]=!1),r=_(r,{enumerable:S(0,!1)})):(i(t,L)||M(t,L,S(1,{})),t[L][n]=!0),q(t,n,r)):M(t,n,r)},H=function(t,n){m(t);for(var r,e=g(n=x(n)),i=0,o=e.length;o>i;)Y(t,r=e[i++],n[r]);return t},$=function(t,n){return void 0===n?_(t):H(_(t),n)},X=function(t){var n=C.call(this,t=w(t,!0));return!(this===G&&i(U,t)&&!i(W,t))&&(!(n||!i(this,t)||!i(U,t)||i(this,L)&&this[L][t])||n)},Q=function(t,n){if(t=x(t),n=w(n,!0),t!==G||!i(U,n)||i(W,n)){var r=F(t,n);return!r||!i(U,n)||i(t,L)&&t[L][n]||(r.enumerable=!0),r}},Z=function(t){for(var n,r=A(x(t)),e=[],o=0;r.length>o;)i(U,n=r[o++])||n==L||n==f||e.push(n);return e},tt=function(t){for(var n,r=t===G,e=A(r?W:x(t)),o=[],u=0;e.length>u;)!i(U,n=e[u++])||r&&!i(G,n)||o.push(U[n]);return o};B||(N=function(){if(this instanceof N)throw TypeError("Symbol is not a constructor!");var t=h(arguments.length>0?arguments[0]:void 0),n=function(r){this===G&&n.call(W,r),i(this,L)&&i(this[L],t)&&(this[L][t]=!1),q(this,t,S(1,r))};return o&&z&&q(G,t,{configurable:!0,set:n}),K(t)},c(N[k],"toString",function(){return this._k}),E.f=Q,P.f=Y,r(71).f=O.f=Z,r(116).f=X,r(125).f=tt,o&&!r(69)&&c(G,"propertyIsEnumerable",X,!0),p.f=function(t){return K(v(t))}),u(u.G+u.W+u.F*!B,{Symbol:N});for(var nt="hasInstance,isConcatSpreadable,iterator,match,replace,search,species,split,toPrimitive,toStringTag,unscopables".split(","),rt=0;nt.length>rt;)v(nt[rt++]);for(var nt=j(v.store),rt=0;nt.length>rt;)d(nt[rt++]);u(u.S+u.F*!B,"Symbol",{for:function(t){return i(D,t+="")?D[t]:D[t]=N(t)},keyFor:function(t){if(J(t))return y(D,t);throw TypeError(t+" is not a symbol!")},useSetter:function(){z=!0},useSimple:function(){z=!1}}),u(u.S+u.F*!B,"Object",{create:$,defineProperty:Y,defineProperties:H,getOwnPropertyDescriptor:Q,getOwnPropertyNames:Z,getOwnPropertySymbols:tt}),T&&u(u.S+u.F*(!B||a(function(){var t=N();return"[null]"!=I([t])||"{}"!=I({a:t})||"{}"!=I(Object(t))})),"JSON",{stringify:function(t){if(void 0!==t&&!J(t)){for(var n,r,e=[t],i=1;arguments.length>i;)e.push(arguments[i++]);return n=e[1],"function"==typeof n&&(r=n),!r&&b(n)||(n=function(t,n){if(r&&(n=r.call(this,t,n)),!J(n))return n}),e[1]=n,I.apply(T,e)}}}),N[k][R]||r(27)(N[k],R,N[k].valueOf),l(N,"Symbol"),l(Math,"Math",!0),l(e.JSON,"JSON",!0)},function(t,n,r){"use strict";var e=r(1),i=r(127),o=r(152),u=r(2),c=r(75),f=r(16),a=r(6),s=r(3).ArrayBuffer,l=r(146),h=o.ArrayBuffer,v=o.DataView,p=i.ABV&&s.isView,d=h.prototype.slice,y=i.VIEW,g="ArrayBuffer";e(e.G+e.W+e.F*(s!==h),{ArrayBuffer:h}),e(e.S+e.F*!i.CONSTR,g,{isView:function(t){return p&&p(t)||a(t)&&y in t}}),e(e.P+e.U+e.F*r(4)(function(){return!new h(2).slice(1,void 0).byteLength}),g,{slice:function(t,n){if(void 0!==d&&void 0===n)return d.call(u(this),t);for(var r=u(this).byteLength,e=c(t,r),i=c(void 0===n?r:n,r),o=new(l(this,h))(f(i-e)),a=new v(this),s=new v(o),p=0;e<i;)s.setUint8(p++,a.getUint8(e++));return o}}),r(74)(g)},function(t,n,r){var e=r(1);e(e.G+e.W+e.F*!r(127).ABV,{DataView:r(152).DataView})},function(t,n,r){r(55)("Float32",4,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Float64",8,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Int16",2,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Int32",4,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Int8",1,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Uint16",2,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Uint32",4,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Uint8",1,function(t){return function(n,r,e){return t(this,n,r,e)}})},function(t,n,r){r(55)("Uint8",1,function(t){return function(n,r,e){return t(this,n,r,e)}},!0)},function(t,n,r){"use strict";var e=r(166);r(118)("WeakSet",function(t){return function(){return t(this,arguments.length>0?arguments[0]:void 0)}},{add:function(t){return e.def(this,t,!0)}},e,!1,!0)},function(t,n,r){"use strict";var e=r(1),i=r(117)(!0);e(e.P,"Array",{includes:function(t){return i(this,t,arguments.length>1?arguments[1]:void 0)}}),r(78)("includes")},function(t,n,r){var e=r(1),i=r(143)(),o=r(3).process,u="process"==r(45)(o);e(e.G,{asap:function(t){var n=u&&o.domain;i(n?n.bind(t):t)}})},function(t,n,r){var e=r(1),i=r(45);e(e.S,"Error",{isError:function(t){return"Error"===i(t)}})},function(t,n,r){var e=r(1);e(e.P+e.R,"Map",{toJSON:r(165)("Map")})},function(t,n,r){var e=r(1);e(e.S,"Math",{iaddh:function(t,n,r,e){var i=t>>>0,o=n>>>0,u=r>>>0;return o+(e>>>0)+((i&u|(i|u)&~(i+u>>>0))>>>31)|0}})},function(t,n,r){var e=r(1);e(e.S,"Math",{imulh:function(t,n){var r=65535,e=+t,i=+n,o=e&r,u=i&r,c=e>>16,f=i>>16,a=(c*u>>>0)+(o*u>>>16);return c*f+(a>>16)+((o*f>>>0)+(a&r)>>16)}})},function(t,n,r){var e=r(1);e(e.S,"Math",{isubh:function(t,n,r,e){var i=t>>>0,o=n>>>0,u=r>>>0;return o-(e>>>0)-((~i&u|~(i^u)&i-u>>>0)>>>31)|0}})},function(t,n,r){var e=r(1);e(e.S,"Math",{umulh:function(t,n){var r=65535,e=+t,i=+n,o=e&r,u=i&r,c=e>>>16,f=i>>>16,a=(c*u>>>0)+(o*u>>>16);return c*f+(a>>>16)+((o*f>>>0)+(a&r)>>>16)}})},function(t,n,r){"use strict";var e=r(1),i=r(17),o=r(26),u=r(11);r(10)&&e(e.P+r(124),"Object",{__defineGetter__:function(t,n){u.f(i(this),t,{get:o(n),enumerable:!0,configurable:!0})}})},function(t,n,r){"use strict";var e=r(1),i=r(17),o=r(26),u=r(11);r(10)&&e(e.P+r(124),"Object",{__defineSetter__:function(t,n){u.f(i(this),t,{set:o(n),enumerable:!0,configurable:!0})}})},function(t,n,r){var e=r(1),i=r(176)(!0);e(e.S,"Object",{entries:function(t){return i(t)}})},function(t,n,r){var e=r(1),i=r(177),o=r(30),u=r(31),c=r(131);e(e.S,"Object",{getOwnPropertyDescriptors:function(t){for(var n,r=o(t),e=u.f,f=i(r),a={},s=0;f.length>s;)c(a,n=f[s++],e(r,n));return a}})},function(t,n,r){"use strict";var e=r(1),i=r(17),o=r(50),u=r(32),c=r(31).f;r(10)&&e(e.P+r(124),"Object",{__lookupGetter__:function(t){var n,r=i(this),e=o(t,!0);do{if(n=c(r,e))return n.get}while(r=u(r))}})},function(t,n,r){"use strict";var e=r(1),i=r(17),o=r(50),u=r(32),c=r(31).f;r(10)&&e(e.P+r(124),"Object",{__lookupSetter__:function(t){var n,r=i(this),e=o(t,!0);do{if(n=c(r,e))return n.set}while(r=u(r))}})},function(t,n,r){var e=r(1),i=r(176)(!1);e(e.S,"Object",{values:function(t){return i(t)}})},function(t,n,r){"use strict";var e=r(1),i=r(3),o=r(52),u=r(143)(),c=r(7)("observable"),f=r(26),a=r(2),s=r(68),l=r(73),h=r(27),v=r(79),p=v.RETURN,d=function(t){return null==t?void 0:f(t)},y=function(t){var n=t._c;n&&(t._c=void 0,n())},g=function(t){return void 0===t._o},b=function(t){g(t)||(t._o=void 0,y(t))},m=function(t,n){a(t),this._c=void 0,this._o=t,t=new x(this);try{var r=n(t),e=r;null!=r&&("function"==typeof r.unsubscribe?r=function(){e.unsubscribe()}:f(r),this._c=r)}catch(n){return void t.error(n)}g(this)&&y(this)};m.prototype=l({},{unsubscribe:function(){b(this)}});var x=function(t){this._s=t};x.prototype=l({},{next:function(t){var n=this._s;if(!g(n)){var r=n._o;try{var e=d(r.next);if(e)return e.call(r,t)}catch(t){try{b(n)}finally{throw t}}}},error:function(t){var n=this._s;if(g(n))throw t;var r=n._o;n._o=void 0;try{var e=d(r.error);if(!e)throw t;t=e.call(r,t)}catch(t){try{y(n)}finally{throw t}}return y(n),t},complete:function(t){var n=this._s;if(!g(n)){var r=n._o;n._o=void 0;try{var e=d(r.complete);t=e?e.call(r,t):void 0}catch(t){try{y(n)}finally{throw t}}return y(n),t}}});var w=function(t){s(this,w,"Observable","_f")._f=f(t)};l(w.prototype,{subscribe:function(t){return new m(t,this._f)},forEach:function(t){var n=this;return new(o.Promise||i.Promise)(function(r,e){f(t);var i=n.subscribe({next:function(n){try{return t(n)}catch(t){e(t),i.unsubscribe()}},error:e,complete:r})})}}),l(w,{from:function(t){var n="function"==typeof this?this:w,r=d(a(t)[c]);if(r){var e=a(r.call(t));return e.constructor===n?e:new n(function(t){return e.subscribe(t)})}return new n(function(n){var r=!1;return u(function(){if(!r){try{if(v(t,!1,function(t){if(n.next(t),r)return p})===p)return}catch(t){if(r)throw t;return void n.error(t)}n.complete()}}),function(){r=!0}})},of:function(){for(var t=0,n=arguments.length,r=Array(n);t<n;)r[t]=arguments[t++];return new("function"==typeof this?this:w)(function(t){var n=!1;return u(function(){if(!n){for(var e=0;e<r.length;++e)if(t.next(r[e]),n)return;t.complete()}}),function(){n=!0}})}}),h(w.prototype,c,function(){return this}),e(e.G,{Observable:w}),r(74)("Observable")},function(t,n,r){var e=r(54),i=r(2),o=e.key,u=e.set;e.exp({defineMetadata:function(t,n,r,e){u(t,n,i(r),o(e))}})},function(t,n,r){var e=r(54),i=r(2),o=e.key,u=e.map,c=e.store;e.exp({deleteMetadata:function(t,n){var r=arguments.length<3?void 0:o(arguments[2]),e=u(i(n),r,!1);if(void 0===e||!e.delete(t))return!1;if(e.size)return!0;var f=c.get(n);return f.delete(r),!!f.size||c.delete(n)}})},function(t,n,r){var e=r(185),i=r(161),o=r(54),u=r(2),c=r(32),f=o.keys,a=o.key,s=function(t,n){var r=f(t,n),o=c(t);if(null===o)return r;var u=s(o,n);return u.length?r.length?i(new e(r.concat(u))):u:r};o.exp({getMetadataKeys:function(t){return s(u(t),arguments.length<2?void 0:a(arguments[1]))}})},function(t,n,r){var e=r(54),i=r(2),o=r(32),u=e.has,c=e.get,f=e.key,a=function(t,n,r){if(u(t,n,r))return c(t,n,r);var e=o(n);return null!==e?a(t,e,r):void 0};e.exp({getMetadata:function(t,n){return a(t,i(n),arguments.length<3?void 0:f(arguments[2]))}})},function(t,n,r){var e=r(54),i=r(2),o=e.keys,u=e.key;e.exp({getOwnMetadataKeys:function(t){
return o(i(t),arguments.length<2?void 0:u(arguments[1]))}})},function(t,n,r){var e=r(54),i=r(2),o=e.get,u=e.key;e.exp({getOwnMetadata:function(t,n){return o(t,i(n),arguments.length<3?void 0:u(arguments[2]))}})},function(t,n,r){var e=r(54),i=r(2),o=r(32),u=e.has,c=e.key,f=function(t,n,r){if(u(t,n,r))return!0;var e=o(n);return null!==e&&f(t,e,r)};e.exp({hasMetadata:function(t,n){return f(t,i(n),arguments.length<3?void 0:c(arguments[2]))}})},function(t,n,r){var e=r(54),i=r(2),o=e.has,u=e.key;e.exp({hasOwnMetadata:function(t,n){return o(t,i(n),arguments.length<3?void 0:u(arguments[2]))}})},function(t,n,r){var e=r(54),i=r(2),o=r(26),u=e.key,c=e.set;e.exp({metadata:function(t,n){return function(r,e){c(t,n,(void 0!==e?i:o)(r),u(e))}}})},function(t,n,r){var e=r(1);e(e.P+e.R,"Set",{toJSON:r(165)("Set")})},function(t,n,r){"use strict";var e=r(1),i=r(147)(!0);e(e.P,"String",{at:function(t){return i(this,t)}})},function(t,n,r){"use strict";var e=r(1),i=r(46),o=r(16),u=r(122),c=r(120),f=RegExp.prototype,a=function(t,n){this._r=t,this._s=n};r(139)(a,"RegExp String",function(){var t=this._r.exec(this._s);return{value:t,done:null===t}}),e(e.P,"String",{matchAll:function(t){if(i(this),!u(t))throw TypeError(t+" is not a regexp!");var n=String(this),r="flags"in f?String(t.flags):c.call(t),e=new RegExp(t.source,~r.indexOf("g")?r:"g"+r);return e.lastIndex=o(t.lastIndex),new a(e,n)}})},function(t,n,r){"use strict";var e=r(1),i=r(181);e(e.P,"String",{padEnd:function(t){return i(this,t,arguments.length>1?arguments[1]:void 0,!1)}})},function(t,n,r){"use strict";var e=r(1),i=r(181);e(e.P,"String",{padStart:function(t){return i(this,t,arguments.length>1?arguments[1]:void 0,!0)}})},function(t,n,r){"use strict";r(82)("trimLeft",function(t){return function(){return t(this,1)}},"trimStart")},function(t,n,r){"use strict";r(82)("trimRight",function(t){return function(){return t(this,2)}},"trimEnd")},function(t,n,r){r(153)("asyncIterator")},function(t,n,r){r(153)("observable")},function(t,n,r){var e=r(1);e(e.S,"System",{global:r(3)})},function(t,n,r){for(var e=r(155),i=r(28),o=r(3),u=r(27),c=r(80),f=r(7),a=f("iterator"),s=f("toStringTag"),l=c.Array,h=["NodeList","DOMTokenList","MediaList","StyleSheetList","CSSRuleList"],v=0;v<5;v++){var p,d=h[v],y=o[d],g=y&&y.prototype;if(g){g[a]||u(g,a,l),g[s]||u(g,s,d),c[d]=l;for(p in e)g[p]||i(g,p,e[p],!0)}}},function(t,n,r){var e=r(1),i=r(151);e(e.G+e.B,{setImmediate:i.set,clearImmediate:i.clear})},function(t,n,r){var e=r(3),i=r(1),o=r(121),u=r(207),c=e.navigator,f=!!c&&/MSIE .\./.test(c.userAgent),a=function(t){return f?function(n,r){return t(o(u,[].slice.call(arguments,2),"function"==typeof n?n:Function(n)),r)}:t};i(i.G+i.B+i.F*f,{setTimeout:a(e.setTimeout),setInterval:a(e.setInterval)})},function(t,n,r){r(330),r(269),r(271),r(270),r(273),r(275),r(280),r(274),r(272),r(282),r(281),r(277),r(278),r(276),r(268),r(279),r(283),r(284),r(236),r(238),r(237),r(286),r(285),r(256),r(266),r(267),r(257),r(258),r(259),r(260),r(261),r(262),r(263),r(264),r(265),r(239),r(240),r(241),r(242),r(243),r(244),r(245),r(246),r(247),r(248),r(249),r(250),r(251),r(252),r(253),r(254),r(255),r(317),r(322),r(329),r(320),r(312),r(313),r(318),r(323),r(325),r(308),r(309),r(310),r(311),r(314),r(315),r(316),r(319),r(321),r(324),r(326),r(327),r(328),r(231),r(233),r(232),r(235),r(234),r(220),r(218),r(224),r(221),r(227),r(229),r(217),r(223),r(214),r(228),r(212),r(226),r(225),r(219),r(222),r(211),r(213),r(216),r(215),r(230),r(155),r(302),r(307),r(184),r(303),r(304),r(305),r(306),r(287),r(183),r(185),r(186),r(342),r(331),r(332),r(337),r(340),r(341),r(335),r(338),r(336),r(339),r(333),r(334),r(288),r(289),r(290),r(291),r(292),r(295),r(293),r(294),r(296),r(297),r(298),r(299),r(301),r(300),r(343),r(369),r(372),r(371),r(373),r(374),r(370),r(375),r(376),r(354),r(357),r(353),r(351),r(352),r(355),r(356),r(346),r(368),r(377),r(345),r(347),r(349),r(348),r(350),r(359),r(360),r(362),r(361),r(364),r(363),r(365),r(366),r(367),r(344),r(358),r(380),r(379),r(378),t.exports=r(52)},function(t,n){function r(t,n){if("string"==typeof n)return t.insertAdjacentHTML("afterend",n);var r=t.nextSibling;return r?t.parentNode.insertBefore(n,r):t.parentNode.appendChild(n)}t.exports=r},,,,,,,,,function(t,n,r){(function(n,r){!function(n){"use strict";function e(t,n,r,e){var i=n&&n.prototype instanceof o?n:o,u=Object.create(i.prototype),c=new p(e||[]);return u._invoke=s(t,r,c),u}function i(t,n,r){try{return{type:"normal",arg:t.call(n,r)}}catch(t){return{type:"throw",arg:t}}}function o(){}function u(){}function c(){}function f(t){["next","throw","return"].forEach(function(n){t[n]=function(t){return this._invoke(n,t)}})}function a(t){function n(r,e,o,u){var c=i(t[r],t,e);if("throw"!==c.type){var f=c.arg,a=f.value;return a&&"object"==typeof a&&m.call(a,"__await")?Promise.resolve(a.__await).then(function(t){n("next",t,o,u)},function(t){n("throw",t,o,u)}):Promise.resolve(a).then(function(t){f.value=t,o(f)},u)}u(c.arg)}function e(t,r){function e(){return new Promise(function(e,i){n(t,r,e,i)})}return o=o?o.then(e,e):e()}"object"==typeof r&&r.domain&&(n=r.domain.bind(n));var o;this._invoke=e}function s(t,n,r){var e=P;return function(o,u){if(e===F)throw new Error("Generator is already running");if(e===M){if("throw"===o)throw u;return y()}for(r.method=o,r.arg=u;;){var c=r.delegate;if(c){var f=l(c,r);if(f){if(f===A)continue;return f}}if("next"===r.method)r.sent=r._sent=r.arg;else if("throw"===r.method){if(e===P)throw e=M,r.arg;r.dispatchException(r.arg)}else"return"===r.method&&r.abrupt("return",r.arg);e=F;var a=i(t,n,r);if("normal"===a.type){if(e=r.done?M:j,a.arg===A)continue;return{value:a.arg,done:r.done}}"throw"===a.type&&(e=M,r.method="throw",r.arg=a.arg)}}}function l(t,n){var r=t.iterator[n.method];if(r===g){if(n.delegate=null,"throw"===n.method){if(t.iterator.return&&(n.method="return",n.arg=g,l(t,n),"throw"===n.method))return A;n.method="throw",n.arg=new TypeError("The iterator does not provide a 'throw' method")}return A}var e=i(r,t.iterator,n.arg);if("throw"===e.type)return n.method="throw",n.arg=e.arg,n.delegate=null,A;var o=e.arg;return o?o.done?(n[t.resultName]=o.value,n.next=t.nextLoc,"return"!==n.method&&(n.method="next",n.arg=g),n.delegate=null,A):o:(n.method="throw",n.arg=new TypeError("iterator result is not an object"),n.delegate=null,A)}function h(t){var n={tryLoc:t[0]};1 in t&&(n.catchLoc=t[1]),2 in t&&(n.finallyLoc=t[2],n.afterLoc=t[3]),this.tryEntries.push(n)}function v(t){var n=t.completion||{};n.type="normal",delete n.arg,t.completion=n}function p(t){this.tryEntries=[{tryLoc:"root"}],t.forEach(h,this),this.reset(!0)}function d(t){if(t){var n=t[w];if(n)return n.call(t);if("function"==typeof t.next)return t;if(!isNaN(t.length)){var r=-1,e=function n(){for(;++r<t.length;)if(m.call(t,r))return n.value=t[r],n.done=!1,n;return n.value=g,n.done=!0,n};return e.next=e}}return{next:y}}function y(){return{value:g,done:!0}}var g,b=Object.prototype,m=b.hasOwnProperty,x="function"==typeof Symbol?Symbol:{},w=x.iterator||"@@iterator",S=x.asyncIterator||"@@asyncIterator",_=x.toStringTag||"@@toStringTag",O="object"==typeof t,E=n.regeneratorRuntime;if(E)return void(O&&(t.exports=E));E=n.regeneratorRuntime=O?t.exports:{},E.wrap=e;var P="suspendedStart",j="suspendedYield",F="executing",M="completed",A={},N={};N[w]=function(){return this};var T=Object.getPrototypeOf,I=T&&T(T(d([])));I&&I!==b&&m.call(I,w)&&(N=I);var k=c.prototype=o.prototype=Object.create(N);u.prototype=k.constructor=c,c.constructor=u,c[_]=u.displayName="GeneratorFunction",E.isGeneratorFunction=function(t){var n="function"==typeof t&&t.constructor;return!!n&&(n===u||"GeneratorFunction"===(n.displayName||n.name))},E.mark=function(t){return Object.setPrototypeOf?Object.setPrototypeOf(t,c):(t.__proto__=c,_ in t||(t[_]="GeneratorFunction")),t.prototype=Object.create(k),t},E.awrap=function(t){return{__await:t}},f(a.prototype),a.prototype[S]=function(){return this},E.AsyncIterator=a,E.async=function(t,n,r,i){var o=new a(e(t,n,r,i));return E.isGeneratorFunction(n)?o:o.next().then(function(t){return t.done?t.value:o.next()})},f(k),k[_]="Generator",k.toString=function(){return"[object Generator]"},E.keys=function(t){var n=[];for(var r in t)n.push(r);return n.reverse(),function r(){for(;n.length;){var e=n.pop();if(e in t)return r.value=e,r.done=!1,r}return r.done=!0,r}},E.values=d,p.prototype={constructor:p,reset:function(t){if(this.prev=0,this.next=0,this.sent=this._sent=g,this.done=!1,this.delegate=null,this.method="next",this.arg=g,this.tryEntries.forEach(v),!t)for(var n in this)"t"===n.charAt(0)&&m.call(this,n)&&!isNaN(+n.slice(1))&&(this[n]=g)},stop:function(){this.done=!0;var t=this.tryEntries[0],n=t.completion;if("throw"===n.type)throw n.arg;return this.rval},dispatchException:function(t){function n(n,e){return o.type="throw",o.arg=t,r.next=n,e&&(r.method="next",r.arg=g),!!e}if(this.done)throw t;for(var r=this,e=this.tryEntries.length-1;e>=0;--e){var i=this.tryEntries[e],o=i.completion;if("root"===i.tryLoc)return n("end");if(i.tryLoc<=this.prev){var u=m.call(i,"catchLoc"),c=m.call(i,"finallyLoc");if(u&&c){if(this.prev<i.catchLoc)return n(i.catchLoc,!0);if(this.prev<i.finallyLoc)return n(i.finallyLoc)}else if(u){if(this.prev<i.catchLoc)return n(i.catchLoc,!0)}else{if(!c)throw new Error("try statement without catch or finally");if(this.prev<i.finallyLoc)return n(i.finallyLoc)}}}},abrupt:function(t,n){for(var r=this.tryEntries.length-1;r>=0;--r){var e=this.tryEntries[r];if(e.tryLoc<=this.prev&&m.call(e,"finallyLoc")&&this.prev<e.finallyLoc){var i=e;break}}i&&("break"===t||"continue"===t)&&i.tryLoc<=n&&n<=i.finallyLoc&&(i=null);var o=i?i.completion:{};return o.type=t,o.arg=n,i?(this.method="next",this.next=i.finallyLoc,A):this.complete(o)},complete:function(t,n){if("throw"===t.type)throw t.arg;return"break"===t.type||"continue"===t.type?this.next=t.arg:"return"===t.type?(this.rval=this.arg=t.arg,this.method="return",this.next="end"):"normal"===t.type&&n&&(this.next=n),A},finish:function(t){for(var n=this.tryEntries.length-1;n>=0;--n){var r=this.tryEntries[n];if(r.finallyLoc===t)return this.complete(r.completion,r.afterLoc),v(r),A}},catch:function(t){for(var n=this.tryEntries.length-1;n>=0;--n){var r=this.tryEntries[n];if(r.tryLoc===t){var e=r.completion;if("throw"===e.type){var i=e.arg;v(r)}return i}}throw new Error("illegal catch attempt")},delegateYield:function(t,n,r){return this.delegate={iterator:d(t),resultName:n,nextLoc:r},"next"===this.method&&(this.arg=g),A}}}("object"==typeof n?n:"object"==typeof window?window:"object"==typeof self?self:this)}).call(n,function(){return this}(),r(158))}])</script><script src="/./main.0cf68a.js"></script><script>!function(){!function(e){var t=document.createElement("script");document.getElementsByTagName("body")[0].appendChild(t),t.setAttribute("src",e)}("/slider.e37972.js")}()</script>



{% if theme.mermaid.enable %}
  <script src='https://unpkg.com/mermaid@{{ theme.mermaid.version }}/dist/mermaid.min.js'></script>
  <script>
    if (window.mermaid) {
      mermaid.initialize({{ JSON.stringify(theme.mermaid.options) }});
    }
  </script>
{% endif %}

    
<div class="tools-col" q-class="show:isShow,hide:isShow|isFalse" q-on="click:stop(e)">
  <div class="tools-nav header-menu">
    
    
      
      
      
    
      
      
      
    
      
      
      
    
    

    <ul style="width: 70%">
    
    
      
      <li style="width: 33.333333333333336%" q-on="click: openSlider(e, 'innerArchive')"><a href="javascript:void(0)" q-class="active:innerArchive">All Items</a></li>
      
        
      
      <li style="width: 33.333333333333336%" q-on="click: openSlider(e, 'friends')"><a href="javascript:void(0)" q-class="active:friends">Links</a></li>
      
        
      
      <li style="width: 33.333333333333336%" q-on="click: openSlider(e, 'aboutme')"><a href="javascript:void(0)" q-class="active:aboutme">About Me</a></li>
      
        
    </ul>
  </div>
  <div class="tools-wrap">
    
    	<section class="tools-section tools-section-all" q-show="innerArchive">
        <div class="search-wrap">
          <input class="search-ipt" q-model="search" type="text" placeholder="find something…">
          <i class="icon-search icon" q-show="search|isEmptyStr"></i>
          <i class="icon-close icon" q-show="search|isNotEmptyStr" q-on="click:clearChose(e)"></i>
        </div>
        <div class="widget tagcloud search-tag">
          <p class="search-tag-wording">tag:</p>
          <label class="search-switch">
            <input type="checkbox" q-on="click:toggleTag(e)" q-attr="checked:showTags">
          </label>
          <ul class="article-tag-list" q-show="showTags">
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">QR Code</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">周易大师</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Hexo Note</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">PHMG</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Smallpdf</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">p62 Draft</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">HPV30</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Nrf2</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">HPV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Root Explorer</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">RE</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">ES File Explorer</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">离线语音助手</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">FTP connection</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Tags in Hexo</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Special symbols</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Exiftool</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">FTP</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">English Correction online</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Image attached</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Legado</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Document Clean-up</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Document Organization</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">SRA</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">integrity</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">vdb-validate</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Macro in Linux WPS</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Hantavirus evolution</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">LibreOffice</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">OpenOffice</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Apache OpenOffice</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">zcat</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">ICTV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">virus</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">International Committee on Taxonomy of Viruses (ICTV)</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">hexo index</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">hexo content</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Comments in Rmd</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">KinhDown</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">pan.baidu.com</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">SRA tumor cell lines</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Zhang Li</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">p62</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">E6</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">E7</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">wget</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">BaiduNetDisk</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">SRA analysis</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">HLA-G analysis</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">HEV Sequence Download</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Yin Wenjiao</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Guo Yifan</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">E-MTAB-1733</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">AnyDesk update</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Usage of my mobile device</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Windows Docker Machine</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">container</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Tips of Hexo GitHub Pages</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Build Github Pages With Jekyll</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">SDS-PAGE</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Protein Marker</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">txid</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">ETE/ETE3</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Minoxidil</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Ji Tianjiao</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Size reduction of PDF</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">tBHQ</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Tert-Butylhydroquinone</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Authentication Required</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Gene Report</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">BioGPS</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">rsync</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">SRA-Tools</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">ACNUC</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Microsoft Office</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">miRBase</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">RNA-Seq</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">pdftk</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">PDF password</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">MUSCLE</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">MSA</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Endometrial Cancer</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Wang Jiao</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Sex Determination</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">endometrial cancer</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">HLA-G</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">HEV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Watch charging</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">代码的魅力</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Flatpak</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Shotcut</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">RGB color</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">VPN</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">AppImage</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Outline</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Bacteriophage</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Phage RnD</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">ContraFect</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Intralytix</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">phagelux</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">菲吉乐科</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">NSFC</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">E-MTAB-173</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Essential</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Kaiju</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Mobile phone</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">NCBI Datasets</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Hexo categories</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">COVID-19 Data Download</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Glossary</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Hexo Categories</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">COVID-19  Vaccine</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Nrf2-HSV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">QQ浏览器</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Word</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Flu Biosafety</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">EBV Detection</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Backup</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">HSV Exosome cn draft</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">B95-8_Nrf2 project</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Offline map</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Google Patents</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">B95-8-Nrf2 project</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">File manager</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Reactive Oxygen Species</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Herpesviridae sequence download</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">HFMD</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">STGCN Model</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Offline Wikipedia</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Virus proliferation cell free system</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">CEB</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">flatpak</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Installation Log in X1</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Cairo-Dock</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Scheme of README documents</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Bacteriophage database</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">凉山项目</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">COVID-19 Vaccine</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">PDF_Learning</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">R update</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">CRAN update</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Thesis Nrf2</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">凉山</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">HSV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">CRAN</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Monkey B virus</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Hexo</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">恢复真实容量</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Pen drive Encrypting</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">中文语音识别</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">speech recognition</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">山西疾控</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">审计</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Antibody Purification</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Water</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">scrcpy</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">ADB</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">算命</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">七千人大会</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Long COVID-19</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">COVID-19</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Vaccine</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">疾病负担</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">BOD</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Burden of Disease</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Collison</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Nebulizer</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">气溶胶发生器</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Figma</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Chinese conversion</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">OpenCC</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">中文简繁转换</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">pH meter</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Potassium Chloride</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">KCl</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Android File Transfer</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">openvpn</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">openvpn3</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">WINE</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">R</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Gist</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">miR</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">miR prediction</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Primer organization</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">HSV-1</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">Exosome</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">国家自然科学基金</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">NFS</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Kiwix</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Wikipedia</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">HGNC</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">file extension</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">RNA-Seq pipeline</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">HEV sequence download</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">HEVnet</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">CSV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Excel</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Sheet</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">MarkText</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Small RNA</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">PDF Note</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Tree structure</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Markdown syntax</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">西部世界</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">IME in Ubuntu</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Markdown Mermaid examples</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Markdown mermaid</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">flowchart</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Markdown</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Text Editor</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Obsidian</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Gingko</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Manuskript</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">FocusWriter</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Typora</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">TreeSheets</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Zettlr</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Protein-Protein Docking</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">PPI</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Margarine</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">Protein Assay</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Proteomics</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">GanttProject</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Tasker</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">Shortcuts</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color1">Agent</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">氢原子</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color5">氢自由基</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">My Linux</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Qv2ray</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">HIV</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">Scheme</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color4">HD Management</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color2">README</a>
              </li>
             
              <li class="article-tag-list-item">
                <a href="javascript:void(0)" class="js-tag color3">HD Structure</a>
              </li>
            
            <div class="clearfix"></div>
          </ul>
        </div>
        <ul class="search-ul">
          <p q-show="jsonFail" style="padding: 20px; font-size: 12px;">
            缺失模块。<br/>1、请确保node版本大于6.2<br/>2、在博客根目录（注意不是yilia根目录）执行以下命令：<br/> npm i hexo-generator-json-content --save<br/><br/>
            3、在根目录_config.yml里添加配置：
<pre style="font-size: 12px;" q-show="jsonFail">
  jsonContent:
    meta: false
    pages: false
    posts:
      title: true
      date: true
      path: true
      text: false
      raw: false
      content: false
      slug: false
      updated: false
      comments: false
      link: false
      permalink: false
      excerpt: false
      categories: false
      tags: true
</pre>
          </p>
          <li class="search-li" q-repeat="items" q-show="isShow">
            <a q-attr="href:path|urlformat" class="search-title"><i class="icon-quo-left icon"></i><span q-text="title"></span></a>
            <p class="search-time">
              <i class="icon-calendar icon"></i>
              <span q-text="date|dateformat"></span>
            </p>
            <p class="search-tag">
              <i class="icon-price-tags icon"></i>
              <span q-repeat="tags" q-on="click:choseTag(e, name)" q-text="name|tagformat"></span>
            </p>
          </li>
        </ul>
    	</section>
    

    
    	<section class="tools-section tools-section-friends" q-show="friends">
  		
        <ul class="search-ul">
          
            <li class="search-li">
              <a href="https://www.ncbi.nlm.nih.gov/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>Old entry NCBI</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.nejm.org/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>The New England J of Medicine</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.thelancet.com/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>Lancet</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.nature.com/nature/current-issue" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>Nature</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.sciencemag.org/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>Science</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.cell.com/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>Cell</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.pnas.org/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>PNAS</a>
            </li>
          
            <li class="search-li">
              <a href="https://www.jbc.org/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>JBC</a>
            </li>
          
            <li class="search-li">
              <a href="https://rupress.org/jcb" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>JCB</a>
            </li>
          
            <li class="search-li">
              <a href="https://clinicaltrials.gov/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>ClinicalTrials.gov</a>
            </li>
          
            <li class="search-li">
              <a href="http://192.168.1.10:8000/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>MarginNote 3</a>
            </li>
          
            <li class="search-li">
              <a href="https://my.pcloud.com/" target="_blank" class="search-title"><i class="icon-quo-left icon"></i>pCloud</a>
            </li>
          
        </ul>
  		
    	</section>
    

    
    	<section class="tools-section tools-section-me" q-show="aboutme">
  	  	
  	  		<div class="aboutme-wrap" id="js-aboutme">Step by step.</div>
  	  	
    	</section>
    
  </div>
  
</div>
    <!-- Root element of PhotoSwipe. Must have class pswp. -->
<div class="pswp" tabindex="-1" role="dialog" aria-hidden="true">

    <!-- Background of PhotoSwipe. 
         It's a separate element as animating opacity is faster than rgba(). -->
    <div class="pswp__bg"></div>

    <!-- Slides wrapper with overflow:hidden. -->
    <div class="pswp__scroll-wrap">

        <!-- Container that holds slides. 
            PhotoSwipe keeps only 3 of them in the DOM to save memory.
            Don't modify these 3 pswp__item elements, data is added later on. -->
        <div class="pswp__container">
            <div class="pswp__item"></div>
            <div class="pswp__item"></div>
            <div class="pswp__item"></div>
        </div>

        <!-- Default (PhotoSwipeUI_Default) interface on top of sliding area. Can be changed. -->
        <div class="pswp__ui pswp__ui--hidden">

            <div class="pswp__top-bar">

                <!--  Controls are self-explanatory. Order can be changed. -->

                <div class="pswp__counter"></div>

                <button class="pswp__button pswp__button--close" title="Close (Esc)"></button>

                <button class="pswp__button pswp__button--share" style="display:none" title="Share"></button>

                <button class="pswp__button pswp__button--fs" title="Toggle fullscreen"></button>

                <button class="pswp__button pswp__button--zoom" title="Zoom in/out"></button>

                <!-- Preloader demo http://codepen.io/dimsemenov/pen/yyBWoR -->
                <!-- element will get class pswp__preloader--active when preloader is running -->
                <div class="pswp__preloader">
                    <div class="pswp__preloader__icn">
                      <div class="pswp__preloader__cut">
                        <div class="pswp__preloader__donut"></div>
                      </div>
                    </div>
                </div>
            </div>

            <div class="pswp__share-modal pswp__share-modal--hidden pswp__single-tap">
                <div class="pswp__share-tooltip"></div> 
            </div>

            <button class="pswp__button pswp__button--arrow--left" title="Previous (arrow left)">
            </button>

            <button class="pswp__button pswp__button--arrow--right" title="Next (arrow right)">
            </button>

            <div class="pswp__caption">
                <div class="pswp__caption__center"></div>
            </div>

        </div>

    </div>

</div>
  </div>
</body>
</html>